U.S. patent application number 17/290651 was filed with the patent office on 2021-12-02 for homodimeric bispecific antibody, preparation method therefor and use thereof.
The applicant listed for this patent is AMPSOURCE BIOPHARMA SHANGHAI INC.. Invention is credited to Si Chen, Xueyuan Cui, Jiasheng Diao, Shixiang Jia, Yingying Jin, Qiang Li, Yuanli Li, Xuemei Liu, Xinlu Ma, Rilong Sun, Yao Xiong, Yuan Yan, Yujie Yan, Lingju Yu, Yuhua Zhang, Li Zhou.
Application Number | 20210371526 17/290651 |
Document ID | / |
Family ID | 1000005824806 |
Filed Date | 2021-12-02 |
United States Patent
Application |
20210371526 |
Kind Code |
A1 |
Li; Qiang ; et al. |
December 2, 2021 |
HOMODIMERIC BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR AND
USE THEREOF
Abstract
Provided is a tetravalent homodimeric bispecific antibody
molecule simultaneously targeting an immune effector cell antigen
CD3 and a tumor-associated antigen, wherein the bispecific antibody
molecule contains, in order from N-terminus to C-terminus, a first
single chain Fv, a second single chain Fv and a Fc fragment;
wherein the first single chain Fv can specifically bind to the
tumor-associated antigen, the second single chain Fv can
specifically bind to CD3, and the first and the second single chain
Fvs are connected by a linker peptide, while the second single
chain Fv and the Fc fragment are directly connected or connected by
a linker peptide; and the Fc fragment does not have effector
functions such as CDC, ADCC and ADCP.
Inventors: |
Li; Qiang; (Shanghai,
CN) ; Ma; Xinlu; (Shanghai, CN) ; Jia;
Shixiang; (Shanghai, CN) ; Yan; Yuan;
(Shanghai, CN) ; Zhang; Yuhua; (Shanghai, CN)
; Zhou; Li; (Shanghai, CN) ; Sun; Rilong;
(Shanghai, CN) ; Cui; Xueyuan; (Shanghai, CN)
; Yu; Lingju; (Shanghai, CN) ; Yan; Yujie;
(Shanghai, CN) ; Jin; Yingying; (Shanghai, CN)
; Xiong; Yao; (Shanghai, CN) ; Li; Yuanli;
(Shanghai, CN) ; Chen; Si; (Shanghai, CN) ;
Liu; Xuemei; (Shanghai, CN) ; Diao; Jiasheng;
(Shanghai, CN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
AMPSOURCE BIOPHARMA SHANGHAI INC. |
Shanghai |
|
CN |
|
|
Family ID: |
1000005824806 |
Appl. No.: |
17/290651 |
Filed: |
October 31, 2019 |
PCT Filed: |
October 31, 2019 |
PCT NO: |
PCT/CN2019/114818 |
371 Date: |
April 30, 2021 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 16/3007 20130101;
C07K 2317/53 20130101; C07K 2317/524 20130101; C07K 16/2809
20130101; A61P 35/00 20180101; C07K 16/303 20130101; C07K 16/2863
20130101; C07K 16/2878 20130101; C07K 16/32 20130101; C07K 2317/92
20130101; C07K 2317/526 20130101; C07K 2317/622 20130101; C07K
2317/31 20130101; A61K 2039/505 20130101; C07K 16/2887
20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; C07K 16/30 20060101 C07K016/30; C07K 16/32 20060101
C07K016/32; A61P 35/00 20060101 A61P035/00 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 1, 2018 |
CN |
201811294887.4 |
Claims
1. A bispecific antibody, which is a tetravalent homodimer formed
by two identical polypeptide chains that bind to each other by a
covalent bond, wherein each of the polypeptide chains comprises a
first single-chain Fv that specifically binds to an
tumor-associated antigen, a second single-chain Fv that
specifically bind to effector cell antigen CD3, and an Fc fragment
in sequence from N-terminus to C-terminus; wherein the first
single-chain Fv is linked to the second single-chain Fv by a linker
peptide, the second single-chain Fv is linked to the Fc fragment
directly or by a linker peptide, and the Fc fragment has no
effector functions comprising CDC, ADCC, and ADCP.
2. The bispecific antibody according to claim 1, wherein the first
single-chain Fv comprises a VH domain and a VL domain that are
linked by a linker peptide, which has an amino acid sequence of
(GGGGX).sub.n, wherein X comprises Ser or Ala, and n is a natural
number of 1 to 5.
3. The bispecific antibody according to claim 1, wherein the
tumor-associated antigen comprises CD19, CD20, CD22, CD25, CD30,
CD33, CD38, CD39, CD40, CD47, CD52, CD73, CD74, CD123, CD133,
CD138, BCMA, CA125, CEA, CS1, DLL3, DLL4, EGFR, EpCAM, FLT3, gpA33,
GPC-3, Her2, MEGE-A3, NYESO1, PSMA, TAG-72, CIX, folate-binding
protein, GD2, GD3, GM2, VEGF, VEGFR2, VEGFR3, Cadherin, Integrin,
Mesothelin, Claudin18, .alpha.V.beta.3, .alpha.5.beta.1, ERBB3,
c-MET, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, B7 protein family,
Mucin family, FAP, and Tenascin.
4. The bispecific antibody according to claim 1, wherein the first
single-chain Fv specifically binds to CD19 and comprises a VH
domain and a VL domain selected from the group consisting of: (i) a
VH domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID
NOs: 9, 10, and 11, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 9, 10, and 11; and a VL domain comprising
LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 12, 13, and 14,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
12, 13, and 14; (ii) a VH domain comprising HCDR1, HCDR2, and HCDR3
as shown in SEQ ID NOs: 17, 18, and 19, respectively or having
sequences that are substantially identical to (for example, are at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 17, 18, and
19; and a VL domain comprising LCDR1, LCDR2, and LCDR3 as shown in
SEQ ID NOs: 20, 21, and 22, respectively or having sequences that
are substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 20, 21, and 22; (iii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 25, 26,
and 27, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) any
of SEQ ID NOs: 25, 26, and 27; and a VL domain comprising LCDR1,
LCDR2, and LCDR3 as shown in SEQ ID NOs: 28, 29, and 30,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
28, 29, and 30; and (iv) a VH domain comprising HCDR1, HCDR2, and
HCDR3 as shown in SEQ ID NOs: 33, 34, and 35, respectively or
having sequences that are substantially identical to (for example,
are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 33, 34, and
35; and a VL domain comprising LCDR1, LCDR2, and LCDR3 as shown in
SEQ ID NOs: 36, 37, and 38, respectively or having sequences that
are substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 36, 37, and 38; or the first single-train
Fv specifically binds to CD20 and comprises a VH domain and a VL
domain selected from the group consisting of: (i) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 41, 42,
and 43, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) any
of SEQ ID NOs: 41, 42, and 43; and a VL domain comprising LCDR1,
LCDR2, and LCDR3 as shown in SEQ ID NOs: 44, 45, and 46,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
44, 45, and 46; (ii) a VH domain comprising HCDR1, HCDR2, and HCDR3
as shown in SEQ ID NOs: 49, 50, and 51, respectively or having
sequences that are substantially identical to (for example, are at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 49, 50, and
51; and a VL domain comprising LCDR1, LCDR2, and LCDR3 as shown in
SEQ ID NOs: 52, 53, and 54, respectively or having sequences that
are substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 52, 53, and 54; (iii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 57, 58,
and 59, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) any
of SEQ ID NOs: 57, 58, and 59; and a VL domain comprising LCDR1,
LCDR2, and LCDR3 as shown in SEQ ID NOs: 60, 61, and 62,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
60, 61, and 62; and (iv) a VH domain comprising HCDR1, HCDR2, and
HCDR3 as shown in SEQ ID NOs: 65, 66, and 67, respectively or
having sequences that are substantially identical to (for example,
are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 33, 34, and
35; and a VL domain comprising LCDR1, LCDR2, and LCDR3 as shown in
SEQ ID NOs: 68, 69, and 70, respectively or having sequences that
are substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 68, 69, and 70; or the first single-train
Fv specifically binds to CD22 and comprises a VH domain and a VL
domain selected from the group consisting of: (i) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 73, 74,
and 75, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) any
of SEQ ID NOs: 73, 74, and 75; and a VL domain comprising LCDR1,
LCDR2, and LCDR3 as shown in SEQ ID NOs: 76, 77, and 78,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
76, 77, and 78; (ii) a VH domain comprising HCDR1, HCDR2, and HCDR3
as shown in SEQ ID NOs: 81, 82, and 83, respectively or having
sequences that are substantially identical to (for example, are at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 81, 82, and
83; and a VL domain comprising LCDR1, LCDR2, and LCDR3 as shown in
SEQ ID NOs: 84, 85, and 86, respectively or having sequences that
are substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 84, 85, and 86; or the first single-train
Fv specifically binds to CD30 and comprises a VH domain and a VL
domain selected from the group consisting of: (i) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 89, 90,
and 91, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) any
of SEQ ID NOs: 89, 90, and 91; and a VL domain comprising LCDR1,
LCDR2, and LCDR3 as shown in SEQ ID NOs: 92, 93, and 94,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
92, 93, and 94; and (ii) a VH domain comprising HCDR1, HCDR2, and
HCDR3 as shown in SEQ ID NOs: 97, 98, and 99, respectively or
having sequences that are substantially identical to (for example,
are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 97, 98, and
99; and a VL domain comprising LCDR1, LCDR2, and LCDR3 as shown in
SEQ ID NOs: 100, 101, and 102, respectively or having sequences
that are substantially identical to (for example, are at least 80%,
85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or
more amino acid substitutions (for example, conservative
substitutions) than) any of SEQ ID NOs: 100, 101, and 102; or the
first single-train Fv specifically binds to ECAM and comprises a VH
domain and a VL domain selected from the group consisting of: (i) a
VH domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID
NOs: 105, 106, and 107, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 105, 106, and 107; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 108,
109, and 110, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 108, 109, and 110; and (ii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 113,
114, and 115, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 113, 114, and 115; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 116,
117, and 118, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 116, 117, and 118; or the first
single-train Fv specifically binds to CEA and comprises a VH domain
and a VL domain selected from the group consisting of: (i) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
121, 122, and 123, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 121, 122, and 123; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 124,
125, and 126, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 124, 125, and 126; (ii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 129,
130, and 131, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 129, 130, and 131; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 132,
133, and 134, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 132, 133, and 134; (iii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 137,
138, and 139, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 137, 138, and 139; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 140,
141, and 142, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 140, 141, and 142; or the first
single-train Fv specifically binds to Her2 and comprises a VH
domain and a VL domain selected from the group consisting of: (i) a
VH domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID
NOs: 145, 146, and 147, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 145, 146, and 147; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 148,
149, and 150, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 148, 149, and 150; (ii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 153,
154, and 155, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 153, 154, and 155; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 156,
157, and 158, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 156, 157, and 158; and (iii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 161,
162, and 163, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 16, 162, and 163; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 164,
165, and 166, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 164, 165, and 166; or the first
single-train Fv specifically binds to EGFR and comprises a VH
domain and a VL domain selected from the group consisting of: (i) a
VH domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID
NOs: 169, 170, and 171, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 169, 170, and 171; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 172,
173, and 174, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 172, 173, and 174; (ii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 177,
178, and 179, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 177, 178, and 179; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 180,
181, and 182, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 180, 181, and 182; and (iii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 185,
186, and 187, respectively or having sequences that are
substantially identical to
(for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99%
or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
185, 186, and 187; and a VL domain comprising LCDR1, LCDR2, and
LCDR3 as shown in SEQ ID NOs: 188, 189, and 190, respectively or
having sequences that are substantially identical to (for example,
are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 188, 189, and
190; or the first single-train Fv specifically binds to GPC-3 and
comprises a VH domain and a VL domain selected from: a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 193,
194, and 195, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 193, 194, and 195; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 196,
197, and 198, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 196, 197, and 198; or the first
single-train Fv specifically binds to Mesothelin and comprises a VH
domain and a VL domain selected from: a VH domain comprising HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 201, 202, and 203,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
201, 202, and 203; and a VL domain comprising LCDR1, LCDR2, and
LCDR3 as shown in SEQ ID NOs: 204, 205, and 206, respectively or
having sequences that are substantially identical to (for example,
are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 204, 205, and
206; or the first single-train Fv specifically binds to Mucin1 and
comprises a VH domain and a VL domain selected from the group
consisting of: (i) a VH domain comprising HCDR1, HCDR2, and HCDR3
as shown in SEQ ID NOs: 209, 210, and 211, respectively or having
sequences that are substantially identical to (for example, are at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 209, 210, and
211; and a VL domain comprising LCDR1, LCDR2, and LCDR3 as shown in
SEQ ID NOs: 212, 213, and 214, respectively or having sequences
that are substantially identical to (for example, are at least 80%,
85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or
more amino acid substitutions (for example, conservative
substitutions) than) any of SEQ ID NOs: 212, 213, and 214; and (ii)
a VH domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID
NOs: 217, 218, and 219, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 217, 218, and 219; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 220,
221, and 222, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 220, 221, and 2222; or the first
single-train Fv specifically binds to CA125 and comprises a VH
domain and a VL domain selected from: a VH domain comprising HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 225, 226, and 227,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
225, 226, and 227; and a VL domain comprising LCDR1, LCDR2, and
LCDR3 as shown in SEQ ID NOs: 228, 229, and 230, respectively or
having sequences that are substantially identical the (for example,
are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 228, 229, and
230.
5-15. (canceled)
16. The bispecific antibody according to claim 1, wherein the first
single-chain Fv specifically binds to CD19 and comprises a VH
domain and a VL domain selected from the group consisting of: (i) a
VH domain comprising an amino acid sequence as shown in SEQ ID NO:
15 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 15; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 16
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 16; (ii) a VH
domain comprising an amino acid sequence as shown in SEQ ID NO: 23
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 23; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 24
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 24; (iii) a
VH domain comprising an amino acid sequence as shown in SEQ ID NO:
31 or having a sequence that is substantially identical (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) to SEQ ID NO: 31; and a
VL domain comprising an amino acid sequence as shown in SEQ ID NO:
32 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 32; and (iv)
a VH domain comprising an amino acid sequence as shown in SEQ ID
NO: 39 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 39; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 40
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 40; or the
first single-chain Fv specifically binds to CD20 and comprises a VH
domain and a VL domain selected from the group consisting of: (i) a
VH domain comprising an amino acid sequence as shown in SEQ ID NO:
47 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 15; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 48
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 48; (ii) a VH
domain comprising an amino acid sequence as shown in SEQ ID NO: 55
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 55; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 24
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 56; (iii) a
VH domain comprising an amino acid sequence as shown in SEQ ID NO:
63 or having a sequence that is substantially identical (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) to SEQ ID NO: 63; and a
VL domain comprising an amino acid sequence as shown in SEQ ID NO:
64 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 64; and (iv)
a VH domain comprising an amino acid sequence as shown in SEQ ID
NO: 71 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 71; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 72
or having a sequence substantially identical to (for example, is at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
has one or more amino acid substitutions (for example, conservative
substitutions) than) SEQ ID NO: 72; or the first single-chain Fv
specifically binds to CD22 and comprises a VH domain and a VL
domain selected from the group consisting of: (i) a VH domain
comprising an amino acid sequence as shown in SEQ ID NO: 79 or
having a sequence that is substantially identical to (for example,
is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or has one or more amino acid substitutions (for example,
conservative substitutions) than) SEQ ID NO: 79; and a VL domain
comprising an amino acid sequence as shown in SEQ ID NO: 80 or
having a sequence that is substantially identical to (for example,
is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or has one or more amino acid substitutions (for example,
conservative substitutions) than) SEQ ID NO: 80; (ii) a VH domain
comprising an amino acid sequence as shown in SEQ ID NO: 87 or
having a sequence that is substantially identical to (for example,
is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or has one or more amino acid substitutions (for example,
conservative substitutions) than) SEQ ID NO: 87; and a VL domain
comprising an amino acid sequence as shown in SEQ ID NO: 88 or
having a sequence that is substantially identical to (for example,
is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or has one or more amino acid substitutions (for example,
conservative substitutions) than) SEQ ID NO: 88; or the first
single-chain Fv specifically binds to CD30 and comprises a VH
domain and a VL domain selected from the group consisting of: (i) a
VH domain comprising an amino acid sequence as shown in SEQ ID NO:
95 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 95; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 96
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 96; and (ii)
a VH domain comprising an amino acid sequence as shown in SEQ ID
NO: 103 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 103; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 104
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 104; or the
first single-chain Fv specifically binds to EpCAM and comprises a
VH domain and a VL domain selected from the group consisting of:
(i) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 111 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 111; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 112
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 112; and (ii)
a VH domain comprising an amino acid sequence as shown in SEQ ID
NO: 119 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 119; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 120
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 120; or the
first single-chain Fv specifically binds to CEA and comprises a VH
domain and a VL domain selected from the group consisting of: (i) a
VH domain comprising an amino acid sequence as shown in SEQ ID NO:
127 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 127; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 128
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 128; (ii) a
VH domain comprising an amino acid sequence as shown in SEQ ID NO:
135 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 135; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 136
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 136; and
(iii) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 143 or having a sequence that is substantially identical
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 143; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 144
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 144; or the
first single-chain Fv specifically binds to Her2 and comprises a VH
domain and a VL domain selected from the group consisting of: (i) a
VH domain comprising an amino acid sequence as shown in SEQ ID NO:
151 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 151; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 152
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 152; (ii) a
VH domain comprising an amino acid sequence as shown in SEQ ID NO:
159 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 159; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 160
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 160; and
(iii) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 167 or having a sequence that is substantially identical
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 167; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 168
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 168; or the
first single-chain Fv specifically binds to EGFR and comprises a VH
domain and a VL domain selected from the group consisting of: (i) a
VH domain comprising an amino acid sequence as shown in SEQ ID NO:
175 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 175; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 152
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 176; (ii) a
VH domain comprising an amino acid sequence as shown in SEQ ID NO:
183 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 183; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 184
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 184; and
(iii) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 191 or having a sequence that is substantially identical
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 191; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 168
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 192; or the
first single-chain Fv specifically binds to GPC-3 and comprises a
VH domain and a VL domain selected from: a VH domain comprising an
amino acid sequence as shown in SEQ ID NO: 199 or having a sequence
substantially identical to (for example, is at least 80%, 85%, 90%,
92%, 95%, 97%, 98%, 99% or more similar to or has one or more amino
acid substitutions (for example, conservative substitutions) than)
SEQ ID NO: 199; and a VL domain comprising an amino acid sequence
as shown in SEQ ID NO: 200 or having a sequence that is
substantially identical to (for example, is at least 80%, 85%, 90%,
92%, 95%, 97%, 98%, 99% or more similar to or has one or more amino
acid substitutions (for example, conservative substitutions) than)
SEQ ID NO: 200; or the first single-chain Fv specifically binds to
Mesothelin and comprises a VH domain and a VL domain selected from:
a VH domain comprising an amino acid sequence as shown in SEQ ID
NO: 207 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 207; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 208
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 208; or the
first single-chain Fv specifically binds to Mucin1 and comprises a
VH domain
and a VL domain selected from the group consisting of: (i) a VH
domain comprising an amino acid sequence as shown in SEQ ID NO: 215
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 215; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 216
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 216; and (ii)
a VH domain comprising an amino acid sequence as shown in SEQ ID
NO: 223 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 159; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 160
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 224; and or
the first single-chain Fv specifically binds to CA125 and comprises
a VH domain and a VL domain selected from: a VH domain comprising
an amino acid sequence as shown in SEQ ID NO: 231 or having a
sequence that is substantially identical to (for example, is at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
has one or more amino acid substitutions (for example, conservative
substitutions) than) SEQ ID NO: 231; and a VL domain comprising an
amino acid sequence as shown in SEQ ID NO: 232 or having a sequence
that is substantially identical to (for example, is at least 80%,
85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or has one or
more amino acid substitutions (for example, conservative
substitutions) than) SEQ ID NO: 232.
17-27. (canceled)
28. The bispecific antibody according to claim 1, wherein the
second single-chain Fv comprises a VH domain and a VL domain that
are linked by a linker peptide which has an amino acid sequence of
(GGGGX).sub.n, wherein X comprises Ser or Ala, preferably Ser, and
n is a natural number of 1 to 5, preferably 3, wherein the single
chain Fv binds to an effector cell at an EC.sub.50 value greater
than about 50 nM, or greater than 100 nM, or greater than 300 nM,
or greater than 500 nM in an in vitro binding affinity assay; and
wherein, the second single-chain Fv of the bispecific antibody is
capable of binding to human CD3 and specifically binding to CD3 of
a cynomolgus monkey or a rhesus monkey.
29. (canceled)
30. The bispecific antibody according to claim 28, wherein the
second single-chain Fv comprises a VH domain comprising HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 241, 242, and 243,
respectively or having sequences that are at least 80%, 85%, 90%,
92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions than SEQ ID NOs: 241, 242, and 243; and a
VL domain comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID
NOs: 244, 245, and 246, respectively or having sequences that are
at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to
or have one or more amino acid substitutions than SEQ ID NOs: 244,
245, and 246, or the second single-chain Fv comprises a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 249,
250, and 251, respectively or having sequences that are at least
80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or have
one or more amino acid substitutions than SEQ ID NOs: 249, 250, and
251; and a VL domain comprising LCDR1, LCDR2, and LCDR3 as shown in
SEQ ID NOs: 252, 253, and 254, respectively or having sequences
that are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or have one or more amino acid substitutions than any of
SEQ ID NOs: 252, 253, and 254.
31. (canceled)
32. The bispecific antibody according to claim 30, wherein the
second single-chain Fv specifically binds to CD3; the VH domain of
the second single-chain Fv comprises an amino acid sequence as
shown in SEQ ID NO: 247 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 247; and the VL domain of the second single-chain Fv
comprises an amino acid sequence as shown in SEQ ID NO: 248 or
having a sequence that is substantially identical to (for example,
is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or has one or more amino acid substitutions (for example,
conservative substitutions) than) SEQ ID NO: 248; or the second
single-chain Fv specifically binds to CD3; the VH domain of the
second single-chain Fv comprises an amino acid sequence as show in
SEQ ID NO: 255 or having a sequence that is substantially identical
to (for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99%, or more similar to or has one or more amino acid substitutions
(for example, conservative substitutions) than) SEQ ID NO: 255; and
the VL domain of the second single-chain Fv comprises an amino acid
sequence as shown in SEQ ID NO: 256 or having a sequence that is
substantially identical to (for example, is at least 80%, 85%, 90%,
92%, 95%, 97%, 98%, 99% or more similar to or has one or more amino
acid substitutions (for example, conservative substitutions) than
SEQ ID NO: 256.
33. (canceled)
34. The bispecific antibody according to claim 31, wherein the
linker peptide that links the first single-chain Fv to the second
single-chain Fv consists of a flexible peptide and a rigid peptide;
wherein the flexible peptide comprises two or more amino acids, and
preferably selected from the following amino acids: Gly(G), Ser(S),
Ala(A), and Thr(T); more preferably, the flexible peptide comprises
G and S residues; most preferably, an amino acid composition
structure of the flexible peptide has a general formula of
G.sub.xS.sub.y(GGGGS).sub.z, wherein x, y, and z are integers
greater than or equal to 0, and x+y+z.gtoreq.1; the rigid peptide
is derived from a full-length sequence consisting of amino acids at
positions 118 to 145 at carboxyl terminus of the natural human
chorionic gonadotropin beta-subunit, or a truncated fragment
thereof; preferably, the rigid peptide comprises SSSSKAPPPS.
35. The bispecific antibody according to claim 34, wherein the
linker peptide comprises an amino acid sequence as shown in SEQ ID
NO: 258.
36. The bispecific antibody according to claim 1, wherein the
linker peptide that links the Fc fragment to the second
single-chain Fv comprises 1 to 20 amino acids, and preferably
selected from the following amino acids: Gly(G), Ser(S), Ala(A),
and Thr(T); more preferably Gly(G) and Ser(S); further preferably,
the linker peptide consists of (GGGGS).sub.n, wherein n=1, 2, 3 or
4.
37. The bispecific antibody according to claim 1, wherein the Fc
fragment comprises a hinge region, a CH2 domain, and a CH3 domain
from a human immunoglobulin heavy chain constant region;
preferably, the Fc fragment is selected from heavy chain constant
regions of human IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and
IgE; more preferably, the Fc fragment is selected from heavy chain
constant regions of human IgG1, IgG2, IgG3, and IgG4; further
preferably, the Fc fragment is selected from heavy chain constant
region of human IgG1 or IgG4; and compared to a natural sequence
from which the Fc fragment is derived, the Fc fragment has one or
more amino acid substitutions, deletions or additions selected from
the group consisting of: (i) amino acid substitutions
L234A/L235A/P331S that are determined according to an EU numbering
system (ii) amino acid substitutions M428L, T250Q/M428L,
M248L/N434S or M252Y/S254T/T25E determined according to the EU
numbering system; (iii) amino acid substitution N297A determined
according to the EU numbering system; and (iv) an amino acid
deletion K447 determined according to the EU numbering system.
38-41. (canceled)
42. The bispecific antibody according to claim 37, wherein the Fc
fragment has an amino acid sequence as shown in SEQ ID NO: 263 that
has six amino acid substitutions or replacements
L234A/L235A/N297A/P331S/T250Q/M428L determined according to the EU
numbering system and a deleted or removed K447 determined according
to the EU numbering system compared to the natural sequence from
which the Fc fragment is derived.
43. The bispecific antibody according to claim 1, wherein the
bispecific antibody binds to human CD19 and CD3 and has an amino
acid sequence as follows: (i) a sequence as shown in SEQ ID NO:
264; (ii) a sequence with one or more substitutions, deletions or
additions (such as 1, 2, 3, 4 or 5 substitutions, deletions or
additions) compared to the sequence as shown in SEQ ID NO: 264; or
(iii) a sequence with at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% or 100%
sequence identity to the sequence as shown in SEQ ID NO: 264; or
the bispecific antibody binds to human CD19 and CD3 and has an
amino acid sequence as follows: (i) a sequence as shown in SEQ ID
NO: 283; (ii) a sequence with one or more substitutions, deletions
or additions (such as 1, 2, 3, 4 or 5 substitutions, deletions or
additions) compared to the sequence as shown in SEQ ID NO: 283; or
(iii) a sequence with at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% or 100%
sequence identity to the sequence as shown in SEQ ID NO: 283; or
the bispecific antibody binds to human CD20 and CD3 and has an
amino acid sequence as follows: (i) a sequence as shown in SEQ ID
NO: 266; (ii) a sequence with one or more substitutions, deletions
or additions (such as 1, 2, 3, 4 or 5 substitutions, deletions or
additions) compared to the sequence as shown in SEQ ID NO: 266; or
(iii) a sequence with at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% or 100%
sequence identity to the sequence as shown in SEQ ID NO: 266; or
the bispecific antibody binds to human CD22 and CD3 and has an
amino acid sequence as follows: (i) a sequence as shown in SEQ ID
NO: 268; (ii) a sequence with one or more substitutions, deletions
or additions (such as 1, 2, 3, 4 or 5 substitutions, deletions or
additions) compared to the sequence as shown in SEQ ID NO: 268; or
(iii) a sequence with at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% or 100%
sequence identity to the sequence as shown in SEQ ID NO: 268; or
the bispecific antibody binds to human CD30 and CD3 and has an
amino acid sequence as follows: (i) a sequence as shown in SEQ ID
NO: 270; (ii) a sequence with one or more substitutions, deletions
or additions (such as 1, 2, 3, 4 or 5 substitutions, deletions or
additions) compared to the sequence as shown in SEQ ID NO: 270; or
(iii) a sequence with at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% or 100%
sequence identity to the sequence as shown in SEQ ID NO: 270; or
the bispecific antibody binds to human EpCAM and CD3 and has an
amino acid sequence as follows: (i) a sequence as shown in SEQ ID
NO: 272; (ii) a sequence with one or more substitutions, deletions
or additions (such as 1, 2, 3, 4 or 5 substitutions, deletions or
additions) compared to the sequence as shown in SEQ ID NO: 272; or
(iii) a sequence with at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% or 100%
sequence identity to the sequence as shown in SEQ ID NO: 272; or
the bispecific antibody binds to human CEA and CD3 and has an amino
acid sequence as follows: (i) a sequence as shown in SEQ ID NO:
274; (ii) a sequence with one or more substitutions, deletions or
additions (such as 1, 2, 3, 4 or 5 substitutions, deletions or
additions) compared to the sequence as shown in SEQ ID NO: 274; or
(iii) a sequence with at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% or 100%
sequence identity to the sequence as shown in SEQ ID NO: 274; or
the bispecific antibody binds to human Her2 and CD3 and has an
amino acid sequence as follows: (i) a sequence as shown in SEQ ID
NO: 8; (ii) a sequence with one or more substitutions, deletions or
additions (such as 1, 2, 3, 4 or 5 substitutions, deletions or
additions) compared to the sequence as shown in SEQ ID NO: 8; or
(iii) a sequence with at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% or 100%
sequence identity to the sequence as shown in SEQ ID NO: 8; or the
bispecific antibody binds to human EGFR and CD3 and has an amino
acid sequence as follows: (i) a sequence as shown in SEQ ID NO:
277; (ii) a sequence with one or more substitutions, deletions or
additions (such as 1, 2, 3, 4 or 5 substitutions, deletions or
additions) compared to the sequence as shown in SEQ ID NO: 277; or
(iii) a sequence with at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% or 100%
sequence identity to the sequence as shown in SEQ ID NO: 277; or
the bispecific antibody binds to human GPC-3 and CD3 and has an
amino acid sequence as follows: (i) a sequence as shown in SEQ ID
NO: 279; (ii) a sequence with one or more substitutions, deletions
or additions (such as 1, 2, 3, 4 or 5 substitutions, deletions or
additions) compared to the sequence as shown in SEQ ID NO: 279; or
(iii) a sequence with at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% or 100%
sequence identity to the sequence as shown in SEQ ID NO: 279; or
the bispecific antibody binds to human Mesothelin and CD3 and has
an amino acid sequence as follows: (i) a sequence as shown in SEQ
ID NO: 281; (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 281; or (iii) a sequence with at least 80%, at least 85%, at
least 90%, at least 91%, at least 92%, at least 93%, at least 94%,
at least 95%, at least 96%, at least 97%, at least 98%, at least
99% or 100% sequence identity to the sequence as shown in SEQ ID
NO: 281; or the bispecific antibody binds to human Mucin1 and CD3
and has an amino acid sequence as follows: (i) a sequence as shown
in SEQ ID NO: 285; (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 285; or (iii) a sequence with at least 80%, at least 85%, at
least 90%, at least 91%, at least 92%, at least 93%, at least 94%,
at least 95%, at least 96%, at least 97%, at least 98%, at least
99% or 100% sequence identity to the sequence as shown in SEQ ID
NO: 285.
44-54. (canceled)
55. A DNA molecule encoding the bispecific antibody according to
claim 1, which has a nucleotide sequence as shown in SEQ ID NO:
265, 267, 269, 271, 273, 275, 276, 278, 280, 282, 284 or 286.
56-58. (canceled)
59. A pharmaceutical composition, comprising the bispecific
antibody according to claim 1 and a pharmaceutically acceptable
excipient, carrier or diluent.
60. A method for preparing the bispecific antibody according to m
claim 1, comprising: (a) obtaining a fusion gene of the bispecific
antibody to construct an expression vector of the bispecific
antibody; (b) transfecting the expression vector into a host cell
by a genetic engineering method; (c) culturing the host cell under
conditions that allow the bispecific antibody to be generated; and
(d) separating and purifying the generated bispecific antibody;
wherein the expression vector in step (a) is one or more selected
from plasmids, bacteria, and viruses, and preferably the expression
vector is a pCDNA3.4 vector; wherein the host cell into which the
constructed vector is transfected by the genetic engineering method
in step (b) comprises a prokaryotic cell, a yeast or a mammalian
cell, such as a CHO cell, an NS0 cell or another mammalian cell,
preferably a CHO cell; and wherein the bispecific antibody is
separated and purified in step (d) by a conventional immunoglobulin
purification method comprising protein A affinity chromatography
and ion exchange, hydrophobic chromatography or molecular
sieve.
61. (canceled)
62. A method for enhancing or stimulating an immune response or
function, comprising administering to a patient, subject or
individual a therapeutically effective amount of the bispecific
antibody of claim 1.
63. A method for treating, delaying development, or reducing/or
inhibiting recurrence of a tumor, comprising: giving or
administering an effective amount of the bispecific antibody of
claim 1 to an individual suffering from cancer, wherein the cancer
comprises mesothelioma, squamous cell carcinoma, myeloma,
osteosarcoma, glioblastoma, neuroglioma, malignant epithelial
tumours, adenocarcinoma, melanoma, sarcoma, acute and chronic
leukemia, lymphoma and meningioma, Hodgkin's lymphoma, Sezary
syndrome, multiple myeloma, lung cancer, non-small cell lung
cancer, small cell lung cancer, laryngeal cancer, breast cancer,
head and neck cancer, bladder cancer, uterine cancer, skin cancer,
prostate cancer, cervical cancer, vaginal cancer, gastric cancer,
renal cell carcinoma, renal carcinoma, pancreatic cancer,
colorectal cancer, endometrial carcinoma, esophageal carcinoma,
hepatobiliary cancer, bone cancer, skin cancer and blood cancer,
and carcinoma of nasal cavity and sinus, nasopharyngeal carcinoma,
oral cancer, oropharyngeal cancer, laryngeal cancer, sublaryngeal
cancer, salivary cancer, mediastinal cancer, cervical cancer, small
intestine cancer, colon cancer, cancer of rectum and anal regions,
ureter cancer, urethral cancer, penile cancer, testicular cancer,
vulva cancer, cancer of endocrine system, cancer of central nervous
system, and plasmocytoma.
Description
CROSS-REFERENCE TO RELATED APPLICATION(S)
[0001] This application claims priority to Chinese patent
application No. CN 201811294887.4 filed on Nov. 1, 2018, the
disclosure of which is incorporated herein by reference in its
entirety.
TECHNICAL FIELD
[0002] The present disclosure relates to the field of immunology
and, more specifically, to an anti-CD3 bispecific antibody that
mediates T-cell killing and the use of such an antibody,
particularly in the use thereof for the treatment of cancer.
BACKGROUND
[0003] In 1985, the concept of killing tumor cells using T cells
was proposed (Stearz U D et al., Nature, 314: 628-631, 1985). It is
generally believed that the effective activation of T cells
requires a dual signal, in which the first signal comes from the
binding of the MHC-antigen complex to the T-cell receptor TCR-CD3
on the antigen-presenting cell and the second signal is a
non-antigen-specific costimulatory signal resulting from the
interaction of the T cell with a costimulatory molecule expressed
by the antigen-presenting cell. Due to the down-regulated
expression or even the deletion of MHC on the surface of most tumor
cells, the tumor cells can escape the immune killing.
[0004] The bispecific antibodies can be classified according to the
action mechanism into dual signal blocking type and cell-mediated
functional type. Generally, the cell-mediated functional bispecific
antibody refers to the anti-CD3 bispecific antibody that mediates
the T-cell killing. The CD3 molecule is expressed on the surface of
all mature T cells, and non-covalently binds to the TCR to form an
intact TCR-CD3 complex, which jointly participates in the immune
response to antigen stimulation and is the most used and the most
successful trigger molecule on the surface of immune effector cells
among bispecific antibodies. The bispecific antibody targeting CD3
can bind to the T cell surface CD3 and the tumor cell surface
antigen, respectively, thus shortening the distance between
cytotoxic T cells (Tc or CTL) and tumor cells and directly
activating T cells to induce T cells to directly kill cancer cells
instead of relying on the conventional dual activation signal of T
cells. However, the agonistic antibody targeting the T cell antigen
CD3, for example, the first generation of mouse monoclonal antibody
OKT3 targeting human CD3 applied to the clinical practice (Kung P
et al., Science, 206: 347-349, 1979), releases a large number of
inflammatory factors such as interleukin-2 (IL-2), TNF-.alpha.,
IFN-.gamma., and interleukin-6 (IL-6) due to the hyperactivation of
T cells, which clinically causes a severe "cytokine storm syndrome"
(Hirsch R et al., J. Immunol., 142: 737-743, 1989) and thus
resulting in "influenza-like" symptoms characterized by fever,
chills, headache, nausea, vomiting, diarrhea, respiratory distress,
aseptic meningitis, and hypotension. Thus, how to attenuate or
avoid the excessive cytokine storm is a priority for the
development of bifunctional antibodies targeting CD3.
[0005] In recent years, to solve the problem of correctly
assembling two different half-antibodies, scientists have designed
and developed bispecific antibodies of various structures. Overall,
there are two categories. The one is that the bispecific antibody
does not include an Fc region. The advantages of bispecific
antibodies in such a structure are that they have a small molecular
weight, can be expressed in prokaryotic cells, and do not need to
be correctly assembled, while their disadvantages are that due to
the lack of the antibody Fc fragment and the relatively low
molecular weight, they have a short half-life period and that such
bispecific antibodies are highly susceptible to polymerization, and
thus have poor stability and low expression, and thus are limited
in the clinical application. Such bispecific antibodies that have
been reported so far include BiTE, DART, TrandAbs, bi-Nanobody,
etc.
[0006] The other is that the bispecific antibody retains an Fc
domain. Such bispecific antibodies form an IgG-like structure with
a larger molecular structure and have a longer half-life period due
to the FcRn-mediated endocytosis and recycling process; meanwhile,
they also retain some or all of the Fc-mediated effector functions,
such as antibody-dependent cell-mediated cytotoxicity (ADCC),
complement-dependent cytotoxicity (CDC), and antibody-dependent
cellular phagocytosis (ADCP). Such bispecific antibodies that have
been reported so far include Triomabs, kih IgG, Cross-mab, orthoFab
IgG, DVD IgG, IgG scFv, scFv2-Fc, etc. As for anti-CD3 bispecific
antibodies, currently, except for configurations TandAb and
scFv-Fv-scFv, other anti-CD3 bispecific antibodies are widely
designed in the form of univalent anti-CD3, mainly because bivalent
anti-CD3 bispecific antibodies can easily lead to hyperactivation
and thus induce T cell apoptosis and massive transient release of
cytokines (Kuhn C et al, Immunotherapy, 8: 889-906, 2016) and, more
seriously, they may also trigger non-antigen-dependent activation
of T cells and thus disrupt immune homeostasis. Therefore, most of
the anti-CD3 bispecific antibodies in the existing art avoid the
introduction of bivalent anti-CD3 antibodies. For example,
bispecific antibodies in configurations of triFab-Fc, DART-Fc, and
BiTE-Fc are designed asymmetrically (that is, heterodimer-type
bispecific antibodies) (Z Wu et al, Pharmacology and Therapeutics,
182: 161-175, 2018), but such a design poses many challenges for
downstream production of such heterodimeric bispecific antibodies,
such as the generation of undesired homodimers or mismatched
impurity molecules, which increase the difficulty of expression and
purification of bispecific antibodies. Although the use of the
"knobs-into-holes" technique to some extent solves the problem of
inter-heavy chain mismatching of heterodimeric bispecific antibody
molecules, "light chain/heavy chain mismatching" brings about
another challenge. One strategy for preventing heavy chain-light
chain mismatching is to interchange the partial domains of the
light chain and heavy chain of one of Fabs of a bispecific antibody
to form a Crossmab (a hybrid antibody), which can allow selective
pairing between the light chains/heavy chains. However, the
disadvantages of this method are that the generation of mismatching
products cannot be completely prevented, and residual fractions of
any mismatching molecule are difficult to separate from the
products, and in addition, this method requires a large number of
genetic engineering modifications such as mutations for two
antibody sequences. Thus, this method cannot become simple and
universal.
[0007] Furthermore, for bispecific antibodies including
CD3-specific IgG-like structures, such bispecific antibodies may
cause unrestricted long-lasting T-cell activation due to their
ability to bind to Fc.gamma.R, and such activation is non-target
cell-restricted, that is, activated T-cells can be found in tissues
expressing Fc.gamma.R (e.g., in hematopoietic, lymphoid, and
reticuloendothelial systems), whether or not such bispecific
antibodies bind to the target antigen. The systemic activation of
such T cells will be accompanied by a substantial release of
cytokines, which is a serious adverse effect during the therapeutic
application of T cells-activated cytokines or antibodies.
Therefore, such anti-CD3 bispecific antibodies that mediate the T
cell killing need to avoid Fc-mediated systemic activation of T
cells, thus allowing immune effector cells to be restrictedly
activated within target cell tissues, that is, relying exclusively
on the binding of the bispecific antibodies to the corresponding
target antigens.
[0008] Therefore, there is an urgent need in the art to develop
novel bispecific molecules with improved properties in terms of
product half-life period, stability, safety, and
productibility.
SUMMARY
[0009] An object of the present disclosure is to provide a
tetravalent homodimer-type bispecific antibody molecule targeting
immune effector cell antigen CD3 and a tumor-associated antigen
(TAA). Such a bispecific antibody can significantly inhibit or kill
tumor cells in vivo, but has significantly reduced non-specific
killing effect for normal cells with low TAA expression, and
meanwhile has controlled toxic side effects that may be caused by
excessive activation of effector cells, and significantly improved
physicochemical and in vivo stabilities.
[0010] In a first aspect of the present disclosure, provided is a
bispecific antibody which is a tetravalent homodimer formed by two
identical polypeptide chains that bind to each other by a covalent
bond, wherein each of the two identical polypeptide chains
includes, in sequence from N-terminus to C-terminus, a first
single-chain Fv that specifically binds to a tumor-associated
antigen (anti-TAA scFv), a second single-chain Fv that specifically
bind to effector cell antigen CD3 (anti-CD3 scFv), and an Fc
fragment; wherein the first and the second single-chain Fvs are
linked by a linker peptide, the second single-chain Fv and the Fc
fragment are linked directly or by a linker peptide, and the Fc
fragment does not have effector functions.
[0011] The first single-chain Fv has specificity to the
tumor-associated antigen and includes a VH domain and a VL domain
linked by a linker peptide (L1), wherein VH, L1, and VL are
arranged in the order of VH-L1-VL or VL-L1-VH, and the amino acid
sequence of the linker peptide L1 is (GGGGX).sub.n, wherein X
includes Ser or Ala, preferably Ser, and n is a natural number of 1
to 5, preferably 3; Illustratively, the tumor-associated antigen
includes, but is not limited to, CD19, CD20, CD22, CD25, CD30,
CD33, CD38, CD39, CD40, CD47, CD52, CD73, CD74, CD123, CD133,
CD138, BCMA, CA125, CEA, CS1, DLL3, DLL4, EGFR, EpCAM, FLT3, gpA33,
GPC-3, Her2, MEGE-A3, NYESO1, PSMA, TAG-72, CIX, folate-binding
protein, GD2, GD3, GM2, VEGF, VEGFR2, VEGFR3, Cadherin, Integrin,
Mesothelin, Claudin18, .alpha.V.beta.3, .alpha.5.beta.1, ERBB3,
c-MET, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, B7 protein family,
Mucin, FAP, and Tenascin; preferably, the tumor-associated antigen
is CD19, CD20, CD22, CD30, CD38, BCMA, CS1, EpCAM, CEA, Her2, EGFR,
CA125, Mucin1, GPC-3, and Mesothelin.
[0012] For example, some preferred amino acid sequences of the VH
domain and its complementary determining regions (HCDR1, HCDR2, and
HCDR3) and amino acid sequences of the VL domain and its
complementary determining regions (LCDR1, LCDR2 and LCDR3) of a
first single-chain Fv targeting the tumor-associated antigen are
exemplified in Table 6-1 of the present disclosure.
[0013] Preferably, the first single-chain Fv specifically binds to
CD19 and is selected from the group consisting of: [0014] (i) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
9, 10, and 11, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 9, 10, and 11; and a VL domain comprising
LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 12, 13, and 14,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
12, 13, and 14; [0015] (ii) a VH domain comprising HCDR1, HCDR2,
and HCDR3 as shown in SEQ ID NOs: 17, 18, and 19, respectively or
having sequences that are substantially identical to (for example,
are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 17, 18, and
19; and a VL domain comprising LCDR1, LCDR2, and LCDR3 as shown in
SEQ ID NOs: 20, 21, and 22, respectively or having sequences that
are substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 20, 21, and 22; [0016] (iii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 25, 26,
and 27, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) any
of SEQ ID NOs: 25, 26, and 27; and a VL domain comprising LCDR1,
LCDR2, and LCDR3 as shown in SEQ ID NOs: 28, 29, and 30,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
28, 29, and 30; and [0017] (iv) a VH domain comprising HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 33, 34, and 35,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
33, 34, and 35; and a VL domain comprising LCDR1, LCDR2, and LCDR3
as shown in SEQ ID NOs: 36, 37, and 38, respectively or having
sequences that are substantially identical to (for example, are at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 36, 37, and
38.
[0018] Preferably, the first single-chain Fv specifically binds to
CD20 and is selected from the group consisting of: [0019] (i) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
41, 42, and 43, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 41, 42, and 43; and a VL domain comprising
LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 44, 45, and 46,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
44, 45, and 46; [0020] (ii) a VH domain comprising HCDR1, HCDR2,
and HCDR3 as shown in SEQ ID NOs: 49, 50, and 51, respectively or
having sequences that are substantially identical to (for example,
are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 49, 50, and
51; and a VL domain comprising LCDR1, LCDR2, and LCDR3 as shown in
SEQ ID NOs: 52, 53, and 54, respectively or having sequences that
are substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 52, 53, and 54; [0021] (iii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 57, 58,
and 59, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) any
of SEQ ID NOs: 57, 58, and 59; and a VL domain comprising LCDR1,
LCDR2, and LCDR3 as shown in SEQ ID NOs: 60, 61, and 62,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
60, 61, and 62; and [0022] (iv) a VH domain comprising HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 65, 66, and 67,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
65, 66, and 67; and a VL domain comprising LCDR1, LCDR2, and LCDR3
as shown in SEQ ID NOs: 68, 69, and 70, respectively or having
sequences that are substantially identical to (for example, are at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 68, 69, and
70.
[0023] Preferably, the first single-chain Fv specifically binds to
CD22 and is selected from the group consisting of: [0024] (i) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
73, 74, and 75, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 73, 74, and 75; and a VL domain comprising
LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 76, 77, and 78,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
76, 77, and 78; and [0025] (ii) a VH domain comprising HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 81, 82, and 83,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
81, 82, and 83; and a VL domain comprising LCDR1, LCDR2, and LCDR3
as shown in SEQ ID NOs: 84, 85, and 86, respectively or having
sequences that are substantially identical to (for example, are at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 84, 85, and
86.
[0026] Preferably, the first single-chain Fv specifically binds to
CD30 and is selected from the group consisting of: [0027] (i) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
89, 90, and 91, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 89, 90, and 91; and a VL domain comprising
LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 92, 93, and 94,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
92, 93, and 94; and [0028] (ii) a VH domain comprising HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 97, 98, and 99,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
97, 98, and 99; and a VL domain comprising LCDR1, LCDR2, and LCDR3
as shown in SEQ ID NOs: 100, 101, and 102, respectively or having
sequences that are substantially identical to (for example, are at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
have one or more amino acid substitutions (for example,
conservative substitutions) than) any of SEQ ID NOs: 100, 101, and
102.
[0029] Preferably, the first single-chain Fv specifically binds to
EpCAM and is selected from the group consisting of: [0030] (i) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
105, 106, and 107, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 105, 106, and 107; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 108,
109, and 110, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 108, 109, and 110; and [0031] (ii) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
113, 114, and 115, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 113, 114, and 115; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 116,
117, and 118, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 116, 117, and 118.
[0032] Preferably, the first single-chain Fv specifically binds to
CEA and is selected from the group consisting of: [0033] (i) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
121, 122, and 123, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 121, 122, and 123; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 124,
125, and 126, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 124, 125, and 126; [0034] (ii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 129,
130, and 131, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 129, 130, and 131; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 132,
133, and 134, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 132, 133, and 134; and [0035] (iii) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
137, 138, and 139, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 137, 138, and 139; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 140,
141, and 142, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 140, 141, and 142.
[0036] Preferably, the first single-chain Fv specifically binds to
Her2 and is selected from the group consisting of: [0037] (i) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
145, 146, and 147, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 145, 146, and 147; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 148,
149, and 150, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 148, 149, and 150; [0038] (ii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 153,
154, and 155, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 153, 154, and 155; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 156,
157, and 158, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 156, 157, and 158; and [0039] (iii) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
161, 162, and 163, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 161, 162, and 163; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 164,
165, and 166, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 164, 165, and 166.
[0040] Preferably, the first single-chain Fv specifically binds to
EGFR and is selected from the group consisting of: [0041] (i) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
169, 170, and 171, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 169, 170, and 171; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 172,
173, and 174, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 172, 173, and 174; [0042] (ii) a VH domain
comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 177,
178, and 179, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 177, 178, and 179; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 180,
181, and 182, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 180, 181, and 182; and [0043] (iii) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
185, 186, and 187, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 185, 186, and 187; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 188,
189, and 190, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 188, 189, and 190.
[0044] Preferably, the first single-chain Fv specifically binds to
GPC-3; the VH domain of the first single-chain Fv includes HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 193, 194, and 195,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
193, 194, and 195; and the VL domain of the first single-chain Fv
includes LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 196, 197,
and 198, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) any
of SEQ ID NOs: 196, 197, and 198.
[0045] Preferably, the first single-chain Fv specifically binds to
Mesothelin; the VH domain of the first single-chain Fv includes
HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 201, 202, and 203,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
201, 202, and 203; and the VL domain of the first single-chain Fv
includes LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 204, 205,
and 206, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) any
of SEQ ID NOs: 204, 205, and 206.
[0046] Preferably, the first single-chain Fv specifically binds to
Mucin1 and is selected from the group consisting of: [0047] (i) a
VH domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID
NOs: 209, 210, and 211, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 209, 210, and 211; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 212,
213, and 214, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 212, 213, and 214; and [0048] (ii) a VH
domain comprising HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs:
217, 218, and 219, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 217, 218, and 219; and a VL domain
comprising LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 220,
221, and 222, respectively or having sequences that are
substantially identical to (for example, are at least 80%, 85%,
90%, 92%, 95%, 97%, 98%, 99% or more similar to or have one or more
amino acid substitutions (for example, conservative substitutions)
than) any of SEQ ID NOs: 220, 221, and 222.
[0049] Preferably, the first single-chain Fv specifically binds to
CA125; the VH domain of the first single-chain Fv includes HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 225, 226, and 227,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
225, 226, and 227; and the VL domain of the first single-chain Fv
includes LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 228, 229,
and 230, respectively or having sequences that are substantially
identical the (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) to
any of SEQ ID NOs: 228, 229, and 230.
[0050] Preferably, the first single-chain Fv specifically binds to
BCMA; the VH domain of the first single-chain Fv includes HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 233, 234, and 235,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) any of SEQ ID NOs:
233, 234, and 235; and the VL domain of the first single-chain Fv
includes LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 236, 237,
and 238, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) any
of SEQ ID NOs: 236, 237, and 238.
[0051] More preferably, the first single-chain Fv specifically
binds to CD19 and is selected from the group consisting of: [0052]
(i) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 15 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 15; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 16
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 16; [0053]
(ii) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 23 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 23; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 24
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 24; [0054]
(iii) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 31 or having a sequence that is substantially identical (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) to SEQ ID NO: 31; and a
VL domain comprising an amino acid sequence as shown in SEQ ID NO:
32 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 32; and
[0055] (iv) a VH domain comprising an amino acid sequence as shown
in SEQ ID NO: 39 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 39; and a VL domain comprising an amino acid sequence as
shown in SEQ ID NO: 40 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 40.
[0056] More preferably, the first single-chain Fv specifically
binds to CD20 and is selected from the group consisting of: [0057]
(i) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 47 or having a sequence that is substantially identical (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) to SEQ ID NO: 47; and a
VL domain comprising an amino acid sequence as shown in SEQ ID NO:
48 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 48; [0058]
(ii) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 55 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 55; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 56
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 56; [0059]
(iii) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 63 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 63; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 64
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 64; and
[0060] (iv) a VH domain comprising an amino acid sequence as shown
in SEQ ID NO: 71 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 71; and a VL domain comprising an amino acid sequence as
shown in SEQ ID NO: 72 or a sequence substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 72.
[0061] More preferably, the first single-chain Fv specifically
binds to CD22 and is selected from the group consisting of: [0062]
(i) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 79 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 79; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 80
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 80; and
[0063] (ii) a VH domain comprising an amino acid sequence as shown
in SEQ ID NO: 87 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 87; and a VL domain comprising an amino acid sequence as
shown in SEQ ID NO: 88 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 88.
[0064] More preferably, the first single-chain Fv specifically
binds to CD30 and is selected from the group consisting of: [0065]
(i) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 95 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 95; anda VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 96
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 96; and
[0066] (ii) a VH domain comprising an amino acid sequence as shown
in SEQ ID NO: 103 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 103; and a VL domain comprising an amino acid sequence as
shown in SEQ ID NO: 104 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 104.
[0067] More preferably, the first single-chain Fv specifically
binds to EpCAM and is selected from the group consisting of: [0068]
(i) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 111 or having a sequence that is substantially identical
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or as one or more amino acid substitutions (for
example, conservative substitutions) than) to SEQ ID NO: 111; and a
VL domain comprising an amino acid sequence as shown in SEQ ID NO:
112 or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 112; and
[0069] (ii) a VH domain comprising an amino acid sequence as shown
in SEQ ID NO: 119 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 119; and a VL domain comprising an amino acid sequence as
shown in SEQ ID NO: 120 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 120.
[0070] More preferably, the first single-chain Fv specifically
binds to CEA and is selected from the group consisting of: [0071]
(i) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 127 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 127; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 128
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 128; [0072]
(ii) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 135 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 135; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 136
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 136; and
[0073] (iii) a VH domain comprising an amino acid sequence as shown
in SEQ ID NO: 143 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 143; and a VL domain comprising an amino acid sequence as
shown in SEQ ID NO: 144 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 144.
[0074] More preferably, the first single-chain Fv specifically
binds to Her2 and is selected from the group consisting of: [0075]
(i) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 151 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 151; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 152
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 152; [0076]
(ii) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 159 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 159; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 160
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 160; and
[0077] (iii) a VH domain comprising an amino acid sequence as shown
in SEQ ID NO: 167 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 167; and a VL domain comprising an amino acid sequence as
shown in SEQ ID NO: 168 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 168.
[0078] More preferably, the first single-chain Fv specifically
binds to EGFR and is selected from the group consisting of: [0079]
(i) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 175 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 175; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 176
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 176; [0080]
(ii) a VH domain comprising an amino acid sequence as shown in SEQ
ID NO: 183 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 183; and a VL
domain comprising an amino acid sequence as shown in SEQ ID NO: 184
or having a sequence that is substantially identical to (for
example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more
similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 184; and
[0081] (iii) a VH domain comprising an amino acid sequence as shown
in SEQ ID NO: 191 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 191; and a VL domain comprising an amino acid sequence as
shown in SEQ ID NO: 192 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 192.
[0082] More preferably, the first single-chain Fv specifically
binds to GPC-3; the VH domain of the first single-chain Fv includes
an amino acid sequence as shown in SEQ ID NO: 199 or having a
sequence that is substantially identical to (for example, is at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
has one or more amino acid substitutions (for example, conservative
substitutions) than) SEQ ID NO: 199; and the VL domain of the first
single-chain Fv includes an amino acid sequence as shown in SEQ ID
NO: 200 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 200.
[0083] More preferably, the first single-chain Fv specifically
binds to Mesothelin; the VH domain of the first single-chain Fv
includes an amino acid sequence as shown in SEQ ID NO: 207 or
having a sequence that is substantially identical to (for example,
is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar
to or has one or more amino acid substitutions (for example,
conservative substitutions) than) SEQ ID NO: 207; and the VL domain
of the first single-chain Fv includes an amino acid sequence as
shown in SEQ ID NO: 208 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 208.
[0084] More preferably, the first single-chain Fv specifically
binds to Mucin1 and is selected from the group consisting of:
[0085] (i) a VH domain comprising an amino acid sequence as shown
in SEQ ID NO: 215 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 215; and a VL domain comprising an amino acid sequence as
shown in SEQ ID NO: 216 or having a sequence that is substantially
identical to (for example, is at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or has one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NO: 216; and [0086] (ii) a VH domain comprising an amino acid
sequence as shown in SEQ ID NO: 223 or having a sequence that is
substantially identical to (for example, is at least 80%, 85%, 90%,
92%, 95%, 97%, 98%, 99% or more similar to or has one or more amino
acid substitutions (for example, conservative substitutions) than)
SEQ ID NO: 223; and a VL domain comprising an amino acid sequence
as shown in SEQ ID NO: 224 or having a sequence that is
substantially identical to (for example, is at least 80%, 85%, 90%,
92%, 95%, 97%, 98%, 99% or more similar to or has one or more amino
acid substitutions (for example, conservative substitutions) than)
SEQ ID NO: 224.
[0087] More preferably, the first single-chain Fv specifically
binds to CA125; the VH domain of the first single-chain Fv includes
an amino acid sequence as shown in SEQ ID NO: 231 or having a
sequence that is substantially identical to (for example, is at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
has one or more amino acid substitutions (for example, conservative
substitutions) than) SEQ ID NO: 231; and the VL domain of the first
single-chain Fv includes an amino acid sequence as shown in SEQ ID
NO: 232 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 232.
[0088] More preferably, the first single-chain Fv specifically
binds to BCMA; the VH domain of the first single-chain Fv includes
an amino acid sequence as shown in SEQ ID NO: 239 or having a
sequence that is substantially identical to (for example, is at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
has one or more amino acid substitutions (for example, conservative
substitutions) than) SEQ ID NO: 239; and the VL domain of the first
single-chain Fv includes an amino acid sequence as shown in SEQ ID
NO: 240 or having a sequence that is substantially identical to
(for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or
more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 240.
[0089] The linker peptide (L2) connecting the first single-chain Fv
and the second single-chain Fv in the present disclosure consists
of a flexible peptide and a rigid peptide.
[0090] Furthermore, the flexible peptide includes two or more amino
acids that are preferably selected from the group consisting of the
following amino acids: Gly(G), Ser(S), Ala(A), and Thr(T). More
preferably, the flexible peptide includes G and S residues. Most
preferably, the amino acid composition structure of the flexible
peptide has a general formula G.sub.xS.sub.y(GGGGS).sub.z, where x,
y, and z are integers greater than or equal to 0, and x+y+z >1.
For example, in a preferred embodiment, the amino acid sequence of
the flexible peptide is G.sub.2(GGGGS).sub.3.
[0091] Furthermore, the rigid peptide is derived from a full-length
sequence (as shown in SEQ ID NO: 257) consisting of amino acids at
positions 118 to 145 of the carboxy-terminus of the natural human
chorionic gonadotropin beta-subunit, or a truncated fragment
thereof (hereinafter collectively referred to as CTP). Preferably,
the CTP rigid peptide includes 10 amino acids at the N-terminal of
SEQ ID NO: 257, that is, SSSSKAPPPS (CTP.sup.1); or the CTP rigid
peptide includes 14 amino acids at the C-terminal of SEQ ID NO:
257, that is, SRLPGPSDTPILPQ (CTP.sup.2); as another example, in
another embodiment, the CTP rigid peptide includes 16 amino acids
at the N-terminal of SEQ ID NO: 257, that is, SSSSKAPPPSLPSPSR
(CTP.sup.3); for another example, in another embodiment, the CTP
rigid peptide includes 28 amino acids that begin at the position
118 and end at position 145 of the human chorionic gonadotropin
beta-subunit, that is, SSSSKAPPPSLPSPSRLPGPSDTPILPQ
(CTP.sup.4).
[0092] For example, some preferred amino acid sequences of the
linker peptide L2 that links the first single-chain Fv and second
single-chain Fv are exemplified listed in Table 6-3 of the present
disclosure.
[0093] In a preferred embodiment of the present disclosure, the
linker peptide has an amino acid sequence as shown in SEQ ID NO:
258, wherein the amino acid composition of the flexible peptide is
G.sub.2(GGGGS).sub.3, and the amino acid composition of the rigid
peptide is SSSSKAPPPS (that is, CTP.sup.1).
[0094] The second single-chain Fv has specificity to immune
effector cell antigen CD3 and includes a VH domain and a VL domain
linked by a linker peptide (L3), wherein VH, L3, and VL are
arranged in the order of VH-L3-VL or VL-L3-VH, and the amino acid
sequence of the linker peptide L3 is (GGGGX).sub.n, wherein X
includes Ser or Ala, preferably Ser; and n is a natural number of 1
to 5, preferably 3;
[0095] Preferably, the second single-chain Fv of the bispecific
antibody binds to an effector cell at an EC.sub.50 value greater
than about 50 nM, or greater than 100 nM, or greater than 300 nM,
or greater than 500 nM in an in vitro FACS binding affinity assay;
more preferably, the second single-chain Fv of the bispecific
antibody not only binds to human CD3, but also specifically binds
to CD3 of a cynomolgus monkey or a rhesus monkey. In a preferred
embodiment of the present disclosure, the bispecific antibody
specifically binds to the effector cell at an EC.sub.50 value of
132.3 nM.
[0096] For example, some preferred amino acid sequences of the VH
domain and its complementary determining regions (HCDR1, HCDR2, and
HCDR3) and amino acid sequences of the VL domain and its
complementary determining regions (LCDR1, LCDR2 and LCDR3) of the
anti-CD3 scFv are exemplified in Table 6-2 of the present
disclosure.
[0097] Preferably, the second single-chain Fv specifically binds to
CD3; the VH domain of the second single-chain Fv includes HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 241, 242, and 243,
respectively or having sequences that are substantially identical
to (for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%,
99% or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) SEQ ID NOs: 241,
242, and 243; and the VL domain of the second single-chain Fv
includes LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 244, 245,
and 246, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NOs: 244, 245, and 246.
[0098] Preferably, the second single-chain Fv specifically binds to
CD3; the VH domain of the second single-chain Fv includes HCDR1,
HCDR2, and HCDR3 as shown in SEQ ID NOs: 249, 250, and 251,
respectively or having sequences are substantially identical to
(for example, are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99%
or more similar to or have one or more amino acid substitutions
(for example, conservative substitutions) than) SEQ ID NOs: 249,
250, and 251; and the VL domain of the second single-chain Fv
includes LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 252, 253,
and 254, respectively or having sequences that are substantially
identical to (for example, are at least 80%, 85%, 90%, 92%, 95%,
97%, 98%, 99% or more similar to or have one or more amino acid
substitutions (for example, conservative substitutions) than) SEQ
ID NOs: 252, 253, and 254.
[0099] More preferably, the second single-chain Fv specifically
binds to CD3; the VH domain of the second single-chain Fv includes
an amino acid sequence as shown in SEQ ID NO: 247 or having a
sequence that is substantially identical to (for example, is at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
has one or more amino acid substitutions (for example, conservative
substitutions) than) SEQ ID NO: 247; and the VL domain of the
second single-chain Fv includes an amino acid sequence as shown in
SEQ ID NO: 248 or having a sequence that is substantially identical
to (for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99%
or more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 248.
[0100] More preferably, the second single-chain Fv specifically
binds to CD3; the VH domain of the second single-chain Fv includes
an amino acid sequence as shown in SEQ ID NO: 255 or having a
sequence that is substantially identical to (for example, is at
least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more similar to or
has one or more amino acid substitutions (for example, conservative
substitutions) than) SEQ ID NO: 255; and the VL domain of the
second single-chain Fv includes an amino acid sequence as shown in
SEQ ID NO: 256 or having a sequence that is substantially identical
to (for example, is at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99%
or more similar to or has one or more amino acid substitutions (for
example, conservative substitutions) than) SEQ ID NO: 256.
[0101] The Fc fragment of the present disclosure is linked to the
second single-chain Fv directly or by the linker peptide L4, and
the linker peptide L4 includes 1 to 20 amino acids, and preferably
selected from the following amino acids: Gly(G), Ser(S), Ala(A),
and Thr(T); more preferably, the linker peptide L4 is selected from
Gly(G) and Ser(S); further preferably, the linker peptide L4
consists of (GGGGS).sub.n, wherein n=1, 2, 3 or 4. In a preferred
embodiment of the present disclosure, the Fc fragment is directly
linked to the second single-chain Fv.
[0102] In another aspect, the Fc fragment of the present disclosure
includes a hinge region, a CH2 domain, and a CH3 domain from a
human immunoglobulin heavy chain constant region. For example, in
some embodiments, the Fc fragment of the present disclosure is
selected from heavy chain constant regions of human IgG1, IgG2,
IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE; particularly selected
from heavy chain constant regions of human IgG1, IgG2, IgG3, and
IgG4, and more particularly selected from a heavy chain constant
region of human IgG1 or IgG4; and the Fc fragment has one or more
amino acid substitutions, deletions or additions (for example, at
most 20, at most 15, at most 10, or at most 5 substitutions,
deletions or additions) than a natural sequence from which the Fc
fragment is derived.
[0103] In some preferred embodiments, the Fc fragment is changed,
for example, mutated to modify the properties of the bispecific
antibody molecule of the present disclosure (for example, to change
one or more of the following properties: Fc receptor binding,
antibody glycosylation, an effector cell function or a complement
function).
[0104] For example, the bispecific antibody provided by the present
disclosure includes an Fc variant containing amino acid
substitutions, deletions or additions that change (for example,
reduce or eliminate) effector functions. Fc region of the antibody
mediates several important effector functions, such as ADCC, ADCP,
and CDC. Methods for changing the affinity of the antibody to an
effector ligand (such as Fc.gamma.R or a complement C1q) by
substituting amino acid residues in the Fc region of the antibody
to change the effector functions are known in the art (see, for
example, EP 388151A1; U.S. Pat. Nos. 5,648,260; 5,624,821; Natsume
A et al., Cancer Res., 68: 3863-3872, 2008; Idusogie E E et al., J.
Immunol., 166: 2571-2575, 2001; Lazar G A et al., PNAS, 103:
4005-4010, 2006; Shields R L et al., JBC, 276: 6591-6604, 2001;
Stavenhagen J B et al., Cancer Res., 67: 8882-8890, 2007;
Stavenhagen J B et al., Advan. Enzyme. Regul., 48: 152-164, 2008;
Alegre M L et al., J. Immunol., 148: 3461-3468, 1992; Kaneko E et
al., Biodrugs, 25: 1-11, 2011). In some preferred embodiments of
the present disclosure, amino acid L235 (EU numbering) in the
constant region of the antibody is modified to change an
interaction with an Fc receptor, such as L235E or L235A. In some
other preferred embodiments, amino acids 234 and 235 in the
constant region of the antibody are modified simultaneously, such
as L234A and L235A (L234A/L235A) (EU numbering).
[0105] For example, the bispecific antibody provided by the present
disclosure may include an Fc variant containing amino acid
substitutions, deletions or additions that extend a circulating
half-life. Studies show that M252Y/S254T/T256E, M428L/N434S or
T250Q/M428L can extend the half-life of the antibody in primates.
For more mutation sites included in the Fc variant with enhanced
binding affinity to a neonatal receptor (FcRn), see Chinese
invention patent CN 201280066663.2, U.S. 2005/0014934A1, WO
97/43316, U.S. Pat. Nos. 5,869,046, 5,747,030 and WO 96/32478. In
some preferred embodiments of the present disclosure, amino acid
M428 (EU numbering) in the constant region of the antibody is
modified to enhance the binding affinity for the FcRn receptor,
such as M428L. In some other preferred embodiments, amino acids 250
and 428 (EU numbering) in the constant region of the antibody are
modified simultaneously, such as T250Q and M428L (T250Q/M428L).
[0106] For example, the bispecific antibody provided by the present
disclosure may also include an Fc variant containing amino acid
substitutions, deletions or additions that may reduce or eliminate
Fc glycosylation. For example, the Fc variant contains reduced
glycosylation of the N-linked glycan normally present at amino acid
site 297 (EU numbering). The glycosylation at position N297 has a
great effect on the activity of IgG. If the glycosylation at this
position is eliminated, the conformation of the upper half of CH2
of an IgG molecule is affected, thus losing the ability of binding
to Fc.gamma.Rs and affecting the biological activity related to the
antibody. In some preferred embodiments of the present disclosure,
amino acid N297 (EU numbering) in the constant region of human IgG
is modified to avoid the glycosylation of the antibody, such as
N297A.
[0107] For example, the bispecific antibody provided by the present
disclosure may also include an Fc variant containing amino acid
substitutions, deletions or additions that eliminate charge
heterogeneity. Various post-translational modifications during
expression in engineered cells will cause the charge heterogeneity
of monoclonal antibodies. The heterogeneity of lysine at C-terminus
of an IgG antibody is one of the main reasons for charge
heterogeneity. Lysine K at C-terminus of a heavy chain may be
deleted at a certain proportion during the production of the
antibody, resulting in charge heterogeneity and affecting the
stability, effectiveness, immunogenicity or pharmacokinetic of the
antibody. In some preferred embodiments of the present disclosure,
K447 (EU numbering) at the C-terminus of the IgG antibody is
removed or deleted to eliminate the charge heterogeneity of the
antibody and improve the homogeneity of the expressed product.
[0108] The amino acid sequences of some preferred Fc fragments are
exemplarily listed in Table 6-4 of the present disclosure. Compared
with a bispecific antibody containing the Fc region of wild-type
human IgG, the bispecific antibody provided by the present
disclosure contains an Fc fragment that exhibits reduced affinity
for at least one of human Fc.gamma.Rs (Fc.gamma.RI, Fc.gamma.RIIa,
or Fc.gamma.RIIIa) and C1q, and has reduced effector cell functions
or complement functions. For example, in a preferred embodiment of
the present disclosure, the bispecific antibody includes an Fc
fragment that is derived from human IgG1, has L234A and L235A
substitutions (L234A/L235A), and exhibits reduced binding ability
for Fc.gamma.RI. In addition, the Fc fragment included in the
bispecific antibody provided by the present disclosure may also
contain amino acid substitutions that change one or more other
properties (e.g., ability of binding to the FcRn receptor, the
glycosylation of the antibody or the charge heterogeneity of the
antibody). For example, in a preferred embodiment of the present
disclosure, the Fc fragment has an amino acid sequence as shown in
SEQ ID NO: 263, which has amino acid substitutions
L234A/L235A/T250Q/N297A/P331S/M428L and a deleted or removed K447
compared with the native sequence from which it is derived.
[0109] The bispecific antibody molecule of the present disclosure
is a tetravalent homodimer formed by two identical polypeptide
chains that bind to each other by an interchain disulfide bond in
the hing region of the Fc fragment, wherein each polypeptide chain
consists of, in sequence from N-terminus to C-terminus, an anti-TAA
scFv, a linker peptide, an anti-CD3 scFv, and an Fc fragment.
[0110] For example, the amino acid sequences of some preferred
bispecific antibodies are exemplified in Table 6-5 of the present
disclosure.
[0111] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human CD19 and CD3 and has an amino
acid sequence as follows: [0112] (i) a sequence as shown in SEQ ID
NO: 264; [0113] (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 264; or [0114] (iii) a sequence with at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% or 100% sequence identity relative to the sequence as
shown in SEQ ID NO: 264;
[0115] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0116] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human CD19 and CD3 and has an amino
acid sequence as follows: [0117] (i) a sequence as shown in SEQ ID
NO: 283; [0118] (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 283; or [0119] (iii) a sequence with at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% or 100% sequence identity to the sequence as shown in
SEQ ID NO: 283.
[0120] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0121] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human CD20 and CD3 and has an amino
acid sequence as follows: [0122] (i) a sequence as shown in SEQ ID
NO: 266; [0123] (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 266; or [0124] (iii) a sequence with at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% or 100% sequence identity to the sequence as shown in
SEQ ID NO: 266.
[0125] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0126] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human CD22 and CD3 and has an amino
acid sequence as follows: [0127] (i) a sequence as shown in SEQ ID
NO: 268; [0128] (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 268; or [0129] (iii) a sequence with at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% or 100% sequence identity to the sequence as shown in
SEQ ID NO: 268.
[0130] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0131] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human CD30 and CD3 and has an amino
acid sequence as follows: [0132] (i) a sequence as shown in SEQ ID
NO: 270; [0133] (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 270; or [0134] (iii) a sequence with at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% or 100% sequence identity to the sequence as shown in
SEQ ID NO: 270.
[0135] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0136] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human EpCAM and CD3 and has an amino
acid sequence as follows: [0137] (i) a sequence as shown in SEQ ID
NO: 272; [0138] (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 272; or [0139] (iii) a sequence with at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% or 100% sequence identity to the sequence as shown in
SEQ ID NO: 272.
[0140] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0141] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human CEA and CD3 and has an amino
acid sequence as follows: [0142] (i) a sequence as shown in SEQ ID
NO: 274; [0143] (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 274; or [0144] (iii) a sequence with at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% or 100% sequence identity to the sequence as shown in
SEQ ID NO: 274.
[0145] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0146] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human Her2 and CD3 and has an amino
acid sequence as follows: [0147] (i) a sequence as shown in SEQ ID
NO: 8; [0148] (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 8; or [0149] (iii) a sequence with at least 80%, at least 85%,
at least 90%, at least 91%, at least 92%, at least 93%, at least
94%, at least 95%, at least 96%, at least 97%, at least 98%, at
least 99% or 100% sequence identity to the sequence as shown in SEQ
ID NO: 8.
[0150] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0151] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human EGFR and CD3 and has an amino
acid sequence as follows: [0152] (i) a sequence as shown in SEQ ID
NO: 277; [0153] (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 277; or [0154] (iii) a sequence with at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% or 100% sequence identity to the sequence as shown in
SEQ ID NO: 277.
[0155] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0156] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human GPC-3 and CD3 and has an amino
acid sequence as follows: [0157] (i) a sequence as shown in SEQ ID
NO: 279; [0158] (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 279; or [0159] (iii) a sequence with at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% or 100% sequence identity to the sequence as shown in
SEQ ID NO: 279.
[0160] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0161] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human Mesothelin and CD3 and has an
amino acid sequence as follows: [0162] (i) a sequence as shown in
SEQ ID NO: 281; [0163] (ii) a sequence with one or more
substitutions, deletions or additions (such as 1, 2, 3, 4 or 5
substitutions, deletions or additions) compared to the sequence as
shown in SEQ ID NO: 281; or [0164] (iii) a sequence with at least
80%, at least 85%, at least 90%, at least 91%, at least 92%, at
least 93%, at least 94%, at least 95%, at least 96%, at least 97%,
at least 98%, at least 99% or 100% sequence identity to the
sequence as shown in SEQ ID NO: 281.
[0165] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0166] In a preferred embodiment of the present disclosure, the
bispecific antibody binds to human Mucin1 and CD3 and has an amino
acid sequence as follows: [0167] (i) a sequence as shown in SEQ ID
NO: 285; [0168] (ii) a sequence with one or more substitutions,
deletions or additions (such as 1, 2, 3, 4 or 5 substitutions,
deletions or additions) compared to the sequence as shown in SEQ ID
NO: 285; or [0169] (iii) a sequence with at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% or 100% sequence identity to the sequence as shown in
SEQ ID NO: 285.
[0170] In some preferred embodiments, the substitutions in (ii) are
conservative substitutions.
[0171] In a second aspect of the present disclosure, a DNA molecule
encoding the bispecific antibody as described above is
provided.
[0172] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 265.
[0173] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 267.
[0174] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 269.
[0175] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 271.
[0176] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 273.
[0177] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 275.
[0178] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 276.
[0179] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 278.
[0180] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 280.
[0181] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 282.
[0182] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 284.
[0183] In a preferred embodiment of the present disclosure, the DNA
molecule encoding the bispecific antibody as described above is a
nucleotide sequence as shown in SEQ ID NO: 286.
[0184] In a third aspect of the present disclosure, a vector
comprising the DNA molecule as described above is provided.
[0185] In a fourth aspect of the present disclosure, a host cell
comprising the vector as described above is provided; the host cell
includes a prokaryotic cell, a yeast or a mammalian cell, such as a
CHO cell, an NS0 cell or another mammalian cell, preferably a CHO
cell.
[0186] In a fifth aspect of the present disclosure, provided is a
pharmaceutical composition, comprising the bispecific antibody as
described above and a pharmaceutically acceptable excipient,
carrier or diluent.
[0187] In a sixth aspect of the present disclosure, further
provided a method for preparing the bispecific antibody as
described in the present disclosure, comprising: (a) obtaining a
fusion gene of the bispecific antibody to construct an expression
vector of the bispecific antibody; (b) transfecting the expression
vector into a host cell by a genetic engineering method; (c)
culturing the host cell under conditions that allow the bispecific
antibody to be generated; and (d) separating and purifying the
generated bispecific antibody;
[0188] The expression vector in step (a) is one or more selected
from plasmids, bacteria, and viruses, and preferably the expression
vector is a pCDNA3.1 vector;
[0189] The host cell into which the constructed vector is
transfected by the genetic engineering method in step (b) includes
a prokaryotic cell, a yeast or a mammalian cell, such as a CHO
cell, an NS0 cell or another mammalian cell, preferably a CHO
cell.
[0190] The bispecific antibody is separated and purified in step
(d) by a conventional immunoglobulin purification method comprising
protein A affinity chromatography and ion exchange, hydrophobic
chromatography or molecular sieve.
[0191] In a seventh aspect of the present disclosure, use of the
bispecific antibody in the preparation of a medicament for the
treatment, prevention or alleviation of tumor is provided; examples
of the cancer include, but are not limited to, mesothelioma,
squamous cell carcinoma, myeloma, osteosarcoma, glioblastoma,
neuroglioma, malignant epithelial tumours, adenocarcinoma,
melanoma, sarcoma, acute and chronic leukemia, lymphoma and
meningioma, Hodgkin's lymphoma, Sezary syndrome, multiple myeloma,
lung cancer, non-small cell lung cancer, small cell lung cancer,
laryngeal cancer, breast cancer, head and neck cancer, bladder
cancer, uterine cancer, skin cancer, prostate cancer, cervical
cancer, vaginal cancer, gastric cancer, renal cell carcinoma, renal
carcinoma, pancreatic cancer, colorectal cancer, endometrial
carcinoma, esophageal carcinoma, hepatobiliary cancer, bone cancer,
skin cancer and blood cancer, and carcinoma of nasal cavity and
sinus, nasopharyngeal carcinoma, oral cancer, oropharyngeal cancer,
laryngeal cancer, sublaryngeal cancer, salivary cancer, mediastinal
cancer, stomach cancer, small intestine cancer, colon cancer,
cancer of rectum and anal regions, ureter cancer, urethral cancer,
carcinoma of penis, testicular cancer, vulva cancer, cancer of
endocrine system, cancer of central nervous system, and
plasmocytoma.
[0192] In an eighth aspect of the present disclosure, provided is
the bispecific antibody for use in a method for enhancing or
stimulating an immune response or function, comprising
administering to a patient/subject individual a therapeutically
effective amount of the bispecific antibody.
[0193] In a ninth aspect of the present disclosure, provided is the
bispecific antibody for use in a method for treating, delaying
development of, or reducing/inhibiting recurrence of a tumor,
comprising: giving or administering an effective amount of the
bispecific antibody to an individual suffering from the foregoing
disease or disorder; examples of the tumor include, but are not
limited to, mesothelioma, squamous cell carcinoma, myeloma,
osteosarcoma, glioblastoma, neuroglioma, malignant epithelial
tumours, adenocarcinoma, melanoma, sarcoma, acute and chronic
leukemia, lymphoma and meningioma, Hodgkin's lymphoma, Sezary
syndrome, multiple myeloma, lung cancer, non-small cell lung
cancer, small cell lung cancer, laryngeal cancer, breast cancer,
head and neck cancer, bladder cancer, uterine cancer, skin cancer,
prostate cancer, cervical cancer, vaginal cancer, gastric cancer,
renal cell carcinoma, renal carcinoma, pancreatic cancer,
colorectal cancer, endometrial carcinoma, esophageal carcinoma,
hepatobiliary cancer, bone cancer, skin cancer and blood cancer,
and carcinoma of nasal cavity and sinus, nasopharyngeal carcinoma,
oral cancer, oropharyngeal cancer, laryngeal cancer, sublaryngeal
cancer, salivary cancer, mediastinal cancer, cervical cancer, small
intestine cancer, colon cancer, cancer of rectum and anal regions,
ureter cancer, carcinoma of urethral cancer, carcinoma of penis,
testicular cancer, vulva cancer, cancer of endocrine system, cancer
of central nervous system, and plasmocytoma.
[0194] The technical solutions provided by the present disclosure
have beneficial effects summarized as follows:
[0195] 1. The bispecific antibody provided by the present
disclosure includes anti-TAA scFv located at the N-terminus of the
bispecific antibody and having changed spatial conformation, so
that the bispecific antibody has reduced binding ability to TAA
under some conditions, especially that the bispecific antibody is
difficult to bind to normal cells with weak expression or low
expression of TAAs, thereby exhibiting reduced non-specific killing
effect. However, the binding specificity to cells with
over-expression or high expression of TAA is not significantly
reduced, and the bispecific antibody exhibits a good killing effect
in vivo. It can be known that when a target antigen is merely
expressed on tumor cells or the bispecific antibody of the present
disclosure specifically binds to tumor cells over-expressing the
target antigen, immune effector cells are activated restrictively
and merely in target cell tissues, which can minimize the
non-specific killing of the bispecific antibody on the normal cells
and the accompanying release of cytokines and reduce the toxic side
effects of the bispecific antibody in clinical treatment.
[0196] 2. The anti-CD3 scFv selected by the bispecific antibody
provided by the present disclosure specifically binds to effector
cells with a weak binding affinity (EC.sub.50 value greater than
about 50 nM, or greater than 100 nM, or greater than 300 nM, or
greater than 500 nM). In addition, the anti-CD3 scFv is embedded
between the anti-TAA scFv and Fc, and the CTP rigid peptide
contained in the linker peptide L3 at the N-terminus and the Fc
fragment located at its C-terminus partially "cover" or "shield"
the antigen-binding domain of the anti-CD3 scFv. Such steric
hindrance effect makes the anti-CD3 scFv bind to CD3 with a weaker
binding affinity (for example, greater than 1 .mu.M), which reduces
its ability to activate and stimulate T cells, limits the excessive
release of cytokines, and provides higher safety. In addition, the
anti-CD3 scFv used in the present disclosure can bind to CD3 native
antigens from humans and cynomolgus monkeys and/or rhesus monkeys
at the same time, so that no alternative molecule needs to be
constructed for preclinical toxicology evaluation and the effective
dose, toxic dose and toxic side effects obtained are more objective
and accurate and can be directly converted into a clinical dose to
reduce the risk of clinical studies. Further, the bispecific
antibody provided by the present disclosure creatively adopts a
divalent anti-CD3 scFv, which avoids an asymmetric structure of a
heterodimer (including a monovalent anti-CD3 scFv) commonly used in
the existing art in terms of the configuration design of the
bispecific antibody and solves the problem of heavy chain
mismatches, thereby simplifying downstream purification steps.
Moreover, unexpectedly, the non-specific binding of the anti-CD3
scFv to T cells is not observed in an in vitro cell binding assay,
and the degree of cell activation (the release of cytokines such as
IL-2) is controlled within a safe and effective range. That is, the
bivalent anti-CD3 scFv structure used in the present disclosure has
not induced the over-activation of T cells in a
non-antigen-dependent manner, whereas for other bispecific
antibodies including bivalent anti-CD3 domains, the uncontrollable
over-activation of T cells is common and thus anti-CD3 bispecific
antibodies are generally designed to avoid the introduction of a
bivalent anti-CD3 structure.
[0197] 3. The modified Fc fragment included in the bispecific
antibody provided by the present disclosure has no ability of
binding to Fc.gamma.R, avoiding the systemic activation of T cells
mediated by Fc.gamma.R and allowing immune effector cells to be
activated restrictively and merely in target cell tissues.
[0198] 4. The bispecific antibody provided by the present
disclosure is homodimeric without mismatches of heavy chains and
light chains. The bispecific antibody is produced by a stable
downstream process and purified by simple and efficient steps, with
a homogeneous expression product and significantly improved
physicochemical and in vivo stability.
[0199] 5. The bispecific antibody provided by the present
disclosure has a relatively long in vivo circulating half-life due
to the inclusion of the Fc fragment. Pharmacokinetic tests show
that the in vivo circulating half-life in mice and cynomolgus
monkeys are about 40 hours and 8 hours, respectively, which will
greatly reduce a clinical administration frequency.
DETAILED DESCRIPTION
Abbreviations and Definitions
[0200] Her2 Human epidermal growth factor receptor 2 [0201] BiAb
Bispecific antibody [0202] CDR Complementarity determining region
in a variable region of an immunoglobulin, defined by a Kabat
numbering system [0203] EC.sub.50 A concentration at which 50%
efficacy or binding is generated [0204] ELISA Enzyme-linked
immunosorbent assay [0205] FR Framework region of an antibody: a
variable region of an immunoglobulin excluding CDRs [0206] HRP
Horseradish peroxidase [0207] IL-2 Interleukin 2 [0208] IFN
Interferon [0209] IC.sub.50 A concentration at which 50% inhibition
is generated [0210] IgG Immunoglobulin G [0211] Kabat
Immunoglobulin comparison and numbering system advocated by Elvin A
Kabat [0212] mAb Monoclonal antibody [0213] PCR Polymerase chain
reaction [0214] V region IgG chain fragment whose sequence is
variable for different antibodies; the V region extends to Kabat
residue 109 of a light chain and residue 113 of a heavy chain.
[0215] VH Heavy chain variable region of an immunoglobulin [0216]
VK .kappa. light chain variable region of an immunoglobulin [0217]
K.sub.D Equilibrium dissociation constant [0218] k.sub.a
Association rate constant [0219] k.sub.d Dissociation rate
constant
[0220] In the present disclosure, unless otherwise specified, the
scientific and technical terms used herein have meanings generally
understood by those skilled in the art. The antibody or fragments
thereof used in the present disclosure may be further modified
using conventional techniques known in the art alone or in
combination, such as amino acid deletion, insertion, substitution,
addition, and/or recombination and/or other modification methods. A
method for introducing such modifications into a DNA sequence of an
antibody according to the amino acid sequence of the antibody is
well known to those skilled in the art. See, for example, Sambrook,
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor
Laboratory (1989), N.Y. Such modifications are preferably performed
at a nucleic acid level. Meanwhile, for a better understanding of
the present disclosure, the definitions and explanations of related
terms are provided below.
[0221] "CD19", as known as Cluster of Differentiation 19
polypeptide, is a single channel Type I transmembrane glycoprotein
with two C2-set Ig-like (immunoglobulin-like) domains and a
relatively large cytoplasmic tail that is highly conserved among
mammalian species. CD19 is expressed in almost all B lineage cells
and follicular cells and plays an indispensable role in B
lymphocyte differentiation. It works with CD21, CD81, and CD225 as
the B cell key co-receptor. Therefore, CD19 acts as a biomarker for
B lymphocyte development, B-cell lymphoma diagnosis, and
B-lymphoblastic leukemia diagnosis. In addition, mutations in CD19
are associated with severe immunodeficiency syndromes. Indications
for CD19 targets also include other related diseases or disorders
found in the existing art or about to be discovered in the future.
The term also includes any variants, isotypes, derivatives, and
species homologues of CD19 that are naturally expressed by cells
including tumor cells or expressed by cells transfected with CD19
genes or cDNA.
[0222] "CD20", as known as Cluster of Differentiation 20
polypeptide, belongs to a four transmembrane protein and is a B
lymphocyte surface-specific differentiation antigen. It is
expressed on more than 90% of B lymphoma cells and normal B
lymphocytes but not expressed on hematopoietic stem cells, primary
B lymphocytes, normal blood cells, and other tissues, and exhibits
no significant internalization and shedding or antigen apoptosis
and change after binding to antibodies, which thus may be used as
an ideal target for treating B cell lymphoma. CD20 exerts an
anti-tumor effect mainly through the action of ADCC, CDC, etc. In
recent years, indications for CD20 targets have been developed,
including, for example, autoimmune diseases (including multiple
sclerosis (MS), Crohn's disease (CD)), inflammatory diseases (e.g.,
ulcerative colitis (UC)), and the like. Indications for CD20
targets also include other related diseases or disorders found in
the existing art or about to be discovered in the future. The term
also includes any variants, isotypes, derivatives, and species
homologues of CD20 that are naturally expressed by cells including
tumor cells or expressed by cells transfected with CD20 genes or
cDNA.
[0223] "CD22", as known as Cluster of Differentiation 22
polypeptide, has an Ig domain and is a transmembrane receptor on
the surface of mature B cells. In humans, CD22 primarily inhibits
the over-activation of B cell surface receptors and reduces the
risk of developing autoimmune diseases (e.g., systemic lupus
erythematosus). Indications associated with CD22 include, for
example, B-cell lymphoma, acute and chronic leukemia, and disorders
associated with other B-cell dysplasia and B-cell dependent
autoimmune diseases. Indications for CD22 targets also include
other related diseases or disorders found in the existing art or
about to be discovered in the future. The term also includes any
variants, isotypes, derivatives, and species homologues of CD22
that are naturally expressed by cells including tumor cells or
expressed by cells transfected with CD22 genes or cDNA.
[0224] "CD30", is a member of the tumor necrosis factor (TNF)
receptor superfamily, belongs to the Type I transmembrane
glycoprotein, and is physiologically expressed by activated T and B
lymphocytes. CD30 is mainly expressed in tumors originate from
lymph, such as all Hodgkin's lymphoma (HL), some certain B-cell
lymphomas, some certain T-cell lymphomas and NK-cell lymphomas, is
low-expressed on the surface of T-cells and B-cells activated in a
non-pathological state, and is not expressed in normal cells, and
therefore may be used as a corresponding tumor marker and an
indicator of disease diagnosis. Indications for CD30 targets also
include other related diseases or disorders found in the existing
art or about to be discovered in the future. The term also includes
any variants, isotypes, derivatives, and species homologues of CD30
that are naturally expressed by cells including tumor cells or
expressed by cells transfected with CD30 genes or cDNA.
[0225] "EpCAM (epithelial cell adhesion molecule)" is a
transmembrane glycoprotein and is one of the earliest TAAs found in
colon cancer. EpCAM is overexpressed to varying degrees in most
human tumors, including, for example, lung cancer, esophageal
cancer, gastric cancer, breast cancer, colorectal cancer, liver
cancer, prostate cancer, and ovarian cancer, and is closely related
to tumor diagnosis and prognosis. In addition, the overexpression
of EpCAM has been developed and applied in clinical trials of EpCAM
antibodies and tumor-associated vaccines. Indications for EpCAM
targets also include other related diseases or disorders found in
the existing art or about to be discovered in the future. The term
also includes any variants, isotypes, derivatives, and species
homologues of EpCAM that are naturally expressed by cells including
tumor cells or expressed by cells transfected with EpCAM genes or
cDNA.
[0226] "CEA (carcinoembryonic antigen)" is an acid glycoprotein. It
is an antigen on the surface of tumor cells, has the properties of
human embryonic antigen and widely exists in the digestive system
cancers originated from endoderm, including gastrointestinal
cancer, liver cancer, pancreatic cancer, and may also exist in
small cell lung cancer, breast cancer, medullary thyroid cancer and
carcinoid tumor. Therefore, it can be used as a broad-spectrum
tumor marker for the diagnosis and treatment of various tumors.
Indications for CEA targets also include other related diseases or
disorders found in the existing art or about to be discovered in
the future. The term also includes any variants, isotypes,
derivatives, and species homologues of CEA that are naturally
expressed by cells including tumor cells or expressed by cells
transfected with CEA genes or cDNA.
[0227] "Her2 (human epidermal growth factor receptor 2)" is a
member of the human epidermal growth factor receptor family. The
occurrence, development and severity of various tumors are closely
related to the activity of Her2. In addition to gene mutations or
amplification, the up-regulation of Her2 may also activate two
downstream signaling pathways, trigger a series of cascade
reactions, promote unlimited cell proliferation, and ultimately
lead to cancer. In addition, Her2 may initiate multiple
metastasis-related mechanisms to increase tumor cell metastasis
ability. The amplification or overexpression of Her2 genes occurs
in various tumors such as breast cancer, ovarian cancer, gastric
cancer, lung adenocarcinoma, prostate cancer, and invasive uterine
cancer. Indications targeting Her2 include other related diseases
or disorders found in the existing art or about to be discovered in
the future. The term also includes any variants, isotypes,
derivatives, and species homologues of Her2 that are naturally
expressed by cells including tumor cells or expressed by cells
transfected with Her2 genes or cDNA. Species homologues include
rhesus monkey Her2.
[0228] "EGFR (epidermal growth factor receptor)" is a member of the
epidermal growth factor receptor family. It is widely distributed
on the surface of mammalian epithelial cells, fibroblasts, glial
cells, keratinocytes and other cells, and is associated with the
proliferation of tumor cells, angiogenesis, tumor invasion, tumor
metastasis and the inhibition of apoptosis. Mutations or
overexpression of EGFR generally lead to tumors, and high or
abnormal expression of EGFR is found in various solid tumors
including glial cells, renal carcinoma, lung cancer, prostate
cancer, pancreatic cancer, breast cancer, and tumors in other
tissues. Indications for EGFR targets also include other related
diseases or disorders found in the existing art or about to be
discovered in the future. The term also includes any variants,
isotypes, derivatives, and species homologues of EGFR that are
naturally expressed by cells including tumor cells or expressed by
cells transfected with EGFR genes or cDNA.
[0229] "GPC-3 (glypican-3)" is a member of the glypican family, is
highly expressed in most embryonic tissues, and is an inhibitor of
cell proliferation. The lack of GPC-3 may lead to
simpson-golabi-behmel syndrome (SGBS). It is overexpressed in early
hepatocellular carcinoma (HCC) tissues and is associated with
various cancers such as HCC, melanoma, ovarian cancer, and prostate
cancer. In addition, GPC-3 is silenced in malignant tumors such as
malignant mesothelioma, breast cancer, lung cancer, gastric cancer
and ovarian cell carcinoma, but not expressed or low expressed in
normal tissues, and thus can be used as a biomarker for the
treatment and diagnosis of various tumors. Indications for GPC-3
targets also include other related diseases or disorders found in
the existing art or about to be discovered in the future. The term
also includes any variants, isotypes, derivatives, and species
homologues of GPC-3 that are naturally expressed by cells including
tumor cells or expressed by cells transfected with GPC-3 genes or
cDNA.
[0230] "Mesothelin" belongs to the mesothelin family and is a
pre-pro-megakaryocyte potentiating factor. It can be
proteolytically cleaved, with a furin invertase protein, into two
chains: megakaryocyte-potentiating factor (MPF) and mesothelin.
Mesothelin is a tumor differentiation antigen and usually found on
mesothelial cells lining the pleura, peritoneum and pericardium.
Mesothelin is overexpressed and immunogenic in a variety of tumors
such as mesothelioma, ovarian cancer, lung cancer, and pancreatic
cancer, and therefore can be used as a tumor marker or antigenic
target for therapeutic cancer vaccines. Indications targeting
Mesothelin include other related diseases or disorders found in the
existing art or about to be discovered in the future. The term also
includes any variants, isotypes, derivatives, and species
homologues of Mesothelin that are naturally expressed by cells
including tumor cells or expressed by cells transfected with
Mesothelin genes or cDNA.
[0231] "Mucin1 (cell surface associated mucin protein 1)" is a
member of the mucin protein family, and is expressed on the apical
surface of epithelial cells in tissue organs including lungs,
breast, stomach and pancreas. The overexpression, aberrant
intracellular localization, and changes in glycosylation of Mucin1
are associated with cancer including, but not limited to, colon
cancer, breast cancer, ovarian cancer, lung cancer, and pancreatic
cancer. Using immunohistochemistry, Mucin1 can be identified in a
wide range of secretory epithelial cells, mesenchymal tumors (e.g.,
synovial sarcoma and granulosa cell tumor of ovary), and their
neoplastic equivalents. Moreover, Mucin1 can be used to distinguish
mesothelioma (in which it is restricted to the cell membranes and
associated microvilli), from adenocarcinoma, in which it is
diffusely spread through the cytoplasm. Therefore, Mucin1 can be
used to diagnose and treat the above related diseases or disorders
and other related diseases or disorders found in the existing art
or about to be discovered in the future. The term also includes any
variants, isotypes, and species homologues of Mucin1 that are
naturally expressed by cells including tumor cells or expressed by
cells transfected with Mucin1 genes or cDNA.
[0232] "CA125 (carbohydrate antigen 125)" is an ovarian
cancer-associated antigen that originates from fetal coelomic
epithelial tissue and is widely distributed on the surface of
mesothelial cells such as pleura, pericardium, peritoneum,
endometrium, genital tract and amniotic membrane. CA-125 levels in
serum are significantly elevated when malignant lesions occur in
these sites or these sites are stimulated by inflammation. As the
most studied ovarian cancer marker, CA125 has been reported in the
study of early screening, diagnosis, treatment and prognosis of
ovarian cancer. CA125 levels in the puncture fluid of benign cystic
tumor and malignant cystic epithelioma of ovarian cancer are
significantly elevated. CA125 serum levels are also elevated in
gastrointestinal malignant tumors (e.g., pancreatic cancer, liver
cancer, gastric cancer, and bowel cancer), chronic pancreatitis,
chronic hepatitis, liver cirrhosis, lung adenocarcinoma, pelvic
inflammatory disease, and endometriosis. Given the research of
CA125 in a variety of cancers and inflammation, CA125 can be widely
used in screening, diagnosis and treatment of the above related
diseases. Indications for CA125 targets also include other related
diseases or disorders found in the existing art or about to be
discovered in the future. The term also includes any variants,
isotypes, and species homologues of CA125 that are naturally
expressed by cells including tumor cells or expressed by cells
transfected with CA125 genes or cDNA.
[0233] "BCMA (B-cell maturation antigen)" is a member of the tumor
necrosis factor receptor superfamily. BCMA is preferentially
expressed in mature B lymphocytes and is also expressed on the
surface of plasmablasts (i.e., plasma cell precursors) and plasma
cells. RNAs of BCMA are detected in the spleen, lymph node, thymus,
adrenal gland and liver, and the level of BCMA mRNA in multiple
B-cell lines also increases after maturation. BCMA is associated
with a variety of diseases such as leukemia, lymphoma (e.g.,
Hodgkin's lymphoma), multiple myeloma, and autoimmune diseases
(e.g., systemic lupus erythematosus), and therefore can be used as
a potential target for related B-cell diseases. Indications for
BCMA targets also include other related diseases or disorders found
in the existing art or about to be discovered in the future. The
term also includes any variants, isotypes, and species homologues
of BCMA that are naturally expressed by cells including tumor cells
or expressed by cells transfected with BCMA genes or cDNA.
[0234] CD3 molecule is an important differentiation antigen on the
T cell membrane and a characteristic marker of mature T cells. It
is composed of six peptide chains, and these chains are associated
with the T cell antigen receptor (TCR) with a non-covalent bond to
constitute a TCR-CD3 complex. CD3 molecule not only participates in
the intracytoplasmic assembly of the TCR-CD3 complex but also
transmits antigen stimulation signals through the immunoreceptor
tyrosine-based activation motif (ITAM) of the cytoplasmic regions
of polypeptide chains. The main functions of CD3 molecule are to
stabilize TCR structure and transmit T cell activation signal. When
TCR specifically recognizes and binds to the antigen, CD3 is
involved in signal transduction into T cell cytoplasm as the first
signal to induce T cell activation and plays a very important role
in T cell antigen recognition and immune response generation.
[0235] "CD3" refers to a part of a T-cell receptor complex and
consists of three different chains CD3.epsilon., CD3.delta. and
CD3.gamma.. CD3 is clustered on T cells by, for example, being
immobilized by an anti-CD3 antibody, leading to the activation of T
cells, which is similar to T cell receptor-mediated activation but
independent of the specificity of TCR clones. Most anti-CD3
antibodies recognize the chain CD3F. The second functional domain
that specifically recognizes the T cell surface receptor CD3 in the
present disclosure is not specifically limited as long as it can
specifically recognize CD3, for example, but not limited to, CD3
antigens mentioned in the following patents: U.S. Pat. Nos.
7,994,289; 6,750,325; 6,706,265; 5,968,509; 8,076,459; 7,728,114;
and U.S. 20100183615. Preferably, the antibody against human CD3
used in the present disclosure is cross-reactive with cynomolgus
monkeys and/or rhesus monkeys, for example, but not limited to, CD3
antigens mentioned in the following patents: WO 2016130726, U.S.
20050176028, WO 2007042261, or WO 2008119565. The term also
includes any variants, isotypes, derivatives, and species
homologues of CD3 that are naturally expressed by cells or
expressed by cells transfected with a gene or cDNA encoding the
preceding chains.
[0236] The term "hypervariable region", "CDR" or "complementarity
determining region" refers to amino acid residues of an antibody,
which are responsible for antigen binding, and is a discontinuous
amino acid sequence. CDR sequences are amino acid residues in the
variable region that may be defined by the IMGT, Kabat, Chothia or
AbM method or identified by any CDR sequence determination method
well known in the art. For example, the hypervariable region
includes the following amino acid residues: amino acid residues
from a "complementarity determining region" or "CDR" defined by
sequence comparison, for example, residues at positions 24-34 (L1),
50-56 (L2) and 89-97 (L3) in a light chain variable domain and
residues at positions 31-35 (H1), 50-65 (H2) and 95-102 (H3) in a
heavy chain variable domain (see Kabat et al., 1991, Sequences of
Proteins of Immunological Interest (5th edition), Public Health
Service, National Institutes of Health, Bethesda, Md.), and/or
amino acid residues from a "hypervariable loop" (HVL) defined
according to the structure, for example, residues at positions
26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable
domain and residues at positions 26-32 (H1), 53-55 (H2) and 96-101
(H3) in the heavy chain variable domain (see Chothia and Leskl, J.
Mol Biol, 196: 901-917, 1987). "Framework" residues or "FR"
residues refer to variable domain residues other than the
hypervariable region residues as defined in the present disclosure.
In some embodiments, the antibody or the antigen-binding fragment
thereof in the present disclosure is preferably determined through
the Kabat, Chothia or IMGT numbering system. Those skilled in the
art may explicitly assign each system to any variable domain
sequence without relying on any experimental data beyond the
sequence itself. For example, the Kabat residue numbering method of
a given antibody may be determined by comparing the sequence of the
given antibody to each "standard" numbered sequence. Based on the
numbers of the sequences provided herein, the numbering scheme of
determining any variable region sequence in the sequence table is
entirely within the conventional technical scope of those skilled
in the art.
[0237] The term "single-chain Fv antibody" (or "scFv antibody")
refers to an antibody fragment comprising VH and VL domains of an
antibody. It is a fusion protein of the variable regions of the
heavy (VH) and light chains (VL) connected with a linker. The
linker enables these two domains to be cross-linked to form an
antigen-binding site, and the sequence of the linker generally
consists of a flexible peptide, for example, but not limited to,
G.sub.2(GGGGS).sub.3. The size of scFv is generally 1/6 of an
intact antibody. The single-chain antibody is preferably an amino
acid chain sequence encoded by a nucleotide chain. For the review
of scFv, reference may be made to Pluckthun (1994), The
Pharmacology of Monoclonal Antibodies, Vol. 113, edited by
Rosenburg and Moore, Springer-Verlag, New York, pages 269-315.
Reference may also be made to International Patent Application
Publication No. WO 88/01649 and U.S. Pat. Nos. 4,946,778 and
5,260,203.
[0238] The term "Fab fragment" consists of a light chain and a CH1
and a variable domain of each of a heavy chain. The heavy chain of
the Fab molecule cannot form a disulfide bond with another heavy
chain molecule. The size of "Fab antibody" is 1/3 of an intact
antibody, and "Fab antibody" includes only one antigen-binding
site.
[0239] The term "Fab' fragment" contains a light chain, and a VH
domain and a CH1 domain of a heavy chain, and a constant region
between CH1 and CH2 domains.
[0240] The term "F(ab').sub.2 fragment" contains two light chains,
VH domains and CH1 domains of two heavy chains, and constant
regions between CH1 and CH2 domains, so that an inter-chain
disulfide bond is formed between the two heavy chains. Therefore,
the F(ab').sub.2 fragment is composed of two Fab' fragments held
together by the disulfide bond between the two heavy chains.
[0241] The term "Fc" region refers to the antibody heavy chain
constant region fragment, including at least a hinge region and CH2
and CH3 domains.
[0242] The term "Fv region" includes variable regions from the
heavy chain and the light chain but lacks the constant regions, and
is the minimum fragment containing a complete antigen recognition
and binding site.
[0243] The term "antibody fragment" and "antigen-binding fragment"
refers to an antigen-binding fragment of the antibody that retains
a specific binding ability to an antigen (e.g., Her2), as well as
antibody analogs. It generally includes at least part of an
antigen-binding region or a variable region of a parental antibody.
The antibody fragment retains at least part of the binding
specificity of the parental antibody. Generally, when the activity
is represented in moles, the antibody fragment retains at least 10%
of parental binding activity. Preferably, the antibody fragment
retains at least 20%, 50%, 70%, 80%, 90%, 95% or 100% of the
binding affinity of the parental antibody to a target. The antibody
fragments include, but are not limited to, Fab fragments, Fab'
fragments, F(ab')2 fragments, Fv fragments, Fd fragments,
complementarity determining region (CDR) fragments,
disulfide-stabilized variable fragments (dsFv); linear antibodies,
single-chain antibodies (e.g., scFv monoclonal antibodies)
(technology from Genmab), bivalent single-chain antibodies,
single-chain phage antibodies, single domain antibodies (e.g., VH
domain antibodies), domain antibodies (technology from AbIynx);
multispecific antibodies formed from antibody fragments (e.g.,
triabodies and tetrabodies); and engineered antibodies such as
chimeric antibodies (e.g., humanized mouse antibodies) and
heteroconjugate antibodies. These antibody fragments can be
obtained using any conventional technologies known to those skilled
in the art, and the utility of these fragments can be screened in
the same way as the intact antibody.
[0244] The term "linker peptide" refers to a peptide linking two
polypeptides, wherein the linker peptide may be two immunoglobulin
variable regions or one variable region. The length of the linker
peptide may be 0 to 30 amino acids or 0 to 40 amino acids. In some
embodiments, the linker peptide may be in the length of 0 to 25, 0
to 20, or 0 to 18 amino acids. In some embodiments, the linker
peptide may be a peptide having no more than 14, 13, 12, 11, 10, 9,
8, 7, 6, or 5 amino acids. In other embodiments, the linker peptide
may include 0 to 25, 5 to 15, 10 to 20, 15 to 20, 20 to 30, or 30
to 40 amino acids. In other embodiments, the linker peptide may
have about 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino
acids. The linker peptide is known to those skilled in the art. The
linker peptide may be prepared by any method in the art. For
example, the linker peptide may be originated from synthesis.
[0245] The term "heavy chain constant region" includes an amino
acid sequence from the immunoglobulin heavy chain. The polypeptide
comprising the heavy chain constant region includes at least one
of: a CH1 domain, a hinge domain (e.g., an upper hinge region, an
intermediate hinge region, and/or a lower hinge region), a CH2
domain, a CH3 domain, or a variant or fragment thereof. For
example, the antigen-binding polypeptide used herein may include a
polypeptide chain having a CH1 domain; a polypeptide having a CH1
domain, at least part of a hinge domain, and a CH2 domain; a
polypeptide chain having a CH1 domain and a CH3 domain; a
polypeptide chain having a CH1 domain, at least part of a hinge
domain, and a CH3 domain; or a polypeptide chain having a CH1
domain, at least part of a hinge domain, a CH2 domain, and a CH3
domain. In another embodiment, the polypeptide of the present
application includes a polypeptide chain having a CH3 domain. In
addition, the antibody used in the present application may lack at
least part of a CH2 domain (e.g., all or part of a CH2 domain). As
described above, it is appreciated by those of ordinary skill in
the art that heavy chain constant regions may be modified such that
they differ in amino acid sequence from naturally immunoglobulin
molecules.
[0246] The term "light chain constant region" includes an amino
acid sequence from the antibody light chain. Preferably, the light
chain constant region includes at least one of a constant kappa
domain and a constant lambda domain.
[0247] The term "VH domain" includes an amino-terminal variable
domain of the immunoglobulin heavy chain, while the term "CH1
domain" includes a first (mostly amino-terminal) constant region of
the immunoglobulin heavy chain. The CH1 domain is adjacent to the
VH domain and is the amino-terminal of the hinge region of the
immunoglobulin heavy chain molecule.
[0248] "Binding" defines the affinity interaction between a
specific epitope on an antigen and its corresponding antibody and
is generally understood as "specific recognition." "Specific
recognition" means that the bispecific antibody of the present
disclosure does not or substantially does not have cross-reaction
with any polypeptide other than the target antigen. The degree of
specificity may be determined by immunological techniques,
including, but not limited to, immunoblotting, immunoaffinity
chromatography, and flow cytometry. In the present disclosure, the
specific recognition is preferably determined by flow cytometry,
and the criteria for the specific recognition in particular cases
can be judged by those of ordinary skill in the art according to
the general knowledge of the art which he/she knows.
[0249] The term "in vivo half-life" refers to the biological
half-life of the polypeptide of interest in the circulation of a
given animal and is expressed as the time it takes to clear half of
the amount present in the circulation of the animal from the
circulation and/or other tissues in the animal.
[0250] The term "identity" refers to the matching of sequences
between two polypeptides or between two nucleic acids. When a
certain position in each of two sequences for comparison is
occupied by the same base group or amino acid monomer subunit
(e.g., a certain position in each of the two DNA molecules is
occupied by adenine, or a certain position in each of the two
polypeptides is occupied by lysine), then the molecules are
identical at that position. The "percentage identity" between two
sequences is a function of the number of matching positions of the
two sequences divided by the number of positions to be compared and
then multiplied by 100. For example, if 6 of the 10 positions in
two sequences are matched, the identity between the two sequences
is 60%. For example, DNA sequences CTGACT and CAGGTT have a total
identity of 50% (three of a total of six positions are matched).
Generally, the comparison is made when two sequences are aligned to
produce maximum identity. Such alignment may be implemented, for
example, through a computer program, such as an Align program
(DNAstar, Inc.) to conveniently perform the method described by
Needleman et al. Mol. Biol., 48: 443-453. The percentage identity
between the two amino acid sequences may also be determined by
using the algorithm proposed by E. Meyers and W. Miller (Comput.
Appl Biosci., 4: 11-17) which has been incorporated into ALIGN
program (version 2), using the PAM 120 weight residue table with a
gap length penalty score of 12 and a gap penalty score of 4. In
addition, the percentage identity between the two amino acid
sequences may also be determined by using the algorithm proposed by
Needleman and Wunsch (J. Mol. Biol., 48: 444-453) which has been
incorporated into the GAP program in the GCG software package
(available on www.gcg.com), using Blossum 62 matrix or PAM 250
matrix with a gap weight of 16, 14, 12, 10, 8, 6 or 4 and a length
weight of 1, 2, 3, 4, 5 or 6.
[0251] The term "Fc region" or "Fc fragment" refers to the
C-terminal regions of the immunoglobulin heavy chain, which
includes at least part of a hinge region, a CH2 domain and a CH3
domain. It mediates the binding of immunoglobulins to host tissues
or factors, including the binding of immunoglobulins to Fc
receptors located on various cells (e.g., effector cells) of the
immune system or the binding of immunoglobulins to the first
component (C1q) of the classical complement system. It includes the
native sequence Fc region and the variant Fc region.
[0252] Generally, the human IgG heavy chain Fc region is a segment
from the amino acid residue at the position Cys226 or Pro230 of the
human IgG heavy chain Fc region to the carboxy terminus, but its
boundaries may vary. The C-terminal lysine of the Fc region
(residue 447, according to the EU numbering system) may or may not
be present. Fc may also refer to this region in isolation, or in
the case of a protein polypeptide comprising Fc, for example,
"binding protein comprising an Fc region", and is also referred to
as "Fc fusion protein" (e.g., antibody or immunoadhesin). The
native Fc region of the antibody of the present disclosure includes
mammalian (e.g., human) IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4.
Among human IgG1 Fc regions, at least two allotypes are known. In
some embodiments, there is a single amino acid substitution,
insertion, and/or deletion of about 10 amino acids per 100 amino
acids in the amino acid sequences of two Fc polypeptide chains
relative to the sequence of the amino acid sequence of the
mammalian Fc polypeptide. In some embodiments, the difference may
be changes in Fc that extend the half-life, changes that increase
FcRn binding, changes that inhibit Fc7 receptor (Fc.gamma.R)
binding, and/or changes that decrease or remove ADCC and CDC.
[0253] The term "Fc receptor" or "FcR" refers to a receptor that
binds to the Fc region of an immunoglobulin. FcR may be a native
sequence human FcR, or may be an FcR that binds to the IgG antibody
(a y receptor), as well as allelic variants and alternatively
spliced forms of these receptors. The Fc.gamma.R family is composed
of three activating receptors (Fc.gamma.RI, Fc.gamma.RIII and
Fc.gamma.RIV in mice; Fc.gamma.RIA, Fc.gamma.RIIA and
Fc.gamma.RIIIA in humans) and one inhibitory receptor
(Fc.gamma.RIIb or equivalent Fc.gamma.RIIB). The Fc.gamma.RII
receptor includes Fc.gamma.RIIA ("activating receptor") and
Fc.gamma.RIIB ("inhibitory receptor") which have similar amino acid
sequences. The cytoplasmic domain of Fc.gamma.RIIA includes an
immunoreceptor tyrosine-based activation motif (ITAM). The
cytoplasmic domain of Fc.gamma.RIIB contains an immunoreceptor
tyrosine-based inhibitory motif (ITIM) (see M. Annu. Rev. Immunol.,
15: 203-234 (1997)). Most native effector cell types co-express one
or more activating Fc.gamma.Rs and inhibitory Fc.gamma.RIIbs, while
NK cells selectively express one activating Fc receptor
(Fc.gamma.RIII in mice and Fc.gamma.RIIIA in humans) but do not
express inhibitory Fc.gamma.RIIb in mice and humans. Human IgG1
binds to most human Fc receptors and is considered equivalent to
murine IgG2a in terms of the type of activating Fc receptor to
which Human IgG1 binds. The term "FcR" herein covers other FcRs,
including those which will be identified in the future. Methods of
measuring the binding to FcRn are known (see, e.g., Ghetie V et
al., Immunol Today, 18: 592-8, 1997); Ghetie V et al., Nature
Biotechnology, 15: 637-40, 1997)). The in vivo binding and serum
half-life of the human FcRn high-affinity binding polypeptide to
FcRn can be determined, for example, in transgenic mice expressing
human FcRn or transfected human cell lines. The term "Fc receptor"
or "FcR" also includes the neonatal receptor FcRn which is
responsible for transferring maternal IgG to the fetus (Guyer R L
et al., J. Immunol., 117: 587, 1976) and Kim Y J et al., J.
Immunol., 24: 249, 1994)).
[0254] The term "humanized antibody" refers to a genetically
engineered non-human antibody whose amino acid sequence has been
modified to increase homology to the sequence of the human
antibody. Most or all of the amino acids outside the CDR domain of
a non-human antibody, for example, a mouse antibody, are
substituted by corresponding amino acids from human
immunoglobulins, while most or all of the amino acids within one or
more CDR regions are not altered. The addition, deletion,
insertion, substitution or modification of small molecule amino
acids is permissible as long as they do not eliminate the ability
of the antibody to bind a particular antigen. The "humanized"
antibody retains antigen specificity similar to that of the
original antibody. The origin of the CDRs is not particularly
limited and may be derived from any animal. For example, antibodies
derived from mouse antibodies, rat antibodies, rabbit antibodies,
or non-human primate (e.g., cynomolgus monkeys) antibodies may be
used. Examples of human frameworks useful in the present disclosure
are KOL, NEWM, REI, EU, TUR, TEI, LAY, and POM (Kabat et al.,
ibid). For example, KOL and NEWM may be used for heavy chains, REI
may be used for light chains, and EU, LAY, and POM may be used for
both heavy and light chains. Alternatively, human germline
sequences may be used, and these sequences are available at
http://www2.mrc-lmb.cam.ac.uk/vbase/list2.php. In the humanized
antibody molecules of the present disclosure, the receptor heavy
and light chains do not need to be derived from the same antibody,
and may, if needed, include complex chains having framework regions
derived from different chains.
[0255] The term "cytokine" generally refers to a protein that is
released by one cell population and that acts as an intercellular
medium on another cell or has an autocrine effect on the cells from
which the protein is produced. Examples of such cytokines include
lymphokines, monokines, interleukins ("IL") such as IL-2, IL-6, and
IL-17A-F, tumor necrosis factors such as TNF-.alpha. and
TNF-.beta., and other polypeptide factors such as leukemia
inhibitory factor ("LIF").
[0256] The term "immunobinding" and "immunobinding property" refers
to a non-covalent interaction between an immunoglobulin molecule
and an antigen (to the antigen, the immunoglobulin is specific).
The strength or affinity of the immunobinding interaction may be
represented by the equilibrium dissociation constant (K.sub.D) of
the interaction, where the smaller the K.sub.D value, the higher
the affinity. The immunobinding property of the selected
polypeptide may be quantified using a method known in the art. One
method relates to the measurement of rates at which an
antigen-binding site/antigen complex is formed and dissociated.
Both the "binding rate constant" (K.sub.a or K.sub.on) and the
"dissociation rate constant" (K.sub.d or K.sub.off) may be
calculated according to the concentration and actual rates of
association and dissociation (see Malmqvist M et al., Nature, 361:
186-187, 1993). The ratio of k.sub.d/k.sub.a is the dissociation
constant K.sub.D (generally see Davies et al., Annual Rev Biochem.,
1990, 59: 439-473). Any effective method may be used for measuring
values of K.sub.D, k.sub.a and k.sub.d.
[0257] The term "cross-reaction" refers to the ability of the
antibody described herein to bind to tumor-associated antigens from
different species. For example, the antibody described herein that
binds to human TAA may also bind to TAAs from other species (e.g.,
cynomolgus monkey TAA). Cross-reactivity may be measured by
detecting specific reactivity with purified antigens in binding
assays (e.g., SPR, ELISA), or detecting the binding to cells
physiologically expressing TAA or the interaction with the function
of cells physiologically expressing TAA. Examples of assays known
in the art for determining the binding affinity include surface
plasmon resonance (e.g., Biacore) or similar techniques (e.g.,
Kinexa or Octet).
[0258] The term "EC.sub.50" refers to the maximum response of the
concentration of the antibody or antigen-binding fragment thereof
that induces a 50% response in an in vitro or in vivo assay using
the antibody or antigen-binding fragment thereof, that is, half
between the maximum response and the baseline.
[0259] "Effector cell" refers to a cell of the immune system, which
expresses one or more FcRs and mediates one or more effector
functions. Preferably, the cell expresses at least one type of
activating Fc receptors such as human Fc.gamma.RIII and performs
ADCC effector function. Examples of human leukocytes which mediate
ADCC include peripheral blood mononuclear cells (PBMCs), natural
killer (NK) cells, monocytes, macrophages, neutrophils, and
eosinophils. Effector cells also include, for example, T cells.
They may be derived from any organism including, but not limited
to, humans, mice, rats, rabbits or monkeys.
[0260] The term "effector function" refers to biological activities
that can be attributed to the biological activities of the antibody
Fc region (a native sequence Fc region or amino acid sequence
variant Fc region) and that vary with antibody isotypes. Examples
of antibody effector functions include, but are not limited to, Fc
receptor binding affinity, ADCC, ADCP, CDC, downregulation of cell
surface receptors (e.g., B cell receptors), B cell activation,
cytokine secretion, and half-life/clearance rate of antibodies and
antigen-antibody complexes. Methods of altering the effector
function of antibodies are known in the art, for example, the
effector function of antibodies may be altered by introducing
mutations in the Fc region.
[0261] The term "antibody-dependent cell-mediated cytotoxicity
(ADCC)" refers to a cytotoxic form in which Ig binds to FcRs on
cytotoxic cells (e.g., NK cells, neutrophils or macrophages) to
enable these cytotoxic effector cells to specifically bind to
antigen-attached target cells and then secret cytotoxins to kill
the target cells. Methods for detecting the ADCC activity of an
antibody are known in the art, for example, the ADCC activity may
be detected by measuring the binding activity between a
to-be-tested antibody and FcR (e.g., CD16a).
[0262] The term "antibody-dependent cell-mediated phagocytosis
(ADCP)" refers to a cell-mediated reaction in which a non-specific
cytotoxic active cell expressing Fc.gamma.R recognizes a bound
antibody on a target cell and subsequently causes phagocytosis of
the target cell.
[0263] The term "complement-dependent cytotoxicity (CDC)" refers to
a cytotoxic form that activates the complement cascade by binding
the complement component C1q to the antibody Fc. Methods for
detecting the CDC activity of an antibody are known in the art, for
example, the CDC activity may be detected by measuring the binding
activity between a to-be-tested antibody and an Fc receptor (e.g.,
C1q).
[0264] The term "pharmaceutically acceptable carrier and/or
excipient and/or diluent" refers to a carrier and/or excipient
and/or stabilizer which is pharmacologically and/or physiologically
compatible with the subject and the active ingredient and which is
non-toxic to the cell or mammal exposed to such a carrier and/or
excipient and/or stabilizer at the dosage and concentration
employed. Examples include, but are not limited to, pH regulators,
surfactants, adjuvants, ionic strength enhancers, diluents,
reagents to maintain osmotic pressure, reagents to delay
absorption, and preservatives. For example, pH adjusting agents
include, but are not limited to, phosphate buffers. Surfactants
include, but are not limited to, cationic surfactant, anionic
surfactant or nonionic surfactants, for example, Tween-80. Ionic
strength enhancers include, but are not limited to, sodium
chloride. Preservatives include, but are not limited to, various
antibacterial reagent and antifungal reagent, such as parabens,
chlorobutanol, phenol, and sorbic acid. Reagents to maintain
osmotic pressure include, but are not limited to, sugars, NaCl, and
analogs thereof. Reagents to delay absorption include, but are not
limited to, monostearate and gelatin. Diluents include, but are not
limited to, water, aqueous buffers (e.g., buffered saline),
alcohols, and polyols (e.g., glycerol). Preservatives include, but
are not limited to, various antibacterial reagent and antifungal
reagent, such as thiomersal, 2-phenoxyethanol, parabens,
chlorobutanol, phenol, and sorbic acid. Stabilizers have the
meaning as commonly understood by those of ordinary skill in the
art. Stabilizers are those capable of stabilizing the desired
activity of the active ingredient in a drug, including, but not
limited to, sodium glutamate, gelatin, SPGA, sugars (e.g.,
sorbitol, mannitol, starch, sucrose, lactose, dextran or glucose),
amino acids (e.g., glutamic acid or glycine), proteins (e.g., dry
whey, albumin or casein), or degradation products thereof (e.g.,
lactalbumin hydrolysate).
[0265] The term "effective amount" refers to an amount sufficient
to obtain or at least partially obtain the desired effect. For
example, a prophylactically (e.g., tumor or infection) effective
amount refers to an amount sufficient to prevent, arrest, or delay
the onset of a disease (e.g., tumor or infection) when used alone
or used together with one or more therapeutic agents; a
therapeutically effective amount refers to an amount sufficient to
cure or at least partially arrest the disease and complications
thereof in a patient already suffering from the disease when used
alone or used together with one or more therapeutic agents. It is
well within the ability of those skilled in the art to determine
such effective amounts. For example, the amount effective for
therapeutic use depends on the severity of the to-be-treated
disease, the overall state of the patient's own immune system, the
general condition of the patient such as age, weight and sex, the
mode of administration of the drug, and other treatments
administered concurrently. The terms "efficacy" and "effectiveness"
with respect to treatment include both pharmacological
effectiveness and physiological safety. The pharmacological
effectiveness refers to the ability of a drug to promote regression
of a condition or symptom in a patient. The physiological safety
refers to the level of toxicity or other adverse physiological
effects (adverse effects) at the cellular, organ and/or organism
level due to drug administration.
[0266] "Treatment" or "therapy" on a subject refers to any type of
intervention or treatment of, or administration of an active agent
to, a subject for the purpose of reversing, alleviating,
ameliorating, inhibiting, slowing or preventing the occurrence,
progression, progression, severity, or recurrence of symptoms,
complications, disorders or biochemical indicators associated with
a disease.
[0267] The term "T-cell receptor (TCR)" is a specific receptor
present on the surface of T cells, i.e., T lymphocytes. In vivo,
the T-cell receptor is present as a complex of several proteins.
The T-cell receptor generally has two separate peptide chains,
typically T-cell receptors .alpha. and .beta. (TCR.alpha. and
TCR.beta.) chains, and in some T cells, they are T-cell receptor
.gamma. and .delta. (TCR.gamma. and TCR.delta.). The other proteins
in the complex are CD3 proteins: CD3.epsilon..gamma. and
CD3.epsilon..delta. heterodimers, most importantly, CD3.zeta.
homodimers having six ITAMs. The ITAMs on CD3.zeta. can be
phosphorylated by Lck, which in turn recruit ZAP-70. Lck and/or
ZAP-70 may also phosphorylate tyrosine on many other molecules,
particularly CD28, LAT, and SLP-76, which allows aggregation of
signal transduction complexes around these proteins.
[0268] The term "bispecific antibody" refers to the bispecific
antibody of the present disclosure, for example, an anti-Her2
antibody or an antigen-binding fragment thereof, which may be
derivatized or linked to another functional molecule, for example,
another peptide or protein (e.g., TAA, a cytokine and a cell
surface receptor), to generate a bispecific antibody that binds to
at least two different binding sites or target molecules. To
produce the bispecific molecule of the present disclosure, the
antibody of the present disclosure may be functionally linked
(e.g., by chemical coupling, gene fusion, non-covalent binding or
other means) to one or more other binding molecules, for example,
another antibody, antibody fragment, peptide or binding mimetic, to
produce the bispecific molecule. For example, the "bispecific
antibody" refers to one including two variable domains or ScFv
units such that the antibody obtained recognizes two different
antigens. Various different forms and uses of the bispecific
antibody are known in the art (Chames P et al., Curr. Opin. Drug
Disc. Dev., 12:276, 2009; Spiess C et al., Mol. Immunol., 67:
95-106, 2015).
[0269] The term "hCG-.beta. carboxy terminal peptide (CTP)" is a
short peptide from the carboxy terminus of a human chorionic
gonadotropin (hCG) .beta.-subunit. Four reproduction-related
polypeptide hormones, follicle-stimulating hormone (FSH),
luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and
human chorionic gonadotropin (hCG), each contain the same a-subunit
and their respective specific P-subunits. The in vivo half-life of
hCG is significantly longer than those of the other three hormones,
mainly due to the specific carboxy terminal peptide (CTP) on the
.beta.-subunit of hCG. The CTP includes 37 amino acid residues and
four O-glycosylation sites, in which sugar side chain terminals are
sialic acid residues. The electronegative highly-sialyl CTP can
resist renal clearance and thus extend the half-life in vivo (Fares
F A et al., Proc Natl Acad. Sci. USA, 1992, 89: 4304-4308,
1992).
[0270] The term "glycosylation" means that an oligosaccharide (a
carbohydrate containing two or more monosaccharides that are linked
together, e.g., a carbohydrate containing 2 to about 12
monosaccharides that are linked together) is attached to form a
glycoprotein. The oligosaccharide side chains are generally linked
to the backbone of the glycoprotein via N- or O-linkages. The
oligosaccharides of the antibodies disclosed herein are generally
CH2 domains linked to the Fc region as N-linked oligosaccharides.
"N-linked glycosylation" refers to carbohydrate moiety attachment
to an asparagine residue of a glycoprotein chain. For example, the
skilled artisan can recognize a single site useful for N-linked
glycosylation at residue 297 of each of CH2 domains of murine IgG1,
IgG2a, IgG2b and IgG3 and human IgG1, IgG2, IgG3, IgG4, IgA and
IgD.
Homologous Antibody
[0271] In another aspect, amino acid sequences included in the
heavy and light chain variable regions of the antibody of the
present disclosure are homologous with amino acid sequences of the
preferred antibody described herein, and the antibody retains
desired functional properties of the bispecific antibody of the
present disclosure, for example, Her2.times.CD3 bispecific
antibody.
Antibody with Conservative Modifications
[0272] The term "conservative modification" is intended to mean
that an amino acid modification does not significantly affect or
change the binding characteristics of the antibody containing an
amino acid sequence. Such conservative modifications include amino
acid substitutions, additions and deletions. A modification may be
introduced into the antibody of the present disclosure by using a
standard technology known in the art, such as a site-directed
mutagenesis and a PCR-mediated mutagenesis. A conservative amino
acid substitution refers to the substitution of an amino acid
residue with an amino acid residue with a similar side chain.
Families of amino acid residues with similar side chains have been
described in detail in the art. These families include amino acids
with basic side chains (such as lysine, arginine and histidine),
amino acids with acidic side chains (such as aspartic acid and
glutamic acid), amino acids with uncharged polar side chains (such
as glycine, asparagine, glutamine, serine, threonine, tyrosine,
cysteine and tryptophan), amino acids with non-polar side chains
(such as alanine, valine, leucine, isoleucine, proline,
phenylalanine and methionine), amino acids with .beta.-branched
side chains (such as threonine, valine and isoleucine) and amino
acids with aromatic side chains (such as tyrosine, phenylalanine,
tryptophan and histidine). Therefore, one or more amino acid
residues in the CDR of the antibody of the present disclosure may
be substituted with other amino acid residues from the same side
chain family.
Fc Variant with Altered Binding Affinity for the Neonatal Receptor
(FcRn)
[0273] "FcRn" used herein refers to a protein that binds to at
least part of the Fc region of the IgG antibody and that is encoded
by the FcRn gene. FcRn may be derived from any organism including,
but not limited to, humans, mice, rats, rabbits or monkeys. The
functional FcRn protein includes two polypeptides that often
referred to as heavy and light chains, in which the light chain is
.beta.-2-microglobulin and the heavy chain is encoded by the FcRn
gene.
[0274] The present disclosure relates to an antibody whose binding
to FcRn is regulated (the regulation includes to increase or
decrease the binding). For example, in some cases, increased
binding may result in cell recirculating antibodies, and thus
extends, for example, the half-life of the therapeutic antibody.
Sometimes, it is desirable to decrease the FcRn binding, for
example, when the antibody is used as a diagnostic or therapeutic
antibody including a radiolabel. In addition, antibodies exhibiting
increased binding to FcRn and altered binding to other Fc receptors
such as Fc.gamma. Rs may be used in the present disclosure.
[0275] The present application relates to an antibody including an
amino acid modification that regulates the binding to FcRn. Of
particular interest is that at lower pH, the binding affinity for
FcRn exhibits an increase, while at higher pH, the binding
basically does not exhibit an altered antibody that minimally
includes the Fc region or functional variants thereof.
Fc Variant with Enhanced Binding Affinity for the Neonatal Receptor
(FcRn)
[0276] The plasma half-life of IgG depends on its binding to FcRn,
where IgG generally binds to FcRn at a pH of 6.0 and dissociates
from FcRn at a pH of 7.4 (the pH of plasma). Through studies on the
binding site, a binding site of IgG to FcRn is modified to increase
the binding capacity at the pH of 6.0. It has been proved that
mutations of some residues of a human Fc.gamma. domain, which are
essential to the binding to FcRn, can increase the serum half-life.
It has been reported that mutations at T250, M252, S254, T256,
V308, E380, M428, and N434 (EU numbering) can increase or decrease
the binding affinity for FcRn (Roopenian et al., Nat. Rev.
Immunol., 7: 715-725, 2007). Korean Patent No. KR 10-1027427
discloses trastuzumab (Herceptin, Genentech) variants with enhanced
binding affinity for FcRn, where these variants include one or more
amino acid modifications selected from 257C, 257M, 257L, 257N,
257Y, 279Q, 279Y, 308F, and 308Y. Korean Patent Publication No. KR
2010-0099179 provides bevacizumab (Avastin, Genentech) variants,
where these variants exhibit an increased in vivo half-life through
amino acid modifications included in N434S, M252Y/M428L,
M252Y/N434S, and M428L/N434S. In addition, Hinton et al. have found
that T250Q and M428L mutants increase the binding to FcRn threefold
and sevenfold, respectively. At the same time, the mutation of two
sites increases the binding 28-fold. In rhesus monkeys, the M428L
or T250QM/428 L mutant exhibits the plasma half-life increased
twofold (Hinton P. R. et al., J. Immunol., 176: 346-356, 2006). For
more mutational sites included in the Fc variant with the enhanced
binding affinity for the neonatal receptor (FcRn), see Chinese
invention patent CN 201280066663.2. In addition, studies have shown
that through the T250Q/M428L mutation on Fc fragments of five
humanized antibodies, the interaction between Fc and FcRn is
improved, and in subsequent in vivo pharmacokinetic assays, the
pharmacokinetic parameters of the Fc-mutation antibody are improved
compared with the wild-type antibody through subcutaneous
administration, for example, the in vivo exposure is increased, the
clearance rate is reduced, and the subcutaneous bioavailability is
increased (Datta-Mannan A et al., MAbs. Taylor & Francis, 4:
267-273, 2012).
[0277] Other mutational sites capable of enhancing the affinity of
the antibody of the present disclosure for FcRn include, but are
not limited to, the following amino acid modifications: 226, 227,
230, 233, 239, 241, 243, 246, 259, 264, 265, 267, 269, 270, 276,
284, 285, 288, 289, 290, 291, 292, 294, 298, 299, 301, 302, 303,
305, 307, 309, 311, 315, 317, 320, 322, 325, 327, 330, 332, 334,
335, 338, 340, 342, 343, 345, 347, 350, 352, 354, 355, 356, 359,
360, 361, 362, 369, 370, 371, 375, 378, 382, 383, 384, 385, 386,
387, 389, 390, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401,
403, 404, 408, 411, 412, 414, 415, 416, 418, 419, 420, 421, 422,
424, 426, 433, 438, 439, 440, 443, 444, 445, and 446, where the
numbers of the amino acids in the Fc region is numbers of the EU
indexes in Kabat.
[0278] Fc variants with enhanced binding affinity for FcRn also
include all other known amino acid modification sites as well as
amino acid modification sites that have not yet been found. In an
optional embodiment, the IgG variant can be optimized to gain
increased or decreased affinity for FcRn and increased or decreased
affinity for human Fc.gamma.R including, but not limited to,
Fc.gamma.RI, Fc.gamma.RIIa, Fc.gamma.RIIb, Fc.gamma.RIIc,
Fc.gamma.RIIIa and Fc.gamma.RIIIb, including allelic variants
thereof.
[0279] Preferentially, the Fc ligand specificity of an IgG variant
determines its therapeutic application. The given IgG variant for
therapeutic purposes depends on the epitope or form of the target
antigen as well as the to-be-treated disease or indication.
Enhanced FcRn binding may be more preferred for most targets and
indications because enhanced FcRn binding may result in extended
serum half-life. A relatively long serum half-life allows
administration at relatively low frequencies and doses during
treatment. This property may be particularly preferred when the
therapeutic agent is administered in order to respond to
indications requiring repeated administration. For some targets and
indications, the reduced affinity for FcRn may be particularly
preferred when the variant Fc is required to have an increased
clearance or reduced serum half-life, for example, when the Fc
polypeptide is used as an imaging agent or a radiotherapy
agent.
[0280] The affinity of the polypeptide for FcRn can be evaluated by
methods well known in the art. For example, those skilled in the
art can perform appropriate ELISA assays. As illustrated in Example
5.6, appropriate ELISA assays enabled the comparison of the binding
strengths of the variants and parents to FcRn. At the pH of 7.0,
the specific signals detected for the variant and the parent
polypeptide are compared, if the specific signal of the variant is
at least 1.9 times weaker than the specific signal of the parent
polypeptide, this variant is a preferred variant of the present
disclosure and is more suitable for clinical application.
[0281] FcRn may be derived from any organism including, but not
limited to, humans, mice, rats, rabbits or monkeys.
Alterations to Inhibit Fc.gamma.R Binding
[0282] As used herein, "alterations to inhibit Fc.gamma.R binding"
refers to one or more insertions, deletions or substitutions in the
Fc polypeptide chain that inhibit binding of Fc.gamma.RIIA,
Fc.gamma.RIIB and/or Fc.gamma.RIIIA, in which the binding is
determined, for example, by a competitive binding assay
(PerkinElmer, Waltham, Mass.). These alterations may be included in
the Fc polypeptide chain as part of the bispecific antibody. More
specifically, alterations that inhibit binding of the Fc.gamma.
receptor (Fc.gamma.R) include L234A, L235A, or any alteration that
inhibits glycosylation at the position N297, including any
substitution at N297. In addition, along with the alterations that
inhibit glycosylation of the position N297, additional alterations
to stabilize the dimer Fc region by establishing additional
disulfide bridges are also expected. Further examples of
alterations that inhibit Fc.gamma.R binding include D265A
alterations in one Fc polypeptide chain and A327Q alterations in
another Fc polypeptide chain. Some of the above mutations are
described, for example, in Xu D et al., Cellular Immunol., 200:
16-26, 2000, of which the section about the above mutations and the
activity evaluation thereof is incorporated herein by reference.
The above numbers are based on EU numbering.
[0283] For example, the Fc fragment included by the bispecific
antibody provided by the present disclosure in the alterations that
inhibit Fc.gamma.R binding exhibits reduced affinity for at least
one of human Fc.gamma.R (Fc.gamma.RI, Fc.gamma.RIIa or
Fc.gamma.RIIIa) or C1q, and has reduced effector cell functions or
complement functions.
[0284] Other alterations that inhibit Fc.gamma.R binding include
sites and modifications thereof that are well known in the art or
may be discovered in the future.
[0285] Fc.gamma.R may be derived from any organism including, but
not limited to, humans, mice, rats, rabbits or monkeys.
Fc Alterations to Extend the Half-Life
[0286] As used herein, "Fc alterations to extend the half-life"
refers to an alteration to extend the in vivo half-life of a
protein that includes an altered Fc polypeptide in the Fc
polypeptide chain as compared with the half-life of a protein that
includes the same Fc polypeptide but does not include any altered
but similar Fc. These alterations may be included in the Fc
polypeptide chain as part of the bispecific antibody. Alterations
T250Q, M252Y, S254T and T256E (alteration of threonine at position
250 to glutamine; alteration of methionine at position 252 to
tyrosine; alteration of serine at position 254 to threonine; and
alteration of threonine at position 256 to glutamic acid; where
numbers are based on EU numbering) is an Fc alteration to extend
half-life and may be used jointly, alone or in any combination.
These and other alterations are described in detail in U.S. Pat.
No. 7,083,784. The section about this alteration described in U.S.
Pat. No. 7,083,784 is incorporated herein by reference.
[0287] Similarly, M428L and N434S are Fc alterations that extend
the half-life and can be used jointly, alone or in any combination.
These alterations and other alterations are described in detail in
U.S. Patent Application Publication No. 2010/0234575 and U.S. Pat.
No. 7,670,600. Sections of such alterations described in U.S.
Patent Application Publication No. 2010/0234575 and U.S. Pat. No.
7,670,600 are incorporated herein by reference.
[0288] In addition, according to the meaning herein, any
substitution at one of the following positions can be considered to
be an Fc alternation that extends the half-life: 250, 251, 252,
259, 307, 308, 332, 378, 380, 428, 430, 434, and 436. Each of these
alterations or a combination of these alterations may be used to
extend the half-life of the bispecific antibody described herein.
Other alternations that can be used to extend the half-life are
described in detail in International Application No.
PCT/US2012/070146 (Publication No. WO 2013/096221) filed Dec. 17,
2012. The section about the above alterations of this application
is incorporated herein by reference.
[0289] Fc alternations that extend the half-life also include sites
and modifications thereof that are well known in the art or may be
discovered in the future.
[0290] Fc may be derived from any organism including, but not
limited to, humans, mice, rats, rabbits or monkeys.
Method for Preparing a Bispecific Antibody
[0291] The bispecific antibody of the present disclosure may be
prepared by any method known in the art. Early methods for
constructing the bispecific antibody include chemical cross-linking
or hybridoma heterozygosis or quadroma method (e.g., Staerz U D et
al., Nature, 314: 628-31, 1985; Milstein C et al., Nature, 305:
537-540, 1983; Karpovsky B et al., J. Exp. Med., 160: 1686-1701,
1984). The chemical coupling method is to connect two different
monoclonal antibodies by chemical coupling to prepare a bispecific
monoclonal antibody. For example, two different monoclonal
antibodies chemically bind to each other, or two antibody
fragments, for example, two Fab fragments chemically bind to each
other. The heterozygosis-hybridoma method is to prepare a
bispecific monoclonal antibody by a cell hybridization method or a
ternary hybridoma method, where the cell hybridoma or the ternary
hybridoma is obtained by the fusion of constructed hybridomas or
the fusion of a constructed hybridoma and lymphocytes derived from
mice. Although these techniques are used to manufacture BiAb,
various generation problems make such complexes difficult to use,
such as the generation of mixed populations containing different
combinations of antigen-binding sites, difficulties in protein
expression, the need for purifying the target BiAb, low yields, and
high production costs.
[0292] Recent methods utilize genetically engineered constructs
that can produce a single homogeneous product of BiAb so that there
is no need for thorough purification to remove unwanted
by-products. Such constructs include tandem scFv, diabodies, tandem
diabodies, double variable domain antibodies, and heterdimeric
antibodies using the Ch1/Ck domain or DNL.TM. motifs (Chames &
Baty, Curr. Opin. Drug. Discov. Devel., 12: 276-83, 2009; Chames
& Baty, mAbs, 1: 539-47). Related purification techniques are
well known.
Tumor Surface Antigen
[0293] The term "tumor surface antigen" refers to antigens that are
or can be present on the tumor cells or on the inner surface of the
tumor cells. Some cancer cell antigens are also expressed on the
surface of some normal cells, which thus may be referred to as
tumor-associated antigens. These tumor-associated antigens may be
overexpressed on tumor cells compared with their expression on
normal cells, or are susceptible to binding to antibodies in tumor
cells due to the less compact structure of the tumor tissue
compared with normal tissues. These antigens may be presented
solely by tumor cells and not by normal cells. Tumor antigens may
also be expressed only on tumor cells or may represent
tumor-specific mutations compared with normal cells. The
corresponding antigens may be called tumor-specific antigens.
[0294] The "tumor-associated antigen" can trigger an immune
response in host and can be used for identifying tumor cells and as
a possible candidate in cancer therapy. Such an antigen may include
normal proteins that evade the immune system well, proteins that
are usually produced in very small amounts, proteins that are
usually produced only in certain developmental stages, or proteins
whose structure is modified by mutations.
[0295] A large number of tumor antigens are known in the art, and
new tumor antigens can be readily determined through screening and
identification. Non-limiting examples of tumor antigens include:
.alpha.-fetoprotein (AFP), .alpha.-actinin-4, A3, antigens specific
to A33 antibodies, ART-4, B7, Ba733, BAGE, BrE3-antigen, CA125,
CAMEL, CAP-1, carbonic anhydrase IX, CASP-8/m, CCCL19, CCCL21, CD1,
CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19,
CD20, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38,
CD40, CD40L, CD44, CD45, CD46, CD47, CD52, CD54, CD55, CD59, CD64,
CD66a-e, CD67, CD70, CD70L, CD74, CD79a, CD80, CD83, CD95, CD123,
CD126, CD132, CD133, CD138, CD147, CD154, CDC27, BCMA, CS1, DLL3,
DLL4, EpCAM, FLT3, gpA33, GPC-3, Her2, MEGE-A3, NYESO1, CIX, GD2,
GD3, GM2, CDK-4/m, CDKN2A, CTLA-4, CXCR4, CXCR7, CXCL12,
HIF-1.alpha., Colon-specific antigen p (CSAp), CEA(CEACAM5),
CEACAM6, c-Met, DAM, EGFR, EGFRvIII, EGP-1(TROP-2), EGP-2, ELF2-M,
Ep-CAM, fibroblast growth factor (FGF), Flt-1, Flt-3,
folate-binding protein, G250 antigen, GAGE, gp100, GRO-.beta.,
HLA-DR, HM1.24, human chorionic gonadotropin (HCG) and subunits
thereof, HER2/neu, HMGB-1, hypoxia-inducible factor (HIF-1),
HSP70-2M, HST-2, Ia, IGF-1R, IFN-.gamma., IFN-.alpha., IFN-.beta.,
IFN-.lamda., IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-2,
IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-23, IL-25, insulin-like
growth factor-1 (IGF-1), KC4-antigen, KS-1-antigen, KS1-4, Le-Y,
LDR/FUT, macrophage migration inhibitory factor (MIF), MAGE,
MAGE-3, MART-1, MART-2, NY-ESO-1, TRAG-3, mCRP, MCP-1, MIP-1A,
MIP-1B, MIF, MUC1, MUC2, MUC3, MUC4, MUC5ac, MUC13, MUC16, MUM-1/2,
MUM-3, NCA66, NCA95, NCA90, PAM4 antigen, pancreatic cancer
mucoprotein, PD-1 receptor, placental growth factor, p53, PLAGL2,
prostatic acid phosphatase, PSA, PRAME, PSMA, P1GF, ILGF, ILGF-1R,
IL-6, IL-25, RS5, RANTES, T101, SAGE, S100, survivin, survivin-2B,
TAC, TAG-72, cytotactin, TRAIL receptor, TNF-.alpha., Tn antigen,
Thomson-Friedenreich antigen, tumor necrosis antigen, VEGF, VEGFR2,
VEGFR3, Cadherin, Integrin, Mesothelin, Claudin18, .alpha.V.beta.3,
.alpha.5.beta.1, ERBB3, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL,
Mucin family, FAP, Tenascin, ED-B fibronectin, WT-1, 17-1A-antigen,
complementation factor C3, C3a, C3b, C5a, C5, angiogenesis marker,
bcl-2, bcl-6, Kras, oncogene marker and oncogene products (see, for
example, Sensi M et al., Clin. Cancer Res., 12: 5023-32, 2006;
Parmiani J et al., J. Immunol., 178: 1975-79, 2007; Novellino L et
al., Cancer Immunol. Immunother., 54: 187-207, 2005). Preferably,
TAA in the present disclosure is CD19, CD20, CD22, CD30, CD38,
BCMA, CS1, EpCAM, CEA, Her2, EGFR, Mucin1, CA125, GPC-3, or
Mesothelin.
[0296] The term also includes any variants, isotypes, derivatives,
and species homologues of TAA that are naturally expressed by cells
including tumor cells or expressed by cells transfected with TAA
genes or cDNA.
[0297] TAA may be derived from any organism including, but not
limited to, humans, mice, rats, rabbits or monkeys.
Target Cell and Target Cell Protein Expressed on the Target
Cell
[0298] As described above, the bispecific antibody can bind to
effector cell proteins and target cell proteins. For example, the
target cell protein may be expressed on the surface of cancer
cells, cells infected by pathogen, or cells mediating diseases
(e.g., inflammatory and autoimmune diseases).
[0299] In some embodiments, the target cell protein can be highly
expressed on the surface of target cells, although such high-level
expression is not required. In some embodiments, the target cell
protein is not expressed or low-expressed on the surface of target
cells.
[0300] When the target cell is a cancer cell, the homodimeric
bispecific antibody as described herein can bind to the cancer cell
antigen as described above. The cancer cell antigen may be a human
protein or a protein derived from other species.
[0301] In some embodiments, the target cell protein may be a
protein that is selectively expressed or overexpressed or not
expressed on the surface of tumor cells.
[0302] In some embodiments, the target cell protein may be a
protein on the surface on cells that mediate lymphatic
system-related diseases.
[0303] In other aspects, the target cell may be a cell that
mediates autoimmune diseases or inflammatory diseases. For example,
human eosinophils in asthma may be the target cell, and in this
case, for example, the EGF-like module-containing mucin-like
hormone receptor (EMR1) may be the target cell protein. Optionally,
excess human B cells in patients suffering from systemic lupus
erythematosus may be the target cell, and in this case, for
example, CD19 or CD20 may be the target cell protein. In other
autoimmune diseases, excess human Th2T cells may be the target
cell, and in this case, for example, CCR4 may be the target cell
protein. Similarly, the target cell may be a fibrotic cell that
mediates, for example, atherosclerosis, chronic obstructive
pulmonary disease (COPD), liver cirrhosis, scleroderma, renal
transplantation fibrosis, renal allograft nephropathy or pulmonary
fibrosis (including idiopathic pulmonary fibrosis and/or idiopathic
pulmonary hypertension). For the fibrosis, for example, fibroblast
activation protein .alpha. (FAP.alpha.) may be the target cell
protein.
[0304] In some embodiments, the target cell protein may be a
protein that is selectively expressed on the surface of infected
cells. For example, in the case of hepatitis B virus (HBV) or
hepatitis C virus (HCV) infection, the target cell protein may be
an envelope protein of HBV or HCV expressed on the surface of the
infected cells. In other embodiments, the target cell protein may
be gp120 encoded by human immunodeficiency virus (HIV) on
HIV-infected cells.
[0305] In some embodiments, the target cell may be a cell that
mediates infections and infectious-related diseases.
[0306] In some embodiments, the target cell may be a cell that
mediates immunodeficiency-related diseases.
[0307] In some embodiments, the target cell may be a cell that
mediates other related diseases, including diseases well known in
the art or about to be discovered in the future.
[0308] The bispecific antibody may bind to target cell proteins
from species of mice, rats, rabbits, New World monkeys, and/or Old
World monkeys. The species include, but are not limited to, the
following species: Mus musculus, Rat tusrattus, Rattus norvegicus,
Cynomolgus monkeys, Macaca fascicularis, Hamadryas baboon, Papio
hamadryas, Guinea baboon, Papio papio, Olive baboon, Papio anubis,
Yellow baboon, Papio cynocephalus, Chacma baboon, Papio ursinus,
Callithrix jacchus, Saguinus oedipus and Saimiri sciureus.
Cancer
[0309] The term "cancer" refers to a broad class of diseases
characterized by uncontrolled growth of abnormal cells in vivo.
"Cancer" includes benign and malignant cancers as well as dormant
tumors or micrometastases. Cancer includes primary malignant cells
or tumors (e.g., tumors in which cells have not migrated to a site
other than the site of the original malignant disease or tumor in
the subject) and secondary malignant cells or tumors (e.g., tumors
resulting from metastasis in which cells are metastasized to
malignant cells or tumor cells and then migrate to a secondary site
different from the original tumor site). Cancers also include
hematologic malignancies. "Hematologic malignancies" include
lymphomas, leukemias, myelomas or lymphoid malignancies, as well as
spleen cancer and lymph node tumors.
[0310] In a preferred embodiment, the bispecific antibody of the
present disclosure or nucleic acids or polynucleotides encoding the
antibody of the present disclosure or immunoconjugates or
pharmaceutical compositions or combination therapies are useful for
the treatment, prevention or alleviation of cancer. Examples of
cancers include, but are not limited to, carcinomas, lymphomas,
glioblastomas, melanomas, sarcomas, leukemia, myelomas or lymphoid
malignancies. More specific examples of such cancers are described
below and include: squamous cell carcinoma (e.g., epithelial
squamous cell carcinoma), Ewing's sarcoma, Wilms' tumor,
astrocytoma, lung cancer (including small-cell lung cancer,
non-small-cell lung cancer, lung adenocarcinoma, and lung
squamous-cell carcinoma), peritoneal carcinoma, hepatocellular
carcinoma, stomach or gastric cancer (including gastrointestinal
cancer), pancreatic cancer, glioblastoma multiforme, cervical
cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma,
hepatocellular carcinoma, neuroendocrine tumor, medullary thyroid
cancer, differentiated thyroid cancer, breast cancer, ovarian
cancer, colon cancer, rectal cancer, endometrial or uterine
carcinoma, salivary gland tumors, kidney or renal carcinoma,
prostate cancer, vaginal cancer, anal cancer, penile cancer, and
head and neck cancer.
[0311] Other examples of cancers or malignancies include, but are
not limited to, childhood acute lymphoblastic leukemia, acute
lymphoblastic leukemia, acute lymphocytic leukemia, acute
myelogenous leukemia, adrenocortical carcinoma, adult (primary)
hepatocellular carcinoma, adult (primary) liver cancer, adult acute
lymphocytic leukemia, adult acute myelogenous leukemia, adult
Hodgkin's lymphoma, adult lymphocytic lymphoma, adult non-Hodgkin's
lymphoma, adult primary liver cancer, adult soft tissue sarcoma,
AIDS-related lymphoma, AIDS-related malignancies, anal cancer,
astrocytoma, cholangiocarcinoma, bladder cancer, bone cancer, brain
stem glioma, brain tumor, breast cancer, renal pelvis and ureter
cancer, central nervous system (primary) lymphoma, central nervous
system lymphoma, cerebellar astrocytoma, cerebral astrocytoma,
cervical cancer, childhood (primary) hepatocellular carcinoma,
childhood (primary) liver cancer, childhood acute lymphoblastic
leukemia, childhood acute myelogenous leukemia, childhood brain
stem glioma, childhood cerebellar astrocytoma, childhood cerebral
astrocytoma, childhood extracranial blastoma, childhood Hodgkin's
disease, childhood Hodgkin's lymphoma, childhood hypothalamic and
visual pathway glioma, childhood lymphoblastic leukemia, childhood
medulloblastoma, childhood non-Hodgkin's lymphoma, childhood pineal
and supratentorial primitive neuroectodermal tumors, childhood
primary liver cancer, childhood rhabdomyosarcoma, childhood
soft-tissue sarcoma, childhood visual pathway and hypothalamic
glioma, chronic lymphocytic leukemia, chronic myelogenous leukemia,
colon cancer, cutaneous T-cell lymphoma, endocrine pancreas islet
cell carcinoma, endometrial cancer, ependymoma, epithelial cancer,
esophageal cancer, Ewing's sarcoma and related tumors, exocrine
pancreatic cancer, extracranial blastoma, extragonadal blastoma,
cholangiocarcinoma, retinoblastoma, female breast cancer, Gaucher's
disease, gallbladder carcinoma, gastric cancer, gastrointestinal
benign tumor, gastrointestinal tumors, blastoma, gestational
trophoblastic tumor, hairy cell leukemia, head and neck cancer,
hepatocellular carcinoma, Hodgkin's lymphoma,
hypergammaglobulinemia, hypopharyngeal cancer, intestinal cancers,
intraocular melanoma, islet cell carcinoma, islet cell pancreatic
cancer, Kaposi's sarcoma, kidney cancer, laryngeal cancer, lip and
oral cavity cancer, liver cancer, lung cancer, lymphoproliferative
disorders, macroglobulinemia, male breast cancer, malignant
mesothelioma, malignant thymoma, medulloblastoma, melanoma,
mesothelioma, metastatic primary latent squamous neck cancer,
metastatic primary squamous neck cancer, metastatic squamous neck
cancer, multiple myeloma, multiple myeloma/plasma cell neoplasm,
myelodysplastic syndrome, myelogenous leukemia, myeloid leukemia,
myeloproliferative disorders, nasal cavity and paranasal sinus
cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's
lymphoma, non-melanoma skin cancer, non-small-cell lung cancer,
metastatic primary latent metastatic squamous neck cancer,
oropharyngeal cancer, osteosarcoma/malignant fibrous sarcoma,
osteosarcoma/malignant fibrous histiocytoma, osteosarcoma/malignant
fibrous histiocytoma of bone, ovarian epicytoma, ovarian blastoma,
ovarian low malignant potential tumor, pancreatic cancer,
paraproteinemias, polycythemia vera, parathyroid cancer, penile
cancer, pheochromocytoma, pituitary tumor, primary central nervous
system lymphoma, primary liver cancer, prostate cancer, rectal
cancer, renal cell cancer, renal pelvis and ureter cancer,
retinoblastoma, rhabdomyosarcoma, salivary gland cancer,
sarcoidosis sarcomas, Sezary syndrome, skin cancer, small-cell lung
cancer, small intestine cancer, soft-tissue sarcoma, squamous neck
cancer, stomach cancer, supratentorial primitive neuroectodermal
and pineal tumors, T-cell lymphoma, testicular cancer, thymoma,
thyroid cancer, transitional cell cancer of the renal pelvis and
ureter, transitional renal pelvis and ureter cancer, trophoblastic
tumors, ureter and renal pelvis cell cancer, urethral cancer,
uterine cancer, uterine sarcoma, vaginal cancer, visual pathway and
hypothalamic glioma, vulvar cancer, Waldenstrom's
macroglobulinemia, Wilm's tumor, and any other hyperproliferative
disease, besides neoplasia, located in an organ system listed
above.
Combination Therapy
[0312] The present disclosure relates to uses of a combination of
the bispecific antibody or nucleic acids or polynucleotides
encoding the antibody of the present disclosure or immunoconjugates
or pharmaceutical compositions and one or more active therapeutic
agents (e.g., chemotherapeutic agents) or other prophylactic or
therapeutic modes (e.g., radiation). In such combination therapies,
the various active agents often have different complementary
mechanisms of action, and the combination therapy may lead to
synergistic effects. The combination therapy includes therapeutic
agents that affect immune responses (e.g., an enhanced or activated
response) and therapeutic agents that affect (e.g., inhibit or
kill) tumor/cancer cells. The combination therapy may reduce the
likelihood of drug-resistant cancer cells. The combination therapy
may allow the dose reduction of one or more reagents to reduce or
eliminate adverse effects associated with the one or more reagents.
Such combination therapies may have synergistic therapeutic or
prophylactic effects on underlying diseases, disorders or
symptoms.
[0313] The "combination" includes therapies that can be
administered separately, for example, separate formulations for
individual administration (e.g., which may be provided in a kit),
and therapies that can be administered together in a single
formulation (i.e., "co-formulation"). In some embodiments, the
bispecific antibody of the present disclosure or nucleic acids or
polynucleotides encoding the antibody of the present disclosure or
immunoconjugates or pharmaceutical compositions may be administered
sequentially. In some embodiments, the bispecific antibody of the
present disclosure or nucleic acids or polynucleotides encoding the
antibody of the present disclosure or immunoconjugates or
pharmaceutical compositions may be administered simultaneously. The
bispecific antibody or nucleic acids or polynucleotides encoding
the antibody of the present disclosure or immunoconjugates or
pharmaceutical compositions may be used in any manner in
combination with at least one other (active) agent.
[0314] Treatment with the bispecific antibody of the present
disclosure may be combined with other treatments that are effective
against the to-be-treated disease. Non-limiting examples of
antibody combination therapies of the present disclosure include
surgery, chemotherapy, radiation therapy, immunotherapy, gene
therapy, DNA therapy, RNA therapy, nanotherapy, viral therapy, and
adjuvant therapy.
[0315] Combination therapies also include all other combination
therapies known in the art or developed in the future.
BRIEF DESCRIPTION OF DRAWINGS
[0316] FIG. 1-1 illustrates configurations of bispecific antibodies
AB7K, AB7K4, AB7K5, AB7K6, AB7K7, and AB7K8 as shown in a, b, c, d,
e and f, respectively.
[0317] FIG. 1-2 illustrates an expression plasmid map of bispecific
antibody AB7K7. The expression plasmid has a full length of 9293 bp
and contains nine major gene fragments which are (1) an hCMV
promoter, (2) target genes, (3) EMCV IRES, (4) mDHFR screening
gene, (5) a Syn discontinuation sequence, (6) an SV40 promoter, (7)
Kalamycin resistance gene; (8) an SV40 termination sequence, and
(9) a PUC replicon.
[0318] FIG. 1-3 illustrates SEC-HPLC detection results of a
purified sample of bispecific antibody AB7K7.
[0319] FIG. 1-4 illustrates SDS-PAGE electrophoresis results of a
purified sample of bispecific antibody AB7K7.
[0320] FIG. 1-5 illustrates SDS-PAGE results of bispecific antibody
AB7K7 in an acceleration test at 25.degree. C.
[0321] FIG. 1-6 illustrates SDS-PAGE results of bispecific antibody
AB7K7 in a freeze-thaw test.
[0322] FIG. 2-1 illustrates abilities, detected by FACS, of
bispecific antibodies AB7K and AB7K4 to bind to tumor cells
BT474.
[0323] FIG. 2-2 illustrates abilities, detected by FACS, of
bispecific antibodies AB7K and AB7K5 to bind to tumor cells
BT474.
[0324] FIG. 2-3 illustrates abilities, detected by FACS, of
bispecific antibodies AB7K and AB7K6 to bind to tumor cells
BT474.
[0325] FIG. 2-4 illustrates abilities, detected by FACS, of
bispecific antibodies AB7K and AB7K7 to bind to tumor cells
BT474.
[0326] FIG. 2-5 illustrates an ability, detected by FACS, of
bispecific antibody AB7K8 to bind to tumor cells BT474.
[0327] FIG. 2-6 illustrates abilities, detected by FACS, of
bispecific antibodies AB7K and AB7K4 to bind to effector cells
CIK.
[0328] FIG. 2-7 illustrates abilities, detected by FACS, of
bispecific antibodies AB7K and AB7K5 to bind to effector cells
CIK.
[0329] FIG. 2-8 illustrates an ability, detected by FACS, of
bispecific antibody AB7K6 to bind to effector cells CIK.
[0330] FIG. 2-9 illustrates abilities, detected by FACS, of
bispecific antibodies AB7K and AB7K7 to bind to effector cells
CIK.
[0331] FIG. 2-10 illustrates an ability, detected by FACS, of
bispecific antibody AB7K8 to bind to effector cells CIK.
[0332] FIG. 2-11 illustrates an ability, detected by FACS, of
bispecific antibody AB7K to bind to cynomolgus monkey T cells.
[0333] FIG. 2-12 illustrates abilities, detected by ELISA, of five
Anti-Her2.times.CD3 bispecific antibodies to bind to CD3 molecules
and Her2 molecules.
[0334] FIG. 2-13 illustrates abilities, detected by a microplate
reader, of five Anti-Her2.times.CD3 bispecific antibodies to
activate Jurkat T cells of a reporter gene cell strain.
[0335] FIG. 2-14 illustrates structural modeling of a CTP linker
and anti-CD3 scFv VH.
[0336] FIG. 2-15 illustrates structural modeling of a GS linker and
anti-CD3 scFv VH.
[0337] FIG. 2-16 illustrates a molecular docking model of anti-CD3
scFv and a CD3 epsilon chain.
[0338] FIG. 3-1 illustrates in vivo anti-tumor effects of
bispecific antibodies AB7K4 and AB7K7 in an NCG mouse model of
transplanted tumor constructed by subcutaneously co-inoculating
human CIK cells and HCC1954 cells.
[0339] FIG. 3-2 illustrates an in vivo anti-tumor effect of
bispecific antibody AB7K7 in an NPG mouse model of transplanted
tumor constructed by subcutaneously co-inoculating human CIK cells
and human breast cancer cells HCC1954.
[0340] FIG. 3-3 illustrates in vivo anti-tumor effects of
bispecific antibodies AB7K7 and AB7K8 at different administration
frequencies in an NPG mouse model of transplanted tumor constructed
by subcutaneously co-inoculating human CIK cells and human breast
cancer cells HCC1954.
[0341] FIG. 3-4 illustrates an in vivo anti-tumor effect of
bispecific antibody AB7K7 in an NPG mouse of transplanted tumor
constructed by subcutaneously co-inoculating human CIK cells and
SK-OV-3 cells.
[0342] FIG. 3-5 illustrates an in vivo anti-tumor effect of
bispecific antibody AB7K7 in an NPG mouse of transplanted tumor
constructed by subcutaneously co-inoculating human CIK cells and
HT-29 cells.
[0343] FIG. 3-6 illustrates an in vivo anti-tumor effect of
bispecific antibody AB7K7 in a CD34 immune-reconstituted NPG mouse
model of transplanted tumor constructed by subcutaneously
inoculating human breast cancer cells HCC1954.
[0344] FIG. 3-7 illustrates an in vivo anti-tumor effect of
bispecific antibody AB7K7 in a PBMC immune-reconstituted NPG mouse
model of transplanted tumor constructed by subcutaneously
inoculating human breast cancer cells HCC1954.
[0345] FIG. 4-1 illustrates in vivo anti-tumor effects of
bispecific antibodies AB7K4 and AB7K7 in an NCG mouse model of
transplanted tumor constructed by subcutaneously co-inoculating
human CIK cells and human Burkkit's lymphoma Raji cells.
[0346] FIG. 4-2 illustrates an anti-tumor effect of bispecific
antibody AB7K7 in an NPG mouse model of transplanted tumor
constructed by subcutaneously inoculating human breast cancer cells
HCC1954.
[0347] FIG. 4-3 illustrates changes of weights in normal cynomolgus
monkeys administered with bispecific antibodies AB7K7 and AB7K8
multiple times.
[0348] FIG. 5-1 illustrates concentration-time curves of bispecific
antibody AB7K7 in SD rats by two ELISA methods.
[0349] FIG. 5-2 illustrates concentration-time curves of bispecific
antibody AB7K8 in SD rats by two ELISA methods.
[0350] FIG. 5-3 illustrates concentration-time curves of bispecific
antibodies AB7K7 and AB7K8 in cynomolgus monkeys.
[0351] FIG. 5-4 illustrates abilities, detected at a pH of 6.0, of
bispecific antibodies AB7K, AB7K5, and AB7K7 to bind to FcRn.
[0352] FIG. 5-5 illustrates abilities, detected at a pH of 7.0, of
bispecific antibodies AB7K, AB7K5, and AB7K7 to bind to FcRn.
[0353] FIG. 6-1 illustrates an in vivo anti-tumor effect of
bispecific antibody AB9K in a NOD-SCID mouse of transplanted tumor
model constructed by subcutaneously co-inoculating human PBMC cells
and Huh-7 cells.
[0354] FIG. 6-2 illustrates an in vivo anti-tumor effect of
bispecific antibody AB9K in a CD34 immune-reconstituted NPG mouse
model of transplanted tumor constructed by subcutaneously
inoculating human liver cancer cells Huh-7.
[0355] FIG. 6-3 illustrates an in vivo anti-tumor effect of
bispecific antibody AB9K in a CD34 immune-reconstituted NPG mouse
model of transplanted tumor constructed by subcutaneously
inoculating human liver cancer cells Huh-7.
[0356] FIG. 7-1 illustrates an ability, detected by flow cytometry,
of bispecific antibody AB2K to bind to CD20-positive tumor
cells.
[0357] FIG. 7-2 illustrates abilities of bispecific antibodies AB2K
and AB7K7 to mediate effector cells to kill Raji-luc cells.
[0358] FIG. 7-3 illustrates abilities, detected by reporter gene
assay, of bispecific antibodies AB2K and AB7K7 to activate Jurkat
NFATRE Luc cells.
[0359] FIG. 7-4 illustrates an in vivo anti-tumor effect of
bispecific antibody AB2K in an NPG mouse model of transplanted
tumor constructed by subcutaneously co-inoculating human CIK cells
and human Burkkit's lymphoma Raji cells.
[0360] FIG. 7-5 illustrates an in vivo anti-tumor effect of
bispecific antibody AB2K in an NPG mouse model of transplanted
tumor constructed by subcutaneously co-inoculating human CIK cells
and human Burkkit's lymphoma Daudi cells.
[0361] FIG. 8 illustrates changes of leukocytes and lymphocytes in
normal cynomolgus monkeys administered with bispecific antibody
AB2K multiple times.
[0362] FIG. 9-1 illustrates an ability, detected by FACS, of an
Anti-CD19.times.CD3 bispecific antibody to bind to tumor cells
Raji.
[0363] FIG. 9-2 illustrates an ability, detected by FACS, of an
Anti-CD19.times.CD3 bispecific antibody to bind to effector cells
CIK.
[0364] FIG. 9-3 illustrates abilities, detected by FACS, of
bispecific antibodies AB1K2 and AB23P10 to bind to cynomolgus
monkey T cells.
[0365] FIG. 9-4 illustrates abilities, detected through an ELISA,
of four Anti-CD19.times.CD3 bispecific antibodies to bind to CD3
molecules and CD19 molecules.
[0366] FIG. 9-5 illustrates abilities, detected by a microplate
reader, of bispecific antibodies AB1K2 and AB23P8 to activate
Jurkat T cells of a reporter gene cell strain.
[0367] FIG. 9-6 illustrates abilities, detected through a
microplate reader, of four Anti-CD19.times.CD3 bispecific
antibodies to activate Jurkat T cells of a reporter gene cell
strain.
[0368] FIG. 10-1 illustrates binding of AB11K to tumor cells that
overexpress antigen Mucin1 and to primary T cells of human or
cynomolgus monkeys.
[0369] FIG. 10-2 illustrates an ability of AB11K to mediate
expanded T cells to kill tumor cells.
[0370] FIG. 10-3 illustrates an ability of AB11K to mediate PBMC to
kill tumor cells.
[0371] FIG. 10-4 illustrates an ability of AB11K to specifically
activate T cells.
[0372] FIG. 11 illustrates an in vivo anti-tumor effect of
bispecific antibody AB8K in an NPG mouse model of transplanted
tumor constructed by subcutaneously co-inoculating human CIK cells
and human skin cancer cells A431.
DETAILED DESCRIPTION
[0373] The present disclosure is further described through examples
that should not be construed as further limitations. All drawings,
all reference documents, and the contents of patents and published
patent applications cited in the entire application are expressly
incorporated herein by reference.
Example 1 Design and Preparation of Anti-Her2.times.CD3 Bispecific
Antibodies Having Different Structures
1.1 Design of Bispecific Antibodies Having Different Structures
[0374] In order to screen bispecific antibodies having suitable
configuration, bispecific antibodies having six different
configurations were designed for Her2 and CD3, among which AB7K5,
AB7K6, and AB7K8 are single-chain bivalent bispecific antibodies
while AB7K, AB7K4, and AB7K7 are double-chain tetravalent
bispecific antibodies (see FIG. 1-1), where only AB7K8 is free of
Fc fragments. Specifically, the configuration of the bispecific
antibodies with the above four configurations and their composition
from the N-terminus to the C-terminus as well as their amino acid
sequence numbers are shown in Table 1-1. The specific structural
composition properties of the six bispecific antibodies are
described below:
[0375] Bispecific antibody AB7K consists of an anti-Her2
full-length antibody whose two heavy chains are each linked at the
C-terminus to an anti-CD3 scFv domain by a linker peptide (L1). For
the amino acid sequence of the intact antibody against Her2
contained in AB7K, reference is made to the sequence of monoclonal
antibody Herceptin.RTM. (IMGT database INN 7637), wherein AB7K
contains an Fc fragment from human IgG1 and has D356E/L358M
mutations (EU numbering). The linker peptide L1 consists of a
flexible peptide and a rigid peptide, wherein the composition of
the flexible peptide is GS(GGGGS).sub.3 and the rigid peptide is
SSSSKAPPPSLPSPSRLPGPSDTPILPQ, wherein the composition of the linker
peptide L2 between VH and VL of the anti-CD3 scFv is
(GGGGS).sub.3.
[0376] Bispecific antibody AB7K4 consists of an anti-Her2
full-length antibody whose two light chains are each linked at the
C-terminus to an anti-CD3 scFv domain by a linker peptide (L1). For
the amino acid sequence of the heavy chain variable region of the
intact antibody against Her2 contained in AB7K4, reference is made
to the available region sequence of the monoclonal antibody
Herceptin.RTM., and for the light chain amino acid sequence
thereof, reference is made to the light chain amino acid sequence
of the monoclonal antibody Herceptin.RTM. (IMGT database INN 7637).
The AB7K4 heavy chain contains an Fc fragment from human IgG1, has
multiple amino acid substitutions/replacements, which are L234A,
L235A, T250Q, N297A, P331S, and M428L (EU numbering), respectively,
and also has a deleted/missed K447 (EU numbering) at the C-terminus
of the Fc fragment. The linker peptide L1 consists of a flexible
peptide and a rigid peptide, wherein the composition of the
flexible peptide is G.sub.2(GGGGS).sub.3 and the rigid peptide is
SSSSKAPPPS, wherein the composition of the linker peptide L2
between VH and VL of the anti-CD3 scFv is (GGGGS).sub.3.
[0377] Bispecific antibody AB7K5 consists of an anti-Her2 scFv, an
Fc fragment, a linker peptide L2 and an anti-CD3 scFv, which are
sequentially connected in series, wherein VH and VL in the
anti-Her2 scFv are connected by a linker peptide L1, and VH and VL
in the anti-CD3 scFv are connected by a linker peptide L3. For the
amino acid sequence of the scFv against Her2 contained in AB7K5,
reference is made to the available region sequence of the
monoclonal antibody Herceptin.RTM.. The AB7K5 contains an Fc
fragment from human IgG1 and has multiple amino acid
substitutions/replacements, which are C226S, C229S, L234A, L235A,
T250Q, N297A, P331S, T366R, L368H, K409T, and M428L (EU numbering),
respectively. Mutations at the five sites C226S, C229S, T366R,
L368H, and K409T can prevent polymerization between Fc fragments,
thereby promoting the formation of a single-chain bivalent
bispecific antibody. ADCC and CDC activities are removed from Fc
fragments carrying the mutations L234A/L235A/P331S. The mutations
T250Q/M428L can enhance the binding affinity of Fc fragments for
the receptor FcRn, thereby extending the half-life. The mutation
N297A avoids antibody glycosylation and loses the ability to bind
Fc.gamma.Rs. In addition, K447 (EU numbering) at the C-terminus of
the Fc fragment is deleted/missed, thereby eliminating the charge
heterogeneity of the antibody. The linker peptide (L2) consists of
a flexible peptide and a rigid peptide, wherein the flexible
peptide is G.sub.2(GGGGS).sub.3 and the rigid peptide is
SSSSKAPPPS. The composition of the linker peptides L1 and L3 inside
each scFv is (GGGGS).sub.3.
[0378] Bispecific antibody AB7K6 consists of an anti-Her2 scFv, a
linker peptide L2, an anti-CD3 scFv, and an Fc fragment, which are
sequentially connected in series, wherein VH and VL in the
anti-Her2 scFv are connected by a linker peptide L1, and VH and VL
in the anti-CD3 scFv are connected by a linker peptide L3. The
AB7K6 contains an Fc fragment from human IgG1 and has multiple
amino acid substitutions/replacements, which are C226S, C229S,
L234A, L235A, T250Q, N297A, P331S, T366R, L368H, K409T, and M428L
(EU numbering), respectively. Mutations at the five sites C226S,
C229S, T366R, L368H, and K409T can prevent polymerization between
Fc fragments, thereby promoting the formation of a single-chain
bivalent bispecific antibody. ADCC and CDC activities are removed
from Fc fragments carrying the mutations L234A/L235A/P331S. The
mutations T250Q/M428L can enhance the binding affinity of Fc
fragments for the receptor FcRn, thereby extending the half-life.
The mutation N297A avoids antibody glycosylation and loses the
ability to bind Fc.gamma.Rs. In addition, K447 (EU numbering) at
the C-terminus of the Fc fragment is deleted/missed, thereby
eliminating the charge heterogeneity of the antibody. The linker
peptide (L2) consists of a flexible peptide and a rigid peptide,
wherein the flexible peptide is G.sub.2(GGGGS).sub.3 and the rigid
peptide is SSSSKAPPPS. The composition of the linker peptides L1
and L3 inside each scFv is (GGGGS).sub.3.
[0379] Bispecific antibody AB7K7 consists of an anti-Her2 scFv, a
linker peptide L2, an anti-CD3 scFv, and an Fc fragment, which are
sequentially connected in series, wherein VH and VL in the
anti-Her2 scFv are connected by a linker peptide L1, and VH and VL
in the anti-CD3 scFv are connected by a linker peptide L3. For the
amino acid sequence of the scFv against Her2 contained in AB7K7,
reference is made to the available region sequence of the
monoclonal antibody Herceptin.RTM.. The AB7K7 contains an Fc
fragment from human IgG1, and has multiple amino acid
substitutions/replacements, which were L234A, L235A, T250Q, N297A,
P331S, and M428L (EU numbering), respectively, and also has a
deleted/missed K447 (EU numbering) at the C-terminus of the Fc
fragment. The linker peptide (L2) consists of a flexible peptide
and a rigid peptide, wherein the flexible peptide is
G.sub.2(GGGGS).sub.3 and the rigid peptide is SSSSKAPPPS. The
composition of the linker peptides L1 and L3 inside each scFv is
(GGGGS).sub.3.
[0380] Bispecific antibody AB7K8 consists of an anti-Her2 scFv, a
linker peptide L2, an anti-CD3 scFv, and a His-tag, which are
sequentially connected in series, wherein VH and VL in the
anti-Her2 scFv are connected by a linker peptide L1, and VH and VL
in the anti-CD3 scFv are connected by a linker peptide L3. For the
amino acid sequence of the scFv against Her2 contained in AB7K8,
reference is made to the available region sequence of the
monoclonal antibody Herceptin.RTM.. AB7K8 is added with a His-tag
at the C-terminus of the anti-CD3 scFv to facilitate antibody
purification, wherein the composition of the His tag is HHHHHHHH.
The linker peptide (L2) consists of a flexible peptide and a rigid
peptide, wherein the flexible peptide is G.sub.2(GGGGS).sub.3 and
the rigid peptide is SSSSKAPPPS. The composition of the linker
peptides L1 and L3 inside each scFv is (GGGGS).sub.3.
[0381] VH and VL amino acid sequences of the anti-CD3 scFv
contained in the above six bispecific antibodies are as shown in
SEQ ID NO: 247 and SEQ ID NO: 248, respectively, wherein VH and VL
are connected to each other by (GGGGS).sub.3. The monoclonal
antibody (designated as CD3-3) specifically binds to human and
cynomolgus monkey CD3 antigens and has a weak binding affinity for
CD3.
TABLE-US-00001 TABLE 1-1 Bispecific antibodies with four different
structures against Her2 and CD3 Amino acid Code Configuration
Composition from N-terminus to C-terminus sequence No. Single-chain
AB7K5 scFv-mFc-scFv [VH-L1-VL].sub.Her2-mFc-L2-[VH-L3-VL].sub.CD3
SEQ ID NO: 1 bivalent AB7K6 scFv-scFv-mFc [VH-L1-VL].sub.Her2
L2-[VH-L3-VL].sub.CD3-mFc SEQ ID NO: 2 bispecific AB7K8
scFv-scFv-His tag [VH-L1-VL].sub.Her2-L2-[VH-L3-VL].sub.CD3-H.sub.8
SEQ ID NO: antibody 3 Double-chain AB7K IgG(H)-scFv
[VH-CH].sub.Her2-L1-[VH-L2-VL].sub.CD3 SEQ ID NO: 4 tetravalent
[VL-CL].sub.Her2 SEQ ID NO: 5 bispecific AB7K4 IgG(L)-scFv
[VH-CH].sub.Her2 SEQ ID NO: 6 antibody
[VL-CL].sub.Her2-L1-[VH-L2-VL].sub.CD3 SEQ ID NO: 7 AB7K7
scFv-scFv-mFc [VH-L1-VL].sub.Her2-L2-[VH-L3-VL].sub.CD3-mFc SEQ ID
NO: 8 Note: Ln in the table represents the linker peptides between
different structural units, wherein n is numbered sequentially in
the order of the linker peptides contained between different
structural units from the N-terminus to the C-terminus of the
bispecific antibody.
1.2 Construction of an Expression Vector of a Bispecific Antibody
Molecule
[0382] Genes encoding the preceding five bispecific antibodies were
synthesized by conventional molecular biology method, and cDNAs
encoding the obtained fusion genes were inserted into corresponding
restriction endonuclease sites of eukaryotic expression plasmids
pCMAB2M modified with PCDNA3.1. The heavy chains and light chains
of AB7K and AB7K4 may be constructed into one vector or separately
into two different vectors. For example, the expression plasmid map
of AB7K7 is as shown in FIG. 1-2, wherein the plasmid contains
cytomegalovirus early promoter. The promoter is an enhancer
required for the high-level expression of foreign genes in
mammalian cells. The plasmid pCMAB2M also contains a selective
marker so that kanamycin resistance may be present in bacteria and
G418 resistance may be present in mammalian cells. In addition,
when host cells are deficient in the expression of DHFR genes, the
pCMAB2M expression vector contains mouse dihydrofolate reductase
(DHFR) genes so that target genes and the DHFR genes can be
co-amplified in the presence of methotrexate (MTX) (see U.S. Pat.
No. 4,399,216).
1.3 Expression of Bispecific Antibody Molecules
[0383] The preceding constructed expression plasmids were
transfected into a mammalian host cell line to express bispecific
antibodies. To maintain stable and high-level expression, the
preferred host cell line is a DHFR deficient CHO-cell (see U.S.
Pat. No. 4,818,679), and in this Example, the host cell was
selected as the CHO-derived cell strain DXB11. A preferred
transfection method is electroporation. Other methods, including
calcium phosphate co-precipitation and lipofection may also be
used. During electroporation, 50 .mu.g of expression vector
plasmids DNA were added to 5.times.10.sup.7 cells in a cuvette with
a Gene Pulser Electroporator (Bio-Rad Laboratories, Hercules,
Calif.) with an electric field of 300 V and capacitance of 1500
.mu.Fd. After two-day transfection, the medium was changed to a
growth medium containing 0.6 mg/mL G418. Transfectants were
subcloned by the limiting dilution method, and the secretion rate
of each cell line was determined by ELISA. Cell strains expressing
bispecific antibodies at high levels were screened.
[0384] To achieve the high-level expression of fusion proteins,
DHFR genes inhibited by MTX should be used for co-amplification.
The transfected fusion protein genes were co-amplified with the
DHFR genes in growth media containing MTX with increasing
concentrations. Subclones that were positive for DHFR expression
were subjected to limiting dilution with gradually increased
pressure to screen transfectants capable of growing in media with
MTX of up to 6 .mu.M. The secretion rates of the transfectants were
determined and cell lines with high foreign protein expression were
screened. Cell lines with a secretion rate of greater than about 5
.mu.g/10.sup.6 (millions) cells/24 hours (preferably about 15
.mu.g/10.sup.6 cells/24 hours) were adaptively suspended using a
serum-free medium. Cell supernatants were collected and bispecific
antibodies were separated and purified.
[0385] Hereinafter, the purification process, stability, in vitro
and in vivo biological functions, safety, and pharmacokinetics of
the bispecific antibodies of several configurations were evaluated
to screen the bispecific antibody of an appropriate
configuration.
1.4 Purification Process and Stability Detection of Bispecific
Antibodies
[0386] Antibodies are generally purified by a three-step
purification strategy: crude purification (sample capture),
intermediate purification, and fine purification. In the crude
purification stage, the target antibodies are generally captured by
affinity chromatography which can effectively remove a large number
of impurities such as heterologous proteins, nucleic acids,
endotoxins, and viruses from the sample. The intermediate
purification is often carried out using hydrophobic chromatography
or CHT hydroxyapatite chromatography to remove most of the
remaining impurity proteins and polymers. Fine purification is
mostly carried out using anion exchange chromatography or gel
filtration chromatography (molecular sieve) to remove the small or
trace amount of remaining impurity proteins whose nature is similar
to the nature of the target antibodies and further to remove
contaminants such as HCP and DNA.
[0387] In the present disclosure, the culture supernatant of
bispecific antibody AB7K8 fused with His-tag can be crudely
purified using a metal chelation affinity chromatography column
(e.g., HisTrap FF from GE). The bispecific antibodies AB7K4, AB7K5,
AB7K6, AB7K, and AB7K7 containing Fc can be crudely purified using
a Protein A/G affinity chromatography column (e.g., Mabselect SURE
from GE). The products obtained after the above crude purification
are then subjected to the intermediate purification and the fine
purification to finally obtain purified target antibodies of high
purity and high quality. The preservation buffers for the above
bispecific antibodies are then replaced with PBS or other suitable
buffers using desalination columns (e.g., HiTrap desalting from
GE).
a) Purification of Double-Chain Tetravalent Bispecific Antibody
AB7K7
[0388] Specific purification steps and solutions for such
bispecific antibodies of a tetravalent homodimer configuration are
illustrated below by using an example of AB7K7.
[0389] The bispecific antibody AB7K7 was purified by three-step
chromatography. The three-step chromatography included affinity
chromatography, hydrophobic chromatography, and anion exchange
chromatography. (The protein purifier used in this example was AKTA
pure 25 M from GE, U.S. Reagents used in this example were
purchased from Sinopharm Chemical Reagent Co., Ltd and had purity
at an analytical grade).
[0390] In a first step, affinity chromatography was performed.
Sample capture and concentration and the removal of partial
pollutants were performed using an affinity chromatography medium
MabSelect Sure from GE or other commercially available affinity
media (e.g., Diamond Protein A from Bestchrom). First,
chromatography columns were equilibrated with 3-5 column volumes
(CVs) of an equilibration buffer (20 mM PB, 140 mM NaCl, pH 7.4) at
a linear flow rate of 100-200 cm/h. The clarified fermentation
broth was loaded at a linear flow rate of 100-200 cm/h with a load
not higher than 20 mg/mL. After loading, the chromatography columns
were equilibrated with 3-5 column volumes (CVs) of an equilibration
buffer (20 mM PB, 140 mM NaCl, pH 7.4) at a linear flow rate of
100-200 cm/h to remove unbound components. The chromatography
columns were rinsed with 3-5 column volumes of decontamination
buffer 1 (50 mM NaAc-HAc, 1 M NaCl, pH 5.0) at a linear flow rate
of 100-200 cm/h to remove partial pollutants. The chromatography
columns were equilibrated with 3-5 column volumes (CVs) of
decontamination buffer 2 (50 mM NaAc-HAc, pH 5.0) at a linear flow
rate of 100-200 cm/h. The target product was eluted using an
elution buffer (40 mM NaAc-HAc, pH 3.5) at a linear flow rate not
higher than 100 cm/h and target peaks were collected.
[0391] In a second step, hydrophobic chromatography was performed.
Intermediate purification was performed using Butyl HP from
Bestchrom or other commercially available hydrophobic
chromatography media to reduce the content of polymers. After the
target proteins were polymerized, since the polymers and monomers
differed in property such as charge characteristics and
hydrophobicity, the polymers and the monomers could be separated on
the basis of the above differences between them. First,
chromatography columns were equilibrated with 3-5 column volumes
(CVs) of an equilibration buffer (20 mM PB, 0.3 M
(NH.sub.4).sub.2SO.sub.4, pH 7.0) at a linear flow rate of 100-200
cm/h. The target proteins separated through the affinity
chromatography in the first step were subjected to conductivity
adjustment to 40-50 ms/cm with the solution of 2 M
(NH.sub.4).sub.2SO.sub.4 and then loaded with a load controlled to
be less than 20 mg/mL. After loading, the chromatography columns
were rinsed with 3-5 column volumes (CVs) of an equilibration
buffer (20 mM PB, 0.3 M (NH.sub.4).sub.2SO.sub.4, pH 7.0) at a
linear flow rate of 100-200 cm/h. Finally, the target proteins were
eluted using 3-5 column volumes (CVs) of an elution buffer (20 mM
PB, pH 7.0) with gradients of 40%, 80% and 100% at a linear flow
rate not higher than 100 cm/h. Eluted fractions were collected and
sent for SEC-HPLC, respectively. Target components with the
percentage of monomers being greater than 90% were combined for
chromatography in the next step.
[0392] In a third step, anion exchange chromatography was
performed. Fine purification was performed by using Q-HP from
Bestchrom or other commercially available anion exchange
chromatography media (e.g., Q HP from GE, Toyopearl GigaCap Q-650
from TOSOH, DEAE Beads 6FF from Smart-Lifesciences, Generik MC-Q
from Sepax Technologies, Inc, Fractogel EMD TMAE from Merck, and Q
Ceramic HyperD F from Pall) to separate structural variants and
further remove pollutants such as HCP and DNA. First,
chromatography columns were rinsed with 3-5 column volumes (CVs) of
an equilibration buffer (20 mM PB, pH 7.0) at a linear flow rate of
100-200 cm/h. The target proteins separated through the
hydroxyapatite chromatography in the second step were loaded and
through-flow peaks were collected. After loading, the
chromatography columns were rinsed with 3-5 column volumes (CVs) of
an equilibration buffer (20 mM PB, pH 7.0) at a linear flow rate of
100-200 cm/h. The through-flow components were collected and sent
for the detection of protein content, SEC-HPLC and
electrophoresis.
[0393] The SEC-HPLC purity results and SDS-PAGE electrophoresis
results of the samples are shown in FIG. 1-3 and FIG. 1-4. The
SEC-HPLC results show that the purity of the main peak of the
bispecific antibody was more than 95% after three-step
chromatography. The band pattern in the SDS-PAGE electrophoresis
was as expected, wherein a band was shown at 180 KDa in the
non-reducing electrophoresis and a clear single-chain band (90 KDa)
was obtained after reduction.
b) Purification of Single-Chain Bivalent Bispecific Antibodies
AB7K5 and AB7K6
[0394] The bispecific antibody AB7K5 was purified by Protein A
affinity chromatography and hydroxyapatite (CHT) chromatography.
After the SEC-HPLC test, it was found that the purity of bispecific
antibody AB7K5 was low, its yield was not high, and there was a
problem of extremely low expression yield.
[0395] For another single-chain bivalent bispecific antibody AB7K6,
there also was a problem of high process development difficulty.
The bispecific antibody AB7K6 was subjected to two-step
purification, that is, Protein A affinity chromatography and
molecular sieve chromatography Superdex 200. After the SEC-HPLC
test, it was found that it was difficult to quantify the purity of
bispecific antibody AB7K6, and there was a significant "shoulder
peak" in the main peak; in addition, the expression yield of AB7K6
was very low and very unstable. After 24 hours of standing in a
refrigerator at 4.degree. C., it was found that the peak shape in
the SEC-HPLC result was changed from two peaks to one main peak,
which attributed, presumably, to the conversion from the
single-chain structure to the double-chain structure in AB7K6. From
the above, it can be seen that the current process development
difficulty of AB7K6 is too high to achieve process scale-up and
industrialization.
[0396] In summary, AB7K7 had significant advantages over AB7K5 and
AB7K6 in terms of process development and had advantages such as
high yield, simple and efficient purification methods, and stable
downstream processes. The physicochemical stability of AB7K7 in
different buffer systems and at different storage conditions was
further studied.
c) Assay on Stability of Bispecific Antibody AB7K7
[0397] The stability of AB7K7 proteins in a citrate buffer system
(20 mM citrate, pH 5.5) and a histidine buffer system (20 mM
histidine, pH 5.5) was studied, respectively. AB7K7 proteins were
stored for four weeks under accelerated conditions at 25.degree. C.
for the evaluation of protein stability.
[0398] AB7K7 proteins were transferred to the preceding citrate
buffer system (F2) and the histidine buffer system (F3),
respectively, with the concentration adjusted to 0.5 mg/mL, wherein
8% sucrose (w/v) and 0.02% PS80 (w/v) were added to both buffer
systems as excipients. The above buffer systems were filtered using
a 0.22 m PES membrane needle filter, and then vialed into 2 mL
penicillin bottles, respectively, 0.8 mL in each bottle. After the
vialing, a stopper was immediately pressed and capped. Samples were
placed in different stability chambers according to the schemes in
Table 1-2. Samples were taken at each sampling point for detection
and analysis, wherein the detection terms included appearance,
concentration, purity (detected by SEC-HPLC), HMW %, LMW %, and
turbidity (A340) of the sample.
TABLE-US-00002 TABLE 1-2 Stability detection scheme Condition
T.sub.0 Sampling point and detection term 40.degree. C. X, Y 1 Week
(W) 2 W 4 W X, Y X X, Y 25.degree. C. 1 W 2 W 4 W X, Y X X, Y
Freeze-thaw 3 cycles (-70.degree. C./ X, Y room temperature) Note:
X = appearance, concentration, SEC-HPLC, SDS-PAGE (reducing &
non-reducing); Y = turbidity (A340)
[0399] The appearance, concentration, turbidity and SEC-HPLC
detection results of two preparations stored for 0-4 weeks at
25.degree. C. are shown in Table 1-3 and Table 1-4, and SDS-PAGE
(reducing/non-reducing) results thereof are shown in FIG. 1-5.
There was no significant change in the appearance and concentration
of the two preparations. In the SEC-HPLC results, the SEC results
of the F2 and F3 preparations did not show any significant change.
The purity after 4 weeks was 97.9% and 98.2%, respectively.
SDS-PAGE (reducing/non-reducing) results were generally consistent
with the trend of LMW % results, and F2 and F3 slightly
changed.
[0400] To know the unfolding temperature of AB7K7 proteins in the
two buffer systems, the Tm (unfolding temperature) and Tmonset (the
temperature at which the protein begins to unfold) in the two
preparations were measured by DSF and the results are shown in
Table 1-5. Both preparations had low Tmonset values, and F2 and F3
had Tmonset values less than 45.degree. C.
TABLE-US-00003 TABLE 1-3 Appearance, concentration, and turbidity
results in the acceleration test at 25.degree. C. Appearance
Concentration Turbidity A340 T 0 1 W 2 W 4 W T 0 1 W 2 W 4 W T 0* 1
W 4 W F2 Colorless clear liquid without 0.46 0.46 0.45 0.46 0.003
0.004 0.002 F3 visible foreign matter 0.47 0.46 0.45 0.47 0.004
0.003 0.005 *T 0 turbidity: the sample to be detected was a sample
subjected to 1 cycle of freeze-thaw.
TABLE-US-00004 TABLE 1-4 SEC-HPLC results in the acceleration test
at 25.degree. C. SEC-Purity % SEC-HMW % SEC-LMW % T 0 1 W 2 W 4 W T
0 1 W 2 W 4 W T 0 1 W 2 W 4 W F2 97.5 98.3 98.5 97.9 2.5 1.5 1.5
1.5 0 0.3 0.0 0.6 F3 97.7 98.8 98.7 98.2 2.3 1.2 1.3 1.2 0 0.0 0.0
0.6
TABLE-US-00005 TABLE 1-5 DSF results Tmonset (.degree. C.) Tm1
(.degree. C.) Tm2 (.degree. C.) F2 42.0 46.0 60.5 F3 41.0 45.0
58.0
[0401] The stability of AB7K7 proteins in the above two buffer
systems during freeze-thaw (-70.degree. C./room temperature, 3
cycles of freeze-thaw) was studied by performing 3 cycles of
freeze-thaw. The preparation and detection solution of the sample
were the same as those described above.
[0402] The appearance, concentration, turbidity and SEC-HPLC
detection results of samples are shown in Table 1-6, and SDS-PAGE
(reducing/non-reducing) results thereof are shown in FIG. 1-6. In
the SDS-PAGE (non-reducing) results, there were no significant
changes in the results of each detection item of both F2 and F3
preparations subjected to three cycles of freeze-thaw.
TABLE-US-00006 TABLE 1-6 Appearance, concentration, turbidity, and
SEC-HPLC results in the freeze-thaw test Appearance Concentration
Turbidity A340 SEC-Purity % SEC-HMW % SEC-LMW % T 0 FT-3 C. T 0
FT-3 C. T 0 FT-3 C. T 0 FT-3 C. T 0 FT-3 C. T 0 FT-3 C. F2
Colorless Colorless 0.46 0.46 0.003 0.005 97.5 98.4 2.5 1.6 0 0.0
F3 clear liquid clear liquid 0.47 0.48 0.004 0.005 97.7 98.5 2.3
1.4 0 0.2 without visible without visible foreign matter foreign
matter *T 0 turbidity: the sample to be detected was a sample
subjected to 1 cycle of freeze-thaw.
Example 2 Evaluation of In Vitro Biological Functions of
Anti-Her2.times.CD3 Bispecific Antibodies
2.1 Detection of Binding Activities of Bispecific Antibodies to
Effector Cells and Target Cells (FACS)
a) Detection of Binding Activities of Bispecific Antibodies to
Her2-Positive Tumor Cells BT-474 by Flow Cytometry
[0403] Tumor cells BT-474 that were positive for Her2 expression
(from the cell bank of Chinese Academy of Sciences, Shanghai) were
cultured, then digested with 0.25% trypsin, and centrifuged to
collect cells. The collected cells were resuspended with 1% PBSB,
placed in 96-well plates after the cell density was adjusted to
(2.times.10.sup.6) cells/ml, 100 .mu.l (2.times.10.sup.5 cells) per
well, and blocked for 0.5 hours at 4.degree. C. The blocked cells
were centrifuged to discard the supernatant, and a series of
diluted bispecific antibodies were added to the cells. The cells
were incubated for 1 hour at 4.degree. C., then centrifuged to
discard the supernatant, and washed three times using a PBS
solution with 1% BSA (PBSB). Diluted AF488-labeled goat anti-human
IgG antibodies or murine anti-6.times.His IgG antibodies were added
to the cells, and the cells were incubated for 1 hour at 4.degree.
C. in the dark. The obtained cells were centrifuged to discard the
supernatant, and washed twice with 1% PBSB, and cells in each well
were resuspended with 100 .mu.l of 1% paraformaldehyde (PF). The
signal intensity was detected by flow cytometry. The analysis was
performed with the average fluorescence intensity as the Y-axis and
the antibody concentration as the X-axis through software GraphPad
to calculate the EC.sub.50 value for the binding of bispecific
antibodies to tumor cells BT-474.
[0404] The results show that bispecific antibodies with different
structures had good binding activity to tumor cells overexpressing
Her2. FIG. 2-1 to FIG. 2-5 show binding curves of bispecific
antibodies with different structures to tumor cells BT-474. As
shown in Table 2-1, the EC.sub.50 for the binding of AB7K to tumor
cells and the EC.sub.50 for the binding of AB7K4 to tumor cells
both were around 5 nM, the EC.sub.50 for the binding of AB7K7 to
tumor cells was close to 50 nM, the EC.sub.50 for the binding of
AB7K5 to tumor cells and the EC.sub.50 for the binding of AB7K8 to
tumor cells both were greater than 100 nM, and the EC.sub.50 for
the binding of AB7K6 to tumor cells was greater than 200 nM.
TABLE-US-00007 TABLE 2-1 Detection of abilities of Anti-Her2
.times. CD3 bispecific antibodies to bind to tumor cells BT474 AB7K
AB7K4 AB7K5 AB7K6 AB7K7 AB7K8 EC.sub.50 (nM) 5.009 4.388 125.0
239.9 51.98 125.3
b) Detection of Binding Activities of Bispecific Antibodies to
Human T Cells by FACS
[0405] PBMCs were prepared from fresh human blood by density
gradient centrifugation. The prepared PBMCs were resuspended in a
1640 medium containing 10% heat-inactivated FBS, added with 2
.mu.g/ml OKT3 for activation for 24 h, then added with 250 IU/ml
IL-2 for amplification for 7 days, to prepare cytokine-induced
killer (CIK) cells which were detected by flow cytometry to be
positive for CD3 expression on the surface. The to-be-detected
samples were prepared and detected in the same manner as in a) of
Example 2.1. Cells resuspended with 1% PF were detected on a
machine and, with the average fluorescence intensity, analyzed by
software OriginPro 8 to calculate the EC.sub.50 value for the
binding of each bispecific antibody to human CIK cells.
[0406] The results show that there were great differences among the
binding of each bispecific antibody to CIK cells (FIG. 2-6 to FIG.
2-10). As shown in Table 2-2, the EC.sub.50 of AB7K was about 20
nM, which was roughly equal to the EC.sub.50 of AB7K4, the
EC.sub.50 of AB7K7 was more than 6 times higher than the EC.sub.50
of AB7K, and the EC.sub.50 of AB7K5, AB7K6 and AB7K8 was more than
10 times higher than the EC.sub.50 of AB7K.
TABLE-US-00008 TABLE 2-2 Detection of abilities of Anti-Her2
.times. CD3 bispecific antibodies to bind to effector cells CIK
AB7K AB7K4 AB7K5 AB7K6 AB7K7 AB7K8 EC.sub.50 (nM) 20.51 19.44 375.2
241.7 132.3 504.1
c) Detection of Cross-Reactivity of Bispecific Antibodies with
Cynomolgus Monkey CIK Cell Membrane CD3 by FACS
[0407] PBMCs were prepared from fresh cynomolgus monkey blood by
density gradient centrifugation. The prepared PBMCs were
resuspended in a 1640 medium containing 10% heat-inactivated FBS,
added with 2 .mu.g/ml OKT3 for activation for 24 h, then added with
250 IU/ml IL-2 for amplification for 7 days, to prepare cynomolgus
monkey CIK cells for use. Human CIK cells and cynomolgus monkey CIK
cells were collected by centrifugation, followed by the same test
procedure as in the above examples. Cells resuspended with 1%
paraformaldehyde solution were detected on a machine and, with the
average fluorescence intensity, analyzed by software OriginPro 8 to
calculate the EC.sub.50 values for the binding of bispecific
antibodies to human CIK cells and the EC.sub.50 values for the
binding of bispecific antibodies to cynomolgus monkey CIK
cells.
[0408] As shown in FIG. 2-11, the bispecific antibody AB7K bound
well to cynomolgus monkey T cells, the ability of AB7K to bind to
cynomolgus monkey T cells was roughly equal to the ability of AB7K
to bind to human T cells, and the EC.sub.50 for the binding of AB7K
to cynomolgus monkey T cells was approximately 26 nM as detected by
flow cytometry. Bispecific antibodies AB7K4, AB7K5, AB7K6, AB7K7,
and AB7K8 bound specifically to cynomolgus monkey T cells, as did
AB7K.
2.2 Detection of Abilities of Bispecific Antibodies to Bind to
Antigens
[0409] The binding of bispecific antibodies to soluble CD3 and Her2
was detected by double antigen sandwich ELISA.
[0410] Her2 proteins (SinoBiological, Beijing, Cat. No.
10004-H08H4) were diluted with PBS to a concentration of 0.1
.mu.g/ml and added to 96-well plates, 100 .mu.l per well. The
plates were coated at 4.degree. C. overnight. The plates were then
blocked with 1% skimmed milk powder for 1 hour at room temperature.
Each bispecific antibody was diluted simultaneously with a 4-fold
gradient for a total of 11 concentration gradients. The 96-well
plates were then washed with PBST, and then the diluted bispecific
antibodies were added. Control wells without antibodies were set.
Incubated for 1 hour at room temperature. Unbound bispecific
antibodies were washed away with PBST. Biotinylated CD3E and CD3D
(ACRO Biosystem, Cat. No. CDD-H82W1) were mixed at 50 ng/ml with
streptavdin HRP (BD, Cat. No. 554066), added in the 96-well plates,
100 .mu.l per well, and incubated for 1 hour at room temperature.
96-well plates were washed with PBST, and TMB was added to the
plates, 100 .mu.l per wellss. Color development was performed at
room temperature for 15 minutes, and then 0.2 M H.sub.2SO.sub.4 was
added to stop the color development reaction. The light absorbance
values at A450-620 nm were measured by a microplate reader.
Analysis was performed by software OriginPro 8, and the EC.sub.50
values for the binding of bispecific antibodies to two antigens
were calculated.
[0411] The results show that each bispecific antibody bound
specifically to both CD3 and Her2 molecules and exhibited good
dose-dependence as the concentration of the antibodies changed
(FIG. 2-12). The abilities of several bispecific antibodies to bind
to soluble CD3 and Her2 are shown in Table 2-3, with EC.sub.50
values ranging from 0.03 nM to 3.8 nM which differ by two orders of
magnitude. AB7K had the best binding activity, binding activities
of AB7K4 and AB7K7 differed by one order of magnitude, and AB7K5
and AB7K8 had the weakest binding activity.
TABLE-US-00009 TABLE 2-3 Detection of abilities of Anti-Her2
.times. CD3 bispecific antibodies to bind to CD3 and Her2 molecules
AB7K AB7K4 AB7K5 AB7K7 AB7K8 EC.sub.50 (nM) 0.03128 0.1518 1.004
0.1398 3.815
2.3 Evaluation of Abilities of Bispecific Antibodies to Activate T
Cells Through Reporter Gene Cell Strains
[0412] Jurkat T cells containing NFAT RE reporter genes (BPS
Bioscience, Cat. No. 60621) can overexpress luciferase in the
presence of bispecific antibodies and target cells, and the degree
of activation of the Jurkat T cells can be quantified by detecting
the activity of the luciferase. A four-parameter curve was fitted
using the concentration of bispecific antibodies as the X-axis and
the fluorescein signal as the Y-axis.
[0413] The test results from FIG. 2-13 show that the monoclonal
antibody Herceptin targeting Her2 cannot activate Jurkat T cells. T
cells can be activated only in the presence of both antibodies. The
ability of each antibody to activate Jurkat T cells is shown in
Table 2-4. AB7K4 had the strongest ability to activate T cells,
AB7K8 had the weakest ability to activate T cells, and their
EC.sub.50 values differed by one order of magnitude.
TABLE-US-00010 TABLE 2-4 Detection of abilities of Anti-Her2
.times. CD3 bispecific antibodies to a reporter gene cell strain
that are Jurkat T cells AB7K AB7K4 AB7K5 AB7K7 AB7K8 Herceptin
EC.sub.50 (nM) 0.02263 0.01338 0.05357 0.08952 0.1575 0.009907
2.4 Abilities of Bispecific Antibodies to Mediate T Cells to Kill
Tumor Cells
[0414] Normally cultured tumor cell lines, including SK-BR-3,
MCF-7, HCC1937, NCI-N87, HCC1954 cells (all purchased from the cell
bank of Chinese Academy of Sciences, Shanghai), as target cells,
were digested with 0.25% trypsin to prepare single-cell
suspensions, added to 96-well cell culture plates after the cell
density was adjusted to 2.times.10.sup.5 cells/ml, 100 .mu.l per
well, and cultured overnight. The antibodies were diluted according
to the test design, and added to the cells, 50 .mu.l per well,
while wells without the addition of antibodies were supplemented
with the same volume of the medium. Effector cells (human PBMCs or
expanded CIK cells) whose number was five times larger than the
number of target cells, were then added, 100 .mu.l per well.
Control wells were set, and wells without the addition of effector
cells were supplemented with the same volume of the medium. After
incubation for 48 hours, the supernatant was discarded from the
96-well plates. The cells were then washed three times with PBS,
and a complete medium containing 10% CCK-8 was added, 100 .mu.l per
well, and the cells were incubated for 4 hours at 37.degree. C. The
light absorbance values at A450-620 nm were measured by a
microplate reader. Analysis was performed by software OriginPro 8,
and the ability of each bispecific antibody to mediate the killing
of tumor cells and the ability of the same target monoclonal
antibody Herceptin to mediate the killing of tumor cells were
calculated and compared.
[0415] The EC.sub.50 values of each bispecific antibody to mediate
effector cells to kill tumor cells are shown in Table 2-5. The
results show that each bispecific antibody exhibited a very
significant killing effect on tumor cells (e.g., SK-BR-3, NCI-N87,
and HCC1954) with high expression of Her2 in a dose-dependent
manner. Each bispecific antibody, in particular AB7K7, also
exhibited a good killing effect on breast cancer cells MCF-7 with
low expression of Her2. Each bispecific antibody also had a good
killing effect on the Herceptin-resistant cell strain HCC1954 while
each bispecific antibody exhibited the killing effect on the cell
strain HCC1937 that was negative for Her2 expression (with little
expression) only at two highest concentrations.
TABLE-US-00011 TABLE 2-5 EC.sub.50 values of bispecific antibodies
to mediate PBMCs to kill different tumor cells EC.sub.50 (nM) AB7K7
AB7K8 AB7K5 Herceptin SK-BR-3 ~0.001 ~0.002 ~0.001 -- ~0.001 0.011
-- 0.067 MCF-7 ~0.005 0.079 0.055 -- HCC1937 0.659 ~2.269 1.223 --
0.579 4.011 -- >6.667 NCI-N87 0.015 0.034 -- 0.129 HCC1954 0.002
0.018 -- 0.050 Note: ~means approximately equal to, and -- means
that no detection is performed.
2.5 Evaluation of the Effect of GS-CTP Linker Peptide on the
Ability of Anti-CD3 scFv to Bind to CD3 Molecules by Computer
Techniques
[0416] The anti-CD3 scFv VH containing the GS-CTP linker peptide
was structurally modeled using computer software and the spatial
conformation of molecular docking of anti-CD3 scFv and its antigen
CD3 epsilon chain was simulated and predicted.
[0417] The sequence of the GS-CTP linker peptide between anti-Her2
scFv and anti-CD3 scFv in the bispecific antibody AB7K7 is
(GGGGGGSGGGGSGGGGSSSSSKAPPPS), wherein the first half of the
sequence is a GS-flexible peptide (GGGGGGSGGGGSGGGGS), and the
second half is CTP-rigid peptide (SSSSKAPPPS). The rigid CTP
portion (SSSSKAPPPS) is connected to the N-terminus of the anti-CD3
scFv VH. Through three-dimensional structural modeling using
software phyre2, it is found that the CTP peptide fragment
structurally overlays on the CDR1 region of VH of the anti-CD3 scFv
(FIG. 2-14), which may hinder or disrupt the binding of the CD3
antibody to its antigen. The VH of the anti-CD3 scFv connected to
the GS linker peptide (containing only the GS flexible peptide with
the removal of CTP) was subjected to three-dimensional structural
modeling using software phyre2, and then it is found that the GS
linker peptide is far from the CDR region (FIG. 2-15) and does not
affect antigen-antibody binding. Even if the GS linker peptide is
close to the CDR region, the GS linker peptide can freely move away
from the antigen-antibody binding region due to its own flexibility
and thus does not affect antigen-antibody binding.
[0418] Further, the molecular docking between the anti-CD3 scFv and
its antigen CD3 epsilon chain was simulated by software Discovery
Studio. Since the structure of the double-chain anti-CD3 FV is
highly similar to the structure of the anti-CD3 scFv, the structure
simulation was performed using the double-chain anti-CD3 FV instead
of the anti-CD3 scFv. The simulation results show that the antigen
CD3 epsilon chain binds to CDR2 and CDR3 of VH of the anti-CD3 Fv
while does not bind to the CDR1 region (FIG. 2-16), which indicates
that the CTP overlaying the VH CDR1 region of the anti-CD3 Fv does
not interfere with the binding of the anti-CD3 scFv to the antigen.
However, given that the CD3 molecule is a complex including one CD3
gamma chain, one CD3 delta chain, and two CD3 epsilon chains, the
CD3 molecule, together with the TCR and Zeta chains, constitutes a
T-cell receptor complex. Although the CTP peptide fragment covering
the VH CDR1 of the anti-CD3 scFv does not directly interfere with
the binding of the anti-CD3 scFv to its antigen CD3 epsilon chain,
the CTP peptide fragment may indirectly affect the binding of the
anti-CD3 scFv to its antigen CD3 epsilon chain by making spatial
structural contact with a certain constituent protein of the T-cell
receptor complex.
[0419] Due to the presence of CTP covering the VH CDR1 region of
the anti-CD3 scFv, the binding affinity of the anti-CD3 scFv for
its antigen is greatly diminished so that there is no substantial
release of cytokines caused by the overactivation of T cells,
thereby avoiding some unnecessary T cell-mediated non-specific
killing.
Example 3 Pharmacodynamics Study of Anti-Her2.times.CD3 Bispecific
Antibodies in a Mouse Transplanted Tumor Model
3.1 NCG Mouse Model of Transplanted Tumor Constructed by
Subcutaneously Co-Inoculating Human CIK Cells and Human Breast
Cancer Cells HCC1954
[0420] Her2-positive human breast cancer cells HCC1954 were
selected to study the effect of bispecific antibodies in inhibiting
tumor growth in vivo in an NCG mouse model of transplanted tumor
constructed by subcutaneously co-inoculating human CIK cells and
HCC1954 cells.
[0421] The peripheral blood of a normal human was subjected to
density gradient centrifugation (Lymphoprep.TM., Lymphocytes
Separation Medium, STEMCELL) to separate human PBMCs. Then the
human PBMCs were resuspended in RPMI-1640 culture medium added with
10% inactivated FBS, and added with OKT3 at a final concentration
of 1 .mu.g/mL and human IL-2 at 250 IU/mL. After three days of
culture, the human PBMCs were centrifuged at 300 g for 5 minutes,
and the medium was changed. The cells were cultured in RPMI-1640
added with 10% inactivated FBS and added with human IL-2 at 250
IU/mL. After that, a fresh medium was then added every 2 days and
CIK cells were collected on the tenth day of culture. Female NCG
mice at the age of seven to eight weeks (purchased from Jiangsu
GemPharmatech Co. Ltd Company) were selected and HCC1954 cells in
the logarithmic growth stage were collected. 5.times.10.sup.6
HCC1954 cells and 5.times.10.sup.5 CIK cells were mixed and
inoculated subcutaneously on the right back of each NCG mouse. One
hour later, the mice were randomly divided into seven groups with
five mice in each group according to their weights and
intraperitoneally administered with corresponding drugs. All
positive control groups and PBS control group were administered
twice a week for a total of 3 doses, wherein the positive control
groups were administered with Herceptin (from Roche) at doses of 1
mg/kg and 3 mg/kg, respectively, and the PBS control group was
administered with a PBS solution of the same volume as Herceptin.
The treated groups were administered with bispecific antibodies
AB7K4 and AB7K7 every day at doses of 0.1 mg/kg and 1 mg/kg,
respectively, for a total of 10 doses. The day of administration
was recorded as Day 0. The maximum diameter (D) and the minimum
diameter (d) of the tumor were measured weekly with an electronic
vernier caliper. The volume of the tumor was calculated using the
following formula: volume (mm.sup.3)=[D.times.d.sup.2]/2. The tumor
growth inhibition rate (TGI) was calculated for each treated group
using the following formula: TGI (%)=(1-volume of the treated
group/volume of the control group).times.100%.
[0422] As shown in FIG. 3-1, on Day 33 of administration, the
average tumor volume of the PBS control group was 1494.61.+-.500.28
mm.sup.3; the average tumor volume of the treated group
administrated with Herceptin at a dose of 1 mg/kg was
1327.29.+-.376.65 mm.sup.3; the average tumor volume of the treated
group administrated with Herceptin at a dose of 3 mg/kg was
510.49.+-.106.07 mm.sup.3, and the TGI was 65.84%, which was not
significantly different from that of the control group.
[0423] The average tumor volumes of treated groups administrated
with AB7K4 at doses of 0.1 mg/kg and 1 mg/kg were 304.10.+-.108.50
mm.sup.3 and 79.70.+-.58.14 mm.sup.3, respectively, and TGIs
thereof were 79.65% and 94.67%, respectively, which were
significantly different from that of the PBS control group
(P<0.05). The average tumor volumes of treated groups
administrated with AB7K7 at doses of 0.1 mg/kg and 1 mg/kg were
385.82.+-.95.41 mm.sup.3 and 209.98.+-.51.74 mm.sup.3,
respectively, and TGIs thereof were 74.19% and 85.95%,
respectively, which were significantly different from that of the
PBS control group (P<0.05). In summary, the results show that
the bispecific antibodies AB7K4 and AB7K7 at different doses could
inhibit the growth of tumor cells by activating human immune cells
in animals and exhibited great anti-tumor effects; and at the same
dose of 1 mg/kg, the anti-tumor effect of the bispecific antibody
was better than that of the monoclonal antibody Herceptin.
3.2 NPG Mouse Model of Transplanted Tumor Constructed by
Subcutaneously Co-Inoculating Human CIK Cells and Human Breast
Cancer Cells HCC1954
[0424] Her2-positive human breast cancer cells HCC1954 were
selected to study the inhibiting effect of bispecific antibodies on
tumor growth in vivo in an NPG mouse model of transplanted tumor
constructed by subcutaneously co-inoculating human CIK cells and
human breast cancer cells HCC1954.
[0425] CIK cells were prepared in the method as described in
Example 3.1. Female NPG mice at the age of seven to eight weeks
(purchased from Beijing Vitalstar Biotechnology Co., Ltd.) were
selected and HCC1954 cells in the logarithmic growth stage were
collected. 5.times.10.sup.6 HCC1954 cells and 5.times.10.sup.5 CIK
cells were mixed and inoculated subcutaneously on the right back of
each NPG mouse. After 6 days of tumor growth, the mice were
randomly divided into three groups with six mice in each group
according to the tumor volumes and weights and intraperitoneally
administered with corresponding drugs. Specifically, AB7K7 treated
groups were administered twice a week at doses of 0.1 mg/kg and 1
mg/kg, respectively, and the control group was administered with a
PBS solution of the same volume as AB7K7. The day of administration
was recorded as Day 0. The maximum diameter (D) and the minimum
diameter (d) of the tumor were measured weekly. The volume
(mm.sup.3) of the tumor of each group and the tumor growth
inhibition rate (TGI) (%) of each treated group were calculated
using the formulas as shown in Example 3.1.
[0426] As shown in FIG. 3-2, on Day 21 of administration, the
average tumor volume of the PBS control group was 821.73.+-.201.82
mm.sup.3; the average tumor volume of the treated group
administrated with AB7K7 at a dose of 0.1 mg/kg was 435.60.+-.51.04
mm.sup.3, and the TGI was 50.83%, which was not significantly
different from that of the control group; the average tumor volume
of the treated group administrated with AB7K7 at a dose of 1 mg/kg
was 40.98.+-.12.64 mm.sup.3, and the TGI was 95.37%, which was
significantly different from that of the control group (P<0.01).
The above results show that the administration of the bispecific
antibody AB7K7 had a good therapeutic effect even when tumors had
grown to a certain volume, wherein 50% tumor inhibition effect was
achieved at the low dose of 0.1 mg/kg, and there was complete tumor
regression in 4 of 6 mice in the treated group at the dose of 1
mg/kg and the tumor volumes in the other 2 mice were both less than
100 mm.sup.3, which was smaller than the tumor volume at the time
of grouping (the average tumor volume of this group at the time of
grouping was 161.37.+-.18.98 mm.sup.3). Therefore, the bispecific
antibody AB7K7 had a great therapeutic effect on tumors.
[0427] In addition, the inhibiting effect of bispecific antibodies
AB7K7 and AB7K8 on tumor growth in the above-described transplanted
tumor model at two administration frequencies were also studied.
CIK cells were prepared in the method as described above. Female
NPG mice at the age of seven to eight weeks were selected, and
5.times.10.sup.6 HCC1954 cells and 5.times.10.sup.5 CIK cells were
mixed and inoculated subcutaneously on the right back of each NPG
mouse. One hour later, the mice were randomly divided into six
groups with six mice in each group according to their weights and
intraperitoneally administered with corresponding drugs.
Specifically, the control group and the Herceptin treated group
were administered twice a week, wherein Herceptin was administrated
at a dose of 3 mg/kg and the control group was administered with a
PBS solution of the same volume as Herceptin. The bispecific
antibody AB7K7 was administered at a dose of 1 mg/kg and AB7K8 was
administered at a dose of 0.7 mg/kg. Two administration frequencies
were set for each of the two bispecific antibodies, wherein the QD
group was administered once a day for 10 consecutive days and the
BIW group was administered twice a week. The day of administration
was recorded as Day 0. The maximum diameter (D) and the minimum
diameter (d) of the tumor were measured weekly. The tumor volume
(mm.sup.3) of each group and the tumor growth inhibition rate (TGI)
(%) of each treated group were calculated using the formulas as
shown above.
[0428] As shown in FIG. 3-3, on Day 25 of administration, the
average tumor volume of the PBS control group was 1588.12.+-.120.46
mm.sup.3; the average tumor volume of the treated group
administrated with Herceptin at a dose of 3 mg/kg was
361.72.+-.134.70 mm.sup.3; the average tumor volumes of the QD
group and the BIW group administrated with AB7K7 were
260.18.+-.45.96 mm.sup.3 and 239.39.+-.40.62 mm.sup.3,
respectively, and TGIs were 83.62% and 84.93%, respectively, which
were significantly different from that of the PBS control group
(P<0.01); the average tumor volumes of the QD group and the BIW
group administrated with AB7K8 were 284.98.+-.26.62 mm.sup.3 and
647.14.+-.118.49 mm.sup.3, respectively, and TGIs were 82.06% and
59.25%, respectively, which were significantly different from that
of the PBS control group (P<0.01). As can be seen from the above
results, the anti-tumor effect of the bispecific antibody AB7K7 was
superior to that of the Herceptin in both the QD group and the BIW
group; at equimolar doses, AB7K8 and AB7K7 in the QD group
exhibited basically equal tumor inhibiting effects, while the
anti-tumor effect of AB7K7 in the BIW group was significantly
superior than that of AB7K8, presumably due to the fact that AB7K8
is a bispecific antibody of BiTE configuration with no Fc domain,
and therefore AB7K7 has a longer half-life than AB7K8, from which
it is anticipated that the clinical administration frequency of
AB7K7 is reduced and AB7K7 has a better therapeutic effect.
3.3 NPG Mouse Model of Transplanted Tumor Constructed by
Subcutaneously Co-Inoculating Human CIK Cells and Human Ovarian
Cancer Cells SK-OV-3
[0429] Her2-positive human ovarian cancer cells SK-OV-3 were
selected to study the inhibiting effect of bispecific antibodies on
tumor growth in vivo in an NPG mouse model of transplanted tumor
constructed by subcutaneously co-inoculating human CIK cells and
SK-OV-3 cells.
[0430] The peripheral blood of a normal human was subjected to
density gradient centrifugation to separate human PBMCs. Then the
human PBMCs were resuspended in McCoy's 5A culture medium added
with 10% inactivated FBS, and added with OKT3 at a final
concentration of 1 .mu.g/mL and human IL-2 at 250 IU/mL. After
three days of culture, the human PBMCs were centrifuged at 300 g
for 5 minutes, and the supernatant was discarded. The cells were
resuspended in RPMI-1640 added with 10% inactivated FBS and added
with 250 IU/mL of human IL-2. After that, a fresh medium was then
added every 2 days and CIK cells were collected on the tenth day of
culture. Female NPG mice at the age of seven to eight weeks were
selected and SK-OV-3 cells (purchased from the cell bank of Chinese
Academy of Sciences, Shanghai) in the logarithmic growth stage were
collected. 3.times.10.sup.6 SK-OV-3 cells and 3.times.10.sup.5 CIK
cells were mixed and inoculated subcutaneously on the right back of
each NPG mouse. One hour after inoculation, the mice were randomly
divided into seven groups with six mice in each group according to
their weights and intraperitoneally administered with corresponding
drugs. Herceptin and AB7K7 treated groups were administered twice a
week at doses of 1 mg/kg, 0.2 mg/kg, and 0.04 mg/kg, respectively,
and the control group was administered with a PBS solution of the
same volume. The day of administration was recorded as Day 0. The
maximum diameter (D) and the minimum diameter (d) of the tumor were
measured weekly. The volume (mm.sup.3) of the tumor of each group
and the tumor growth inhibition rate (TGI) (%) of each treated
group were calculated using the formulas as shown in Example
3.1.
[0431] As shown in FIG. 3-4, on Day 21 of administration, the
average tumor volume of the PBS control group was 834.09.+-.45.64
mm.sup.3; the average tumor volumes of the treated groups
administrated with Herceptin at doses of 1 mg/kg, 0.2 mg/kg, and
0.04 mg/kg were 644.84.+-.58.22 mm.sup.3, 884.95.+-.38.63 mm.sup.3,
and 815.79.+-.78.39 mm.sup.3, respectively; and the tumors in all
AB7K7 treated groups were completely regressed. The above results
show that in the ovarian cancer SK-OV-3 model, AB7K7 enabled the
tumor to completely regress even at a very low dose of 0.04 mg/kg,
exhibiting an excellent anti-tumor effect.
3.4 NPG Mouse Model of Transplanted Tumor Constructed by
Subcutaneously Co-Inoculating Human CIK Cells and Human Colon
Cancer Cells HT-29
[0432] Her2-positive human colon cancer cells HT-29 were selected
to study the inhibiting effect of bispecific antibodies on tumor
growth in vivo in an NPG mouse model of transplanted tumor
constructed by subcutaneously co-inoculating human CIK cells and
HT-29 cells.
[0433] CIK cells were prepared in the method as described in
Example 3.1. Female NPG mice at the age of seven to eight weeks
were selected and HT-29 cells (purchased from the cell bank of
Chinese Academy of Sciences, Shanghai) in the logarithmic growth
stage were collected. 3.times.10.sup.6 HT-29 cells and
3.times.10.sup.6 CIK cells were mixed and inoculated subcutaneously
on the right back of each NPG mouse. One hour after inoculation,
the mice were randomly divided into five groups with six mice in
each group according to their weights and intraperitoneally
administered with corresponding drugs. Specifically, Herceptin was
administered at a dose of 3 mg/kg, and AB7K7 was administered at
doses of 3 mg/kg, 1 mg/kg, and 0.3 mg/kg, respectively. All treated
groups were administered twice a week. The control group was
administered with a PBS solution of the same volume. The day of
administration was recorded as Day 0. The maximum diameter (D) and
the minimum diameter (d) of the tumor were measured weekly. The
volume (mm.sup.3) of the tumor of each group and the tumor growth
inhibition rate (TGI) (%) of each treated group were calculated
using the formulas as shown in Example 3.1.
[0434] As shown in FIG. 3-5, on Day 21 of administration, the
average tumor volume of the PBS control group was 1880.52.+-.338.26
mm.sup.3; the average tumor volume of the treated group
administrated with Herceptin at a dose of 3 mg/kg was
1461.36.+-.177.94 mm.sup.3; the average tumor volumes of the
treated groups administrated with AB7K7 at doses of 3 mg/kg, 1
mg/kg, and 0.3 mg/kg were 13.94.+-.7.06 mm.sup.3, 26.31.+-.10.75
mm.sup.3, and 10.47.+-.6.71 mm.sup.3, wherein tumors in four mice
in the treated group at a dose of 0.3 mg/kg were completely
regressed, tumors in three mice in the treated group at a dose of 1
mg/kg were completely regressed, and tumors in four mice in the
treated group at a dose of 3 mg/kg were completely regressed. The
above results show that in the colon cancer HT-29 model, Herceptin
had few pharmacological effect on this tumor model, whereas AB7K7
exhibited complete tumor regression in mice at all three doses and
exhibited excellent anti-tumor effect even at very low doses.
3.5 CD34 Immune-Reconstituted NPG Mouse Model of Transplanted Tumor
Constructed by Inoculating Human Breast Cancer Cells HCC1954
[0435] Her2-positive human breast cancer cells HCC1954 were
selected to study the inhibiting effect of bispecific antibodies on
tumor growth in vivo in a CD34 immune-reconstituted NPG mouse model
of transplanted tumor constructed by subcutaneously inoculating
human breast cancer cells HCC1954.
[0436] CD34-positive hematopoietic stem cells were enriched from
fresh umbilical cord blood using CD34-positive selective magnetic
beads (purchased from Miltenyi Biotec, Germany). Female NPG mice at
the age of seven to eight weeks (purchased from Beijing Vitalstar
Biotechnology Co., Ltd.) were selected and injected with
CD34-positive hematopoietic stem cells via the tail vein to
reconstitute a human immune system in each mouse. Sixteen weeks
later, blood was collected from the orbital venous plexus of mice
for flow cytometry, and when the proportion of human CD45 in mice
was greater than 15%, it was considered that the immune
reconstitution succeeded. HCC1954 cells in the logarithmic growth
stage were collected and 5.times.10.sup.6 HCC1954 cells were
inoculated subcutaneously on the right back of the mice with
successful immune reconstitution. One hour after inoculation, the
mice were randomly divided into three groups with six mice in each
group according to their weights. The treated groups were
intraperitoneally administered with AB7K7 and Herceptin at a dose
of 1 mg/kg, and the control group was administered with a PBS
solution of the same volume, twice a week for a total of 6 doses.
The day of administration was recorded as Day 0. The maximum
diameter (D) and the minimum diameter (d) of the tumor were
measured weekly. The volume (mm.sup.3) of the tumor of each group
and the tumor growth inhibition rate (TGI) (%) of each treated
group were calculated using the formulas as shown in Example
3.1.
[0437] As shown in FIG. 3-6, on Day 21 of administration, the
average tumor volume of the PBS control group was 475.23.+-.58.82
mm.sup.3; the average tumor volume of the treated group
administrated with Herceptin was 293.27.+-.66.35 mm.sup.3, and the
TGI was 38.29%, which was not significantly different from that of
the control group; the average tumor volume of the treated group
administrated with AB7K7 was 0.67.+-.0.67 mm.sup.3, and the TGI was
99.86%, meaning that basically all tumors were regressed, which was
significantly different from that of the control group (P<0.01).
In summary, the above results show that the bispecific antibody
AB7K7 had an excellent anti-tumor effect in the CD34
immune-reconstituted model.
3.6 PBMC Immune-Reconstituted NPG Mouse Model of Transplanted Tumor
Constructed by Inoculating Human Breast Cancer Cells HCC1954
[0438] Her2-positive HCC1954 cells were selected to study the
inhibiting effect of bispecific antibodies on tumor growth in vivo
in a PBMC immune-reconstituted NPG mouse model of transplanted
tumor constructed by inoculating human breast cancer cells
HCC1954.
[0439] The peripheral blood of a normal human was subjected to
density gradient centrifugation to separate human PBMCs. Female NPG
mice at the age of five to six weeks were selected and
intraperitoneally injected with human PBMC cells to reconstitute a
human immune system in each mouse. After seven days of PBMC
injection, HCC1954 cells in the logarithmic growth stage were
collected and 5.times.10.sup.6 HCC1954 cells were inoculated
subcutaneously on the right back of each mouse. After 13 days of
PBMC injection, blood was collected from the orbital venous plexus
for flow cytometry, and when the proportion of human CD45 in mice
was greater than 15%, it was considered that the immune
reconstitution succeeded. After 14 days of PBMC injection, the mice
with successful immune reconstitution were randomly divided into
two groups with six mice in each group according to the tumor
volumes and weights. The treated group was intraperitoneally
administered with AB7K7 at a dose of 1 mg/kg, and the control group
was administered with PBS, three times a week. The day of
administration was recorded as Day 0. The maximum diameter (D) and
the minimum diameter (d) of the tumor were measured weekly. The
volume (mm.sup.3) of the tumor of each group and the tumor growth
inhibition rate (TGI) (%) of each treated group were calculated
using the formulas as shown in Example 3.1.
[0440] As shown in FIG. 3-7, on Day 23 of administration, the
average tumor volume of the PBS control group was 1224.05.+-.224.39
mm.sup.3; the average tumor volume of the treated group
administrated with AB7K7 was 32.00.+-.0.00 mm.sup.3, and the TGI
was 97.41%, meaning that basically all tumors were regressed, which
was significantly different from that of the control group
(P<0.001). In summary, the above results show that the
bispecific antibody AB7K7 had an excellent anti-tumor effect in the
PBMC immune-reconstituted model.
Example 4 Evaluation of the Safety of Anti-Her2.times.CD3
Bispecific Antibodies
[0441] 4.1 Bispecific Antibodies being Incapable of Mediating
Non-Specific Killing on Her2-Negative Tumor Cells
[0442] Her2-negative human Burkkit's lymphoma Raji cells were
selected to study whether bispecific antibodies can inhibit tumor
growth in an NCG mouse model of transplanted tumor constructed by
subcutaneously co-inoculating human CIK cells and human Burkkit's
lymphoma Raji cells.
[0443] CIK cells were prepared in the method as described in
Example 3.1. Female NCG mice at the age of seven to eight weeks
were selected and Raji cells (purchased from the cell bank of
Chinese Academy of Sciences, Shanghai) in the logarithmic growth
stage were collected. 5.times.10.sup.6 Raji cells and
2.times.10.sup.6 CIK cells were mixed and inoculated subcutaneously
on the right back of each NCG mouse. One hour after inoculation,
the mice were randomly divided into three groups with five mice in
each group according to their weights. The treated groups were
intraperitoneally administered with AB7K4 and AB7K7 at a dose of 1
mg/kg, and the control group was administered with a PBS solution
of the same volume, once a day continuously for 10 days. The day of
administration was recorded as Day 0. The maximum diameter (D) and
the minimum diameter (d) of the tumor were measured weekly. The
volume (mm.sup.3) of the tumor of each group and the tumor growth
inhibition rate (TGI) (%) of each treated group were calculated
using the formulas as shown in Example 3.1.
[0444] As shown in FIG. 4-1, on Day 25 of administration, the
average tumor volume of the PBS control group was 2439.88.+-.193.66
mm.sup.3; the average tumor volume of the treated group
administrated with AB7K4 was 2408.81.+-.212.44 mm.sup.3; the
average tumor volume of the treated group administrated with AB7K7
was 2598.11.+-.289.35 mm.sup.3; and there was no difference between
the average tumor volume of each of the two treated groups and the
average tumor volume of the control group. In summary, the results
show that bispecific antibodies AB7K4 and AB7K7 exhibited no
non-specific killing on Her2-negative cell strains, which indicates
that AB7K4 and AB7K7 do not mediate T cells to kill non-target
tissues in vivo (i.e., specifically dependent on binding of
bispecific antibodies to corresponding target antigens), there is
no off-target toxicity, and the safety is high.
4.2 Bispecific Antibodies Killing Tumor Cells Depending on the
Activation of T Cells
[0445] Her2-positive human breast cancer cells HCC1954 were
selected to study whether bispecific antibodies inhibit tumor
growth in an NPG mouse model of transplanted tumor constructed by
subcutaneously inoculating human breast cancer cells HCC1954.
[0446] Female NPG mice at the age of seven to eight weeks were
selected and HCC1954 cells in the logarithmic growth stage were
collected. 5.times.10.sup.6 HCC1954 cells and Matrigel (Corning,
Cat. No. 354234) were mixed in a volume ratio of 1:1 and then
inoculated subcutaneously on the right back of each NPG mouse.
After 6 days of tumor growth, the mice were randomly divided into
three groups with six mice in each group according to the tumor
volumes and weights. The treated groups were intraperitoneally
administered with Herceptin at a dose of 3 mg/kg and AB7K7 at a
dose of 1 mg/kg, respectively, and the control group was
administered with a PBS solution of the same volume, twice a week.
The day of administration was recorded as Day 0. The maximum
diameter (D) and the minimum diameter (d) of the tumor were
measured weekly. The volume (mm.sup.3) of the tumor of each group
and the tumor growth inhibition rate (TGI) (%) of each treated
group were calculated using the formulas as shown in Example
3.1.
[0447] As shown in FIG. 4-2, on Day 21 of administration, the
average tumor volume of the PBS control group was 1311.35.+-.215.70
mm.sup.3; the average tumor volume of the treated group
administrated with Herceptin was 273.98.+-.60.10 mm.sup.3; the
average tumor volume of the treated group administrated with AB7K7
was 1243.20.+-.340.31 mm.sup.3, which was not different from the
average tumor volume of the control group. In summary, the results
show that AB7K7 did not inhibit the growth of HCC1954 subcutaneous
tumors in the absence of human immune cells, indicating that
bispecific antibody AB7K7 needs to be mediated by immune effector
cells so as to kill tumor cells, unlike Herceptin, which primarily
depends on Fc.gamma.R-mediated ADCC or CDC effects to kill tumor
cells. Thus, it is proved that Fc variants contained in AB7K7
cannot bind to Fc.gamma.R, which avoids mediating systemic
activation of T cells caused by extensive expression of its
receptor Fc.gamma.R, resulting in higher drug safety.
4.3 Evaluation of Toxicity of Bispecific Antibodies to Normal
Cynomolgus Monkeys
[0448] Adult cynomolgus monkeys (purchased from Guangzhou Xiangguan
Biotechnology Co., Ltd.) at the age of 3-4 years and with the
weight of 3-4 kg were divided into three groups with one monkey in
each group, wherein the three groups were a vehicle control group,
an AB7K7 treated group and an AB7K8 treated group. The groups were
administrated via intravenous drip by a peristaltic pump for 1 hour
on Day 0 (D0), Day 7 (D7), Day 21 (D21), and Day 28 (D28),
respectively, for a total of four doses, and the drug dose was
gradually increased each time. The monkeys were weighed weekly. The
dose amount and volume administered are shown in Table 4-1.
[0449] On D0, after administration, cynomolgus monkeys in the AB7K8
treated group exhibited somnolence and pupil contraction and
recovered to normal the next day while there was no abnormality in
the other groups. On D7, after administration, cynomolgus monkeys
in the AB7K7 treated group exhibited vomiting symptoms 2-3 hours
after administration and recovered to normal the next day of
administration while there was no abnormality in the other groups.
On D21, after administration, cynomolgus monkeys in the AB7K7
treated group exhibited symptoms of vomiting food 3 hours after
administration and excreted jelly-like feces, cynomolgus monkeys in
the AB7K8 treated group exhibited symptoms of vomiting food 1 hour
after administration, and cynomolgus monkeys in both groups
recovered to normal on the second day after administration; On D28,
after administration, cynomolgus monkeys in both AB7K7 treated
group and AB7K8 treated group exhibited vomiting symptoms 40 to 50
minutes later and excreted feces 3 hours later, in which jelly-like
mucus was found; cynomolgus monkeys in the AB7K7 treated group
excreted watery feces with fishy smelling; and 24 hours later, all
the animals recovered to normal and ingested normally. The body
weight change of cynomolgus monkeys is shown in FIG. 4-3, wherein
the arrow represents the administration time. It can be seen that
the body weight of each group does not change too much and
fluctuates within the normal physiological range.
TABLE-US-00012 TABLE 4-1 Dosing schedule for cynomolgus monkey
acute toxicity evaluation To-be-tested Group drugs name Dose volume
Dose amount G1 Vehicle D0: 5 mL/kg N/A control D7: 5 mL/kg group
D21: 10 mL/kg D28: 10 mL/kg G2 AB7K7 D0: 5 mL/kg D0: 0.06 mg/kg D7:
5 mL/kg D7: 0.3 mg/kg D21: 10 mL/kg D21: 1.5 mg/kg D28: 10 mL/kg
D28: 3 mg/kg G3 AB7K8 D0: 5 mL/kg D0: 0.04 mg/kg D7: 5 mL/kg D7:
0.2 mg/kg D21: 10 mL/kg D21: 1 mg/kg D28: 10 mL/kg D28: 2 mg/kg
[0450] The different degree of diarrhea observed in this example
may be related to the expression of related receptors in the gut,
which is supposed to be caused by the imbalance of chloride ion in
the gut caused by the inhibition of heterodimer of Her1/Her2 or
Her2/Her3 by bispecific antibodies, which belongs to the extension
of pharmacological action and can recover to normal after 24 hours
of administration. Cynomolgus monkeys were still well tolerated
when administrated with AB7K7 at a high dose of 3 mg/kg. The
results of pharmacodynamics test in mice show that AB7K7 at a low
dose shows a good anti-tumor effect, which indicates that AB7K7 has
a wide treatment window and high safety.
Example 5 Pharmacokinetics Study of Anti-Her2.times.CD3
Antibodies
5.1 In Vivo Pharmacokinetics Test of Bispecific Antibody AB7K7 in
SD Mice
[0451] AB7K7 was administered to four healthy Sprague-Dawley (SD)
rats (purchased from Shanghai Salccas Laboratory Animals Co.,
Ltd.,) via the tail vein at a dose of 1 mg/kg. The blood sampling
time points were Hour 1, Hour 3, Hour 6, Hour 24, Hour 72, Hour 96,
Hour 120, Hour 168, Hour 216 and Hour 264, respectively. A certain
amount of whole blood was taken at each time point, the serum was
separated, and then the drug concentration in the serum was
detected by two ELISA methods.
[0452] Method I. Plates were coated with the anti-AB7K7 antibody A
(Ampsource Biopharma Shanghai Inc., mouse-anti-herceptin) at a
concentration of 0.5 .mu.g/mL. AB7K7 was formulated at
concentrations of 100 ng/mL, 50 ng/mL, 25 ng/mL, 12.5 ng/mL, 6.25
ng/mL, 3.125 ng/mL and 1.56 ng/mL, separately. Standard curves were
established. HRP-labeled anti-AB7K7 antibody B (Ampsource Biopharma
Shanghai Inc., anti-herceptin-HRP) was used at a concentration of
1:5000, and developed with TMB. The pharmacokinetics parameters
were calculated using software PKSolver. Specific parameters are
shown in Table 5-1.
[0453] Method II. The drug concentration in the serum of the SD
rats was detected. Plates were coated with the anti-AB7K7 antibody
A (Ampsource Biopharma Shanghai Inc., mouse-anti-herceptin) at a
concentration of 0.5 .mu.g/mL. AB7K7 was formulated at
concentrations of 5 ng/mL, 2.5 ng/mL, 1.25 ng/mL, 0.625 ng/mL,
0.3125 ng/mL, 0.156 ng/mL and 0.078 ng/mL, separately. Standard
curves were established. Mouse anti-human IgG Fc-HRP (Ampsource
Biopharma Shanghai Inc.) was added at a concentration of 1:5000,
and developed with TMB. The pharmacokinetics parameters were
calculated using software PKSolver. Specific parameters are shown
in Table 5-2.
[0454] FIG. 5-1 shows the blood drug concentration of AB7K7 in the
body of rats detected using two different detection methods. It can
be seen that the blood drug concentrations obtained by detecting
the concentration of AB7K7 in blood using two different detection
methods were basically the same, and the calculated
pharmacokinetics parameters were roughly equivalent, which
indicates that AB7K7 can be metabolized in the form of intact
molecules in vivo, thereby ensuring the biological function of
AB7K7.
TABLE-US-00013 TABLE 5-1 Pharmacokinetics parameters of bispecific
antibody AB7K7 in SD rats (Method 1) AUC 0-inf_ob Vz_obs Cl_obs
AB7K7 t.sub.1/2 (h) (ng/mL*h) (.mu.g)/(ng/mL) (.mu.g)/(ng/mL)/h
Pharmacokinetics 42.10 550236.77 0.02351 3.811E-4 parameter
TABLE-US-00014 TABLE 5-2 Pharmacokinetics parameters of bispecific
antibody AB7K7 in SD rats (Method 2) AUC 0-inf_ob Vz_obs Cl_obs
AB7K7 t.sub.1/2 (h) (ng/mL*h) (.mu.g)/(ng/mL) (.mu.g)/(ng/mL)/h
Pharmacokinetics 41.02 706126.89 0.01720 2.899E-4 parameter
5.2 In Vivo Pharmacokinetics Test on Bispecific Antibody AB7K7 in
NPG Model Mice
[0455] NPG mice (purchased from Beijing Vitalstar Biotechnology
Co., Ltd.) were inoculated with HCC1954 cells (purchased from the
Institute of Cells, Chinese Academy of Sciences) one week before
administration, with an inoculum density of
3.5.times.10.sup.6/mouse. CIK cells were resuscitated two days
before administration, cultured for 24 hours and then collected and
injected intravenously into mice. The mice were randomly divided
into three groups with four mice in each group. The three treated
groups were administrated at doses of 0.3 mg/kg, 1 mg/kg and 3
mg/kg, respectively. The blood sampling time points were Hour 1,
Hour 3, Hour 6, Hour 24, Hour 48, Hour 72, Hour 96, Hour 120, Hour
168, Hour 216 and Hour 264, respectively. A certain amount of whole
blood was taken at each time point, the serum was separated, and
then the drug concentration in the serum was detected by ELISA.
[0456] Plates were coated with the anti-AB7K7 antibody A (Ampsource
Biopharma Shanghai Inc., mouse-anti-herceptin) at a concentration
of 0.5 .mu.g/mL. AB7K7 was formulated at concentrations of 100
ng/mL, 50 ng/mL, 25 ng/mL, 12.5 ng/mL, 6.25 ng/mL, 3.125 ng/mL and
1.56 ng/mL, separately. Standard curves were established.
HRP-labeled anti-AB7K7 antibody B (Ampsource Biopharma Shanghai
Inc., mouse-anti-herceptin) was used at a concentration of 1:5000,
and developed with TMB. The pharmacokinetics parameters were
calculated using software PKSolver. Specific parameters are shown
in Table 5-3. It can be seen from Table 5-3 that the
pharmacokinetics parameters of AB7K7 in NPG model mice were not
significantly different from those in SD rats.
TABLE-US-00015 TABLE 5-3 Pharmacokinetics parameters of bispecific
antibody AB7K7 in NPG model mice Parameter AUC0-inf_obs Vz_ob
Cl_obs Group t.sub.1/2 (h) (ng/mL*h) (.mu.g)/(ng/mL)
(.mu.g)/(ng/mL)/h 0.3 mg/kg IV 39.54 79932.39 0.004872 8.968E-05 1
mg/kg IV 42.70 597036.63 0.002461 3.996E-05 3 mg/kg IV 46.03
2171649.41 0.002292 3.469E-05
5.3 In Vivo Pharmacokinetics Test on Bispecific Antibody AB7K8 in
SD Rats
[0457] AB7K8 was administered to three healthy SD rats via the tail
vein at doses of 1 mg/kg and 3 mg/kg, respectively. The blood
sampling time points were Hour 0.25, Hour 0.5, Hour 1, Hour 2, Hour
3, Hour 4, Hour 5, and Hour 7, respectively. A certain amount of
whole blood was taken at each time point, the serum was separated,
and then the drug concentration in the serum was detected by
ELISA.
[0458] Plates were coated with the anti-AB7K8 antibody C (Ampsource
Biopharma Shanghai Inc., mouse-anti-herceptin) at a concentration
of 2.5 .mu.g/mL. AB7K8 was formulated at concentrations of 25
ng/mL, 12.5 ng/mL, 6.25 ng/mL, 3.125 ng/mL, 1.56 ng/mL, and 0.78
ng/mL, separately. Standard curves were established. HRP-labeled
anti-his antibody (Ampsource Biopharma Shanghai Inc.) was used at a
concentration of 1:5000, and developed with TMB. The
pharmacokinetics parameters were calculated using software
PKSolver. Specific parameters are shown in Table 5-4.
[0459] The pharmacokinetics parameter T.sub.1/2 of AB7K8 were
almost the same at two doses, which indicates that AB7K8 showed
linear metabolic kinetics in SD rats. Since AB7K8 does not contain
Fc, T.sub.1/2 of AB7K8 is very short, about twenty times shorter
than T.sub.1/2 of AB7K7.
TABLE-US-00016 TABLE 5-4 Pharmacokinetics parameters of bispecific
antibody AB7K8 in SD rats AUC 0-inf_ob Vz_obs Cl_obs AB7K8
t.sub.1/2 (h) (ng/mL*h) (.mu.g)/(ng/mL) (.mu.g)/(ng/mL)/h 1 mg/kg
IV 2.27 4623.14 0.17082 0.05191 3 mg/kg IV 1.98 20608.77 0.10220
0.03579
5.4 In Vivo Pharmacokinetics Test on Bispecific Antibody AB7K in SD
Rats
[0460] AB7K was administered to four healthy SD rats via the tail
vein at a dose of 0.8 mg/kg. The blood sampling time points were
Hour 2, Hour 24, Hour 48, Hour 72, Hour 96, Hour 120, Hour 144,
Hour 168, Hour 216 and Hour 264, respectively. A certain amount of
whole blood was taken at each time point, the serum was separated,
and then the drug concentration in the serum was detected by two
ELISA methods.
[0461] Method I. Plates were coated with the anti-AB7K antibody A
(Ampsource Biopharma Shanghai Inc., mouse-anti-herceptin) at a
concentration of 1 .mu.g/mL. AB7K was formulated at concentrations
of 20 ng/mL, 10 ng/mL, 5 ng/mL, 2.5 ng/mL, 1.25 ng/mL, 0.625 ng/mL
and 0.3125 ng/mL, separately. Standard curves were established. 25
ng/mL of biotin-labeled human CD3E&CD3D (Acro, Cat. No.
CDD-H82W0) was added, incubated for 1 hour, and after that,
HRP-labeled streptavidin (BD Pharmingen, Cat. No. 554066) diluted
at a factor of 1:500 was added, and developed with TMB. The
pharmacokinetics parameters were calculated using software
PKSolver. Specific parameters are shown in Table 5-5.
TABLE-US-00017 TABLE 5-5 Pharmacokinetics parameters of bispecific
antibody AB7K AUC 0-inf_ob Vz_obs Cl_obs AB7K t.sub.1/2 (h)
(ng/mL*h) (.mu.g)/(ng/mL) (.mu.g)/(ng/mL)/h Pharmacokinetics 60.47
1022788.69 0.01726 1.985E-4 parameter
[0462] Method II. Plates were coated with the anti-AB7K antibody A
(Ampsource Biopharma Shanghai Inc., mouse-anti-herceptin) at a
concentration of 1 .mu.g/mL. AB7K was formulated at concentrations
of 20 ng/mL, 10 ng/mL, 5 ng/mL, 2.5 ng/mL, 1.25 ng/mL, 0.625 ng/mL
and 0.3125 ng/mL, separately. Standard curves were established.
Mouse anti-human IgG Fc-HRP (diluted at 1:10000) (Ampsource
Biopharma Shanghai Inc.) was added, incubated in an incubator for 1
hour, and developed with TMB.
[0463] FIG. 5-2 shows the blood drug concentration of AB7K in rats
by using two different detection methods. From the results, it is
showed that the difference between the two detection methods is
large. The concentrations of the first two points (2h, 1D) on the
curve were close, but after the next day, the concentrations
detected by the two methods differed greatly, which is supposed to
be caused by the fact that the linkage peptide between the heavy
chains of anti-CD3 scFv and anti-Her2 antibodies was broken. AB7K
is structurally unstable in vivo and thus can't play its biological
function, while the improved AB7K7 can metabolize in complete form
in vivo and thus can play its biological function normally.
5.5 In Vivo Pharmacokinetics Test on Bispecific Antibodies AB7K7
and AB7K8 in Cynomolgus Monkeys
[0464] Female cynomolgus monkeys (purchased from Guangzhou
Xiangguan Biotechnology Co., Ltd.) with the weight of 3-4 kg were
divided into three groups with one monkey in each group. The first
group (G1-1) was a blank control group; the second group (G2-1) was
an AB7K7 treated group administrated at a dose of 0.3 mg/kg; and
the third group (G3-1) was an AB7K8 treated group administrated at
a dose of 0.2 mg/kg. The blood sampling time points were Minute 15,
Hour 1, Hour 3, Hour 6, Hour 24, Hour 48, Hour 72, Hour 96, Hour
144, Hour 192, Hour 240 and Hour 288, respectively, a total of 13
time points. Serum was collected from blood and frozen at
-80.degree. C. The concentration of the drug in serum was
determined by ELISA.
[0465] Plates were coated with the anti-AB7K7 antibody A (Ampsource
Biopharma Shanghai Inc., mouse-anti-herceptin) at a concentration
of 0.5 .mu.g/mL. AB7K7 was formulated at concentrations of 100
ng/mL, 50 ng/mL, 25 ng/mL, 12.5 ng/mL, 6.25 ng/mL, 3.125 ng/mL and
1.56 ng/mL, separately. Standard curves were established.
HRP-labeled anti-AB7K7 antibody B (Ampsource Biopharma Shanghai
Inc., mouse-anti-herceptin) was used at a concentration of 1:5000,
and developed with TMB. The pharmacokinetics parameters were
calculated using software PKSolver. Specific parameters are shown
in Table 5-6.
[0466] FIG. 5-3 shows the blood drug concentration of AB7K7 in
rats. T.sub.1/2 of AB7K7 in the normal cynomolgus monkey was only
about eight hours. Pharmacokinetics parameters of AB7K8 could not
be calculated due to too few points on the concentration-time curve
of AB7K8. However, it can be seen from the concentration-time curve
that the half-life of AB7K7 in the normal cynomolgus monkey was
much longer than the half-life of AB7K8.
TABLE-US-00018 TABLE 5-6 Pharmacokinetics parameters of bispecific
antibody AB7K7 in cynomolgus monkeys AUC 0-inf_obs Vz_obs Cl_obs
AB7K7 t.sub.1/2 (h) (ng/mL*h) (.mu.g)/(ng/mL) (.mu.g)/(ng/mL)/h
Pharmacokinetics 7.95 87995.48 0.1563 0.01364 parameter
5.6 Evaluation of Abilities of Bispecific Antibodies to Bind to
FcRn by ELISA
[0467] Each bispecific antibody was diluted with the PBS solution
to a concentration of 10 .mu.g/ml and added to 96-well plates, 100
.mu.l per well. The plates were coated at 4.degree. C. overnight.
The plates were then blocked with 1% skimmed milk powder for 1 hour
at room temperature. Biotin-labeled FcRn proteins (ACRO Biosystem,
Cat. No. FCM-H8286) were diluted using diluents at pH of 6.0 and
7.0, respectively, with a 4-fold gradient for a total of 11
concentration gradients. The 96-well plates were then washed with
PBST of the same pH, and then each of the bispecific antibodies
diluted with the diluent at the same pH was added. Control wells
without antibodies were set. Incubated for 1 hour at room
temperature. Plates were washed with the PBST solution of the same
pH, streptavidin-HRP (BD, Cat. No. 554066) was added to 96-well
plates, 100 .mu.l per well, and the plates were incubated for 0.5
hours at room temperature. 96-well plates were washed with PBST,
and TMB was added to the plates, 100 .mu.l per wells. Color
development was performed at room temperature for 15 minutes, and
then 0.2 M H.sub.2SO.sub.4 was added to stop the color development
reaction. The light absorbance values at A450-620 nm were measured
by a microplate reader. Analysis was performed by software
OriginPro 8, and the EC.sub.50 values for the binding of bispecific
antibodies to FcRn were calculated.
[0468] The results show that the ability of each antibody to bind
to FcRn was different under different pH conditions, and it is
analyzed in conjunction with data of in vivo PK that the half-life
of bispecific antibody AB7K7 was longer than the half-life of AB7K
but shorter than the half-life of Herceptin, which may be more
favorable for clinical application (FIGS. 5-4 and 5-5). Table 5-7
and Table 5-8 show the detection results of the ability of each
antibody to bind to FcRn at pHs 6.0 and 7.0, respectively.
TABLE-US-00019 TABLE 5-7 Detection of abilities of bispecific
antibodies AB7K, AB7K5 and AB7K7 to bind to FcRn at pH 6.0
Herceptin AB7K AB7K5 AB7K7 EC.sub.50 (.mu.g/ml) 2.591 0.8027 1.706
0.4630
TABLE-US-00020 TABLE 5-8 Detection of abilities of bispecific
antibodies AB7K, AB7K5 and AB7K7 to bind to FcRn at pH 7.0
Herceptin AB7K AB7K5 AB7K7 EC.sub.50 (.mu.g/ml) -287.1 1.651 13.43
4.838
Example 6 Preparation of Bispecific Antibody with scFv1-scFv2-Fc
Configuration
[0469] According to the above research results of six kinds of
anti-Her2.times.CD3 bispecific antibodies, it can be determined
that the bispecific antibody with scFv1-scFv2-Fc configuration such
as AB7K7 is easy to be prepared, can be purified in a simple and
efficient method, and has great stability in preparation and
storage process. More advantageously, such a bispecific antibody
has a weak non-specific killing effect on normal cells, has
significant advantages of controlled toxic and side effects
possibly caused by overactivation of effector cells, and has good
druggability.
[0470] With reference to the design and preparation method of the
bispecific antibody AB7K7 in Example 1, a series of bispecific
antibody molecules that target immune effector cell antigen CD3 and
a tumor-associated antigen were constructed. Such bispecific
antibody molecules are tetravalent homodimers formed by two
identical polypeptide chains that bind to each other by an
interchain disulfide bond in the hing region of the Fc fragment,
wherein each polypeptide chain consists of, in sequence from
N-terminus to C-terminus, an anti-TAA scFv, a linker peptide, an
anti-CD3 scFv, and an Fc fragment. The molecular composition of
each structural unit of each bispecific antibody is described below
in detail.
[0471] The tumor-associated antigen includes, but is not limited
to, CD19, CD20, CD22, CD25, CD30, CD33, CD38, CD39, CD40, CD47,
CD52, CD73, CD74, CD123, CD133, CD138, BCMA, CA125, CEA, CS1, DLL3,
DLL4, EGFR, EpCAM, FLT3, gpA33, GPC-3, Her2, MEGE-A3, NYESO1, PSMA,
TAG-72, CIX, folate-binding protein, GD2, GD3, GM2, VEGF, VEGFR2,
VEGFR3, Cadherin, Integrin, Mesothelin, Claudin18, .alpha.V.beta.3,
.alpha.5.beta.1, ERBB3, c-MET, IGF1R, EPHA3, TRAILR1, TRAILR2,
RANKL, B7 protein family, Mucin family, FAP, and Tenascin;
preferably, the tumor-associated antigen is CD19, CD20, CD22, CD30,
CD38, BCMA, CS1, EpCAM, CEA, Her2, EGFR, CA125, Mucin1, GPC-3, and
Mesothelin.
[0472] Some preferred amino acid sequences of the VH domain and its
complementary determining regions (HCDR1, HCDR2, and HCDR3) and
amino acid sequences of the VL domain and its complementary
determining regions (LCDR1, LCDR2 and LCDR3) of a first
single-chain Fv targeting the tumor-associated antigen are
exemplified in Table 6-1, wherein the amino acid composition of the
linker peptide between VH and VL of the anti-TAA scFv is
(GGGGS).sub.n, wherein n=1, 2, 3, 4 or 5.
TABLE-US-00021 TABLE 6-1 Amino acid sequences of the anti-TAA scFv
included in the bispecific antibody and amino acid sequences of its
CDR regions CD19 SEQ ID NO: 9 HCDR1 SYWMN SEQ ID NO: 10 HCDR2
QIWPGDGDTNYNGKFKG SEQ ID NO: 11 HCDR3 RETTTVGRYYYAMDY SEQ ID NO: 12
LCDR1 KASQSVDYDGDSYLN SEQ ID NO: 13 LCDR2 DASNLVS SEQ ID NO: 14
LCDR3 QQSTEDPWT QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMN SEQ ID NO: 15
VH WVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATL
TADESSSTAYMQLSSLASEDSAVYFCARRETTTVG RYYYAMDYWGQGTTVTVSS
DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDS SEQ ID NO: 16 VL
YLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSG
SGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGG TKLEIK CD19 SEQ ID NO: 17 HCDR1
SNWMH SEQ ID NO: 18 HCDR2 EIDPSDSYTNYNQNFQG SEQ ID NO: 19 HCDR3
GSNPYYYAMDY SEQ ID NO: 20 LCDR1 SASSGVNYMH SEQ ID NO: 21 LCDR2
DTSKLAS SEQ ID NO: 22 LCDR3 HQRGSYT
QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMH SEQ ID NO: 23 VH
WVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKL
TVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYY AMDYWGQGTSVTVSS SEQ ID NO: 24
VL EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWY
QQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTDY
SLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK CD19 SEQ ID NO: 25 HCDR1 TSGMGVG
SEQ ID NO: 26 HCDR2 HIWWDDDKRYNPALKS SEQ ID NO: 27 HCDR3 MELWSYYFDY
SEQ ID NO: 28 LCDR1 SASSSVSYMH SEQ ID NO: 29 LCDR2 DTSKLAS SEQ ID
NO: 30 LCDR3 FQGSVYPFT SEQ ID NO: 31 VH
QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMG
VGWIRQHPGKGLEWIGHIWWDDDKRYNPALKSRVT
ISVDTSKNQFSLKLSSVTAADTAVYYCARMELWSY YFDYWGQGTLVTVSS SEQ ID NO: 32
VL EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWY
QQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDF
TLTISSLEPEDVAVYYCFQGSVYPFTFGQGTKLEI K CD19 SEQ ID NO: 33 HCDR1
SSWMN SEQ ID NO: 34 HCDR2 RIYPGDGDTNYNVKFKG SEQ ID NO: 35 HCDR3
SGFITTVRDFDY SEQ ID NO: 36 LCDR1 RASESVDTFGISFMN SEQ ID NO: 37
LCDR2 EASNQGS SEQ ID NO: 38 LCDR3 QQSKEVPFT SEQ ID NO: 39 VH
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMN
WVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTI
SRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTV RDFDYWGQGTLVTVSS SEQ ID NO: 40
VL EIVLTQSPDFQSVTPKEKVTITCRASESVDTFGIS
FMNWFQQKPDQSPKLLIHEASNQGSGVPSRFSGSG
SGTDFTLTINSLEAEDAATYYCQQSKEVPFTFGGG TKVEIK CD20 SEQ ID NO: 41 HCDR1
SYNMH SEQ ID NO: 42 HCDR2 AIYPGNGDTSYNQKFKG SEQ ID NO: 43 HCDR3
STYYGGDWYFNV SEQ ID NO: 44 LCDR1 RASSSVSYIH SEQ ID NO: 45 LCDR2
ATSNLAS SEQ ID NO: 46 LCDR3 QQWTSNPPT SEQ ID NO: 47 VH
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMH
WVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATL
TADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGD WYFNVWGAGTTVTVSA SEQ ID NO: 48
VL QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWF
QQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSY
SLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEI K CD20 SEQ ID NO: 49 HCDR1
NYYIH SEQ ID NO: 50 HCDR2 WIYPGDGNTKYNEKFKG SEQ ID NO: 51 HCDR3
DSYSNYYFDY SEQ ID NO: 52 LCDR1 RASSSVSYMH SEQ ID NO: 53 LCDR2
APSNLAS SEQ ID NO: 54 LCDR3 QQWSFNPPT SEQ ID NO: 55 VH
EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIH
WVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATL
TADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYY FDYWGQGTLVTVSS SEQ ID NO: 56 VL
DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWY
QQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDF
TLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEI K CD20 SEQ ID NO: 57 HCDR1
YSWIN SEQ ID NO: 58 HCDR2 RIFPGDGDTDYNGKFKG SEQ ID NO: 59 HCDR3
NVFDGYWLVY SEQ ID NO: 60 LCDR1 RSSKSLLHSNGITYLY SEQ ID NO: 61 LCDR2
QMSNLVS SEQ ID NO: 62 LCDR3 AQNLELPYT SEQ ID NO: 63 VH
QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWIN
WVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTI
TADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYW LVYWGQGTLVTVSS SEQ ID NO: 64 VL
DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGI
TYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGS
GSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGG GTKVEIK CD20 SEQ ID NO: 65
HCDR1 DYAMH SEQ ID NO: 66 HCDR2 TISWNSGSIGYADSVKG SEQ ID NO: 67
HCDR3 DIQYGNYYYGMDV SEQ ID NO: 68 LCDR1 RASQSVSSYLA SEQ ID NO: 69
LCDR2 DASNRAT SEQ ID NO: 70 LCDR3 QQRSNWPIT SEQ ID NO: 71 VH
EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMH
WVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTI
SRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNY YYGMDVWGQGTTVTVSS SEQ ID NO: 72
VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAW
YQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTD
FTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLE IK CD22 SEQ ID NO: 73 HCDR1
RSWMN SEQ ID NO: 74 HCDR2 RIYPGDGDTNYSGKFKG SEQ ID NO: 75 HCDR3
DGSSWDWYFDV SEQ ID NO: 76 LCDR1 RSSQSIVHSVGNTFLE SEQ ID NO: 77
LCDR2 KVSNRFS SEQ ID NO: 78 LCDR3 FQGSQFPYT SEQ ID NO: 79 VH
EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMN
WVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTI
SADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDW YFDVWGQGTLVTVSS SEQ ID NO: 80
VL DIQMTQSPSSLSASVGDRVTITCRSSQSIVHSVGN
TFLEWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGS
GSGTDFTLTISSLQPEDFATYYCFQGSQFPYTFGQ GTKVEIK CD22 SEQ ID NO: 81
HCDR1 IYDMS SEQ ID NO: 82 HCDR2 YISSGGGTTYYPDTVKG SEQ ID NO: 83
HCDR3 HSGYGTHWGVLFAY SEQ ID NO: 84 LCDR1 RASQDISNYLN SEQ ID NO: 85
LCDR2 YTSILHS SEQ ID NO: 86 LCDR3 QQGNTLPWT SEQ ID NO: 87 VH
EVQLVESASTGGGLVKPGGSLKLSCAASGFAFSIY
DMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGR
FTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGY GTHWGVLFAYWGQGTLVT SEQ ID NO:
88 VL DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNW
YQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTD
YSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLE IK CD30 SEQ ID NO: 89 HCDR1
DYYIT SEQ ID NO: 90 HCDR2 WIYPGSGNTKYNEKFKG SEQ ID NO: 91 HCDR3
YGNYWFAY SEQ ID NO: 92 LCDR1 KASQSVDFDGDSYMN SEQ ID NO: 93 LCDR2
AASNLES SEQ ID NO: 94 LCDR3 QQSNEDPWT SEQ ID NO: 95 VH
QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYIT
WVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATL
TVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFA YWGQGTQVTVSA SEQ ID NO: 96 VL
DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDS
YMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSG
SGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGG TKLEIK CD30 SEQ ID NO: 97 HCDR1
AYYWS SEQ ID NO: 98 HCDR2 DINHGGGTNYNPSLKS SEQ ID NO: 99 HCDR3 LTAY
SEQ ID NO: 100 LCDR1 RASQGISSWLT SEQ ID NO: 101 LCDR2 AASSLQS SEQ
ID NO: 102 LCDR3 QQYDSYPIT SEQ ID NO: 103 VH
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSAYYWS
WIRQPPGKGLEWIGDINHGGGTNYNPSLKSRVTIS
VDTSKNQFSLKLNSVTAADTAVYYCASLTAYWGQG SLVTVSS SEQ ID NO: 104 VL
DIQMTQSPTSLSASVGDRVTITCRASQGISSWLTW
YQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQYDSYPITFGQGTRLE IK EpCAM SEQ ID NO: 105 HCDR1
SYGMH SEQ ID NO: 106 HCDR2 VISYDGSNKYYADSVKG SEQ ID NO: 107 HCDR3
DMGWGSGWRPYYYYGMDV SEQ ID NO: 108 LCDR1 RTSQSISSYLN SEQ ID NO: 109
LCDR2 WASTRES SEQ ID NO: 110 LCDR3 QQSYDIPYT SEQ ID NO: 111 VH
EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMH
WVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTI
SRDNSKNTLYLQMNSLRAEDTAVYYCAKDMGWGSG WRPYYYYGMDVWGQGTTVTVSS SEQ ID
NO: 112 VL ELQMTQSPSSLSASVGDRVTITCRTSQSISSYLNW
YQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTD
FTLTISSLQPEDSATYYCQQSYDIPYTFGQGTKLE IK EpCAM SEQ ID NO: 113 HCDR1
NYGMN SEQ ID NO: 114 HCDR2 WINTYTGESTYADSFKG SEQ ID NO: 115 HCDR3
FAIKGDY SEQ ID NO: 116 LCDR1 RSTKSLLHSNGITYLY SEQ ID NO: 117 LCDR2
QMSNLAS SEQ ID NO: 118 LCDR3 AQNLEIPRT SEQ ID NO: 119 VH
EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMN
WVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTF
SLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDY WGQGTLLTVSS SEQ ID NO: 120 VL
DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGI
TYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSS
GSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQ GTKVELK CEA SEQ ID NO: 121
HCDR1 DTYMH SEQ ID NO: 122 HCDR2 RIDPANGNSKYADSVKG SEQ ID NO: 123
HCDR3 FGYYVSDYAMAY SEQ ID NO: 124 LCDR1 RAGESVDIFGVGFLH SEQ ID NO:
125 LCDR2 RASNLES SEQ ID NO: 126 LCDR3 QQTNEDPYT SEQ ID NO: 127 VH
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYMH
WVRQAPGKGLEWVARIDPANGNSKYADSVKGRFTI
SADTSKNTAYLQMNSLRAEDTAVYYCAPFGYYVSD YAMAYWGQGTLVTVSS SEQ ID NO: 128
VL DIQLTQSPSSLSASVGDRVTITCRAGESVDIFGVG
FLHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSG
SRTDFTLTISSLQPEDFATYYCQQTNEDPYTFGQG TKVEIK CEA SEQ ID NO: 129 HCDR1
TYWMS SEQ ID NO: 130 HCDR2 EIHPDSSTINYAPSLKD SEQ ID NO: 131 HCDR3
LYFGFPWFAY SEQ ID NO: 132 LCDR1 KASQDVGTSVA SEQ ID NO: 133 LCDR2
WTSTRHT SEQ ID NO: 134 LCDR3 QQYSLYRS SEQ ID NO: 135 VH
EVQLVESGGGVVQPGRSLRLSCSASGFDFTTYWMS
WVRQAPGKGLEWIGEIHPDSSTINYAPSLKDRFTI
SRDNAKNTLFLQMDSLRPEDTGVYFCASLYFGFPW FAYWGQGTPVTVSS SEQ ID NO: 136
VL DIQLTQSPSSLSASVGDRVTITCKASQDVGTSVAW
YQQKPGKAPKLLIYWTSTRHTGVPSRFSGSGSGTD
FTFTISSLQPEDIATYYCQQYSLYRSFGQGTKVEI K CEA SEQ ID NO: 137 HCDR1
EFGMN SEQ ID NO: 138 HCDR2 WINTKTGEATYVEEFKG SEQ ID NO: 139 HCDR3
WDFAYYVEAMDY SEQ ID NO: 140 LCDR1 KASAAVGTYVA SEQ ID NO: 141 LCDR2
SASYRKR SEQ ID NO: 142 LCDR3 HQYYTYPLFT SEQ ID NO: 143 VH
QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMN
WVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTF
TTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYV EAMDYWGQGTTVTVSS SEQ ID NO: 144
VL DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAW
YQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKL EIK Her2 SEQ ID NO: 145 HCDR1
DTYIH SEQ ID NO: 146 HCDR2 RIYPTNGYTRYADSVKG SEQ ID NO: 147 HCDR3
WGGDGFYAMDY SEQ ID NO: 148 LCDR1 RASQDVNTAVA SEQ ID NO: 149 LCDR2
SASFLYS SEQ ID NO: 150 LCDR3 QQHYTTPPT SEQ ID NO: 151 VH
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH
WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI
SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGTLVTVSS SEQ ID NO: 152
VL DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAW
YQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTD
FTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVE IK Her2 SEQ ID NO: 153 HCDR1
DYTMD SEQ ID NO: 154 HCDR2 DVNPNSGGSIYNQRFKG SEQ ID NO: 155 HCDR3
NLGPSFYFDY SEQ ID NO: 156 LCDR1 KASQDVSIGVA SEQ ID NO: 157 LCDR2
SASYRYT SEQ ID NO: 158 LCDR3 QQYYIYPYT SEQ ID NO: 159 VH
EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMD
WVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTL
SVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFY FDYWGQGTLVTVSS SEQ ID NO: 160
VL DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAW
YQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVE IK Her2 SEQ ID NO: 161 HCDR1
DTYIH SEQ ID NO: 162 HCDR2 RIYPTNGYTRYDPKFQD SEQ ID NO: 163 HCDR3
WGGDGFYAMDY SEQ ID NO: 164 LCDR1 KASQDVNTAVA SEQ ID NO: 165 LCDR2
SASFRYT SEQ ID NO: 166 LCDR3 QQHYTTPPT SEQ ID NO: 167 VH
QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIH
WVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATI
TADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFY AMDYWGQGASVTVSS SEQ ID NO: 168
VL DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAW
YQQKPGHSPKLLIYSASFRYTGVPDRFTGSRSGTD
FTFTISSVQAEDLAVYYCQQHYTTPPTFGGGTKVE IK EGFR SEQ ID NO: 169 HCDR1
NYGVH SEQ ID NO: 170 HCDR2 VIWSGGNTDYNTPFTS SEQ ID NO: 171 HCDR3
ALTYYDYEFAY SEQ ID NO: 172 LCDR1 RASQSIGTNIH SEQ ID NO: 173 LCDR2
YASESIS SEQ ID NO: 174 LCDR3 QQNNNWPTT SEQ ID NO: 175 VH
QVQLKQSGPGLVQPSQSLSITCTVSGF SLTNYGVH
WVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSIN
KDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYE FAYWGQGTLVTVSA SEQ ID NO: 176
VL DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHW
YQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD
FTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLE LK EGFR SEQ ID NO: 177 HCDR1
SGDYYWS SEQ ID NO: 178 HCDR2 YIYYSGSTDYNPSLKS SEQ ID NO: 179 HCDR3
VSIFGVGTFDY SEQ ID NO: 180 LCDR1 RASQSVSSYLA SEQ ID NO: 181 LCDR2
DASNRAT SEQ ID NO: 182 LCDR3 HQYGSTP LT
SEQ ID NO: 183 VH QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYY
WSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVT
MSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGV GTFDYWGQGTLVTVSS SEQ ID NO: 184
VL EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAW
YQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTD
FTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAE IK EGFR SEQ ID NO: 185 HCDR1
NYYIY SEQ ID NO: 186 HCDR2 GINPTSGGSNFNEKFKT SEQ ID NO: 187 HCDR3
QGLWFDSDGRGFDF SEQ ID NO: 188 LCDR1 RSSQNIVHSNGNTYLD SEQ ID NO: 189
LCDR2 KVSNRFS SEQ ID NO: 190 LCDR3 FQYSHVPWT SEQ ID NO: 191 VH
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIY
WVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTI
TVDESTNTAYMELSSLRSEDTAFYFCARQGLWFDS DGRGFDFWGQGSTVTVSS SEQ ID NO:
192 VL DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGN
TYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGS
GSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQ GTKLQIT GPC-3 SEQ ID NO: 193
HCDR1 DYEMH SEQ ID NO: 194 HCDR2 AIDPQTGNTAFNQKFKG SEQ ID NO: 195
HCDR3 FYSLTY SEQ ID NO: 196 LCDR1 RSSQSIVHSNGNTYLQ SEQ ID NO: 197
LCDR2 KVSNRFS SEQ ID NO: 198 LCDR3 FQGSHFPYA SEQ ID NO: 199 VH
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMH
WVKQAPGQGLEWIGAIDPQTGNTAFNQKFKGRVTL
TRDKSSSTVYMELSSLRSEDTAVYYCTRFYSLTYW GQGTLVTVSS SEQ ID NO: 200 VL
DVLMTQSPLSLPVTLGQPASISCRSSQSIVHSNGN
TYLQWYLQRPGQSPKLLIYKVSNRFSGVPDRFSGS
GSGTYFTLKISRVEAEDVGVYYCFQGSHFPYAFGG GTKVEIK Mesothelin SEQ ID NO:
201 HCDR1 IYGMH SEQ ID NO: 202 HCDR2 VIWYDGSHEYYADSVKG SEQ ID NO:
203 HCDR3 DGDYYDSGSPLDY SEQ ID NO: 204 LCDR1 RASQSVSSYLA SEQ ID NO:
205 LCDR2 DASNRAT SEQ ID NO: 206 LCDR3 QQRSNWPLT SEQ ID NO: 207 VH
QVYLVESGGGVVQPGRSLRLSCAASGITFSIYGMH
WVRQAPGKGLEWVAVIWYDGSHEYYADSVKGRFTI
SRDNSKNTLYLLMNSLRAEDTAVYYCARDGDYYDS GSPLDYWGQGTLVTVSS SEQ ID NO:
208 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAW
YQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTD
FTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVE IK Mucin1 SEQ ID NO: 209 HCDR1
SYVLH SEQ ID NO: 210 HCDR2 YINPYNDGTQYNEKFKG SEQ ID NO: 211 HCDR3
GFGGSYGFAY SEQ ID NO: 212 LCDR1 SASSSVSSSYLY SEQ ID NO: 213 LCDR2
STSNLAS SEQ ID NO: 214 LCDR3 HQWNRYPYT SEQ ID NO: 215 VH
QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLH
WVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATL
TRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYG FAYWGQGTLVTVSS SEQ ID NO: 216
VL DIQLTQSPSSLSASVGDRVTMTCSASSSVSSSYLY
WYQQKPGKAPKLWIYSTSNLASGVPARFSGSGSGT
DFTLTISSLQPEDSASYFCHQWNRYPYTFGGGTRL EIK Mucin1 SEQ ID NO: 217 HCDR1
NYWMN SEQ ID NO: 218 HCDR2 EIRLKSNNYTTHYAESVKG SEQ ID NO: 219 HCDR3
HYYFDY SEQ ID NO: 220 LCDR1 RSSKSLLHSNGITYFF SEQ ID NO: 221 LCDR2
QMSNLAS SEQ ID NO: 222 LCDR3 AQNLELPPT SEQ ID NO: 223 VH
EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMN
WVRQAPGKGLEWVGEIRLKSNNYTTHYAESVKGRF
TISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFD YWGQGTLVTVSS SEQ ID NO: 224 VL
DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGI
TYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSGS
GSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQ GTKVEIK CA125 SEQ ID NO: 225
HCDR1 SYAMS SEQ ID NO: 226 HCDR2 TISSAGGYIFYSDSVQG SEQ ID NO: 227
HCDR3 QGFGNYGDYYAMDY SEQ ID NO: 228 LCDR1 KSSQSLLNSRTRKNQLA SEQ ID
NO: 229 LCDR2 WASTRQS SEQ ID NO: 230 LCDR3 QQSYNLLT SEQ ID NO: 231
VH VKLQESGGGFVKPGGSLKVSCAASGFTFSSYAMSW
VRLSPEMRLEWVATISSAGGYIFYSDSVQGRFTIS
RDNAKNTLHLQMGSLRSGDTAMYYCARQGFGNYGD YYAMDYWGQGTTVTVSS SEQ ID NO:
232 VL DIELTQSPSSLAVSAGEKVTMSCKSSQSLLNSRTR
KNQLAWYQQKPGQSPELLIYWASTRQSGVPDRFTG
SGSGTDFTLTISSVQAEDLAVYYCQQSYNLLTFGP GTKLEVK BCMA SEQ ID NO: 233
HCDR1 NYWMH SEQ ID NO: 234 HCDR2 ATYRGHSDTYYNQKFKG SEQ ID NO: 235
HCDR3 GAIYDGYDVLDN SEQ ID NO: 236 LCDR1 SASQDISNYLN SEQ ID NO: 237
LCDR2 YTSNLHS SEQ ID NO: 238 LCDR3 QQYRKLPWT SEQ ID NO: 239 VH
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMH
WVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTI
TADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGY DVLDNWGQGTLVTVSS SEQ ID NO: 240
VL DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNW
YQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLE IK
[0473] The anti-CD3 scFv binds to an effector cell at an EC.sub.50
value greater than about 50 nM, or greater than 100 nM, or greater
than 300 nM, or greater than 500 nM in an in vitro FACS binding
affinity assay; more preferably, the second single-chain Fv of the
bispecific antibody not only binds to human CD3 but also
specifically binds to CD3 of cynomolgus monkeys or rhesus
monkeys.
[0474] Some preferred amino acid sequences of the VH domain and its
complementary determining regions (HCDR1, HCDR2, and HCDR3) and
amino acid sequences of the VL domain and its complementary
determining regions (LCDR1, LCDR2 and LCDR3) of the anti-CD3 scFv
are exemplified in Table 6-2, wherein the amino acid residues
contained in the CDRs are defined according to the Kabat rule,
wherein the amino acid composition of the linker peptide between VH
and VL of the anti-CD3 scFv is (GGGGS).sub.n, wherein n=1, 2, 3, 4
or 5.
TABLE-US-00022 TABLE 6-2 Amino acid sequences of the anti-CD3 scFv
included in the bispecific antibody and amino acid sequences of its
CDR regions CD3-3 SEQ ID HCDR1 TYAMN NO: 241 SEQ ID HCDR2
RIRSKYNNYATYYADSVKD NO: 242 SEQ ID HCDR3 HGNFGNSYVSWFAY NO: 243 SEQ
ID LCDR1 RSSTGAVTTSNYAN NO: 244 SEQ ID LCDR2 GTNKRAP NO: 245 SEQ ID
LCDR3 ALWYSNLWV NO: 246 SEQ ID VH
EVQLLESGGGLVQPGGSLKLSCAASGFTFNTYAMN NO: 247
WVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRF
TISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFG NSYVSWFAYWGQGTLVTVSS SEQ ID VL
ELVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYA NO: 248
NWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLG
GKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTK LTVL CD3-4 SEQ ID HCDR1 KYAMN
NO: 249 SEQ ID HCDR2 RIRSKYNNYATYYADSVKD NO: 250 SEQ ID HCDR3
HGNFGNSYISYWAY NO: 251 SEQ ID LCDR1 GSSTGAVTSGYYPN NO: 252 SEQ ID
LCDR2 GTKFLAP NO: 253 SEQ ID LCDR3 ALWYSNRWV NO: 254 SEQ ID VH
EVQLLESGGGLVQPGGSLKLSCAASGFTFNKYAMN NO: 255
WVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRF
TISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFG NSYISYWAYWGQGTLVTVSS SEQ ID VL
ELVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGYYP NO: 256
NWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLG
GKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTK LTVL
[0475] The linker peptide that connects the anti-TAA scFv to the
anti-CD3 scFv consists of a flexible peptide and a rigid peptide;
preferably, the amino acid composition of the flexible peptide has
a general formula G.sub.xS.sub.y(GGGGS).sub.z, wherein x, y, and z
are integers greater than or equal to 0, and x+y+z .gtoreq.1. The
rigid peptide is derived from a full-length sequence (as shown in
SEQ ID NO: 257) consisting of amino acids at positions 118 to 145
of the carboxy terminus of the natural human chorionic gonadotropin
beta subunit, or a truncated fragment thereof, preferably, the
composition of the CTP rigid peptide is SSSSKAPPPS (CTP.sup.1).
Some preferred amino acid sequences of the linker peptide that
connects the anti-TAA scFv and the anti-CD3 scFv are exemplified in
Table 6-3.
TABLE-US-00023 TABLE 6-3 Amino acid sequences of the linker peptide
that connects the anti-TAA scFv and the anti-CD3 scFv SEQ ID NO:
G.sub.2(GGGGS).sub.3CTP.sup.1 GGGGGGSGGGGSGGGGSSSSSK 258 APPPS SEQ
ID NO: (GGGGS).sub.3CTP.sup.1 GGGGSGGGGSGGGGSSSSSKAP 259 PPS SEQ ID
NO: GS(GGGGS).sub.2CTP.sup.1 GSGGGGSGGGGSSSSSKAPPPS 260 SEQ ID NO:
(GGGGS).sub.1CTP.sup.4 GGGGSSSSSKAPPPSLPSPSRL 261 PGPSDTPILPQ
[0476] The Fc fragment is directly connected or connected by a
linker peptide to the anti-CD3 scFv, wherein the linker peptide
includes 1 to 20 amino acids that are preferably selected from the
following amino acids: Gly(G), Ser(S), Ala(A), and Thr(T), more
preferably Gly(G) and Ser(S); and most preferably, the linker
peptide consists of (GGGGS)n, wherein n=1, 2, 3 or 4.
[0477] The Fc fragment is preferably selected from heavy chain
constant regions of human IgG1, IgG2, IgG3 and IgG4 and more
particularly selected from heavy chain constant regions of human
IgG1 or IgG4; and Fc is mutated to modify the properties of the
bispecific antibody molecule, e.g., reduced affinity to at least
one of human Fc.gamma.Rs (Fc.gamma.RJ, Fc.gamma.RIIa or
Fc.gamma.RIIIa) and C1q, a reduced effector cell function, or a
reduced complement function. In addition, the Fc fragment may also
contain amino acid substitutions that change one or more other
characteristics (e.g., an ability of binding to an FcRn receptor,
the glycosylation of the antibody or the charge heterogeneity of
the antibody).
[0478] Some amino acid sequences of the Fc fragment with one or
more amino acid mutations are exemplified in Table 6-4.
TABLE-US-00024 TABLE 6-4 Amino acid sequences of Fc from human IgG
Amino acid sequence of a constant region of an IgG1 Fc
(L234A/L235A) mutant (EU numbering) SEQ ID DKTHTCPPCP APEAAGGPSV
FLFPPKPKDT LMISRTPEVT NO: 262 CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL
TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK Amino acid sequence of a
constant region of an IgG1 (L234A/L235A/T250Q/N297A/
P331S/M428L/K447-)mutant (EU numbering) SEQ ID DKTHTCPPCP
APEAAGGPSV FLFPPKPKDQ LMISRTPEVT NO: 263 CVVVDVSHED PEVKFNWYVD
GVEVHNAKTK PREEQYASTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA SIEKTISKAK
GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS
DGSFFLYSKL TVDKSRWQQG NVFSCSVLHE ALHNHYTQKS LSLSPGK
[0479] Amino acid sequences of some preferred bispecific antibodies
and corresponding nucleotide sequences thereof are exemplified in
Table 6-5.
TABLE-US-00025 TABLE 6-5 several bispecific antibodies of
scFv1-scFv2-Fc configuration Antibody Amino acid Nucleotide
sequence code Target site sequence No. No. AB1K1 Anti-CD19 .times.
CD3 SEQ ID NO: 264 SEQ ID NO: 265 AB1K2 Anti-CD19 .times. CD3 SEQ
ID NO: 283 SEQ ID NO: 284 AB2K Anti-CD20 .times. CD3 SEQ ID NO: 266
SEQ ID NO: 267 AB3K Anti-CD22 .times. CD3 SEQ ID NO: 268 SEQ ID NO:
269 AB4K Anti-CD30 .times. CD3 SEQ ID NO: 270 SEQ ID NO: 271 AB5K
Anti-EpCAM .times. CD3 SEQ ID NO: 272 SEQ ID NO: 273 AB6K .sup.
Anti-CEA .times. CD3 SEQ ID NO: 274 SEQ ID NO: 275 AB7K7 .sup.
Anti-Her2 .times. CD3 SEQ ID NO: 8 SEQ ID NO: 276 AB8K Anti-EGFR
.times. CD3.sup. SEQ ID NO: 277 SEQ ID NO: 278 AB9K Anti-GPC-3
.times. CD3.sup. SEQ ID NO: 279 SEQ ID NO: 280 AB10K
Anti-Mesothelin .times. CD3 .sup. SEQ ID NO: 281 SEQ ID NO: 282
AB11k Anti-Mucin 1 .times. CD3 SEQ ID NO: 285 SEQ ID NO: 286
Example 7 Pharmacodynamics Study of Anti-GPC-3.times.CD3 Bispecific
Antibodies in a Mouse Transplanted Tumor Model
7.1 NOD-SCID Mouse Model of Transplanted Tumor Constructed by
Subcutaneously Co-Inoculating Human PBMCs and Human Liver Cancer
Cells Huh-7
[0480] GPC-3-positive human liver cancer cells Huh-7 were selected
to study the inhibiting effect of bispecific antibodies on tumor
growth in vivo in a NOD-SCID mouse model of transplanted tumor
constructed by subcutaneously co-inoculating human PBMC cells and
Huh-7 cells.
[0481] The peripheral blood of a normal human was subjected to
density gradient centrifugation to separate human PBMCs. Female
NOD-SCID mice (purchased from Shanghai Lingchang Biotechnology Co.,
Ltd.) at the age of seven to eight weeks were selected and Huh-7
cells in the logarithmic growth stage were collected.
3.times.10.sup.6 Huh-7 cells and 3.times.10.sup.6 PBMCs were mixed
and inoculated subcutaneously on the right back of each NOD-SCID
mouse. One hour after inoculation, the mice were randomly divided
into two groups with six mice in each group according to their
weights. The treated group was intraperitoneally administered with
AB9K at a dose of 1 mg/kg, and the control group was administered
with a PBS solution of the same volume, once a day continuously for
6 days. The day of administration was recorded as Day 0. The
maximum diameter (D) and the minimum diameter (d) of the tumor were
measured weekly. The volume (mm.sup.3) of the tumor of each group
and the tumor growth inhibition rate (TGI) (%) of each treated
group were calculated using the formulas as shown in Example
3.1.
[0482] As shown in FIG. 6-1, on Day 21 of administration, the
average tumor volume of the PBS control group was 1311.03.+-.144.89
mm.sup.3; the average tumor volume of the treated group
administrated with AB9K was 60.83.+-.12.63 mm.sup.3, and the TGI
was 95.36%, wherein the tumor in one mouse was completely
regressed, which was significantly different from that of the
control group (P<0.001). The above results show that most of
PBMCs are inactivated primary T cells, the bispecific antibody AB9K
can activate the primary T cells in the animals and draw the
distance between the T cells and the target cell Huh-7 so that the
T cells can directly kill the tumor cells and inhibit the growth of
the tumor, and thus AB9K has a very good anti-tumor effect at a
dose of 1 mg/kg.
7.2 NPG Mouse Model of Transplanted Tumor Constructed by
Subcutaneously Co-Inoculating Human CIK Cells and Human Burkkit's
Lymphoma Raji Cells
[0483] GPC-3-negative human Burkkit's lymphoma Raji cells were
selected to study the inhibiting effect of bispecific antibodies on
tumor growth in vivo in an NPG mouse model of transplanted tumor
constructed by subcutaneously co-inoculating human CIK cells and
human Burkkit's lymphoma Raji cells.
[0484] CIK cells were prepared in the method as described in
Example 3.1. Female NPG mice at the age of seven to eight weeks
were selected, and Raji cells in the logarithmic growth stage were
collected. 5.times.10.sup.6 Raji cells and 2.times.10.sup.6 CIK
cells were mixed and inoculated subcutaneously on the right back of
each NPG mouse. One hour after inoculation, the mice were randomly
divided into three groups with five mice in each group according to
their weights. The treated group was intraperitoneally administered
with AB9K at a dose of 1 mg/kg, and the control group was
administered with a PBS solution of the same volume, once a day
continuously for 10 days. The day of administration was recorded as
Day 0. The maximum diameter (D) and the minimum diameter (d) of the
tumor were measured weekly. The volume (mm.sup.3) of the tumor of
each group and the tumor growth inhibition rate (TGI) (%) of each
treated group were calculated using the formulas as shown in
Example 3.1.
[0485] As shown in FIG. 6-2, on Day 26 of administration, the
average tumor volume of the PBS control group was 2636.66.+-.196.62
mm.sup.3; the average tumor volume of the treated group
administrated with AB9K was 2739.57.+-.220.13 mm.sup.3, which was
not significantly different from that of the control group. In
summary, the results show that bispecific antibody AB9K exhibited
no non-specific killing on GPC-3-negative cell strains, which
indicates that the bispecific antibody does not mediate T cells to
kill non-target tissues in vivo, there is no drug toxicity, and the
safety is high.
7.3 CD34 Immune-Reconstituted NPG Mouse Model of Transplanted Tumor
Constructed by Inoculating Human Liver Cancer Huh-7 Cells
[0486] GPC-3-positive human liver cancer Huh-7 cells were selected
to study the inhibiting effect of bispecific antibodies on tumor
growth in vivo in a CD34 immune-reconstituted NPG mouse model of
transplanted tumor constructed by subcutaneously inoculating human
liver cancer Huh-7 cells.
[0487] CD34 immune-reconstituted NPG mice were prepared in the
method as described in Example 3.5. Huh-7 cells in the logarithmic
growth stage were collected and 2.5.times.10.sup.6 Huh-7 cells were
inoculated subcutaneously on the right back of the
immune-reconstituted mice. Four days after inoculation, the mice
were randomly divided into two groups with seven mice in each group
according to the tumor volumes and weights. The treated group was
intraperitoneally administered with AB9K at a dose of 1 mg/kg, and
the control group was administered with a PBS solution of the same
volume, once a day until the test was completed. The day of
administration was recorded as Day 0. The maximum diameter (D) and
the minimum diameter (d) of the tumor were measured weekly. The
volume (mm.sup.3) of the tumor of each group and the tumor growth
inhibition rate (TGI) (%) of each treated group were calculated
using the formulas as shown in Example 3.1.
[0488] As shown in FIG. 6-3, on Day 21 of administration, the
average tumor volume of the PBS control group was 2102.84.+-.275.71
mm.sup.3; the average tumor volume of the treated group
administrated with AB9K at the dose of 1 mg/kg was 325.01.+-.282.21
mm.sup.3, and the TGI was 86.53%, wherein the tumor in four mice
was completely regressed, which was significantly different from
that of the control group (P<0.001). The above results show that
the bispecific antibody AB9K had an excellent anti-tumor effect in
the CD34 immune-reconstituted model.
Example 8 In Vitro Biological Function Evaluation of
Anti-CD20.times.CD3 Bispecific Antibodies and Pharmacodynamics
Study of Anti-CD20.times.CD3 Bispecific Antibodies in a Mouse
Transplanted Tumor Model
8.1 Detection of the Binding Activity of AB2K to CD20-Positive
Tumor Cells by Flow Cytometry
[0489] Raji cells (purchased from the cell bank of Chinese Academy
of Sciences) were cultured and collected by centrifugation. The
collected cells were resuspended with 1% PBSB and placed in 96-well
plates, 100 .mu.l (i.e., 2.times.10.sup.5 cells) per well, after
the cell density was adjusted to (2.times.10.sup.6) cells/ml.
Diluted bispecific antibodies with a series of concentrations were
added and incubated for 1 hour at 4.degree. C. The cells were
centrifuged to discard the supernatant and then washed three times
using a PBS solution with 1% BSA (PBSB). Diluted AF488-labeled goat
anti-human IgG antibodies (Jackson Immuno Research Inc., Cat. No.
109-545-088) or mouse anti-6.times.His IgG antibodies (R&D
Systems, Cat. No. IC050P) were added to the cells, and the cells
were incubated for 1 hour at 4.degree. C. in the dark. The obtained
cells were centrifuged to discard the supernatant and then washed
twice with 1% PBSB, and cells in each well were resuspended with
100 .mu.l of 1% paraformaldehyde. The signal intensity was detected
by flow cytometry. The analysis was performed with the average
fluorescence intensity as the Y-axis and the antibody concentration
as the X-axis through software GraphPad to calculate the EC.sub.50
value for the binding of AB2K to Raji cells.
[0490] As shown in FIG. 7-1, AB2K bound well to CD20-positive
cells, the signal intensity was proportional to the antibody
concentration, and the EC.sub.50 value for AB2K binding to Raji
cells was calculated, which was about 69.97 nM.
8.2 AB2K Mediating Effector Cells to Target and Kill CD20-Positive
Tumor Cells
[0491] Normally cultured Raji-luc cells (purchased from Beijing
Biocytogen Biotechnology Co., Ltd.) were added to 96-well white
plates after the cell density was adjusted to 1.times.10.sup.5
cells/ml, 40 .mu.l per well. AB2K antibodies were diluted into a
series of gradients and added to the 96-well white plates. After
the CIK cell density was adjusted to 5.times.10.sup.5 cells/ml, the
CIK cells were added to the 96-well white plates, 40 .mu.l per
well, to make the effector:target ratio (E:T) equal to 5:1, and
cultured for 24 hours at 37.degree. C. After 24 hours, the white
plates were taken out, 100 .mu.l of One-Glo (Promega, Cat. No.
E6120) solution was added to each well, and then the white plates
were placed for at least three minutes at room temperature. The
luminescence value was measured by a microplate reader. The
analysis was performed with the fluorescence intensity as the
Y-axis and the antibody concentration as the X-axis through
software GraphPad to calculate the EC.sub.50 value of AB2K killing
Raji-luc cells.
[0492] As shown in FIG. 7-2, the EC.sub.50 for AB2K mediating
effector cells to kill Raji-luc cells was only 42.8 ng/ml and AB2K
had target specificity, while the EC.sub.50 of AB7K7 as a negative
control was 229.5 ng/ml and AB7K7 had little killing effect on
Raji-luc cells.
8.3 Evaluation of Abilities of Bispecific Antibodies to Activate T
Cells Through Reporter Gene Cell Strains
[0493] Jurkat T cells containing NFAT RE reporter genes (BPS
Bioscience, Cat. No. 60621) can overexpress luciferase in the
presence of bispecific antibodies and CD20-positive Raji cells, and
the degree of activation of the Jurkat T cells can be quantified by
detecting the activity of the luciferase. A four-parameter curve
was fitted using the concentration of bispecific antibody as the
X-axis and the fluorescein signal as the Y-axis.
[0494] As shown in FIG. 7-3, AB2K can specifically activate Jurkat
NFATRE Luc cells, wherein the EC.sub.50 value was 0.2006 .mu.g/ml
and its concentration was proportional to signal intensity, while
AB7K7 as a negative control had little ability to activate T
cells.
8.4 NPG Mouse Model of Transplanted Tumor Constructed by
Subcutaneously Co-Inoculating Human CIK Cells and Human Burkkit's
Lymphoma Raji Cells
[0495] CD20-positive human Burkkit's lymphoma Raji cells were
selected to study the inhibiting effect of bispecific antibodies on
tumor growth in vivo in an NPG mouse model of transplanted tumor
constructed by subcutaneously co-inoculating human CIK cells and
human Burkkit's lymphoma cells Raji.
[0496] CIK cells were prepared in the method as described in
Example 3.1. Female NPG mice (purchased from Beijing Vitalstar
Biotechnology Co., Ltd.) at the age of seven to eight weeks were
selected, and Raji cells in the logarithmic growth stage were
collected. 4.times.10.sup.6 Raji cells and 8.times.10.sup.5 CIK
cells were mixed and inoculated subcutaneously on the right back of
each NPG mouse. One hour after inoculation, the mice were randomly
divided into five groups with six mice in each group according to
their weights and intraperitoneally administered with corresponding
drugs. Specifically, all treated groups were administered with
Rituxan (from Roche) and bispecific antibody AB2K, respectively, at
doses of 1 mg/kg and 0.1 mg/kg, twice a week. The day of
administration was recorded as Day 0. The maximum diameter (D) and
the minimum diameter (d) of the tumor were measured weekly. The
volume (mm.sup.3) of the tumor of each group and the tumor growth
inhibition rate (TGI) (%) of each treated group were calculated
using the formulas as shown in Example 3.1.
[0497] As shown in FIG. 7-4, on Day 24 of administration, the
average tumor volume of the PBS control group was 1766.84.+-.155.62
mm.sup.3; the average tumor volume of the treated group
administrated with Rituxan at a dose of 1 mg/kg was
647.92.+-.277.11 mm.sup.3, and TGI was 63.33%, which was
significantly different from that of the control group (P<0.01);
the average tumor volume of the treated group administrated with
Rituxan at a dose of 0.1 mg/kg was 1893.81.+-.186.99 mm.sup.3, and
Rituxan herein exhibited no efficacy; the average tumor volume of
the treated group administrated with AB2K at a dose of 1 mg/kg was
116.18.+-.39.50 mm.sup.3, and TGI was 93.42%, which was
significantly different from that of the control group (P<0.01);
the average tumor volume of the treated group administrated with
AB2K at a dose of 0.1 mg/kg was 1226.03.+-.340.05 mm.sup.3, and TGI
was 30.61%, which was not significantly different from that of the
control group. The results show that the bispecific antibody AB2K
could inhibit the growth of tumor cells by activating human immune
cells in animals; and at the same dose, the efficacy of the
bispecific antibody was better than the efficacy of the monoclonal
antibody Rituxan, and the bispecific antibody exhibited great
anti-tumor effects.
8.5 NPG Mouse Model of Transplanted Tumor Constructed by
Subcutaneously Co-Inoculating Human CIK Cells and Human Burkkit's
Lymphoma Daudi Cells
[0498] CD20-positive human Burkkit's lymphoma Daudi cells were
selected to study the inhibiting effect of bispecific antibodies on
tumor growth in vivo in an NPG mouse model of transplanted tumor
constructed by subcutaneously co-inoculating human CIK cells and
human Burkkit's lymphoma Daudi cells.
[0499] CIK cells were prepared in the method as described in
Example 3.1. Female NPG mice at the age of seven to eight weeks
were selected, and Daudi cells in the logarithmic growth stage were
collected. 4.times.10.sup.6 Daudi cells and 8.times.10.sup.5 CIK
cells were mixed and inoculated subcutaneously on the right back of
each NPG mouse. One hour later, the mice were randomly divided into
five groups with six mice in each group according to their weights
and intraperitoneally administered with corresponding drugs. All
treated groups were administrated twice a week. Rituxan and
bispecific antibody AB2K were both administered at doses of 1 mg/kg
and 0.1 mg/kg, respectively. The day of administration was recorded
as Day 0. The maximum diameter (D) and the minimum diameter (d) of
the tumor were measured weekly. The volume (mm.sup.3) of the tumor
of each group and the tumor growth inhibition rate (TGI) (%) of
each treated group were calculated using the formulas as shown in
Example 3.1.
[0500] As shown in FIG. 7-5, on Day 30 of administration, the
average tumor volume of the PBS control group was 889.68.+-.192.13
mm.sup.3; the average tumor volume of the treated group
administrated with Rituxan at a dose of 1 mg/kg was 241.51.+-.44.91
mm.sup.3, and TGI was 72.85%, which was significantly different
from that of the control group (P<0.01); the average tumor
volume of the treated group administrated with Rituxan at a dose of
0.1 mg/kg was 746.11.+-.299.71 mm.sup.3, which was not
significantly different from that of the control group; the average
tumor volume of the treated group administrated with AB2K at a dose
of 1 mg/kg was 72.05.+-.11.89 mm.sup.3, and TGI was 91.9%, which
was significantly different from that of the control group
(P<0.01); the average tumor volume of the treated group
administrated with AB2K at a dose of 0.1 mg/kg was 75.36.+-.11.81
mm.sup.3, and TGI was 91.53%, which was significantly different
from that of the control group (P<0.01). The results show that
the bispecific antibody AB2K could inhibit the growth of tumor
cells by activating human immune cells in animals; and at the same
dose, the efficacy of the bispecific antibody was better than the
efficacy of the monoclonal antibody Rituxan, and AB2K exhibited
good anti-tumor effects even at a low dose.
Example 9 Evaluation of the Safety of Anti-CD20.times.CD3
Bispecific Antibodies
[0501] The toxicity of AB2K was evaluated to determine appropriate
dose ranges and observation indicators for subsequent toxicity
tests. Adult Female cynomolgus monkeys (purchased from Guangzhou
Xiangguan Biotechnology Co., Ltd.) at the age of 3-4 years and with
the weight of 3-4 kg were divided into two groups with one mouse in
each group, wherein the two groups were a vehicle control group and
an AB2K treated group. The groups were administrated via
intravenous drip by a peristaltic pump for 1 hour. The dose amount
and volume administered are shown in Table 7. The groups were
administrated on Day 0 (D0), Day 7 (D7), Day 21 (D21), and Day 28
(D28), respectively, for a total of four doses, and the drug dose
was gradually escalated each time. The monkeys were weighed
weekly.
TABLE-US-00026 TABLE 7 Dosing schedule for cynomolgus monkey acute
toxicity evaluation To-be-tested Group drugs name Dose volume Dose
amount G1 Vehicle D0: 5 mL/kg N/A control D7: 5 mL/kg group D21: 10
mL/kg D28: 10 mL/kg G2 AB2K D0: 5 mL/kg D0: 0.06 mg/kg D7: 5 mL/kg
D7: 0.3 mg/kg D21: 10 mL/kg D21: 1.5 mg/kg D28: 10 mL/kg D28: 3
mg/kg
[0502] During the test, animals were periodically monitored for
clinical symptoms, body weight, food consumption, body temperature,
electrocardiogram, blood pressure, clinicopathological indexes
(blood cell count, coagulation function measure, and blood
biochemistry), lymphocyte subsets, cytokines, drug plasma
concentration measure, and toxicokinetics analyses. After
administration of AB2K, the physical signs of cynomolgus monkeys
exhibited no abnormal reaction, the body weight was relatively
stable, the body temperature fluctuation was similar to the body
temperature fluctuation of the vehicle control group, and no death
or impending death was observed among animals during the
administration period. As shown in FIG. 8, after administration,
the white blood cell changes of cynomolgus monkeys in the AB2K
group were similar to the white blood cell changes in the control
group; the first administration of AB2K at a dose of 0.06 mg/kg had
little effect on lymphocytes; 1 hour to 6 hours after the second
administration, the number of lymphocytes in the animals of the
treated group decreased sharply and recovered to normal after 24
hours; as the number of administrations increased, the effect of
AB2K on the decrease in the number of lymphocytes was weaker and
weaker despite increasing doses. In addition, after the first
administration of AB2K, the release of IL-2, IL-6 and TNF-.alpha.
factors was promoted and the release of IL-5 was slightly
stimulated, but the release of IFN-.gamma. was not stimulated; as
the number of administrations increased, the release-promoting
effect of AB2K on cytokines became less and less significant,
indicating that the body had already been adapted to the
stimulation by bispecific antibodies.
Example 10 Pharmacokinetics Evaluation of Anti-CD20.times.CD3
Bispecific Antibodies
[0503] Female cynomolgus monkeys with the weight of 3-4 kg were
divided into two groups with one in one monkey in each group. The
first group was a blank control group, and the second group was an
AB2K treated group administrated at a dose of 0.3 mg/kg. The blood
sampling time points were Minute 15, Hour 1, Hour 3, Hour 6, Hour
10, Hour 24, Hour 30, Hour 48, Hour 54, Hour 72, Hour 96, and Hour
144, respectively, a total of 13 time points. Serum was collected
from blood and frozen at -80.degree. C.
[0504] The drug concentration of AB2K in serum was determined by
ELISA. The pharmacokinetics parameters were calculated using
software PKSolver. Specific parameters are shown in Table 8. The
results show that T.sub.1/2 of AB2K in normal cynomolgus monkeys
was about 8.5 hours.
TABLE-US-00027 TABLE 8 Pharmacokinetics parameters of bispecific
antibody AB2K in cynomolgus monkeys AUC 0-inf_obs Vz_obs Cl_obs
AB2K t.sub.1/2 (h) (.mu.g/mL*h) (.mu.g/kg)/(.mu.g/mL)
(.mu.g/kg)/(.mu.g/mL)/h Pharmacokinetics 8.45 168.63 21.68 1.78
parameter
Example 11 Evaluation of In Vitro Biological Functions of
Anti-CD19.times.CD3 Bispecific Antibodies
11.1 Detection of Binding Activities of Bispecific Antibodies to
Effector Cells and Target Cells (FACS)
a) Detection of Binding Activities of Bispecific Antibodies to
CD19-Positive Tumor Raji Cells by Flow Cytometry
[0505] CD19-positive tumor cells Raji cells were cultured and
collected by centrifugation. The collected cells were resuspended
with 1% PBSB, placed in 96-well plates after the cell density was
adjusted to (2.times.10.sup.6) cells/ml, 100 .mu.l
(2.times.10.sup.5 cells) per well, and blocked for 0.5 hours at
4.degree. C. The blocked cells were centrifuged to discard the
supernatant, and then diluted bispecific antibodies AB1K2 with a
series of concentrations and isotype CD19 bispecific antibodies
AB23P8, AB23P9 and AB23P10 were added and incubated for 1 hour at
4.degree. C. The cells were centrifuged to discard the supernatant
and then washed three times using PBSB with 1% BSA. Diluted
AF647-labeled goat anti-human IgG antibodies were added to the
cells, and the cells were incubated for 1 hour at 4.degree. C. in
the dark. The obtained cells were centrifuged to discard the
supernatant and washed twice with 1% PBSB, and cells in each well
were resuspended with 100 .mu.l of 1% PF. The signal intensity was
detected by flow cytometry. The analysis was performed with the
average fluorescence intensity as the Y-axis and the antibody
concentration as the X-axis through software GraphPad to calculate
the EC.sub.50 value for the binding of bispecific antibodies to
tumor cells Raji.
[0506] The results show that bispecific antibodies with different
structures had a good binding activity to tumor cells
over-expressing CD19. FIG. 9-1 shows binding curves of bispecific
antibodies with different structures to tumor cells Raji. As shown
in Table 9-1, EC.sub.50 for the binding of each of four bispecific
antibodies to tumor cells Raji was at the nM level.
TABLE-US-00028 TABLE 9-1 Detection of abilities of Anti-CD19
.times. CD3 bispecific antibodies to bind to tumor cells Raji AB1K2
AB23P8 AB23P9 AB23P10 EC.sub.50 (nM) 1.393 1.924 2.600 2.678
b) Detection of Binding Activities of Bispecific Antibodies to
Human T Cells by FACS
[0507] PBMCs were prepared from fresh human blood by density
gradient centrifugation. The prepared PBMCs were resuspended in a
1640 medium containing 10% heat-inactivated FBS, added with 2
.mu.g/ml of CD3 antibody for activation for 24 h, then added with
250 IU/ml of IL-2 for amplification for 7 days, to prepare expanded
T cells which were detected by flow cytometry to be positive for
CD3 expression on the surface. The to-be-detected sample was
prepared and detected in the same manner as in a) of Example 11.1.
Cells resuspended with 1% PF were detected on a machine and, with
the average fluorescence intensity, analyzed by software GraphPad
to calculate EC.sub.50 value for the binding of each bispecific
antibody to human T cells.
[0508] The results in FIG. 9-2 show that each bispecific antibody
had a good binding activity to CIK. As shown in Table 9-2, the
EC.sub.50 of AB1K2 was about 16 nM, which was roughly equal to the
EC.sub.50 of AB23P8, and the EC.sub.50 of AB23P9 and AB23P10 were
about 50 nM and 30 nM, respectively.
TABLE-US-00029 TABLE 9-2 Detection of abilities of Anti-CD19
.times. CD3 bispecific antibodies to bind to effector cells CIK
AB1K2 AB23P8 AB23P9 AB23P10 EC.sub.50 (nM) 15.69 16.69 49.52
32.41
c) Detection of Cross-Reactivity of Bispecific Antibodies with CD3
on the Surface of Cynomolgus Monkey CIK Cell Membrane by FACS
[0509] PBMCs were prepared from fresh cynomolgus monkey blood by
density gradient centrifugation. The prepared PBMCs were
resuspended in a 1640 medium containing 10% heat-inactivated FBS,
added with 2 .mu.g/ml of OKT3 for activation for 24 h, then added
with 250 IU/ml of IL-2 for amplification for 7 days to prepare
cynomolgus monkey CIK cells for use. Human CIK cells and cynomolgus
monkey CIK cells were collected by centrifugation. The
to-be-detected sample was prepared and detected in the same manner
as in a) of Example 11.1. Cells resuspended with 1%
paraformaldehyde solution were detected on a machine and, with the
average fluorescence intensity, analyzed by software GraphPad to
calculate the EC.sub.50 values for the binding of bispecific
antibodies to human CIK cells and the EC.sub.50 values for the
binding of bispecific antibodies to cynomolgus monkey CIK
cells.
[0510] As shown in FIG. 9-3, there was no difference between the
binding ability of the bispecific antibody AB1K2 to cynomolgus
monkey T cells and the ability of the bispecific antibody AB23P10
to cynomolgus monkey T cells, the EC.sub.50 for the binding of each
of both bispecific antibodies to cynomolgus monkey T cells was
approximately 5.5 nM as detected by flow cytometry, and the ability
of the both bispecific antibodies to cynomolgus monkey T cells was
stronger than the ability of the both bispecific antibodies to
human T cells.
11.2 Detection of Abilities of Bispecific Antibodies to Bind to
Antigens
[0511] The binding of bispecific antibodies to soluble CD3 and CD19
was detected by double antigen sandwich ELISA.
[0512] CD19 proteins (ACRO Biosystems, Cat. No. CD9-H5251) were
diluted with PBS to a concentration of 1 .mu.g/ml and added to
96-well plates, 100 .mu.l per well. The plates were coated at
4.degree. C. overnight. The plates were then blocked with 1%
skimmed milk powder for 1 hour at room temperature. Each bispecific
antibody was diluted with a 5-fold gradient for a total of 10
concentration gradients. The 96-well plates were then washed with
PBST, and then the diluted bispecific antibodies were added.
Control wells without antibodies were set. Incubated for 2 hours at
room temperature. Unbound bispecific antibodies were washed away
with PBST. Biotinylated CD3E&CD3D (ACRO Biosystem, Cat. No.
CDD-H82W1) were mixed at 50 ng/ml with streptavdin HRP (BD, Cat.
No. 554066), added in 96-well plates, 100 .mu.l per well, and
incubated for 1 hour at room temperature. 96-well plates were
washed with PBST, and TMB was added to the plates, 100 .mu.l per
wells. Color development was performed at room temperature for 15
minutes, and then 0.2 M H.sub.2SO.sub.4 was added to stop the color
development reaction. The light absorbance values at A450-620 nm
were measured by a microplate reader. Analysis was performed by
software GraphPa, and the EC.sub.50 values for the binding of
bispecific antibodies to two antigens were calculated.
[0513] The results show that each bispecific antibody bound
specifically to both CD3 and CD19 molecules and exhibited good
dose-dependence as the concentration of the antibodies changed
(FIG. 9-4). The abilities of several bispecific antibodies to bind
to soluble CD3 and CD19 are shown in Table 9-3, with EC.sub.50
values ranging from 0.19 nM to 0.47 nM, and there was little
difference between binding activities at both ends.
TABLE-US-00030 TABLE 9-3 Detection of abilities of Anti-CD19
.times. CD3 bispecific antibodies to bind to CD3 and CD19 molecules
AB1K2 AB23P8 AB23P9 AB23P10 EC.sub.50 (nM) 0.2185 0.1925 0.2211
0.4704
11.3 Evaluation of Abilities of Bispecific Antibodies to Activate T
Cells Through Reporter Gene Cell Strains
[0514] Jurkat T cells containing NFAT RE reporter genes can
overexpress luciferase in the presence of bispecific antibodies and
target cells Raji, and the degree of activation of the Jurkat T
cells can be quantified by detecting the activity of the
luciferase. A four-parameter curve was fitted using the
concentration of bispecific antibody as the X-axis and the
fluorescein signal as the Y-axis.
[0515] The test results in FIGS. 9-5 and 9-6 show that Jurkat T
cells can hardly be activated in the absence of target cells
overexpressing CD19, and T cells can be activated only in the
presence of both the bispecific antibody and the target cells at
both ends. The ability of each bispecific antibody to activate
Jurkat T cells is shown in Table 9-4, and the ability of each
bispecific antibody to activate Jurkat T cells was almost
equivalent to each other.
TABLE-US-00031 TABLE 9-4 Detection of abilities of Anti-CD19
.times. CD3 bispecific antibodies to activate a reporter gene cell
strain that are Jurkat T cells AB1K2 AB23P8 AB23P9 AB23P10 Blincyto
EC.sub.50 (nM) 1.080 1.123 0.8527 0.7093 2.714
11.4 Abilities of Bispecific Antibodies to Mediate T Cells to Kill
Tumor Cells
[0516] Normally cultured tumor cell lines, including Raji-Luc,
NALM6 and Reh cells (all purchased from the cell bank of Chinese
Academy of Sciences, Shanghai) were used as target cells, and cell
suspensions were collected and centrifuged, added to 96-well cell
culture plates after the cell density was adjusted to
2.times.10.sup.5 cells/ml, 100 .mu.l per well, and cultured
overnight. The antibodies were diluted according to the test
design, and added to the cells, 50 .mu.l per well, while wells
without the addition of antibodies were supplemented with the same
volume of the medium. Effector cells (human PBMCs or expanded CIK
cells) whose number was five times larger than the number of target
cells, were then added, 100 .mu.l per well. Control wells were set,
and wells without the addition of effector cells were supplemented
with the same volume of the medium. After 48 hours of culture,
Raji-Luc cells were detected by Steady-Glo Luciferase Assay System
(Promega) and other cells were detected by CytoTox96 Non-Radio
Cytotoxicity Assay (Promega). The analysis was performed with the
detection results as the Y-axis and the bispecific antibody
concentration as the X-axis through software GraphPad to calculate
and compare the ability of each bispecific antibody to mediate the
killing on Raji-luc cells.
[0517] The EC.sub.50 values of each bispecific antibody to mediate
effector cells to kill tumor cells are shown in Tables 9-5 to 9-7.
The results show that each bispecific antibody exhibited a very
significant killing effect on tumor cells with high expression of
CD19 in a dose-dependent manner, wherein EC.sub.50 of each
bispecific antibody reached the pM level.
TABLE-US-00032 TABLE 9-5 EC.sub.50 values of bispecific antibodies
to mediate CIK to kill tumor cells EC.sub.50 (pM) AB1K2 AB23P8
AB23P9 AB23P10 Blincyto Raji-LUC 0.6988 0.5861 0.1480 0.1280 0.5952
0.2024 -- -- 0.4834 5.654 Note: --means that no detection is
performed.
TABLE-US-00033 TABLE 9-6 EC.sub.50 values of bispecific antibodies
to mediate PBMCs to kill tumor cells EC.sub.50 (pM) AB1K2 AB23P8
AB23P9 AB23P10 Blincyto Raji-LUC 1.225 1.025 1.014 0.9462 5.452
1.254 -- -- 1.254 21.22 -- -- -- 4.176 22.58 Note: --means that no
detection is performed.
TABLE-US-00034 TABLE 9-7 EC.sub.50 values of bispecific antibodies
to mediate CIK to kill different tumor cells EC.sub.50 (pM) AB1K2
AB23P10 Blincyto NALM6 -- 4.402 77.29 Reh 1.709 1.640 11.87 Note:
--means that no detection is performed.
Example 12 Evaluation of In Vitro Biological Functions of
Anti-Mucin1.times.CD3 Bispecific Antibodies
12.1 Binding Activities of AB11K to Tumor Cells Over-Expressing
Mucin1 and to Human or Cynomolgus Monkey Primary T Cells
[0518] Human breast cancer cells MCF-7, BT-549, HCC70, T-47D and
HCC1954, human ovarian cancer cell SK-OV-3, human cervical cancer
cell Hela and human colon cancer cell HT-29 were cultured, wherein
MCF-7, BT-549, T-47D, HCC1954, SK-OV-3, Hela and HT-29 cells were
purchase from the cell bank of Chinese Academy of Sciences, and
HCC70 cells were purchase from Nanjing Cobioer Biotechnology Co.,
Ltd. Each kind of the above cells was digested with trypsin,
collected by centrifugation, resuspended with 1% PBSB, placed in
96-well plates after the cell density of each kind of cells was
adjusted to 5.times.10.sup.5 cells/ml, 100 .mu.l per well, and
blocked for 30 minutes at 4.degree. C. Human or cynomolgus monkey
primary T cells were collected by centrifugation, resuspended with
1% PBSB, placed in 96-well plates after the cell density of each
kind of cells was adjusted to 5.times.10.sup.5 cells/ml, 100 .mu.l
per well, and blocked for 30 minutes at 4.degree. C. The cells were
washed once with 1% PBSB. Diluted AB11K with a series of
concentrations was added at 100 .mu.l per well and incubated for 1
hour at 4.degree. C. The cells were centrifuged to discard the
supernatant and then washed twice with 1% PBSB. Diluted AF647 goat
anti human IgG (H+L) antibodies (Jackson Immuno Research Inc.,
diluted at 1:250) were added, 100 .mu.l per well, and then the
cells were incubated for 1 hour at 4.degree. C. in the dark. The
cells were centrifuged to discard the supernatant. The plates were
washed, and after that, 4% PFA was added, 150 .mu.l per well, to
resuspend the cells. The signal intensity was detected by flow
cytometry. The analysis was performed with the average fluorescence
intensity as the Y-axis and the antibody molar concentration as the
X-axis through software GraphPad Prism 6 to calculate the EC.sub.50
values for the binding of AB11K to the above tumor cells and human
or cynomolgus monkey primary T cells.
[0519] As shown in FIG. 10-1 and Table 10-1, at the cellular level,
AB11K bound to the above tumor cells and human or cynomolgus monkey
primary T cells, and the signal intensity was proportional to the
antibody concentration, and EC.sub.50 calculated for the binding of
AB11K to the above tumor cells ranged from 5 nM to 300 nM, wherein
the binding to T-47D and Hela was strongest, followed by the
binding to HCC70, HCC1954, SKOV-3 and BT-549, while the binding to
MCF-7 and HT-29 was the weakest, which did not reach the upper
platform. The EC.sub.50 values for the binding of AB7K to human or
cynomolgus monkey T cells were 13.43 nM and 9.996 nM, respectively,
and the ability of AB11K to bind to cynomolgus monkey T cells was
roughly equivalent to the ability of AB11K to bind to human T
cells.
TABLE-US-00035 TABLE 10-1 EC.sub.50 results for the binding of
AB11K to tumor cells over-expressing Mucin 1 and to human or
cynomolgus monkey primary T cells Cell name EC.sub.50 (nM) MCF-7 /
BT-549 287.2 HCC70 58.98 T-47D 5.053 HCC1954 81.24 Hela 5.515
SK-OV-3 93.72 HT-29 / Human T cells 13.43 cynomolgus monkey 9.996 T
cells
12.2 Ability of AB11K to Mediate T Cells to Kill Tumor Cells
[0520] Normally cultured cells MCF-7, BT-549, HCC70, T-47D,
HCC1954, SK-OV-3, Hela and HT-29 were used as target cells,
respectively. Each kind of cells was digested with trypsin, placed
in 96-well cell culture plates after the cell density of each kind
of cells was adjusted to 2.times.10.sup.5 cells/ml, 100 .mu.l per
well, and cultured overnight at 37.degree. C. with 5% CO.sub.2.
Effector cells (expanded T cells) whose number was five times
larger than the number of corresponding target cells were added as
T cell group, and effector cells (PBMCs from healthy volunteers)
whose number was ten times larger than the number of corresponding
target cells were added as PBMC groups, 100 .mu.l per well. Blank
wells and wells without the addition of effector cells were set.
AB11K was diluted to 50 .mu.g/mL with a medium, after the 4-fold
dilution, added to 96-well plates, 50 .mu.l per well, and incubated
for 48 hours at 37.degree. C. with 5% CO.sub.2. The cell culture
plates were washed three times with PBS and the suspended cells
were removed. A medium containing 10% CCK-8 was added, 100 .mu.l
per well, and incubated for 4 hours at 37.degree. C. with 5%
CO.sub.2. Readings at 450 nm and 620 nm were obtained. The specific
killing rates of the antibodies were calculated according to values
at [OD450-OD620] using the formula as follows:
Antibody .times. .times. specific .times. .times. killing .times.
.times. rate .times. .times. ( % ) = [ OD .times. .times. 450 - OD
.times. .times. 620 ] ( effector .times. .times. cells + target
.times. .times. cells ) - [ OD .times. .times. 450 - OD .times.
.times. 620 ] ( antibody .times. .times. treated .times. .times.
group ) [ OD .times. .times. 450 - OD .times. .times. 620 ] (
effector .times. .times. cells + target .times. .times. cells ) - [
OD .times. .times. 450 - OD .times. .times. 620 ] ( blank .times.
.times. group ) .times. 100 ##EQU00001##
[0521] The analysis was performed with the specific killing rate
(%) as the Y-axis and the antibody molar concentration as the
X-axis through software GraphPad Prism 6 to calculate the EC.sub.50
value for AB11K to mediate the killing on tumor target cells.
[0522] As shown in FIGS. 10-2 and 10-3 and Table 10-2, the
bispecific antibody AB11K exhibited very significant killing
effects on tumor cells highly expressing Mucin1 through its
mediation on effector cells. When expanded T cells were used as
effector cells, the maximum specific killing of AB11K reached 99%
or more, wherein the specific killing effects on MCF-7, BT-549,
HCC70 and T-47D were the best with EC.sub.50 ranging from 100 pM to
200 pM, followed by the specific killing effects on Hela, HCC1954
and SK-OV-3, while the specific killing effect on HT-29 was the
weakest with a relatively large EC.sub.50, about 1577 pM. When
PBMCs were used as effector cells, the specific killing effects of
AB11K on MCF-7 and BT-549 were the best with the maximum specific
killing of 95% or more and EC.sub.50 of 131.2 pM and 955.9 pM,
respectively, followed by the specific killing effects on HCC1954
and HCC70, and EC.sub.50 for specifically killing Hela and HT-29
were relatively large, which were 4810 pM and 9550 pM,
respectively.
TABLE-US-00036 TABLE 10-2 EC.sub.50 results of AB11K to mediate
effector cells to kill tumor cells T cell killing EC.sub.50 PBMC
killing EC.sub.50 Cell name (pM) (pM) MCF-7 152.7 131.2 BT-549
140.9 955.9 HCC70 185.4 595.2 T-47D 84.53 / HCC1954 280.9 1893 Hela
278.2 4810 SK-OV-3 689.4 / HT-29 1577 9550
12.3 Evaluation of Abilities of Bispecific Antibodies to Activate T
Cells
[0523] Jurkat T cells containing NFAT RE reporter genes (purchased
from BPS Bioscience) can overexpress luciferase in the presence of
bispecific antibodies and Mucin1-positive cells, and the degree of
activation of the Jurkat T cells can be quantified by detecting the
activity of the luciferase.
[0524] Specifically, cells MCF-7, BT-549, HCC70, T-47D, HCC1954,
SK-OV-3, Hela and HT-29 were digested with trypsin, placed in
96-well cell culture plates after the cell density of each kind of
cells was adjusted to 2.times.10.sup.5 cells/ml, 50 .mu.l per well,
and cultured overnight at 37.degree. C. with 5% CO.sub.2. The cell
density of Jurkat-NFAT cells was adjusted to 2.5.times.10.sup.6
cells/ml, 40 .mu.l per well. AB11K was diluted to 400 .mu.g/mL with
a medium, after the 4-fold dilution, added to 96-well plates, 10
.mu.l per well, and incubated for 48 hours at 37.degree. C. with 5%
CO.sub.2 in an incubator. Steady-Glo.RTM. Luciferase was added, 100
.mu.l per well and reacted for 5 minutes. After that, the
luminescence value was measured by a microplate reader. The
analysis was performed with the fluorescein intensity as the Y-axis
and the antibody molar concentration as the X-axis through software
GraphPad Prism 6 to calculate the EC.sub.50 for bispecific
antibodies to activate T cells.
[0525] As shown in FIG. 10-4 and Table 10-3, AB11K specifically
activated Jurkat-NFAT cells, wherein the EC.sub.50 value was at the
nM level and its concentration was proportional to signal
intensity.
TABLE-US-00037 TABLE 10-3 EC.sub.50 results of the ability of AB11K
to activate T cells T cell activation EC.sub.50 Cell name (nM)
MCF-7 14.22 BT-549 10.49 HCC70 3.016 T-47D 0.6294 HCC1954 5.599
Hela 7.241 SK-OV-3 10.37 HT-29 6.711
Example 13 Pharmacodynamics Study of Anti-EGFR.times.CD3 Bispecific
Antibodies in a Mouse Transplanted Tumor Model
[0526] A mouse transplanted tumor model of human skin cancer A431
cells that highly expressed EGFR was selected to perform the
pharmacodynamics study of Anti-EGFR.times.CD3 bispecific antibodies
AB8K, AB2K and Erbitux (from Merck KGaA) on the in vivo inhibition
of tumor growth.
[0527] CIK cells were prepared in the method as described in
Example 3.1. A431 cells in the logarithmic growth stage were
collected. Female NPG mice at the age of seven to eight weeks were
selected, and 3.times.10.sup.6 A431 cells and 1.times.10.sup.6 CIK
cells were mixed and inoculated subcutaneously on the right back of
each NPG mouse. One hour later, the mice were randomly divided into
five groups with six mice in each group according to their weights
and intraperitoneally administered with corresponding drugs. All
treated groups and the PBS control group were administrated twice a
week, wherein AB2K and Erbitux were administrated at a dose of 1
mg/kg. AB8K was administrated at doses of 1 mg/kg and 0.1 mg/kg.
The day of administration was recorded as Day 0. The maximum
diameter (D) and the minimum diameter (d) of the tumor were
measured weekly. The volume (mm.sup.3) of the tumor of each group
and the tumor growth inhibition rate (TGI) (%) of each treated
group were calculated using the formulas as shown in Example
3.1.
[0528] As shown in FIG. 11, on Day 17 of administration, the
average tumor volume of the PBS control group was 1370.76.+-.216.35
mm.sup.3; the average tumor volume of the treated group
administrated with Erbitux at a dose of 1 mg/kg was
1060.35.+-.115.86 mm.sup.3, which was not significantly different
from that of the control group; the average tumor volume of the
treated group administrated with AB2K at a dose of 1 mg/kg was
877.76.+-.120.38 mm.sup.3, which was not significantly different
from that of the control group; the average tumor volumes of the
treated groups administrated with AB8K at doses of 0.1 mg/kg and 1
mg/kg were 233.30.+-.135.51 mm.sup.3 and 8.14.+-.8.14 mm.sup.3,
respectively, and TGIs were 82.98% and 98.36%, respectively, which
were significantly different from that of the control group
(P<0.01), wherein the tumors in five of six mice of the treated
group administrated with AB8K at a dose of 1 mg/kg exhibited
complete regression. AB2K was an isotype control of AB8K. A431
cells did not express CD20. AB2K exhibited no pharmacological
effect in this model, indicating that the structure of the
bispecific antibody is relatively safe and does not cause
non-specific killing. More than 90% of CIK cells were activated T
cells. AB8K inhibited and killed tumor cells by activating human
immune cells in animals, and completely inhibited tumor growth at a
dose of 1 mg/kg and exhibited a good anti-tumor effect even at a
dose of 0.1 mg/kg.
[0529] All the publications mentioned in the present invention are
incorporated herein by reference as if each publication is
separately incorporated herein by reference. In addition, it should
be understood that those skilled in the art, who have read the
disclosure, can make various changes or modifications on the
present disclosure, and these equivalent forms fall within the
scope of the appended claims.
Sequence CWU 1
1
2861744PRTArtificial sequencebispecific antibody AB7K5 amino acid
sequence 1Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile
Lys Asp Thr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg
Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr
Ser Lys Asn Thr Ala Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ser Arg Trp Gly Gly Asp Gly
Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125Gly Ser Gly
Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser 130 135 140Ser
Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala145 150
155 160Ser Gln Asp Val Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro
Gly 165 170 175Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu
Tyr Ser Gly 180 185 190Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly
Thr Asp Phe Thr Leu 195 200 205Thr Ile Ser Ser Leu Gln Pro Glu Asp
Phe Ala Thr Tyr Tyr Cys Gln 210 215 220Gln His Tyr Thr Thr Pro Pro
Thr Phe Gly Gln Gly Thr Lys Val Glu225 230 235 240Ile Lys Asp Lys
Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Ala 245 250 255Ala Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Gln 260 265
270Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
275 280 285Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
Gly Val 290 295 300Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
Gln Tyr Ala Ser305 310 315 320Thr Tyr Arg Val Val Ser Val Leu Thr
Val Leu His Gln Asp Trp Leu 325 330 335Asn Gly Lys Glu Tyr Lys Cys
Lys Val Ser Asn Lys Ala Leu Pro Ala 340 345 350Ser Ile Glu Lys Thr
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 355 360 365Gln Val Tyr
Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 370 375 380Val
Ser Leu Arg Cys His Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala385 390
395 400Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
Thr 405 410 415Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
Ser Thr Leu 420 425 430Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
Val Phe Ser Cys Ser 435 440 445Val Leu His Glu Ala Leu His Asn His
Tyr Thr Gln Lys Ser Leu Ser 450 455 460Leu Ser Pro Gly Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser465 470 475 480Gly Gly Gly Gly
Ser Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Glu 485 490 495Val Gln
Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 500 505
510Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala
515 520 525Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
Val Ala 530 535 540Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr
Tyr Ala Asp Ser545 550 555 560Val Lys Asp Arg Phe Thr Ile Ser Arg
Asp Asp Ser Lys Asn Thr Ala 565 570 575Tyr Leu Gln Met Asn Asn Leu
Lys Thr Glu Asp Thr Ala Val Tyr Tyr 580 585 590Cys Val Arg His Gly
Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala 595 600 605Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly 610 615 620Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Val Thr625 630
635 640Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu
Thr 645 650 655Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr
Ala Asn Trp 660 665 670Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
Leu Ile Gly Gly Thr 675 680 685Asn Lys Arg Ala Pro Gly Thr Pro Ala
Arg Phe Ser Gly Ser Leu Leu 690 695 700Gly Gly Lys Ala Ala Leu Thr
Leu Ser Gly Val Gln Pro Glu Asp Glu705 710 715 720Ala Glu Tyr Tyr
Cys Ala Leu Trp Tyr Ser Asn Leu Trp Val Phe Gly 725 730 735Gly Gly
Thr Lys Leu Thr Val Leu 7402744PRTArtificial sequencebispecific
antibody AB7K6 amino acid sequence 2Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30Tyr Ile His Trp Val Arg
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Arg Ile Tyr Pro
Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe
Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65 70 75 80Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ser
Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105
110Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
115 120 125Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser
Pro Ser 130 135 140Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile
Thr Cys Arg Ala145 150 155 160Ser Gln Asp Val Asn Thr Ala Val Ala
Trp Tyr Gln Gln Lys Pro Gly 165 170 175Lys Ala Pro Lys Leu Leu Ile
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly 180 185 190Val Pro Ser Arg Phe
Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu 195 200 205Thr Ile Ser
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln 210 215 220Gln
His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu225 230
235 240Ile Lys Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly 245 250 255Gly Gly Ser Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser
Glu Val Gln 260 265 270Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly Ser Leu Lys 275 280 285Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Asn Thr Tyr Ala Met Asn 290 295 300Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val Ala Arg Ile305 310 315 320Arg Ser Lys Tyr
Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 325 330 335Asp Arg
Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 340 345
350Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val
355 360 365Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala
Tyr Trp 370 375 380Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
Gly Gly Ser Gly385 390 395 400Gly Gly Gly Ser Gly Gly Gly Gly Ser
Glu Leu Val Val Thr Gln Glu 405 410 415Pro Ser Leu Thr Val Ser Pro
Gly Gly Thr Val Thr Leu Thr Cys Arg 420 425 430Ser Ser Thr Gly Ala
Val Thr Thr Ser Asn Tyr Ala Asn Trp Val Gln 435 440 445Gln Lys Pro
Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Asn Lys 450 455 460Arg
Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly465 470
475 480Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala
Glu 485 490 495Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Leu Trp Val Phe
Gly Gly Gly 500 505 510Thr Lys Leu Thr Val Leu Asp Lys Thr His Thr
Ser Pro Pro Ser Pro 515 520 525Ala Pro Glu Ala Ala Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys 530 535 540Pro Lys Asp Gln Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys Val545 550 555 560Val Val Asp Val
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 565 570 575Val Asp
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 580 585
590Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
595 600 605Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
Asn Lys 610 615 620Ala Leu Pro Ala Ser Ile Glu Lys Thr Ile Ser Lys
Ala Lys Gly Gln625 630 635 640Pro Arg Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Asp Glu Leu 645 650 655Thr Lys Asn Gln Val Ser Leu
Arg Cys His Val Lys Gly Phe Tyr Pro 660 665 670Ser Asp Ile Ala Val
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 675 680 685Tyr Lys Thr
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 690 695 700Tyr
Ser Thr Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val705 710
715 720Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr
Gln 725 730 735Lys Ser Leu Ser Leu Ser Pro Gly 7403526PRTArtificial
sequencebispecific antibody AB7K8 amino acid sequence 3Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30Tyr
Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val
50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala
Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp
Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser Gly Gly
Gly Gly Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Asp
Ile Gln Met Thr Gln Ser Pro Ser 130 135 140Ser Leu Ser Ala Ser Val
Gly Asp Arg Val Thr Ile Thr Cys Arg Ala145 150 155 160Ser Gln Asp
Val Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly 165 170 175Lys
Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly 180 185
190Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu
195 200 205Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
Cys Gln 210 215 220Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly
Thr Lys Val Glu225 230 235 240Ile Lys Gly Gly Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Gly Ser Ser Ser Ser Ser
Lys Ala Pro Pro Pro Ser Glu Val Gln 260 265 270Leu Leu Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 275 280 285Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 290 295 300Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile305 310
315 320Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val
Lys 325 330 335Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
Ala Tyr Leu 340 345 350Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala
Val Tyr Tyr Cys Val 355 360 365Arg His Gly Asn Phe Gly Asn Ser Tyr
Val Ser Trp Phe Ala Tyr Trp 370 375 380Gly Gln Gly Thr Leu Val Thr
Val Ser Ser Gly Gly Gly Gly Ser Gly385 390 395 400Gly Gly Gly Ser
Gly Gly Gly Gly Ser Glu Leu Val Val Thr Gln Glu 405 410 415Pro Ser
Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Arg 420 425
430Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn Trp Val Gln
435 440 445Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr
Asn Lys 450 455 460Arg Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
Leu Leu Gly Gly465 470 475 480Lys Ala Ala Leu Thr Leu Ser Gly Val
Gln Pro Glu Asp Glu Ala Glu 485 490 495Tyr Tyr Cys Ala Leu Trp Tyr
Ser Asn Leu Trp Val Phe Gly Gly Gly 500 505 510Thr Lys Leu Thr Val
Leu His His His His His His His His 515 520 5254744PRTArtificial
sequencebispecific antibody AB7K heavy chain amino acid sequence
4Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5
10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp
Thr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala
Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys
Asn Thr Ala Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ser Arg Trp Gly Gly Asp Gly Phe Tyr
Ala Met Asp Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser
Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125Phe Pro Leu Ala Pro
Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140Leu Gly Cys
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser145 150 155
160Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
Val Pro 180 185 190Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
Val Asn His Lys 195 200 205Pro Ser Asn Thr Lys Val Asp Lys Lys Val
Glu Pro Lys Ser Cys Asp 210 215 220Lys Thr His Thr Cys Pro Pro Cys
Pro Ala Pro Glu Leu Leu Gly Gly225 230 235 240Pro Ser Val Phe Leu
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255Ser Arg Thr
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270Asp
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280
285Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
290 295 300Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
Gly Lys305 310 315 320Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
Pro Ala Pro Ile Glu 325 330 335Lys Thr Ile Ser Lys Ala Lys Gly Gln
Pro Arg Glu Pro Gln Val Tyr 340 345 350Thr Leu Pro Pro Ser Arg Glu
Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365Thr Cys Leu Val Lys
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380Glu Ser Asn
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val385 390 395
400Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
405 410 415Lys Ser Arg Trp Gln Gln Gly
Asn Val Phe Ser Cys Ser Val Met His 420 425 430Glu Ala Leu His Asn
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445Gly Lys Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 450 455 460Gly
Gly Ser Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser465 470
475 480Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln
Glu 485 490 495Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly Ser 500 505 510Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Asn Thr Tyr Ala 515 520 525Met Asn Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val Ala 530 535 540Arg Ile Arg Ser Lys Tyr Asn
Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser545 550 555 560Val Lys Asp Arg
Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala 565 570 575Tyr Leu
Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr 580 585
590Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala
595 600 605Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
Gly Gly 610 615 620Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu
Leu Val Val Thr625 630 635 640Gln Glu Pro Ser Leu Thr Val Ser Pro
Gly Gly Thr Val Thr Leu Thr 645 650 655Cys Arg Ser Ser Thr Gly Ala
Val Thr Thr Ser Asn Tyr Ala Asn Trp 660 665 670Val Gln Gln Lys Pro
Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr 675 680 685Asn Lys Arg
Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu 690 695 700Gly
Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu705 710
715 720Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Leu Trp Val Phe
Gly 725 730 735Gly Gly Thr Lys Leu Thr Val Leu 7405214PRTArtificial
sequencebispecific antibody AB7K light chain amino acid sequence
5Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5
10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr
Ala 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
His Tyr Thr Thr Pro Pro 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro
Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln
Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155
160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys
2106449PRTArtificial sequencebispecific antibody AB7K4 heavy chain
amino acid sequence 6Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Asn Ile Lys Asp Thr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Arg Ile Tyr Pro Thr Asn Gly
Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser
Ala Asp Thr Ser Lys Asn Thr Ala Tyr65 70 75 80Leu Gln Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ser Arg Trp Gly
Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110Gly Thr
Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120
125Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
Val Ser145 150 155 160Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
Thr Phe Pro Ala Val 165 170 175Leu Gln Ser Ser Gly Leu Tyr Ser Leu
Ser Ser Val Val Thr Val Pro 180 185 190Ser Ser Ser Leu Gly Thr Gln
Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205Pro Ser Asn Thr Lys
Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220Lys Thr His
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly225 230 235
240Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Gln Leu Met Ile
245 250 255Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
His Glu 260 265 270Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
Val Glu Val His 275 280 285Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr Ala Ser Thr Tyr Arg 290 295 300Val Val Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly Lys305 310 315 320Glu Tyr Lys Cys Lys
Val Ser Asn Lys Ala Leu Pro Ala Ser Ile Glu 325 330 335Lys Thr Ile
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350Thr
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 355 360
365Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val385 390 395 400Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
Lys Leu Thr Val Asp 405 410 415Lys Ser Arg Trp Gln Gln Gly Asn Val
Phe Ser Cys Ser Val Leu His 420 425 430Glu Ala Leu His Asn His Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445Gly7490PRTArtificial
sequencebispecific antibody AB7K4 light chain amino acid sequence
7Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5
10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr
Ala 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
His Tyr Thr Thr Pro Pro 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro
Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln
Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155
160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly
Gly Gly Ser Gly Gly Gly 210 215 220Gly Ser Gly Gly Gly Gly Ser Ser
Ser Ser Ser Lys Ala Pro Pro Pro225 230 235 240Ser Glu Val Gln Leu
Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 245 250 255Gly Ser Leu
Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr 260 265 270Tyr
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 275 280
285Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala
290 295 300Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser
Lys Asn305 310 315 320Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
Glu Asp Thr Ala Val 325 330 335Tyr Tyr Cys Val Arg His Gly Asn Phe
Gly Asn Ser Tyr Val Ser Trp 340 345 350Phe Ala Tyr Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ser Gly Gly 355 360 365Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val 370 375 380Val Thr Gln
Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr385 390 395
400Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala
405 410 415Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu
Ile Gly 420 425 430Gly Thr Asn Lys Arg Ala Pro Gly Thr Pro Ala Arg
Phe Ser Gly Ser 435 440 445Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu
Ser Gly Val Gln Pro Glu 450 455 460Asp Glu Ala Glu Tyr Tyr Cys Ala
Leu Trp Tyr Ser Asn Leu Trp Val465 470 475 480Phe Gly Gly Gly Thr
Lys Leu Thr Val Leu 485 4908744PRTArtificial sequencebispecific
antibody AB7K7 amino acid sequence 8Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30Tyr Ile His Trp Val Arg
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Arg Ile Tyr Pro
Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe
Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65 70 75 80Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ser
Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105
110Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
115 120 125Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser
Pro Ser 130 135 140Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile
Thr Cys Arg Ala145 150 155 160Ser Gln Asp Val Asn Thr Ala Val Ala
Trp Tyr Gln Gln Lys Pro Gly 165 170 175Lys Ala Pro Lys Leu Leu Ile
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly 180 185 190Val Pro Ser Arg Phe
Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu 195 200 205Thr Ile Ser
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln 210 215 220Gln
His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu225 230
235 240Ile Lys Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly 245 250 255Gly Gly Ser Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser
Glu Val Gln 260 265 270Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly Ser Leu Lys 275 280 285Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Asn Thr Tyr Ala Met Asn 290 295 300Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val Ala Arg Ile305 310 315 320Arg Ser Lys Tyr
Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 325 330 335Asp Arg
Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 340 345
350Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val
355 360 365Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala
Tyr Trp 370 375 380Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
Gly Gly Ser Gly385 390 395 400Gly Gly Gly Ser Gly Gly Gly Gly Ser
Glu Leu Val Val Thr Gln Glu 405 410 415Pro Ser Leu Thr Val Ser Pro
Gly Gly Thr Val Thr Leu Thr Cys Arg 420 425 430Ser Ser Thr Gly Ala
Val Thr Thr Ser Asn Tyr Ala Asn Trp Val Gln 435 440 445Gln Lys Pro
Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Asn Lys 450 455 460Arg
Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly465 470
475 480Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala
Glu 485 490 495Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Leu Trp Val Phe
Gly Gly Gly 500 505 510Thr Lys Leu Thr Val Leu Asp Lys Thr His Thr
Cys Pro Pro Cys Pro 515 520 525Ala Pro Glu Ala Ala Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys 530 535 540Pro Lys Asp Gln Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys Val545 550 555 560Val Val Asp Val
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 565 570 575Val Asp
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 580 585
590Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
595 600 605Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
Asn Lys 610 615 620Ala Leu Pro Ala Ser Ile Glu Lys Thr Ile Ser Lys
Ala Lys Gly Gln625 630 635 640Pro Arg Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Asp Glu Leu 645 650 655Thr Lys Asn Gln Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro 660 665 670Ser Asp Ile Ala Val
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 675 680 685Tyr Lys Thr
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 690 695 700Tyr
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val705 710
715 720Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr
Gln 725 730 735Lys Ser Leu Ser Leu Ser Pro Gly 74095PRTArtificial
sequenceanti-CD19 antibody 1 HCDR1 amino acid sequence 9Ser Tyr Trp
Met Asn1 51017PRTArtificial sequenceanti-CD19 antibody 1 HCDR2
amino acid sequence 10Gln Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr
Asn Gly Lys Phe Lys1 5 10 15Gly1115PRTArtificial sequenceanti-CD19
antibody 1 HCDR3 amino acid sequence 11Arg Glu Thr Thr Thr Val Gly
Arg Tyr Tyr Tyr Ala Met Asp Tyr1 5 10 151215PRTArtificial
sequenceanti-CD19 antibody 1 LCDR1 amino acid sequence 12Lys Ala
Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Leu Asn1 5 10
15137PRTArtificial sequenceanti-CD19 antibody 1 LCDR2 amino acid
sequence 13Asp Ala Ser Asn Leu Val Ser1 5149PRTArtificial
sequenceanti-CD19 antibody 1 LCDR3 amino acid sequence 14Gln Gln
Ser Thr Glu Asp Pro Trp Thr1 515124PRTArtificial sequenceanti-CD19
antibody 1 VH amino acid sequence 15Gln Val Gln Leu Gln Gln Ser Gly
Ala Glu Leu Val Arg Pro Gly Ser1 5 10 15Ser Val Lys Ile Ser Cys Lys
Ala Ser Gly Tyr Ala Phe Ser Ser Tyr 20 25 30Trp Met Asn Trp Val Lys
Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Gln Ile Trp Pro
Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60Lys Gly Lys Ala
Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr Ala Tyr65 70
75 80Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Phe
Cys 85 90 95Ala Arg Arg Glu Thr Thr Thr Val Gly Arg Tyr Tyr Tyr Ala
Met Asp 100 105 110Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12016111PRTArtificial sequenceanti-CD19 antibody 1 VL amino
acid sequence 16Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser Leu Ala Val
Ser Leu Gly1 5 10 15Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser
Val Asp Tyr Asp 20 25 30Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Ile
Pro Gly Gln Pro Pro 35 40 45Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu
Val Ser Gly Ile Pro Pro 50 55 60Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Asn Ile His65 70 75 80Pro Val Glu Lys Val Asp Ala
Ala Thr Tyr His Cys Gln Gln Ser Thr 85 90 95Glu Asp Pro Trp Thr Phe
Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110175PRTArtificial
sequenceanti-CD19 antibody 2 HCDR1 amino acid sequence 17Ser Asn
Trp Met His1 51817PRTArtificial sequenceanti-CD19 antibody 2 HCDR2
amino acid sequence 18Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr
Asn Gln Asn Phe Gln1 5 10 15Gly1911PRTArtificial sequenceanti-CD19
antibody 2 HCDR3 amino acid sequence 19Gly Ser Asn Pro Tyr Tyr Tyr
Ala Met Asp Tyr1 5 102010PRTArtificial sequenceanti-CD19 antibody 2
LCDR1 amino acid sequence 20Ser Ala Ser Ser Gly Val Asn Tyr Met
His1 5 10217PRTArtificial sequenceanti-CD19 antibody 2 LCDR2 amino
acid sequence 21Asp Thr Ser Lys Leu Ala Ser1 5227PRTArtificial
sequenceanti-CD19 antibody 2 LCDR3 amino acid sequence 22His Gln
Arg Gly Ser Tyr Thr1 523120PRTArtificial sequenceanti-CD19 antibody
2 VH amino acid sequence 23Gln Val Gln Leu Val Gln Pro Gly Ala Glu
Val Val Lys Pro Gly Ala1 5 10 15Ser Val Lys Leu Ser Cys Lys Thr Ser
Gly Tyr Thr Phe Thr Ser Asn 20 25 30Trp Met His Trp Val Lys Gln Ala
Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Glu Ile Asp Pro Ser Asp
Ser Tyr Thr Asn Tyr Asn Gln Asn Phe 50 55 60Gln Gly Lys Ala Lys Leu
Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Val Ser
Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly
Ser Asn Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110Gly
Thr Ser Val Thr Val Ser Ser 115 12024104PRTArtificial
sequenceanti-CD19 antibody 2 VL amino acid sequence 24Glu Ile Val
Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly1 5 10 15Glu Arg
Val Thr Met Thr Cys Ser Ala Ser Ser Gly Val Asn Tyr Met 20 25 30His
Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Arg Arg Trp Ile Tyr 35 40
45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
50 55 60Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Ser Met Glu Pro
Glu65 70 75 80Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Gly Ser Tyr
Thr Phe Gly 85 90 95Gly Gly Thr Lys Leu Glu Ile Lys
100257PRTArtificial sequenceanti-CD19 antibody 3 HCDR1 amino acid
sequence 25Thr Ser Gly Met Gly Val Gly1 52616PRTArtificial
sequenceanti-CD19 antibody 3 HCDR2 amino acid sequence 26His Ile
Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser1 5 10
152710PRTArtificial sequenceanti-CD19 antibody 3 HCDR3 amino acid
sequence 27Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr1 5
102810PRTArtificial sequenceanti-CD19 antibody 3 LCDR1 amino acid
sequence 28Ser Ala Ser Ser Ser Val Ser Tyr Met His1 5
10297PRTArtificial sequenceanti-CD19 antibody 3 LCDR2 amino acid
sequence 29Asp Thr Ser Lys Leu Ala Ser1 5309PRTArtificial
sequenceanti-CD19 antibody 3 LCDR3 amino acid sequence 30Phe Gln
Gly Ser Val Tyr Pro Phe Thr1 531120PRTArtificial sequenceanti-CD19
antibody 3 VH amino acid sequence 31Gln Val Gln Leu Gln Glu Ser Gly
Pro Gly Leu Val Lys Pro Ser Gln1 5 10 15Thr Leu Ser Leu Thr Cys Thr
Val Ser Gly Gly Ser Ile Ser Thr Ser 20 25 30Gly Met Gly Val Gly Trp
Ile Arg Gln His Pro Gly Lys Gly Leu Glu 35 40 45Trp Ile Gly His Ile
Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala 50 55 60Leu Lys Ser Arg
Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe65 70 75 80Ser Leu
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95Cys
Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln 100 105
110Gly Thr Leu Val Thr Val Ser Ser 115 12032106PRTArtificial
sequenceanti-CD19 antibody 3 VL amino acid sequence 32Glu Ile Val
Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg
Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 20 25 30His
Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 35 40
45Asp Thr Ser Lys Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser
50 55 60Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
Glu65 70 75 80Asp Val Ala Val Tyr Tyr Cys Phe Gln Gly Ser Val Tyr
Pro Phe Thr 85 90 95Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100
105335PRTArtificial sequenceanti-CD19 antibody 4 HCDR1 amino acid
sequence 33Ser Ser Trp Met Asn1 53417PRTArtificial
sequenceanti-CD19 antibody 4 HCDR2 amino acid sequence 34Arg Ile
Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Val Lys Phe Lys1 5 10
15Gly3512PRTArtificial sequenceanti-CD19 antibody 4 HCDR3 amino
acid sequence 35Ser Gly Phe Ile Thr Thr Val Arg Asp Phe Asp Tyr1 5
103615PRTArtificial sequenceanti-CD19 antibody 4 LCDR1 amino acid
sequence 36Arg Ala Ser Glu Ser Val Asp Thr Phe Gly Ile Ser Phe Met
Asn1 5 10 15377PRTArtificial sequenceanti-CD19 antibody 4 LCDR2
amino acid sequence 37Glu Ala Ser Asn Gln Gly Ser1
5389PRTArtificial sequenceanti-CD19 antibody 4 LCDR3 amino acid
sequence 38Gln Gln Ser Lys Glu Val Pro Phe Thr1 539121PRTArtificial
sequenceanti-CD19 antibody 4 VH amino acid sequence 39Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser 20 25 30Trp
Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Val Lys Phe
50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu
Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Ser Gly Phe Ile Thr Thr Val Arg Asp Phe
Asp Tyr Trp Gly 100 105 110Gln Gly Thr Leu Val Thr Val Ser Ser 115
12040111PRTArtificial sequenceanti-CD19 antibody 4 VL amino acid
sequence 40Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr
Pro Lys1 5 10 15Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Glu Ser Val
Asp Thr Phe 20 25 30Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro
Asp Gln Ser Pro 35 40 45Lys Leu Leu Ile His Glu Ala Ser Asn Gln Gly
Ser Gly Val Pro Ser 50 55 60Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Asn65 70 75 80Ser Leu Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Ser Lys 85 90 95Glu Val Pro Phe Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys 100 105 110415PRTArtificial
sequenceanti-CD20 antibody 1 HCDR1 amino acid sequence 41Ser Tyr
Asn Met His1 54217PRTArtificial sequenceanti-CD20 antibody 1 HCDR2
amino acid sequence 42Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe Lys1 5 10 15Gly4312PRTArtificial sequenceanti-CD20
antibody 1 HCDR3 amino acid sequence 43Ser Thr Tyr Tyr Gly Gly Asp
Trp Tyr Phe Asn Val1 5 104410PRTArtificial sequenceanti-CD20
antibody 1 LCDR1 amino acid sequence 44Arg Ala Ser Ser Ser Val Ser
Tyr Ile His1 5 10457PRTArtificial sequenceanti-CD20 antibody 1
LCDR2 amino acid sequence 45Ala Thr Ser Asn Leu Ala Ser1
5469PRTArtificial sequenceanti-CD20 antibody 1 LCDR3 amino acid
sequence 46Gln Gln Trp Thr Ser Asn Pro Pro Thr1 547121PRTArtificial
sequenceanti-CD20 antibody 1 VH amino acid sequence 47Gln Val Gln
Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala1 5 10 15Ser Val
Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30Asn
Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile 35 40
45Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
50 55 60Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
Tyr65 70 75 80Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe
Asn Val Trp Gly 100 105 110Ala Gly Thr Thr Val Thr Val Ser Ala 115
12048106PRTArtificial sequenceanti-CD20 antibody 1 VL amino acid
sequence 48Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser
Pro Gly1 5 10 15Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val
Ser Tyr Ile 20 25 30His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys
Pro Trp Ile Tyr 35 40 45Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val
Arg Phe Ser Gly Ser 50 55 60Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
Ser Arg Val Glu Ala Glu65 70 75 80Asp Ala Ala Thr Tyr Tyr Cys Gln
Gln Trp Thr Ser Asn Pro Pro Thr 85 90 95Phe Gly Gly Gly Thr Lys Leu
Glu Ile Lys 100 105495PRTArtificial sequenceanti-CD20 antibody 2
HCDR1 amino acid sequence 49Asn Tyr Tyr Ile His1 55017PRTArtificial
sequenceanti-CD20 antibody 2 HCDR2 amino acid sequence 50Trp Ile
Tyr Pro Gly Asp Gly Asn Thr Lys Tyr Asn Glu Lys Phe Lys1 5 10
15Gly5110PRTArtificial sequenceanti-CD20 antibody 2 HCDR3 amino
acid sequence 51Asp Ser Tyr Ser Asn Tyr Tyr Phe Asp Tyr1 5
105210PRTArtificial sequenceanti-CD20 antibody 2 LCDR1 amino acid
sequence 52Arg Ala Ser Ser Ser Val Ser Tyr Met His1 5
10537PRTArtificial sequenceanti-CD20 antibody 2 LCDR2 amino acid
sequence 53Ala Pro Ser Asn Leu Ala Ser1 5549PRTArtificial
sequenceanti-CD20 antibody 2 LCDR3 amino acid sequence 54Gln Gln
Trp Ser Phe Asn Pro Pro Thr1 555119PRTArtificial sequenceanti-CD20
antibody 2 VH amino acid sequence 55Glu Val Gln Leu Val Gln Ser Gly
Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30Tyr Ile His Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Trp Ile Tyr Pro
Gly Asp Gly Asn Thr Lys Tyr Asn Glu Lys Phe 50 55 60Lys Gly Arg Ala
Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80Leu Glu
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala
Arg Asp Ser Tyr Ser Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105
110Thr Leu Val Thr Val Ser Ser 11556106PRTArtificial
sequenceanti-CD20 antibody 2 VL amino acid sequence 56Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg
Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met 20 25 30His
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu Ile Tyr 35 40
45Ala Pro Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
Glu65 70 75 80Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Phe Asn
Pro Pro Thr 85 90 95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
105575PRTArtificial sequenceanti-CD20 antibody 3 HCDR1 amino acid
sequence 57Tyr Ser Trp Ile Asn1 55817PRTArtificial
sequenceanti-CD20 antibody 3 HCDR2 amino acid sequence 58Arg Ile
Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe Lys1 5 10
15Gly5910PRTArtificial sequenceanti-CD20 antibody 3 HCDR3 amino
acid sequence 59Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr1 5
106016PRTArtificial sequenceanti-CD20 antibody 3 LCDR1 amino acid
sequence 60Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr
Leu Tyr1 5 10 15617PRTArtificial sequenceanti-CD20 antibody 3 LCDR2
amino acid sequence 61Gln Met Ser Asn Leu Val Ser1
5629PRTArtificial sequenceanti-CD20 antibody 3 LCDR3 amino acid
sequence 62Ala Gln Asn Leu Glu Leu Pro Tyr Thr1 563119PRTArtificial
sequenceanti-CD20 antibody 3 VH amino acid sequence 63Gln Val Gln
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30Trp
Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40
45Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala
Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr
Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser
11564112PRTArtificial sequenceanti-CD20 antibody 3 VL amino acid
sequence 64Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr
Pro Gly1 5 10 15Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu
Leu His Ser 20 25 30Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys
Pro Gly Gln Ser 35 40 45Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu
Val Ser Gly Val Pro 50 55 60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Lys Ile65 70 75 80Ser Arg Val Glu Ala Glu Asp Val
Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95Leu Glu Leu Pro Tyr Thr Phe
Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110655PRTArtificial
sequenceanti-CD20 antibody 4 HCDR1 amino acid sequence 65Asp Tyr
Ala Met His1 56617PRTArtificial sequenceanti-CD20 antibody 4 HCDR2
amino acid sequence 66Thr Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr
Ala Asp Ser Val Lys1 5 10 15Gly6713PRTArtificial sequenceanti-CD20
antibody 4 HCDR3 amino acid sequence 67Asp Ile Gln Tyr Gly Asn Tyr
Tyr Tyr Gly Met Asp Val1 5 106811PRTArtificial sequenceanti-CD20
antibody 4 LCDR1 amino acid sequence 68Arg Ala Ser Gln Ser Val Ser
Ser Tyr Leu Ala1 5
10697PRTArtificial sequenceanti-CD20 antibody 4 LCDR2 amino acid
sequence 69Asp Ala Ser Asn Arg Ala Thr1 5709PRTArtificial
sequenceanti-CD20 antibody 4 LCDR3 amino acid sequence 70Gln Gln
Arg Ser Asn Trp Pro Ile Thr1 571122PRTArtificial sequenceanti-CD20
antibody 4 VH amino acid sequence 71Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Phe Thr Phe Asn Asp Tyr 20 25 30Ala Met His Trp Val Arg
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Thr Ile Ser Trp
Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys Lys Ser Leu Tyr65 70 75 80Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Ala
Lys Asp Ile Gln Tyr Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp 100 105
110Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115
12072107PRTArtificial sequenceanti-CD20 antibody 4 VL amino acid
sequence 72Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser
Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val
Ser Ser Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro
Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Arg Ser Asn Trp Pro Ile 85 90 95Thr Phe Gly Gln Gly Thr Arg
Leu Glu Ile Lys 100 105735PRTArtificial sequenceanti-CD22 antibody
1 HCDR1 amino acid sequence 73Arg Ser Trp Met Asn1
57417PRTArtificial sequenceanti-CD22 antibody 1 HCDR2 amino acid
sequence 74Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Ser Gly Lys
Phe Lys1 5 10 15Gly7511PRTArtificial sequenceanti-CD22 antibody 1
HCDR3 amino acid sequence 75Asp Gly Ser Ser Trp Asp Trp Tyr Phe Asp
Val1 5 107616PRTArtificial sequenceanti-CD22 antibody 1 LCDR1 amino
acid sequence 76Arg Ser Ser Gln Ser Ile Val His Ser Val Gly Asn Thr
Phe Leu Glu1 5 10 15777PRTArtificial sequenceanti-CD22 antibody 1
LCDR2 amino acid sequence 77Lys Val Ser Asn Arg Phe Ser1
5789PRTArtificial sequenceanti-CD22 antibody 1 LCDR3 amino acid
sequence 78Phe Gln Gly Ser Gln Phe Pro Tyr Thr1 579120PRTArtificial
sequenceanti-CD22 antibody 1 VH amino acid sequence 79Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Tyr Glu Phe Ser Arg Ser 20 25 30Trp
Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Ser Gly Lys Phe
50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala
Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Asp Gly Ser Ser Trp Asp Trp Tyr Phe Asp
Val Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115
12080112PRTArtificial sequenceanti-CD22 antibody 1 VL amino acid
sequence 80Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile
Val His Ser 20 25 30Val Gly Asn Thr Phe Leu Glu Trp Tyr Gln Gln Lys
Pro Gly Lys Ala 35 40 45Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg
Phe Ser Gly Val Pro 50 55 60Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile65 70 75 80Ser Ser Leu Gln Pro Glu Asp Phe
Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95Ser Gln Phe Pro Tyr Thr Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110815PRTArtificial
sequenceanti-CD22 antibody 2 HCDR1 amino acid sequence 81Ile Tyr
Asp Met Ser1 58217PRTArtificial sequenceanti-CD22 antibody 2 HCDR2
amino acid sequence 82Tyr Ile Ser Ser Gly Gly Gly Thr Thr Tyr Tyr
Pro Asp Thr Val Lys1 5 10 15Gly8314PRTArtificial sequenceanti-CD22
antibody 2 HCDR3 amino acid sequence 83His Ser Gly Tyr Gly Thr His
Trp Gly Val Leu Phe Ala Tyr1 5 108411PRTArtificial
sequenceanti-CD22 antibody 2 LCDR1 amino acid sequence 84Arg Ala
Ser Gln Asp Ile Ser Asn Tyr Leu Asn1 5 10857PRTArtificial
sequenceanti-CD22 antibody 2 LCDR2 amino acid sequence 85Tyr Thr
Ser Ile Leu His Ser1 5869PRTArtificial sequenceanti-CD22 antibody 2
LCDR3 amino acid sequence 86Gln Gln Gly Asn Thr Leu Pro Trp Thr1
587123PRTArtificial sequenceanti-CD22 antibody 2 VH amino acid
sequence 87Glu Val Gln Leu Val Glu Ser Ala Ser Thr Gly Gly Gly Leu
Val Lys1 5 10 15Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
Phe Ala Phe 20 25 30Ser Ile Tyr Asp Met Ser Trp Val Arg Gln Thr Pro
Glu Lys Cys Leu 35 40 45Glu Trp Val Ala Tyr Ile Ser Ser Gly Gly Gly
Thr Thr Tyr Tyr Pro 50 55 60Asp Thr Val Lys Gly Arg Phe Thr Ile Ser
Arg Asp Asn Ala Lys Asn65 70 75 80Thr Leu Tyr Leu Gln Met Ser Ser
Leu Lys Ser Glu Asp Thr Ala Met 85 90 95Tyr Tyr Cys Ala Arg His Ser
Gly Tyr Gly Thr His Trp Gly Val Leu 100 105 110Phe Ala Tyr Trp Gly
Gln Gly Thr Leu Val Thr 115 12088107PRTArtificial sequenceanti-CD22
antibody 2 VL amino acid sequence 88Asp Ile Gln Met Thr Gln Thr Thr
Ser Ser Leu Ser Ala Ser Leu Gly1 5 10 15Asp Arg Val Thr Ile Ser Cys
Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30Leu Asn Trp Tyr Gln Gln
Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45Tyr Tyr Thr Ser Ile
Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly
Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln65 70 75 80Glu Asp
Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95Thr
Phe Gly Cys Gly Thr Lys Leu Glu Ile Lys 100 105895PRTArtificial
sequenceanti-CD30 antibody 1 HCDR1 amino acid sequence 89Asp Tyr
Tyr Ile Thr1 59017PRTArtificial sequenceanti-CD30 antibody 1 HCDR2
amino acid sequence 90Trp Ile Tyr Pro Gly Ser Gly Asn Thr Lys Tyr
Asn Glu Lys Phe Lys1 5 10 15Gly918PRTArtificial sequenceanti-CD30
antibody 1 HCDR3 amino acid sequence 91Tyr Gly Asn Tyr Trp Phe Ala
Tyr1 59215PRTArtificial sequenceanti-CD30 antibody 1 LCDR1 amino
acid sequence 92Lys Ala Ser Gln Ser Val Asp Phe Asp Gly Asp Ser Tyr
Met Asn1 5 10 15937PRTArtificial sequenceanti-CD30 antibody 1 LCDR2
amino acid sequence 93Ala Ala Ser Asn Leu Glu Ser1
5949PRTArtificial sequenceanti-CD30 antibody 1 LCDR3 amino acid
sequence 94Gln Gln Ser Asn Glu Asp Pro Trp Thr1 595117PRTArtificial
sequenceanti-CD30 antibody 1 VH amino acid sequence 95Gln Ile Gln
Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Ala1 5 10 15Ser Val
Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30Tyr
Ile Thr Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 35 40
45Gly Trp Ile Tyr Pro Gly Ser Gly Asn Thr Lys Tyr Asn Glu Lys Phe
50 55 60Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala
Phe65 70 75 80Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val
Tyr Phe Cys 85 90 95Ala Asn Tyr Gly Asn Tyr Trp Phe Ala Tyr Trp Gly
Gln Gly Thr Gln 100 105 110Val Thr Val Ser Ala
11596111PRTArtificial sequenceanti-CD30 antibody 1 VL amino acid
sequence 96Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser
Leu Gly1 5 10 15Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val
Asp Phe Asp 20 25 30Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro
Gly Gln Pro Pro 35 40 45Lys Val Leu Ile Tyr Ala Ala Ser Asn Leu Glu
Ser Gly Ile Pro Ala 50 55 60Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
Phe Thr Leu Asn Ile His65 70 75 80Pro Val Glu Glu Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95Glu Asp Pro Trp Thr Phe Gly
Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110975PRTArtificial
sequenceanti-CD30 antibody 2 HCDR1 amino acid sequence 97Ala Tyr
Tyr Trp Ser1 59816PRTArtificial sequenceanti-CD30 antibody 2 HCDR2
amino acid sequence 98Asp Ile Asn His Gly Gly Gly Thr Asn Tyr Asn
Pro Ser Leu Lys Ser1 5 10 15994PRTArtificial sequenceanti-CD30
antibody 2 HCDR3 amino acid sequence 99Leu Thr Ala
Tyr110011PRTArtificial sequenceanti-CD30 antibody 2 LCDR1 amino
acid sequence 100Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Thr1 5
101017PRTArtificial sequenceanti-CD30 antibody 2 LCDR2 amino acid
sequence 101Ala Ala Ser Ser Leu Gln Ser1 51029PRTArtificial
sequenceanti-CD30 antibody 2 LCDR3 amino acid sequence 102Gln Gln
Tyr Asp Ser Tyr Pro Ile Thr1 5103112PRTArtificial sequenceanti-CD30
antibody 2 VH amino acid sequence 103Gln Val Gln Leu Gln Gln Trp
Gly Ala Gly Leu Leu Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys
Ala Val Tyr Gly Gly Ser Phe Ser Ala Tyr 20 25 30Tyr Trp Ser Trp Ile
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Asp Ile Asn
His Gly Gly Gly Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg Val
Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys
Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90
95Ser Leu Thr Ala Tyr Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser
100 105 110104107PRTArtificial sequenceanti-CD30 antibody 2 VL
amino acid sequence 104Asp Ile Gln Met Thr Gln Ser Pro Thr Ser Leu
Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
Gln Gly Ile Ser Ser Trp 20 25 30Leu Thr Trp Tyr Gln Gln Lys Pro Glu
Lys Ala Pro Lys Ser Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe
Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr
Tyr Tyr Cys Gln Gln Tyr Asp Ser Tyr Pro Ile 85 90 95Thr Phe Gly Gln
Gly Thr Arg Leu Glu Ile Lys 100 1051055PRTArtificial
sequenceanti-EpCAM antibody 1 HCDR1 amino acid sequence 105Ser Tyr
Gly Met His1 510617PRTArtificial sequenceanti-EpCAM antibody 1
HCDR2 amino acid sequence 106Val Ile Ser Tyr Asp Gly Ser Asn Lys
Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly10718PRTArtificial
sequenceanti-EpCAM antibody 1 HCDR3 amino acid sequence 107Asp Met
Gly Trp Gly Ser Gly Trp Arg Pro Tyr Tyr Tyr Tyr Gly Met1 5 10 15Asp
Val10811PRTArtificial sequenceanti-EpCAM antibody 1 LCDR1 amino
acid sequence 108Arg Thr Ser Gln Ser Ile Ser Ser Tyr Leu Asn1 5
101097PRTArtificial sequenceanti-EpCAM antibody 1 LCDR2 amino acid
sequence 109Trp Ala Ser Thr Arg Glu Ser1 51109PRTArtificial
sequenceanti-EpCAM antibody 1 LCDR3 amino acid sequence 110Gln Gln
Ser Tyr Asp Ile Pro Tyr Thr1 5111127PRTArtificial
sequenceanti-EpCAM antibody 1 VH amino acid sequence 111Glu Val Gln
Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Gly
Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Lys Asp Met Gly Trp Gly Ser Gly Trp Arg Pro
Tyr Tyr Tyr Tyr 100 105 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr
Val Thr Val Ser Ser 115 120 125112107PRTArtificial
sequenceanti-EpCAM antibody 1 VL amino acid sequence 112Glu Leu Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg
Val Thr Ile Thr Cys Arg Thr Ser Gln Ser Ile Ser Ser Tyr 20 25 30Leu
Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 35 40
45Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro65 70 75 80Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Asp
Ile Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100
1051135PRTArtificial sequenceanti-EpCAM antibody 2 HCDR1 amino acid
sequence 113Asn Tyr Gly Met Asn1 511417PRTArtificial
sequenceanti-EpCAM antibody 2 HCDR2 amino acid sequence 114Trp Ile
Asn Thr Tyr Thr Gly Glu Ser Thr Tyr Ala Asp Ser Phe Lys1 5 10
15Gly1157PRTArtificial sequenceanti-EpCAM antibody 2 HCDR3 amino
acid sequence 115Phe Ala Ile Lys Gly Asp Tyr1 511616PRTArtificial
sequenceanti-EpCAM antibody 2 LCDR1 amino acid sequence 116Arg Ser
Thr Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr Leu Tyr1 5 10
151177PRTArtificial sequenceanti-EpCAM antibody 2 LCDR2 amino acid
sequence 117Gln Met Ser Asn Leu Ala Ser1 51189PRTArtificial
sequenceanti-EpCAM antibody 2 LCDR3 amino acid sequence 118Ala Gln
Asn Leu Glu Ile Pro Arg Thr1 5119116PRTArtificial
sequenceanti-EpCAM antibody 2 VH amino acid sequence 119Glu Val Gln
Leu Val Gln Ser Gly Pro Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Val
Arg Ile Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30Gly
Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40
45Gly Trp Ile Asn Thr Tyr Thr Gly Glu Ser Thr Tyr Ala Asp Ser Phe
50 55 60Lys Gly Arg Phe Thr Phe Ser Leu Asp Thr Ser Ala Ser Ala Ala
Tyr65 70 75 80Leu Gln Ile Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Phe Ala Ile Lys Gly Asp Tyr Trp Gly Gln
Gly Thr Leu Leu 100 105 110Thr Val Ser Ser 115120112PRTArtificial
sequenceanti-EpCAM antibody 2 VL amino acid sequence 120Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg
Val Thr Ile Thr Cys Arg Ser Thr Lys Ser Leu Leu His Ser 20 25 30Asn
Gly Ile Thr Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Lys Ala 35 40
45Pro Lys Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro
50 55 60Ser Arg Phe
Ser Ser Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile65 70 75 80Ser
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Gln Asn 85 90
95Leu Glu Ile Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Lys
100 105 1101215PRTArtificial sequenceanti-CEA antibody 1 HCDR1
amino acid sequence 121Asp Thr Tyr Met His1 512217PRTArtificial
sequenceanti-CEA antibody 1 HCDR2 amino acid sequence 122Arg Ile
Asp Pro Ala Asn Gly Asn Ser Lys Tyr Ala Asp Ser Val Lys1 5 10
15Gly12312PRTArtificial sequenceanti-CEA antibody 1 HCDR3 amino
acid sequence 123Phe Gly Tyr Tyr Val Ser Asp Tyr Ala Met Ala Tyr1 5
1012415PRTArtificial sequenceanti-CEA antibody 1 LCDR1 amino acid
sequence 124Arg Ala Gly Glu Ser Val Asp Ile Phe Gly Val Gly Phe Leu
His1 5 10 151257PRTArtificial sequenceanti-CEA antibody 1 LCDR2
amino acid sequence 125Arg Ala Ser Asn Leu Glu Ser1
51269PRTArtificial sequenceanti-CEA antibody 1 LCDR3 amino acid
sequence 126Gln Gln Thr Asn Glu Asp Pro Tyr Thr1
5127121PRTArtificial sequenceanti-CEA antibody 1 VH amino acid
sequence 127Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile
Lys Asp Thr 20 25 30Tyr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45Ala Arg Ile Asp Pro Ala Asn Gly Asn Ser Lys
Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr
Ser Lys Asn Thr Ala Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Pro Phe Gly Tyr Tyr Val
Ser Asp Tyr Ala Met Ala Tyr Trp Gly 100 105 110Gln Gly Thr Leu Val
Thr Val Ser Ser 115 120128111PRTArtificial sequenceanti-CEA
antibody 1 VL amino acid sequence 128Asp Ile Gln Leu Thr Gln Ser
Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr
Cys Arg Ala Gly Glu Ser Val Asp Ile Phe 20 25 30Gly Val Gly Phe Leu
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45Lys Leu Leu Ile
Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ser 50 55 60Arg Phe Ser
Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Ser65 70 75 80Ser
Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Asn 85 90
95Glu Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
105 1101295PRTArtificial sequenceanti-CEA antibody 2 HCDR1 amino
acid sequence 129Thr Tyr Trp Met Ser1 513017PRTArtificial
sequenceanti-CEA antibody 2 HCDR2 amino acid sequence 130Glu Ile
His Pro Asp Ser Ser Thr Ile Asn Tyr Ala Pro Ser Leu Lys1 5 10
15Asp13110PRTArtificial sequenceanti-CEA antibody 2 HCDR3 amino
acid sequence 131Leu Tyr Phe Gly Phe Pro Trp Phe Ala Tyr1 5
1013211PRTArtificial sequenceanti-CEA antibody 2 LCDR1 amino acid
sequence 132Lys Ala Ser Gln Asp Val Gly Thr Ser Val Ala1 5
101337PRTArtificial sequenceanti-CEA antibody 2 LCDR2 amino acid
sequence 133Trp Thr Ser Thr Arg His Thr1 51348PRTArtificial
sequenceanti-CEA antibody 2 LCDR3 amino acid sequence 134Gln Gln
Tyr Ser Leu Tyr Arg Ser1 5135119PRTArtificial sequenceanti-CEA
antibody 2 VH amino acid sequence 135Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu Ser Cys
Ser Ala Ser Gly Phe Asp Phe Thr Thr Tyr 20 25 30Trp Met Ser Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Glu Ile His
Pro Asp Ser Ser Thr Ile Asn Tyr Ala Pro Ser Leu 50 55 60Lys Asp Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe65 70 75 80Leu
Gln Met Asp Ser Leu Arg Pro Glu Asp Thr Gly Val Tyr Phe Cys 85 90
95Ala Ser Leu Tyr Phe Gly Phe Pro Trp Phe Ala Tyr Trp Gly Gln Gly
100 105 110Thr Pro Val Thr Val Ser Ser 115136106PRTArtificial
sequenceanti-CEA antibody 2 VL amino acid sequence 136Asp Ile Gln
Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg
Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ser 20 25 30Val
Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40
45Tyr Trp Thr Ser Thr Arg His Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln
Pro65 70 75 80Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Leu
Tyr Arg Ser 85 90 95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
1051375PRTArtificial sequenceanti-CEA antibody 3 HCDR1 amino acid
sequence 137Glu Phe Gly Met Asn1 513817PRTArtificial
sequenceanti-CEA antibody 3 HCDR2 amino acid sequence 138Trp Ile
Asn Thr Lys Thr Gly Glu Ala Thr Tyr Val Glu Glu Phe Lys1 5 10
15Gly13912PRTArtificial sequenceanti-CEA antibody 3 HCDR3 amino
acid sequence 139Trp Asp Phe Ala Tyr Tyr Val Glu Ala Met Asp Tyr1 5
1014011PRTArtificial sequenceanti-CEA antibody 3 LCDR1 amino acid
sequence 140Lys Ala Ser Ala Ala Val Gly Thr Tyr Val Ala1 5
101417PRTArtificial sequenceanti-CEA antibody 3 LCDR2 amino acid
sequence 141Ser Ala Ser Tyr Arg Lys Arg1 514210PRTArtificial
sequenceanti-CEA antibody 3 LCDR3 amino acid sequence 142His Gln
Tyr Tyr Thr Tyr Pro Leu Phe Thr1 5 10143121PRTArtificial
sequenceanti-CEA antibody 3 VH amino acid sequence 143Gln Val Gln
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Phe 20 25 30Gly
Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40
45Gly Trp Ile Asn Thr Lys Thr Gly Glu Ala Thr Tyr Val Glu Glu Phe
50 55 60Lys Gly Arg Val Thr Phe Thr Thr Asp Thr Ser Thr Ser Thr Ala
Tyr65 70 75 80Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Trp Asp Phe Ala Tyr Tyr Val Glu Ala Met
Asp Tyr Trp Gly 100 105 110Gln Gly Thr Thr Val Thr Val Ser Ser 115
120144108PRTArtificial sequenceanti-CEA antibody 3 VL amino acid
sequence 144Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Ala Ala Val
Gly Thr Tyr 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
Lys Leu Leu Ile 35 40 45Tyr Ser Ala Ser Tyr Arg Lys Arg Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys
His Gln Tyr Tyr Thr Tyr Pro Leu 85 90 95Phe Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile Lys 100 1051455PRTArtificial sequenceanti-Her2
antibody 1 HCDR1 amino acid sequence 145Asp Thr Tyr Ile His1
514617PRTArtificial sequenceanti-Her2 antibody 1 HCDR2 amino acid
sequence 146Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser
Val Lys1 5 10 15Gly14711PRTArtificial sequenceanti-Her2 antibody 1
HCDR3 amino acid sequence 147Trp Gly Gly Asp Gly Phe Tyr Ala Met
Asp Tyr1 5 1014811PRTArtificial sequenceanti-Her2 antibody 1 LCDR1
amino acid sequence 148Arg Ala Ser Gln Asp Val Asn Thr Ala Val Ala1
5 101497PRTArtificial sequenceanti-Her2 antibody 1 LCDR2 amino acid
sequence 149Ser Ala Ser Phe Leu Tyr Ser1 51509PRTArtificial
sequenceanti-Her2 antibody 1 LCDR3 amino acid sequence 150Gln Gln
His Tyr Thr Thr Pro Pro Thr1 5151120PRTArtificial sequenceanti-Her2
antibody 1 VH amino acid sequence 151Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30Tyr Ile His Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Arg Ile Tyr
Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg
Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65 70 75 80Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln
100 105 110Gly Thr Leu Val Thr Val Ser Ser 115
120152107PRTArtificial sequenceanti-Her2 antibody 1 VL amino acid
sequence 152Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val
Asn Thr Ala 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
Lys Leu Leu Ile 35 40 45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln His Tyr Thr Thr Pro Pro 85 90 95Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys 100 1051535PRTArtificial sequenceanti-Her2 antibody
2 HCDR1 amino acid sequence 153Asp Tyr Thr Met Asp1
515417PRTArtificial sequenceanti-Her2 antibody 2 HCDR2 amino acid
sequence 154Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg
Phe Lys1 5 10 15Gly15510PRTArtificial sequenceanti-Her2 antibody 2
HCDR3 amino acid sequence 155Asn Leu Gly Pro Ser Phe Tyr Phe Asp
Tyr1 5 1015611PRTArtificial sequenceanti-Her2 antibody 2 LCDR1
amino acid sequence 156Lys Ala Ser Gln Asp Val Ser Ile Gly Val Ala1
5 101577PRTArtificial sequenceanti-Her2 antibody 2 LCDR2 amino acid
sequence 157Ser Ala Ser Tyr Arg Tyr Thr1 51589PRTArtificial
sequenceanti-Her2 antibody 2 LCDR3 amino acid sequence 158Gln Gln
Tyr Tyr Ile Tyr Pro Tyr Thr1 5159119PRTArtificial sequenceanti-Her2
antibody 2 VH amino acid sequence 159Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25 30Thr Met Asp Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Asp Val Asn
Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60Lys Gly Arg
Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr65 70 75 80Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly
100 105 110Thr Leu Val Thr Val Ser Ser 115160107PRTArtificial
sequenceanti-Her2 antibody 2 VL amino acid sequence 160Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg
Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30Val
Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40
45Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile
Tyr Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
1051615PRTArtificial sequenceanti-Her2 antibody 3 HCDR1 amino acid
sequence 161Asp Thr Tyr Ile His1 516217PRTArtificial
sequenceanti-Her2 antibody 3 HCDR2 amino acid sequence 162Arg Ile
Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Asp Pro Lys Phe Gln1 5 10
15Asp16311PRTArtificial sequenceanti-Her2 antibody 3 HCDR3 amino
acid sequence 163Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr1 5
1016411PRTArtificial sequenceanti-Her2 antibody 3 LCDR1 amino acid
sequence 164Lys Ala Ser Gln Asp Val Asn Thr Ala Val Ala1 5
101657PRTArtificial sequenceanti-Her2 antibody 3 LCDR2 amino acid
sequence 165Ser Ala Ser Phe Arg Tyr Thr1 51669PRTArtificial
sequenceanti-Her2 antibody 3 LCDR3 amino acid sequence 166Gln Gln
His Tyr Thr Thr Pro Pro Thr1 5167120PRTArtificial sequenceanti-Her2
antibody 3 VH amino acid sequence 167Gln Val Gln Leu Gln Gln Ser
Gly Pro Glu Leu Val Lys Pro Gly Ala1 5 10 15Ser Leu Lys Leu Ser Cys
Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30Tyr Ile His Trp Val
Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45Gly Arg Ile Tyr
Pro Thr Asn Gly Tyr Thr Arg Tyr Asp Pro Lys Phe 50 55 60Gln Asp Lys
Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr65 70 75 80Leu
Gln Val Ser Arg Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln
100 105 110Gly Ala Ser Val Thr Val Ser Ser 115
120168107PRTArtificial sequenceanti-Her2 antibody 3 VL amino acid
sequence 168Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser
Val Gly1 5 10 15Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val
Asn Thr Ala 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly His Ser Pro
Lys Leu Leu Ile 35 40 45Tyr Ser Ala Ser Phe Arg Tyr Thr Gly Val Pro
Asp Arg Phe Thr Gly 50 55 60Ser Arg Ser Gly Thr Asp Phe Thr Phe Thr
Ile Ser Ser Val Gln Ala65 70 75 80Glu Asp Leu Ala Val Tyr Tyr Cys
Gln Gln His Tyr Thr Thr Pro Pro 85 90 95Thr Phe Gly Gly Gly Thr Lys
Val Glu Ile Lys 100 1051695PRTArtificial sequenceanti-EGFR antibody
1 HCDR1 amino acid sequence 169Asn Tyr Gly Val His1
517016PRTArtificial sequenceanti-EGFR antibody 1 HCDR2 amino acid
sequence 170Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe
Thr Ser1 5 10 1517111PRTArtificial sequenceanti-EGFR antibody 1
HCDR3 amino acid sequence 171Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe
Ala Tyr1 5 1017211PRTArtificial sequenceanti-EGFR antibody 1 LCDR1
amino acid sequence 172Arg Ala Ser Gln Ser Ile Gly Thr Asn Ile His1
5 101737PRTArtificial sequenceanti-EGFR antibody 1 LCDR2 amino acid
sequence 173Tyr Ala Ser Glu Ser Ile Ser1 51749PRTArtificial
sequenceanti-EGFR antibody 1 LCDR3 amino acid sequence 174Gln Gln
Asn Asn Asn Trp Pro Thr Thr1 5175119PRTArtificial sequenceanti-EGFR
antibody 1 VH amino acid sequence 175Gln Val Gln Leu Lys Gln Ser
Gly Pro Gly Leu Val Gln Pro Ser Gln1 5 10 15Ser Leu Ser Ile Thr Cys
Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30Gly Val His Trp Val
Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45Gly Val Ile Trp
Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr 50 55 60Ser Arg Leu
Ser Ile Asn Lys Asp Asn Ser Lys Ser
Gln Val Phe Phe65 70 75 80Lys Met Asn Ser Leu Gln Ser Asn Asp Thr
Ala Ile Tyr Tyr Cys Ala 85 90 95Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu
Phe Ala Tyr Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ala
115176107PRTArtificial sequenceanti-EGFR antibody 1 VL amino acid
sequence 176Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser
Pro Gly1 5 10 15Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile
Gly Thr Asn 20 25 30Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro
Arg Leu Leu Ile 35 40 45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro
Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser
Ile Asn Ser Val Glu Ser65 70 75 80Glu Asp Ile Ala Asp Tyr Tyr Cys
Gln Gln Asn Asn Asn Trp Pro Thr 85 90 95Thr Phe Gly Ala Gly Thr Lys
Leu Glu Leu Lys 100 1051777PRTArtificial sequenceanti-EGFR antibody
2 HCDR1 amino acid sequence 177Ser Gly Asp Tyr Tyr Trp Ser1
517816PRTArtificial sequenceanti-EGFR antibody 2 HCDR2 amino acid
sequence 178Tyr Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu
Lys Ser1 5 10 1517911PRTArtificial sequenceanti-EGFR antibody 2
HCDR3 amino acid sequence 179Val Ser Ile Phe Gly Val Gly Thr Phe
Asp Tyr1 5 1018011PRTArtificial sequenceanti-EGFR antibody 2 LCDR1
amino acid sequence 180Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala1
5 101817PRTArtificial sequenceanti-EGFR antibody 2 LCDR2 amino acid
sequence 181Asp Ala Ser Asn Arg Ala Thr1 51829PRTArtificial
sequenceanti-EGFR antibody 2 LCDR3 amino acid sequence 182His Gln
Tyr Gly Ser Thr Pro Leu Thr1 5183121PRTArtificial sequenceanti-EGFR
antibody 2 VH amino acid sequence 183Gln Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Gln1 5 10 15Thr Leu Ser Leu Thr Cys
Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 20 25 30Asp Tyr Tyr Trp Ser
Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45Trp Ile Gly Tyr
Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser 50 55 60Leu Lys Ser
Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe65 70 75 80Ser
Leu Lys Val Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90
95Cys Ala Arg Val Ser Ile Phe Gly Val Gly Thr Phe Asp Tyr Trp Gly
100 105 110Gln Gly Thr Leu Val Thr Val Ser Ser 115
120184107PRTArtificial sequenceanti-EGFR antibody 2 VL amino acid
sequence 184Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser
Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val
Ser Ser Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro
Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys
His Gln Tyr Gly Ser Thr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys
Ala Glu Ile Lys 100 1051855PRTArtificial sequenceanti-EGFR antibody
3 HCDR1 amino acid sequence 185Asn Tyr Tyr Ile Tyr1
518617PRTArtificial sequenceanti-EGFR antibody 3 HCDR2 amino acid
sequence 186Gly Ile Asn Pro Thr Ser Gly Gly Ser Asn Phe Asn Glu Lys
Phe Lys1 5 10 15Thr18714PRTArtificial sequenceanti-EGFR antibody 3
HCDR3 amino acid sequence 187Gln Gly Leu Trp Phe Asp Ser Asp Gly
Arg Gly Phe Asp Phe1 5 1018816PRTArtificial sequenceanti-EGFR
antibody 3 LCDR1 amino acid sequence 188Arg Ser Ser Gln Asn Ile Val
His Ser Asn Gly Asn Thr Tyr Leu Asp1 5 10 151897PRTArtificial
sequenceanti-EGFR antibody 3 LCDR2 amino acid sequence 189Lys Val
Ser Asn Arg Phe Ser1 51909PRTArtificial sequenceanti-EGFR antibody
3 LCDR3 amino acid sequence 190Phe Gln Tyr Ser His Val Pro Trp Thr1
5191123PRTArtificial sequenceanti-EGFR antibody 3 VH amino acid
sequence 191Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
Thr Asn Tyr 20 25 30Tyr Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly
Leu Glu Trp Ile 35 40 45Gly Gly Ile Asn Pro Thr Ser Gly Gly Ser Asn
Phe Asn Glu Lys Phe 50 55 60Lys Thr Arg Val Thr Ile Thr Val Asp Glu
Ser Thr Asn Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser
Glu Asp Thr Ala Phe Tyr Phe Cys 85 90 95Ala Arg Gln Gly Leu Trp Phe
Asp Ser Asp Gly Arg Gly Phe Asp Phe 100 105 110Trp Gly Gln Gly Ser
Thr Val Thr Val Ser Ser 115 120192112PRTArtificial
sequenceanti-EGFR antibody 3 VL amino acid sequence 192Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg
Val Thr Ile Thr Cys Arg Ser Ser Gln Asn Ile Val His Ser 20 25 30Asn
Gly Asn Thr Tyr Leu Asp Trp Tyr Gln Gln Thr Pro Gly Lys Ala 35 40
45Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr
Ile65 70 75 80Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
Phe Gln Tyr 85 90 95Ser His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys
Leu Gln Ile Thr 100 105 1101935PRTArtificial sequenceanti-GPC-3
antibody HCDR1 amino acid sequence 193Asp Tyr Glu Met His1
519417PRTArtificial sequenceanti-GPC-3 antibody HCDR2 amino acid
sequence 194Ala Ile Asp Pro Gln Thr Gly Asn Thr Ala Phe Asn Gln Lys
Phe Lys1 5 10 15Gly1956PRTArtificial sequenceanti-GPC-3 antibody
HCDR3 amino acid sequence 195Phe Tyr Ser Leu Thr Tyr1
519616PRTArtificial sequenceanti-GPC-3 antibody LCDR1 amino acid
sequence 196Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr
Leu Gln1 5 10 151977PRTArtificial sequenceanti-GPC-3 antibody LCDR2
amino acid sequence 197Lys Val Ser Asn Arg Phe Ser1
51989PRTArtificial sequenceanti-GPC-3 antibody LCDR3 amino acid
sequence 198Phe Gln Gly Ser His Phe Pro Tyr Ala1
5199115PRTArtificial sequenceanti-GPC-3 antibody VH amino acid
sequence 199Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
Thr Asp Tyr 20 25 30Glu Met His Trp Val Lys Gln Ala Pro Gly Gln Gly
Leu Glu Trp Ile 35 40 45Gly Ala Ile Asp Pro Gln Thr Gly Asn Thr Ala
Phe Asn Gln Lys Phe 50 55 60Lys Gly Arg Val Thr Leu Thr Arg Asp Lys
Ser Ser Ser Thr Val Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Thr Arg Phe Tyr Ser Leu Thr
Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser
115200112PRTArtificial sequenceanti-GPC-3 antibody VL amino acid
sequence 200Asp Val Leu Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr
Leu Gly1 5 10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile
Val His Ser 20 25 30Asn Gly Asn Thr Tyr Leu Gln Trp Tyr Leu Gln Arg
Pro Gly Gln Ser 35 40 45Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg
Phe Ser Gly Val Pro 50 55 60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
Tyr Phe Thr Leu Lys Ile65 70 75 80Ser Arg Val Glu Ala Glu Asp Val
Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95Ser His Phe Pro Tyr Ala Phe
Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 1102015PRTArtificial
sequenceanti-Mesothelin antibody HCDR1 amino acid sequence 201Ile
Tyr Gly Met His1 520217PRTArtificial sequenceanti-Mesothelin
antibody HCDR2 amino acid sequence 202Val Ile Trp Tyr Asp Gly Ser
His Glu Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly20313PRTArtificial
sequenceanti-Mesothelin antibody HCDR3 amino acid sequence 203Asp
Gly Asp Tyr Tyr Asp Ser Gly Ser Pro Leu Asp Tyr1 5
1020411PRTArtificial sequenceanti-Mesothelin antibody LCDR1 amino
acid sequence 204Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala1 5
102057PRTArtificial sequenceanti-Mesothelin antibody LCDR2 amino
acid sequence 205Asp Ala Ser Asn Arg Ala Thr1 52069PRTArtificial
sequenceanti-Mesothelin antibody LCDR3 amino acid sequence 206Gln
Gln Arg Ser Asn Trp Pro Leu Thr1 5207122PRTArtificial
sequenceanti-Mesothelin antibody VH amino acid sequence 207Gln Val
Tyr Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Ile Tyr 20 25
30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ala Val Ile Trp Tyr Asp Gly Ser His Glu Tyr Tyr Ala Asp Ser
Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
Leu Tyr65 70 75 80Leu Leu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95Ala Arg Asp Gly Asp Tyr Tyr Asp Ser Gly Ser
Pro Leu Asp Tyr Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser
Ser 115 120208107PRTArtificial sequenceanti-Mesothelin antibody VL
amino acid sequence 208Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu
Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser
Gln Ser Val Ser Ser Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly
Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Arg Ala Thr
Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe
Thr Leu Thr Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val
Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu 85 90 95Thr Phe Gly Gly
Gly Thr Lys Val Glu Ile Lys 100 1052095PRTArtificial
sequenceanti-Mucin1 antibody 1 HCDR1 amino acid sequence 209Ser Tyr
Val Leu His1 521017PRTArtificial sequenceanti-Mucin1 antibody 1
HCDR2 amino acid sequence 210Tyr Ile Asn Pro Tyr Asn Asp Gly Thr
Gln Tyr Asn Glu Lys Phe Lys1 5 10 15Gly21110PRTArtificial
sequenceanti-Mucin1 antibody 1 HCDR3 amino acid sequence 211Gly Phe
Gly Gly Ser Tyr Gly Phe Ala Tyr1 5 1021212PRTArtificial
sequenceanti-Mucin1 antibody 1 LCDR1 amino acid sequence 212Ser Ala
Ser Ser Ser Val Ser Ser Ser Tyr Leu Tyr1 5 102137PRTArtificial
sequenceanti-Mucin1 antibody 1 LCDR2 amino acid sequence 213Ser Thr
Ser Asn Leu Ala Ser1 52149PRTArtificial sequenceanti-Mucin1
antibody 1 LCDR3 amino acid sequence 214His Gln Trp Asn Arg Tyr Pro
Tyr Thr1 5215119PRTArtificial sequenceanti-Mucin1 antibody 1 VH
amino acid sequence 215Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val
Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Glu Ala Ser Gly
Tyr Thr Phe Pro Ser Tyr 20 25 30Val Leu His Trp Val Lys Gln Ala Pro
Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Tyr Ile Asn Pro Tyr Asn Asp
Gly Thr Gln Tyr Asn Glu Lys Phe 50 55 60Lys Gly Lys Ala Thr Leu Thr
Arg Asp Thr Ser Ile Asn Thr Ala Tyr65 70 75 80Met Glu Leu Ser Arg
Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Phe
Gly Gly Ser Tyr Gly Phe Ala Tyr Trp Gly Gln Gly 100 105 110Thr Leu
Val Thr Val Ser Ser 115216108PRTArtificial sequenceanti-Mucin1
antibody 1 VL amino acid sequence 216Asp Ile Gln Leu Thr Gln Ser
Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Met Thr
Cys Ser Ala Ser Ser Ser Val Ser Ser Ser 20 25 30Tyr Leu Tyr Trp Tyr
Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Trp 35 40 45Ile Tyr Ser Thr
Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 50 55 60Gly Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln65 70 75 80Pro
Glu Asp Ser Ala Ser Tyr Phe Cys His Gln Trp Asn Arg Tyr Pro 85 90
95Tyr Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys 100
1052175PRTArtificial sequenceanti-Mucin1 antibody 2 HCDR1 amino
acid sequence 217Asn Tyr Trp Met Asn1 521819PRTArtificial
sequenceanti-Mucin1 antibody 2 HCDR2 amino acid sequence 218Glu Ile
Arg Leu Lys Ser Asn Asn Tyr Thr Thr His Tyr Ala Glu Ser1 5 10 15Val
Lys Gly2196PRTArtificial sequenceanti-Mucin1 antibody 2 HCDR3 amino
acid sequence 219His Tyr Tyr Phe Asp Tyr1 522016PRTArtificial
sequenceanti-Mucin1 antibody 2 LCDR1 amino acid sequence 220Arg Ser
Ser Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr Phe Phe1 5 10
152217PRTArtificial sequenceanti-Mucin1 antibody 2 LCDR2 amino acid
sequence 221Gln Met Ser Asn Leu Ala Ser1 52229PRTArtificial
sequenceanti-Mucin1 antibody 2 LCDR3 amino acid sequence 222Ala Gln
Asn Leu Glu Leu Pro Pro Thr1 5223117PRTArtificial
sequenceanti-Mucin1 antibody 2 VH amino acid sequence 223Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Met Arg Leu Ser Cys Val Ala Ser Gly Phe Pro Phe Ser Asn Tyr 20 25
30Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Gly Glu Ile Arg Leu Lys Ser Asn Asn Tyr Thr Thr His Tyr Ala
Glu 50 55 60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys
Asn Ser65 70 75 80Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp
Thr Ala Val Tyr 85 90 95Tyr Cys Thr Arg His Tyr Tyr Phe Asp Tyr Trp
Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ser
115224112PRTArtificial sequenceanti-Mucin1 antibody 2 VL amino acid
sequence 224Asp Ile Val Met Thr Gln Ser Pro Leu Ser Asn Pro Val Thr
Pro Gly1 5 10 15Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu
Leu His Ser 20 25 30Asn Gly Ile Thr Tyr Phe Phe Trp Tyr Leu Gln Lys
Pro Gly Gln Ser 35 40 45Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu
Ala Ser Gly Val Pro 50 55 60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Arg Ile65 70 75 80Ser Arg Val Glu Ala Glu Asp Val
Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95Leu Glu Leu Pro Pro Thr Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 1102255PRTArtificial
sequenceanti-CA125 antibody HCDR1 amino acid sequence 225Ser Tyr
Ala Met Ser1 522617PRTArtificial sequenceanti-CA125 antibody HCDR2
amino acid sequence 226Thr Ile Ser Ser Ala Gly Gly Tyr Ile Phe Tyr
Ser Asp Ser Val
Gln1 5 10 15Gly22714PRTArtificial sequenceanti-CA125 antibody HCDR3
amino acid sequence 227Gln Gly Phe Gly Asn Tyr Gly Asp Tyr Tyr Ala
Met Asp Tyr1 5 1022817PRTArtificial sequenceanti-CA125 antibody
LCDR1 amino acid sequence 228Lys Ser Ser Gln Ser Leu Leu Asn Ser
Arg Thr Arg Lys Asn Gln Leu1 5 10 15Ala2297PRTArtificial
sequenceanti-CA125 antibody LCDR2 amino acid sequence 229Trp Ala
Ser Thr Arg Gln Ser1 52308PRTArtificial sequenceanti-CA125 antibody
LCDR3 amino acid sequence 230Gln Gln Ser Tyr Asn Leu Leu Thr1
5231122PRTArtificial sequenceanti-CA125 antibody VH amino acid
sequence 231Val Lys Leu Gln Glu Ser Gly Gly Gly Phe Val Lys Pro Gly
Gly Ser1 5 10 15Leu Lys Val Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
Ser Tyr Ala 20 25 30Met Ser Trp Val Arg Leu Ser Pro Glu Met Arg Leu
Glu Trp Val Ala 35 40 45Thr Ile Ser Ser Ala Gly Gly Tyr Ile Phe Tyr
Ser Asp Ser Val Gln 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Asn Thr Leu His Leu65 70 75 80Gln Met Gly Ser Leu Arg Ser Gly
Asp Thr Ala Met Tyr Tyr Cys Ala 85 90 95Arg Gln Gly Phe Gly Asn Tyr
Gly Asp Tyr Tyr Ala Met Asp Tyr Trp 100 105 110Gly Gln Gly Thr Thr
Val Thr Val Ser Ser 115 120232112PRTArtificial sequenceanti-CA125
antibody VL amino acid sequence 232Asp Ile Glu Leu Thr Gln Ser Pro
Ser Ser Leu Ala Val Ser Ala Gly1 5 10 15Glu Lys Val Thr Met Ser Cys
Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30Arg Thr Arg Lys Asn Gln
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45Ser Pro Glu Leu Leu
Ile Tyr Trp Ala Ser Thr Arg Gln Ser Gly Val 50 55 60Pro Asp Arg Phe
Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65 70 75 80Ile Ser
Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 85 90 95Ser
Tyr Asn Leu Leu Thr Phe Gly Pro Gly Thr Lys Leu Glu Val Lys 100 105
1102335PRTArtificial sequenceanti-BCMA antibody HCDR1 amino acid
sequence 233Asn Tyr Trp Met His1 523417PRTArtificial
sequenceanti-BCMA antibody HCDR2 amino acid sequence 234Ala Thr Tyr
Arg Gly His Ser Asp Thr Tyr Tyr Asn Gln Lys Phe Lys1 5 10
15Gly23512PRTArtificial sequenceanti-BCMA antibody HCDR3 amino acid
sequence 235Gly Ala Ile Tyr Asp Gly Tyr Asp Val Leu Asp Asn1 5
1023611PRTArtificial sequenceanti-BCMA antibody LCDR1 amino acid
sequence 236Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn1 5
102377PRTArtificial sequenceanti-BCMA antibody LCDR2 amino acid
sequence 237Tyr Thr Ser Asn Leu His Ser1 52389PRTArtificial
sequenceanti-BCMA antibody LCDR3 amino acid sequence 238Gln Gln Tyr
Arg Lys Leu Pro Trp Thr1 5239121PRTArtificial sequenceanti-BCMA
antibody VH amino acid sequence 239Gln Val Gln Leu Val Gln Ser Gly
Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Gly Thr Phe Ser Asn Tyr 20 25 30Trp Met His Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Ala Thr Tyr Arg
Gly His Ser Asp Thr Tyr Tyr Asn Gln Lys Phe 50 55 60Lys Gly Arg Val
Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala
Arg Gly Ala Ile Tyr Asp Gly Tyr Asp Val Leu Asp Asn Trp Gly 100 105
110Gln Gly Thr Leu Val Thr Val Ser Ser 115 120240107PRTArtificial
sequenceanti-BCMA antibody VL amino acid sequence 240Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg
Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30Leu
Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40
45Tyr Tyr Thr Ser Asn Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Arg Lys
Leu Pro Trp 85 90 95Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100
1052415PRTArtificial sequenceanti-CD3 antibody 3 HCDR1 amino acid
sequence 241Thr Tyr Ala Met Asn1 524219PRTArtificial
sequenceanti-CD3 antibody 3 HCDR2 amino acid sequence 242Arg Ile
Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser1 5 10 15Val
Lys Asp24314PRTArtificial sequenceanti-CD3 antibody 3 HCDR3 amino
acid sequence 243His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe
Ala Tyr1 5 1024414PRTArtificial sequenceanti-CD3 antibody 3 LCDR1
amino acid sequence 244Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn
Tyr Ala Asn1 5 102457PRTArtificial sequenceanti-CD3 antibody 3
LCDR2 amino acid sequence 245Gly Thr Asn Lys Arg Ala Pro1
52469PRTArtificial sequenceanti-CD3 antibody 3 LCDR3 amino acid
sequence 246Ala Leu Trp Tyr Ser Asn Leu Trp Val1
5247125PRTArtificial sequenceanti-CD3 antibody 3 VH amino acid
sequence 247Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly1 5 10 15Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
Asn Thr Tyr 20 25 30Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
Thr Tyr Tyr Ala Asp 50 55 60Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
Asp Asp Ser Lys Asn Thr65 70 75 80Ala Tyr Leu Gln Met Asn Asn Leu
Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Val Arg His Gly Asn
Phe Gly Asn Ser Tyr Val Ser Trp Phe 100 105 110Ala Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser 115 120 125248109PRTArtificial
sequenceanti-CD3 antibody 3 VL amino acid sequence 248Glu Leu Val
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly1 5 10 15Thr Val
Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30Asn
Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40
45Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Thr Pro Ala Arg Phe
50 55 60Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
Val65 70 75 80Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp
Tyr Ser Asn 85 90 95Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val
Leu 100 1052495PRTArtificial sequenceanti-CD3 antibody 4 HCDR1
amino acid sequence 249Lys Tyr Ala Met Asn1 525019PRTArtificial
sequenceanti-CD3 antibody 4 HCDR2 amino acid sequence 250Arg Ile
Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser1 5 10 15Val
Lys Asp25114PRTArtificial sequenceanti-CD3 antibody 4 HCDR3 amino
acid sequence 251His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp
Ala Tyr1 5 1025214PRTArtificial sequenceanti-CD3 antibody 4 LCDR1
amino acid sequence 252Gly Ser Ser Thr Gly Ala Val Thr Ser Gly Tyr
Tyr Pro Asn1 5 102537PRTArtificial sequenceanti-CD3 antibody 4
LCDR2 amino acid sequence 253Gly Thr Lys Phe Leu Ala Pro1
52549PRTArtificial sequenceanti-CD3 antibody 4 LCDR3 amino acid
sequence 254Ala Leu Trp Tyr Ser Asn Arg Trp Val1
5255125PRTArtificial sequenceanti-CD3 antibody 4 VH amino acid
sequence 255Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly1 5 10 15Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
Asn Lys Tyr 20 25 30Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
Thr Tyr Tyr Ala Asp 50 55 60Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
Asp Asp Ser Lys Asn Thr65 70 75 80Ala Tyr Leu Gln Met Asn Asn Leu
Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Val Arg His Gly Asn
Phe Gly Asn Ser Tyr Ile Ser Tyr Trp 100 105 110Ala Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser 115 120 125256109PRTArtificial
sequenceanti-CD3 antibody 4 VL amino acid sequence 256Glu Leu Val
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly1 5 10 15Thr Val
Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly 20 25 30Tyr
Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 35 40
45Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
50 55 60Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly
Val65 70 75 80Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp
Tyr Ser Asn 85 90 95Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val
Leu 100 10525728PRTHomo sapiens 257Ser Ser Ser Ser Lys Ala Pro Pro
Pro Ser Leu Pro Ser Pro Ser Arg1 5 10 15Leu Pro Gly Pro Ser Asp Thr
Pro Ile Leu Pro Gln 20 2525827PRTArtificial sequenceG2(GGGGS)3CTP1
peptide linker 258Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly1 5 10 15Ser Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser
20 2525925PRTArtificial sequence(GGGGS)3CTP1 peptide linker 259Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser1 5 10
15Ser Ser Ser Lys Ala Pro Pro Pro Ser 20 2526022PRTArtificial
sequenceGS(GGGGS)2CTP1 peptide linker 260Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Ser Ser Ser Ser1 5 10 15Lys Ala Pro Pro Pro
Ser 2026133PRTArtificial sequence(GGGGS)1CTP4 peptide linker 261Gly
Gly Gly Gly Ser Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu1 5 10
15Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro
20 25 30Gln262227PRTArtificial sequenceIgG1 Fc(L234A,L235A) mutant
constant region amino acid sequence 262Asp Lys Thr His Thr Cys Pro
Pro Cys Pro Ala Pro Glu Ala Ala Gly1 5 10 15Gly Pro Ser Val Phe Leu
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr65 70 75 80Arg
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90
95Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
Gln Val 115 120 125Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys
Asn Gln Val Ser 130 135 140Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
Ser Asp Ile Ala Val Glu145 150 155 160Trp Glu Ser Asn Gly Gln Pro
Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175Val Leu Asp Ser Asp
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190Asp Lys Ser
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205His
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215
220Pro Gly Lys225263226PRTArtificial sequenceIgG1(L234A,L235A,
T250Q,N297A,P331S,M428L, K447-) mutant constant region amino acid
sequence 263Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
Ala Gly1 5 10 15Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
Gln Leu Met 20 25 30Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
Asp Val Ser His 35 40 45Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
Asp Gly Val Glu Val 50 55 60His Asn Ala Lys Thr Lys Pro Arg Glu Glu
Gln Tyr Ala Ser Thr Tyr65 70 75 80Arg Val Val Ser Val Leu Thr Val
Leu His Gln Asp Trp Leu Asn Gly 85 90 95Lys Glu Tyr Lys Cys Lys Val
Ser Asn Lys Ala Leu Pro Ala Ser Ile 100 105 110Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125Tyr Thr Leu
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu145 150
155 160Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
Pro 165 170 175Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
Leu Thr Val 180 185 190Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser Cys Ser Val Leu 195 200 205His Glu Ala Leu His Asn His Tyr Thr
Gln Lys Ser Leu Ser Leu Ser 210 215 220Pro
Gly225264752PRTArtificial sequencebispecific antibody AB1K1 amino
acid sequence 264Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val
Arg Pro Gly Ser1 5 10 15Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr
Ala Phe Ser Ser Tyr 20 25 30Trp Met Asn Trp Val Lys Gln Arg Pro Gly
Gln Gly Leu Glu Trp Ile 35 40 45Gly Gln Ile Trp Pro Gly Asp Gly Asp
Thr Asn Tyr Asn Gly Lys Phe 50 55 60Lys Gly Lys Ala Thr Leu Thr Ala
Asp Glu Ser Ser Ser Thr Ala Tyr65 70 75 80Met Gln Leu Ser Ser Leu
Ala Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95Ala Arg Arg Glu Thr
Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp 100 105 110Tyr Trp Gly
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr 130 135
140Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr
Ile145 150 155 160Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly
Asp Ser Tyr Leu 165 170 175Asn Trp Tyr Gln Gln Ile Pro Gly Gln Pro
Pro Lys Leu Leu Ile Tyr 180 185 190Asp Ala Ser Asn Leu Val Ser Gly
Ile Pro Pro Arg Phe Ser Gly Ser 195 200 205Gly Ser Gly Thr Asp Phe
Thr Leu Asn Ile His Pro Val Glu Lys Val 210 215 220Asp Ala Ala Thr
Tyr His Cys Gln Gln Ser Thr Glu Asp Pro Trp Thr225 230 235 240Phe
Gly Gly Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Gly Gly 245 250
255Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Ser Ser Ser Lys
260 265 270Ala Pro Pro Pro Ser Glu Val Gln Leu Leu Glu Ser Gly Gly
Gly Leu 275 280 285Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala
Ala Ser Gly Phe 290 295 300Thr Phe Asn Thr Tyr Ala Met Asn Trp Val
Arg Gln Ala Pro Gly Lys305 310 315 320Gly Leu Glu Trp Val Ala Arg
Ile Arg Ser Lys Tyr Asn Asn Tyr Ala 325
330 335Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg
Asp 340 345 350Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu
Lys Thr Glu 355 360 365Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly
Asn Phe Gly Asn Ser 370 375 380Tyr Val Ser Trp Phe Ala Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val385 390 395 400Ser Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 405 410 415Ser Glu Leu Val
Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly 420 425 430Gly Thr
Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 435 440
445Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg
450 455 460Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Thr Pro
Ala Arg465 470 475 480Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala
Leu Thr Leu Ser Gly 485 490 495Val Gln Pro Glu Asp Glu Ala Glu Tyr
Tyr Cys Ala Leu Trp Tyr Ser 500 505 510Asn Leu Trp Val Phe Gly Gly
Gly Thr Lys Leu Thr Val Leu Asp Lys 515 520 525Thr His Thr Cys Pro
Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro 530 535 540Ser Val Phe
Leu Phe Pro Pro Lys Pro Lys Asp Gln Leu Met Ile Ser545 550 555
560Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
565 570 575Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
His Asn 580 585 590Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser
Thr Tyr Arg Val 595 600 605Val Ser Val Leu Thr Val Leu His Gln Asp
Trp Leu Asn Gly Lys Glu 610 615 620Tyr Lys Cys Lys Val Ser Asn Lys
Ala Leu Pro Ala Ser Ile Glu Lys625 630 635 640Thr Ile Ser Lys Ala
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 645 650 655Leu Pro Pro
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 660 665 670Cys
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 675 680
685Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
690 695 700Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
Asp Lys705 710 715 720Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
Ser Val Leu His Glu 725 730 735Ala Leu His Asn His Tyr Thr Gln Lys
Ser Leu Ser Leu Ser Pro Gly 740 745 7502652256DNAArtificial
sequencebispecific antibody AB1K1 nucleotide sequence 265caggtgcagc
tgcagcagtc tggagctgag ctggtgcggc ctggctccag cgtgaagatc 60tcttgtaagg
cttccggcta cgccttctct tcctattgga tgaattgggt gaagcagaga
120cctggacagg gactggagtg gatcggacag atctggccag gcgatggcga
cacaaactac 180aatggcaagt ttaagggcaa ggctacactg accgccgacg
agagctcttc caccgcctac 240atgcagctga gctctctggc ttccgaggat
agcgccgtgt atttctgcgc taggagggag 300accacaaccg tgggccgcta
ctattacgct atggattact ggggccaggg cacaaccgtg 360accgtgtcca
gcggaggagg aggatctgga ggaggaggct ccggaggagg aggaagcgac
420atccagctga cacagagccc cgcttctctg gccgtgagcc tgggacagag
ggctaccatc 480tcttgcaagg cttcccagag cgtggactac gatggcgact
cttacctgaa ctggtatcag 540cagatccctg gccagccccc taagctgctg
atctatgatg cctccaatct ggtgagcggc 600atcccaccca ggttttctgg
ctccggcagc ggcacagact tcaccctgaa catccacccc 660gtggagaagg
tggatgccgc tacctaccat tgccagcaga gcacagagga cccttggacc
720tttggcggcg gcacaaagct ggagatcaag ggtggcggcg gtggaggatc
cggcggtgga 780ggtagcggcg gaggcggtag ctccagctct agtaaagctc
cccctccttc cgaggtgcag 840ctgctggagt ccggaggagg actggtgcag
ccaggaggct ccctgaagct gagctgtgct 900gcctctggct ttaccttcaa
cacatatgcc atgaattggg tgcggcaggc tccaggcaag 960ggactggagt
gggtggctag gatcaggtct aagtacaaca attatgccac ctactatgct
1020gattccgtga aggacaggtt caccatctcc cgcgacgata gcaagaacac
agcctacctg 1080cagatgaaca atctgaagac cgaggatacc gccgtgtact
actgcgtgag acatggcaac 1140tttggcaata gctacgtgtc ctggttcgct
tactggggac agggcaccct ggtcacagtg 1200agctctggag gaggaggatc
tggaggagga ggctccggag gaggaggaag cgagctggtg 1260gtgacccagg
agccatctct gacagtgtcc cccggcggca cagtgaccct gacatgtaga
1320tccagcaccg gcgccgtgac cacatccaac tacgctaatt gggtgcagca
gaagccagga 1380caggctccaa ggggactgat cggaggaacc aacaagaggg
ctcctggaac accagctcgg 1440tttagcggat ctctgctggg aggcaaggct
gccctgaccc tgtccggagt gcagccagag 1500gatgaggccg agtattattg
cgctctgtgg tatagcaatc tgtgggtgtt cggaggagga 1560accaagctga
cagtgctgga caagacccat acatgcccac catgccctgc ccctgaagcc
1620gccggaggac cttccgtgtt cctgttccct cccaagccaa aagatcagct
gatgatctct 1680agaacccccg aagtcacctg cgtggtcgtc gacgtgtccc
atgaggaccc tgaagtcaag 1740ttcaactggt acgtggacgg tgtcgaagtc
cacaacgcca agaccaagcc tagggaggag 1800cagtatgcca gcacataccg
ggtggtgtct gtgctgaccg tgctgcatca ggattggctg 1860aatggcaagg
aatataaatg taaggtgagc aataaggctc tgccggctag cattgaaaaa
1920accatttcca aggctaaggg ccagcccagg gagcctcagg tctacaccct
gcctccatct 1980agagatgaac tgaccaaaaa ccaggtgagc ctgacttgcc
tggtcaaagg cttctacccc 2040agcgacattg ccgtggagtg ggagtctaat
ggccagcctg aaaataacta caaaactacc 2100cctcctgtgc tggactctga
tggctccttc tttctgtact ctaaactgac cgtggacaag 2160tctcgctggc
agcagggtaa cgtgttttct tgctccgtgc tgcacgaggc tctgcataac
2220cattacaccc agaagagcct gtctctgtcc ccagga 2256266744PRTArtificial
sequencebispecific antibody AB2K amino acid sequence 266Gln Val Gln
Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala1 5 10 15Ser Val
Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30Asn
Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile 35 40
45Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
50 55 60Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
Tyr65 70 75 80Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe
Asn Val Trp Gly 100 105 110Ala Gly Thr Thr Val Thr Val Ser Ala Gly
Gly Gly Gly Ser Gly Gly 115 120 125Gly Gly Ser Gly Gly Gly Gly Ser
Gln Ile Val Leu Ser Gln Ser Pro 130 135 140Ala Ile Leu Ser Ala Ser
Pro Gly Glu Lys Val Thr Met Thr Cys Arg145 150 155 160Ala Ser Ser
Ser Val Ser Tyr Ile His Trp Phe Gln Gln Lys Pro Gly 165 170 175Ser
Ser Pro Lys Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly 180 185
190Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu
195 200 205Thr Ile Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr
Cys Gln 210 215 220Gln Trp Thr Ser Asn Pro Pro Thr Phe Gly Gly Gly
Thr Lys Leu Glu225 230 235 240Ile Lys Gly Gly Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Gly Ser Ser Ser Ser Ser
Lys Ala Pro Pro Pro Ser Glu Val Gln 260 265 270Leu Leu Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 275 280 285Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 290 295 300Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile305 310
315 320Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val
Lys 325 330 335Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
Ala Tyr Leu 340 345 350Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala
Val Tyr Tyr Cys Val 355 360 365Arg His Gly Asn Phe Gly Asn Ser Tyr
Val Ser Trp Phe Ala Tyr Trp 370 375 380Gly Gln Gly Thr Leu Val Thr
Val Ser Ser Gly Gly Gly Gly Ser Gly385 390 395 400Gly Gly Gly Ser
Gly Gly Gly Gly Ser Glu Leu Val Val Thr Gln Glu 405 410 415Pro Ser
Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Arg 420 425
430Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn Trp Val Gln
435 440 445Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr
Asn Lys 450 455 460Arg Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser
Leu Leu Gly Gly465 470 475 480Lys Ala Ala Leu Thr Leu Ser Gly Val
Gln Pro Glu Asp Glu Ala Glu 485 490 495Tyr Tyr Cys Ala Leu Trp Tyr
Ser Asn Leu Trp Val Phe Gly Gly Gly 500 505 510Thr Lys Leu Thr Val
Leu Asp Lys Thr His Thr Cys Pro Pro Cys Pro 515 520 525Ala Pro Glu
Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 530 535 540Pro
Lys Asp Gln Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val545 550
555 560Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
Tyr 565 570 575Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
Arg Glu Glu 580 585 590Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His 595 600 605Gln Asp Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys 610 615 620Ala Leu Pro Ala Ser Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln625 630 635 640Pro Arg Glu Pro
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 645 650 655Thr Lys
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 660 665
670Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
675 680 685Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
Phe Leu 690 695 700Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
Gln Gly Asn Val705 710 715 720Phe Ser Cys Ser Val Leu His Glu Ala
Leu His Asn His Tyr Thr Gln 725 730 735Lys Ser Leu Ser Leu Ser Pro
Gly 7402672232DNAArtificial sequencebispecific antibody AB2K
nucleotide sequence 267caagtgcagc tgcagcagcc tggagctgag ctggtgaaac
ccggcgcctc cgtcaagatg 60tcctgtaagg cctccggata caccttcacc agctacaaca
tgcactgggt gaaacagacc 120cctggaaggg gcctggagtg gatcggcgcc
atttaccctg gcaacggcga tacctcctat 180aatcagaagt ttaagggcaa
ggccaccctg accgctgata agagcagcag cacagcctac 240atgcagctgt
ccagcctgac ctccgaggac agcgccgtgt actactgtgc tcggagcacc
300tactacggcg gcgactggta ctttaacgtg tggggagctg gcaccacagt
gaccgtgagc 360gccggaggag gaggatctgg aggaggaggc tccggaggag
gaggaagcca gatcgtgctg 420agccagagcc ccgccatcct gagcgccagc
cccggcgaga aggtgaccat gacctgccgc 480gccagcagca gcgtgagcta
catccactgg ttccagcaga agcccggcag cagccccaag 540ccctggatct
acgccaccag caacctggcc agcggcgtgc ccgtgcgctt cagcggcagc
600ggcagcggca ccagctacag cctgaccatc agccgcgtgg aggccgagga
cgccgccacc 660tactactgcc agcagtggac cagcaacccc cccaccttcg
gcggcggcac caagctggag 720atcaagggtg gcggcggtgg aggatccggc
ggtggaggta gcggcggagg cggtagctcc 780agctctagta aagctccccc
tccttccgag gtgcagctgc tggagtccgg aggaggactg 840gtgcagccag
gaggctccct gaagctgagc tgtgctgcct ctggctttac cttcaacaca
900tatgccatga attgggtgcg gcaggctcca ggcaagggac tggagtgggt
ggctaggatc 960aggtctaagt acaacaatta tgccacctac tatgctgatt
ccgtgaagga caggttcacc 1020atctcccgcg acgatagcaa gaacacagcc
tacctgcaga tgaacaatct gaagaccgag 1080gataccgccg tgtactactg
cgtgagacat ggcaactttg gcaatagcta cgtgtcctgg 1140ttcgcttact
ggggacaggg caccctggtc acagtgagct ctggaggagg aggatctgga
1200ggaggaggct ccggaggagg aggaagcgag ctggtggtga cccaggagcc
atctctgaca 1260gtgtcccccg gcggcacagt gaccctgaca tgtagatcca
gcaccggcgc cgtgaccaca 1320tccaactacg ctaattgggt gcagcagaag
ccaggacagg ctccaagggg actgatcgga 1380ggaaccaaca agagggctcc
tggaacacca gctcggttta gcggatctct gctgggaggc 1440aaggctgccc
tgaccctgtc cggagtgcag ccagaggatg aggccgagta ttattgcgct
1500ctgtggtata gcaatctgtg ggtgttcgga ggaggaacca agctgacagt
gctggacaag 1560acccatacat gcccaccatg ccctgcccct gaagccgccg
gaggaccttc cgtgttcctg 1620ttccctccca agccaaaaga tcagctgatg
atctctagaa cccccgaagt cacctgcgtg 1680gtcgtcgacg tgtcccatga
ggaccctgaa gtcaagttca actggtacgt ggacggtgtc 1740gaagtccaca
acgccaagac caagcctagg gaggagcagt atgccagcac ataccgggtg
1800gtgtctgtgc tgaccgtgct gcatcaggat tggctgaatg gcaaggaata
taaatgtaag 1860gtgagcaata aggctctgcc ggctagcatt gaaaaaacca
tttccaaggc taagggccag 1920cccagggagc ctcaggtcta caccctgcct
ccatctagag atgaactgac caaaaaccag 1980gtgagcctga cttgcctggt
caaaggcttc taccccagcg acattgccgt ggagtgggag 2040tctaatggcc
agcctgaaaa taactacaaa actacccctc ctgtgctgga ctctgatggc
2100tccttctttc tgtactctaa actgaccgtg gacaagtctc gctggcagca
gggtaacgtg 2160ttttcttgct ccgtgctgca cgaggctctg cataaccatt
acacccagaa gagcctgtct 2220ctgtccccag ga 2232268749PRTArtificial
sequencebispecific antibody AB3K amino acid sequence 268Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Tyr Glu Phe Ser Arg Ser 20 25 30Trp
Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Ser Gly Lys Phe
50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala
Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Asp Gly Ser Ser Trp Asp Trp Tyr Phe Asp
Val Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser Gly Gly
Gly Gly Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Asp
Ile Gln Met Thr Gln Ser Pro Ser 130 135 140Ser Leu Ser Ala Ser Val
Gly Asp Arg Val Thr Ile Thr Cys Arg Ser145 150 155 160Ser Gln Ser
Ile Val His Ser Val Gly Asn Thr Phe Leu Glu Trp Tyr 165 170 175Gln
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Val Ser 180 185
190Asn Arg Phe Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
195 200 205Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp
Phe Ala 210 215 220Thr Tyr Tyr Cys Phe Gln Gly Ser Gln Phe Pro Tyr
Thr Phe Gly Gln225 230 235 240Gly Thr Lys Val Glu Ile Lys Gly Gly
Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Gly Ser Gly Gly Gly Gly
Ser Ser Ser Ser Ser Lys Ala Pro Pro 260 265 270Pro Ser Glu Val Gln
Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro 275 280 285Gly Gly Ser
Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn 290 295 300Thr
Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu305 310
315 320Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr
Tyr 325 330 335Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp
Asp Ser Lys 340 345 350Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys
Thr Glu Asp Thr Ala 355 360 365Val Tyr Tyr Cys Val Arg His Gly Asn
Phe Gly Asn Ser Tyr Val Ser 370 375 380Trp Phe Ala Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser Gly385 390 395 400Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu 405 410 415Val Val
Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val 420 425
430Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr
435 440 445Ala Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
Leu Ile 450 455 460Gly Gly Thr Asn Lys Arg Ala Pro Gly Thr Pro Ala
Arg Phe Ser Gly465 470 475 480Ser Leu Leu Gly Gly Lys Ala Ala Leu
Thr Leu Ser Gly Val Gln Pro 485 490 495Glu Asp Glu Ala Glu Tyr Tyr
Cys Ala Leu Trp Tyr Ser Asn Leu Trp 500 505 510Val Phe Gly Gly Gly
Thr Lys Leu Thr Val Leu Asp Lys Thr
His Thr 515 520 525Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly
Pro Ser Val Phe 530 535 540Leu Phe Pro Pro Lys Pro Lys Asp Gln Leu
Met Ile Ser Arg Thr Pro545 550 555 560Glu Val Thr Cys Val Val Val
Asp Val Ser His Glu Asp Pro Glu Val 565 570 575Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys Thr 580 585 590Lys Pro Arg
Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val 595 600 605Leu
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 610 615
620Lys Val Ser Asn Lys Ala Leu Pro Ala Ser Ile Glu Lys Thr Ile
Ser625 630 635 640Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
Thr Leu Pro Pro 645 650 655Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
Ser Leu Thr Cys Leu Val 660 665 670Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val Glu Trp Glu Ser Asn Gly 675 680 685Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 690 695 700Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp705 710 715 720Gln
Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His 725 730
735Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 740
7452692247DNAArtificial sequencebispecific antibody AB3K nucleotide
sequence 269gaggtgcagc tggtggagtc cggaggagga ctggtgcagc caggaggaag
cctgaggctg 60tcttgtgctg cctccggcta tgagttttct cgctcctgga tgaactgggt
gaggcaggct 120ccaggcaagg gactggagtg ggtgggaagg atctaccctg
gcgatggcga cacaaattat 180tccggcaagt ttaagggcag attcaccatc
agcgccgaca catctaagaa caccgcttac 240ctgcagatga atagcctgcg
ggctgaggac accgccgtgt attactgcgc tagagatggc 300tccagctggg
actggtattt cgacgtgtgg ggccagggca cactggtgac cgtgtcttcc
360ggaggaggag gatctggagg aggaggctcc ggaggaggag gaagcgacat
ccagatgacc 420cagagcccaa gctctctgag cgcctctgtg ggcgatcgcg
tgacaatcac ctgtaggtcc 480agccagtcca tcgtgcacag cgtgggcaac
acctttctgg agtggtacca gcagaagccc 540ggcaaggctc caaaactgct
gatctataag gtgtctaatc ggttttccgg agtgccaagc 600agattctccg
gaagcggctc tggcacagat ttcacactga ccatctcttc cctgcagcct
660gaggactttg ccacctatta ctgcttccag ggctctcagt ttccatacac
cttcggccag 720ggcacaaagg tggagatcaa gggtggcggc ggtggaggat
ccggcggtgg aggtagcggc 780ggaggcggta gctccagctc tagtaaagct
ccccctcctt ccgaggtgca gctgctggag 840tccggaggag gactggtgca
gccaggaggc tccctgaagc tgagctgtgc tgcctctggc 900tttaccttca
acacatatgc catgaattgg gtgcggcagg ctccaggcaa gggactggag
960tgggtggcta ggatcaggtc taagtacaac aattatgcca cctactatgc
tgattccgtg 1020aaggacaggt tcaccatctc ccgcgacgat agcaagaaca
cagcctacct gcagatgaac 1080aatctgaaga ccgaggatac cgccgtgtac
tactgcgtga gacatggcaa ctttggcaat 1140agctacgtgt cctggttcgc
ttactgggga cagggcaccc tggtcacagt gagctctgga 1200ggaggaggat
ctggaggagg aggctccgga ggaggaggaa gcgagctggt ggtgacccag
1260gagccatctc tgacagtgtc ccccggcggc acagtgaccc tgacatgtag
atccagcacc 1320ggcgccgtga ccacatccaa ctacgctaat tgggtgcagc
agaagccagg acaggctcca 1380aggggactga tcggaggaac caacaagagg
gctcctggaa caccagctcg gtttagcgga 1440tctctgctgg gaggcaaggc
tgccctgacc ctgtccggag tgcagccaga ggatgaggcc 1500gagtattatt
gcgctctgtg gtatagcaat ctgtgggtgt tcggaggagg aaccaagctg
1560acagtgctgg acaagaccca tacatgccca ccatgccctg cccctgaagc
cgccggagga 1620ccttccgtgt tcctgttccc tcccaagcca aaagatcagc
tgatgatctc tagaaccccc 1680gaagtcacct gcgtggtcgt cgacgtgtcc
catgaggacc ctgaagtcaa gttcaactgg 1740tacgtggacg gtgtcgaagt
ccacaacgcc aagaccaagc ctagggagga gcagtatgcc 1800agcacatacc
gggtggtgtc tgtgctgacc gtgctgcatc aggattggct gaatggcaag
1860gaatataaat gtaaggtgag caataaggct ctgccggcta gcattgaaaa
aaccatttcc 1920aaggctaagg gccagcccag ggagcctcag gtctacaccc
tgcctccatc tagagatgaa 1980ctgaccaaaa accaggtgag cctgacttgc
ctggtcaaag gcttctaccc cagcgacatt 2040gccgtggagt gggagtctaa
tggccagcct gaaaataact acaaaactac ccctcctgtg 2100ctggactctg
atggctcctt ctttctgtac tctaaactga ccgtggacaa gtctcgctgg
2160cagcagggta acgtgttttc ttgctccgtg ctgcacgagg ctctgcataa
ccattacacc 2220cagaagagcc tgtctctgtc cccagga
2247270745PRTArtificial sequencebispecific antibody AB4K amino acid
sequence 270Gln Ile Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro
Gly Ala1 5 10 15Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe
Thr Asp Tyr 20 25 30Tyr Ile Thr Trp Val Lys Gln Lys Pro Gly Gln Gly
Leu Glu Trp Ile 35 40 45Gly Trp Ile Tyr Pro Gly Ser Gly Asn Thr Lys
Tyr Asn Glu Lys Phe 50 55 60Lys Gly Lys Ala Thr Leu Thr Val Asp Thr
Ser Ser Ser Thr Ala Phe65 70 75 80Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95Ala Asn Tyr Gly Asn Tyr Trp
Phe Ala Tyr Trp Gly Gln Gly Thr Gln 100 105 110Val Thr Val Ser Ala
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120 125Gly Gly Gly
Ser Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala 130 135 140Val
Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser145 150
155 160Val Asp Phe Asp Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys
Pro 165 170 175Gly Gln Pro Pro Lys Val Leu Ile Tyr Ala Ala Ser Asn
Leu Glu Ser 180 185 190Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr 195 200 205Leu Asn Ile His Pro Val Glu Glu Glu
Asp Ala Ala Thr Tyr Tyr Cys 210 215 220Gln Gln Ser Asn Glu Asp Pro
Trp Thr Phe Gly Gly Gly Thr Lys Leu225 230 235 240Glu Ile Lys Gly
Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 245 250 255Gly Gly
Gly Ser Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Glu Val 260 265
270Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
275 280 285Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr
Ala Met 290 295 300Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val Ala Arg305 310 315 320Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
Thr Tyr Tyr Ala Asp Ser Val 325 330 335Lys Asp Arg Phe Thr Ile Ser
Arg Asp Asp Ser Lys Asn Thr Ala Tyr 340 345 350Leu Gln Met Asn Asn
Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys 355 360 365Val Arg His
Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr 370 375 380Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser385 390
395 400Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Val Thr
Gln 405 410 415Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr
Leu Thr Cys 420 425 430Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn
Tyr Ala Asn Trp Val 435 440 445Gln Gln Lys Pro Gly Gln Ala Pro Arg
Gly Leu Ile Gly Gly Thr Asn 450 455 460Lys Arg Ala Pro Gly Thr Pro
Ala Arg Phe Ser Gly Ser Leu Leu Gly465 470 475 480Gly Lys Ala Ala
Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala 485 490 495Glu Tyr
Tyr Cys Ala Leu Trp Tyr Ser Asn Leu Trp Val Phe Gly Gly 500 505
510Gly Thr Lys Leu Thr Val Leu Asp Lys Thr His Thr Cys Pro Pro Cys
515 520 525Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro 530 535 540Lys Pro Lys Asp Gln Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys545 550 555 560Val Val Val Asp Val Ser His Glu Asp
Pro Glu Val Lys Phe Asn Trp 565 570 575Tyr Val Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys Pro Arg Glu 580 585 590Glu Gln Tyr Ala Ser
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 595 600 605His Gln Asp
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 610 615 620Lys
Ala Leu Pro Ala Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly625 630
635 640Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp
Glu 645 650 655Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
Gly Phe Tyr 660 665 670Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
Gly Gln Pro Glu Asn 675 680 685Asn Tyr Lys Thr Thr Pro Pro Val Leu
Asp Ser Asp Gly Ser Phe Phe 690 695 700Leu Tyr Ser Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn705 710 715 720Val Phe Ser Cys
Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr 725 730 735Gln Lys
Ser Leu Ser Leu Ser Pro Gly 740 7452712235DNAArtificial
sequencebispecific antibody AB4K nucleotide sequence 271cagatccagc
tgcagcagtc cggaccagag gtggtgaagc caggagcctc tgtgaagatc 60tcctgtaagg
ctagcggcta cacattcacc gactattaca tcacatgggt gaagcagaag
120ccaggccagg gcctggagtg gatcggatgg atctaccccg gcagcggcaa
caccaagtat 180aatgagaagt ttaagggcaa ggccacactg accgtggaca
caagctcttc caccgctttc 240atgcagctgt cttccctgac atctgaggat
accgccgtgt acttttgcgc taactacggc 300aattattggt tcgcctattg
gggacaggga acacaggtga ccgtgtccgc tggaggagga 360ggatctggag
gaggaggctc cggaggagga ggaagcgata tcgtgctgac acagtctcca
420gcttccctgg ccgtgtccct gggccagaga gctaccatca gctgtaaagc
ctcccagagc 480gtggattttg acggcgattc ttacatgaat tggtaccagc
agaaacctgg ccagcctcca 540aaggtgctga tctacgctgc ctctaatctg
gagtccggca tcccagccag attttctggt 600tctggcagcg gcacagattt
caccctgaac attcatccag tggaggagga ggacgctgct 660acctattact
gccagcagtc caatgaggac ccttggacct tcggcggtgg taccaaactg
720gagatcaagg gtggcggcgg tggaggatcc ggcggtggag gtagcggcgg
aggcggtagc 780tccagctcta gtaaagctcc ccctccttcc gaggtgcagc
tgctggagtc cggaggagga 840ctggtgcagc caggaggctc cctgaagctg
agctgtgctg cctctggctt taccttcaac 900acatatgcca tgaattgggt
gcggcaggct ccaggcaagg gactggagtg ggtggctagg 960atcaggtcta
agtacaacaa ttatgccacc tactatgctg attccgtgaa ggacaggttc
1020accatctccc gcgacgatag caagaacaca gcctacctgc agatgaacaa
tctgaagacc 1080gaggataccg ccgtgtacta ctgcgtgaga catggcaact
ttggcaatag ctacgtgtcc 1140tggttcgctt actggggaca gggcaccctg
gtcacagtga gctctggagg aggaggatct 1200ggaggaggag gctccggagg
aggaggaagc gagctggtgg tgacccagga gccatctctg 1260acagtgtccc
ccggcggcac agtgaccctg acatgtagat ccagcaccgg cgccgtgacc
1320acatccaact acgctaattg ggtgcagcag aagccaggac aggctccaag
gggactgatc 1380ggaggaacca acaagagggc tcctggaaca ccagctcggt
ttagcggatc tctgctggga 1440ggcaaggctg ccctgaccct gtccggagtg
cagccagagg atgaggccga gtattattgc 1500gctctgtggt atagcaatct
gtgggtgttc ggaggaggaa ccaagctgac agtgctggac 1560aagacccata
catgcccacc atgccctgcc cctgaagccg ccggaggacc ttccgtgttc
1620ctgttccctc ccaagccaaa agatcagctg atgatctcta gaacccccga
agtcacctgc 1680gtggtcgtcg acgtgtccca tgaggaccct gaagtcaagt
tcaactggta cgtggacggt 1740gtcgaagtcc acaacgccaa gaccaagcct
agggaggagc agtatgccag cacataccgg 1800gtggtgtctg tgctgaccgt
gctgcatcag gattggctga atggcaagga atataaatgt 1860aaggtgagca
ataaggctct gccggctagc attgaaaaaa ccatttccaa ggctaagggc
1920cagcccaggg agcctcaggt ctacaccctg cctccatcta gagatgaact
gaccaaaaac 1980caggtgagcc tgacttgcct ggtcaaaggc ttctacccca
gcgacattgc cgtggagtgg 2040gagtctaatg gccagcctga aaataactac
aaaactaccc ctcctgtgct ggactctgat 2100ggctccttct ttctgtactc
taaactgacc gtggacaagt ctcgctggca gcagggtaac 2160gtgttttctt
gctccgtgct gcacgaggct ctgcataacc attacaccca gaagagcctg
2220tctctgtccc cagga 2235272751PRTArtificial sequencebispecific
antibody AB5K amino acid sequence 272Glu Val Gln Leu Leu Glu Ser
Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Gly Met His Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Val Ile Ser
Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95Ala Lys Asp Met Gly Trp Gly Ser Gly Trp Arg Pro Tyr Tyr Tyr Tyr
100 105 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
Ser Gly 115 120 125Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Glu Leu 130 135 140Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
Ala Ser Val Gly Asp Arg145 150 155 160Val Thr Ile Thr Cys Arg Thr
Ser Gln Ser Ile Ser Ser Tyr Leu Asn 165 170 175Trp Tyr Gln Gln Lys
Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp 180 185 190Ala Ser Thr
Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly 195 200 205Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp 210 215
220Ser Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Asp Ile Pro Tyr Thr
Phe225 230 235 240Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly
Gly Gly Gly Ser 245 250 255Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Ser Ser Ser Ser Lys Ala 260 265 270Pro Pro Pro Ser Glu Val Gln Leu
Leu Glu Ser Gly Gly Gly Leu Val 275 280 285Gln Pro Gly Gly Ser Leu
Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr 290 295 300Phe Asn Thr Tyr
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly305 310 315 320Leu
Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr 325 330
335Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp
340 345 350Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr
Glu Asp 355 360 365Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe
Gly Asn Ser Tyr 370 375 380Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly
Thr Leu Val Thr Val Ser385 390 395 400Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser 405 410 415Glu Leu Val Val Thr
Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 420 425 430Thr Val Thr
Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 435 440 445Asn
Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 450 455
460Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Thr Pro Ala Arg
Phe465 470 475 480Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr
Leu Ser Gly Val 485 490 495Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys
Ala Leu Trp Tyr Ser Asn 500 505 510Leu Trp Val Phe Gly Gly Gly Thr
Lys Leu Thr Val Leu Asp Lys Thr 515 520 525His Thr Cys Pro Pro Cys
Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser 530 535 540Val Phe Leu Phe
Pro Pro Lys Pro Lys Asp Gln Leu Met Ile Ser Arg545 550 555 560Thr
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 565 570
575Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
580 585 590Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg
Val Val 595 600 605Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
Gly Lys Glu Tyr 610 615 620Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
Ala Ser Ile Glu Lys Thr625 630 635 640Ile Ser Lys Ala Lys Gly Gln
Pro Arg Glu Pro Gln Val Tyr Thr Leu 645 650 655Pro Pro Ser Arg Asp
Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 660 665 670Leu Val Lys
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 675 680 685Asn
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 690 695
700Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser705 710 715 720Arg Trp Gln Gln Gly Asn Val
Phe Ser Cys Ser Val Leu His Glu Ala 725 730 735Leu His Asn His Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 740 745
7502732253DNAArtificial sequencebispecific antibody AB5K nucleotide
sequence 273gaggtgcagc tgctggagtc tggaggagga gtggtgcagc caggcaggtc
cctgaggctg 60agctgtgctg cttctggctt cacctttagc tcttatggaa tgcactgggt
gcggcaggct 120ccaggcaagg gactggagtg ggtggccgtg atctcctacg
acggcagcaa caagtactat 180gctgattccg tgaagggcag attcacaatc
tctcgcgaca actccaagaa taccctgtac 240ctgcagatga actctctgag
agctgaggac accgccgtgt actattgcgc caaggatatg 300ggatggggct
ccggatggag gccttactat tactatggca tggacgtgtg gggccagggc
360accacagtga cagtgtcctc cggaggagga ggatctggag gaggaggctc
cggaggagga 420ggaagcgagc tgcagatgac acagagccca tcttccctga
gcgcctctgt gggcgataga 480gtgaccatca catgtcgcac ctcccagagc
atcagctctt atctgaattg gtatcagcag 540aagccaggcc agccacccaa
gctgctgatc tactgggcta gcacaaggga gtctggagtg 600ccagaccggt
tctctggctc cggaagcgga accgacttca ccctgacaat ctccagcctg
660cagccagagg actccgccac atactattgc cagcagagct atgacatccc
ctacacattc 720ggccagggta ctaagctgga gatcaagggt ggcggcggtg
gaggatccgg cggtggaggt 780agcggcggag gcggtagctc cagctctagt
aaagctcccc ctccttccga ggtgcagctg 840ctggagtccg gaggaggact
ggtgcagcca ggaggctccc tgaagctgag ctgtgctgcc 900tctggcttta
ccttcaacac atatgccatg aattgggtgc ggcaggctcc aggcaaggga
960ctggagtggg tggctaggat caggtctaag tacaacaatt atgccaccta
ctatgctgat 1020tccgtgaagg acaggttcac catctcccgc gacgatagca
agaacacagc ctacctgcag 1080atgaacaatc tgaagaccga ggataccgcc
gtgtactact gcgtgagaca tggcaacttt 1140ggcaatagct acgtgtcctg
gttcgcttac tggggacagg gcaccctggt cacagtgagc 1200tctggaggag
gaggatctgg aggaggaggc tccggaggag gaggaagcga gctggtggtg
1260acccaggagc catctctgac agtgtccccc ggcggcacag tgaccctgac
atgtagatcc 1320agcaccggcg ccgtgaccac atccaactac gctaattggg
tgcagcagaa gccaggacag 1380gctccaaggg gactgatcgg aggaaccaac
aagagggctc ctggaacacc agctcggttt 1440agcggatctc tgctgggagg
caaggctgcc ctgaccctgt ccggagtgca gccagaggat 1500gaggccgagt
attattgcgc tctgtggtat agcaatctgt gggtgttcgg aggaggaacc
1560aagctgacag tgctggacaa gacccataca tgcccaccat gccctgcccc
tgaagccgcc 1620ggaggacctt ccgtgttcct gttccctccc aagccaaaag
atcagctgat gatctctaga 1680acccccgaag tcacctgcgt ggtcgtcgac
gtgtcccatg aggaccctga agtcaagttc 1740aactggtacg tggacggtgt
cgaagtccac aacgccaaga ccaagcctag ggaggagcag 1800tatgccagca
cataccgggt ggtgtctgtg ctgaccgtgc tgcatcagga ttggctgaat
1860ggcaaggaat ataaatgtaa ggtgagcaat aaggctctgc cggctagcat
tgaaaaaacc 1920atttccaagg ctaagggcca gcccagggag cctcaggtct
acaccctgcc tccatctaga 1980gatgaactga ccaaaaacca ggtgagcctg
acttgcctgg tcaaaggctt ctaccccagc 2040gacattgccg tggagtggga
gtctaatggc cagcctgaaa ataactacaa aactacccct 2100cctgtgctgg
actctgatgg ctccttcttt ctgtactcta aactgaccgt ggacaagtct
2160cgctggcagc agggtaacgt gttttcttgc tccgtgctgc acgaggctct
gcataaccat 2220tacacccaga agagcctgtc tctgtcccca gga
2253274749PRTArtificial sequencebispecific antibody AB6K amino acid
sequence 274Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile
Lys Asp Thr 20 25 30Tyr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45Ala Arg Ile Asp Pro Ala Asn Gly Asn Ser Lys
Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr
Ser Lys Asn Thr Ala Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Pro Phe Gly Tyr Tyr Val
Ser Asp Tyr Ala Met Ala Tyr Trp Gly 100 105 110Gln Gly Thr Leu Val
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125Gly Gly Ser
Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro 130 135 140Ser
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg145 150
155 160Ala Gly Glu Ser Val Asp Ile Phe Gly Val Gly Phe Leu His Trp
Tyr 165 170 175Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
Arg Ala Ser 180 185 190Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Ser
Gly Ser Gly Ser Arg 195 200 205Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro Glu Asp Phe Ala 210 215 220Thr Tyr Tyr Cys Gln Gln Thr
Asn Glu Asp Pro Tyr Thr Phe Gly Gln225 230 235 240Gly Thr Lys Val
Glu Ile Lys Gly Gly Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Gly
Ser Gly Gly Gly Gly Ser Ser Ser Ser Ser Lys Ala Pro Pro 260 265
270Pro Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
275 280 285Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Asn 290 295 300Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu305 310 315 320Trp Val Ala Arg Ile Arg Ser Lys Tyr
Asn Asn Tyr Ala Thr Tyr Tyr 325 330 335Ala Asp Ser Val Lys Asp Arg
Phe Thr Ile Ser Arg Asp Asp Ser Lys 340 345 350Asn Thr Ala Tyr Leu
Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala 355 360 365Val Tyr Tyr
Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser 370 375 380Trp
Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly385 390
395 400Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu
Leu 405 410 415Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly
Gly Thr Val 420 425 430Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val
Thr Thr Ser Asn Tyr 435 440 445Ala Asn Trp Val Gln Gln Lys Pro Gly
Gln Ala Pro Arg Gly Leu Ile 450 455 460Gly Gly Thr Asn Lys Arg Ala
Pro Gly Thr Pro Ala Arg Phe Ser Gly465 470 475 480Ser Leu Leu Gly
Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro 485 490 495Glu Asp
Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Leu Trp 500 505
510Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Asp Lys Thr His Thr
515 520 525Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser
Val Phe 530 535 540Leu Phe Pro Pro Lys Pro Lys Asp Gln Leu Met Ile
Ser Arg Thr Pro545 550 555 560Glu Val Thr Cys Val Val Val Asp Val
Ser His Glu Asp Pro Glu Val 565 570 575Lys Phe Asn Trp Tyr Val Asp
Gly Val Glu Val His Asn Ala Lys Thr 580 585 590Lys Pro Arg Glu Glu
Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val 595 600 605Leu Thr Val
Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 610 615 620Lys
Val Ser Asn Lys Ala Leu Pro Ala Ser Ile Glu Lys Thr Ile Ser625 630
635 640Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
Pro 645 650 655Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val 660 665 670Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly 675 680 685Gln Pro Glu Asn Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp 690 695 700Gly Ser Phe Phe Leu Tyr Ser
Lys Leu Thr Val Asp Lys Ser Arg Trp705 710 715 720Gln Gln Gly Asn
Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His 725 730 735Asn His
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 740
7452752247DNAArtificial sequencebispecific antibody AB6K nucleotide
sequence 275gaggtgcagc tggtggagtc tggaggagga ctggtgcagc caggaggatc
tctgaggctg 60tcctgcgccg ctagcggctt caacatcaag gatacctaca tgcattgggt
gagacaggct 120ccaggcaagg gactggagtg ggtggctagg atcgacccag
ctaacggcaa tagcaagtac 180gctgattctg tgaagggcag gttcaccatc
tctgccgaca cctccaagaa cacagcttat 240ctgcagatga actccctgcg
ggccgaggat acagccgtgt actattgcgc cccttttggc 300tactatgtga
gcgactacgc catggcttat tggggccagg gcaccctggt gacagtgtcc
360tctggaggag gaggatctgg aggaggaggc tccggaggag gaggaagcga
catccagctg 420acccagtctc catcttccct gtctgcctcc gtgggcgata
gggtgaccat cacatgtcgg 480gctggcgagt ccgtggacat cttcggcgtg
ggctttctgc actggtacca gcagaagccc 540ggcaaggccc ctaagctgct
gatctatagg gctagcaacc tggagtctgg cgtgccttcc 600agattcagcg
gctctggctc ccgcacagac tttaccctga caatcagctc tctgcagcct
660gaggatttcg ccacctacta ttgccagcag acaaatgagg acccatacac
ctttggccag 720ggcacaaagg tggagatcaa gggtggcggc ggtggaggat
ccggcggtgg aggtagcggc 780ggaggcggta gctccagctc tagtaaagct
ccccctcctt ccgaggtgca gctgctggag 840tccggaggag gactggtgca
gccaggaggc tccctgaagc tgagctgtgc tgcctctggc 900tttaccttca
acacatatgc catgaattgg gtgcggcagg ctccaggcaa gggactggag
960tgggtggcta ggatcaggtc taagtacaac aattatgcca cctactatgc
tgattccgtg 1020aaggacaggt tcaccatctc ccgcgacgat agcaagaaca
cagcctacct gcagatgaac 1080aatctgaaga ccgaggatac cgccgtgtac
tactgcgtga gacatggcaa ctttggcaat 1140agctacgtgt cctggttcgc
ttactgggga cagggcaccc tggtcacagt gagctctgga 1200ggaggaggat
ctggaggagg aggctccgga ggaggaggaa gcgagctggt ggtgacccag
1260gagccatctc tgacagtgtc ccccggcggc acagtgaccc tgacatgtag
atccagcacc 1320ggcgccgtga ccacatccaa ctacgctaat tgggtgcagc
agaagccagg acaggctcca 1380aggggactga tcggaggaac caacaagagg
gctcctggaa caccagctcg gtttagcgga 1440tctctgctgg gaggcaaggc
tgccctgacc ctgtccggag tgcagccaga ggatgaggcc 1500gagtattatt
gcgctctgtg gtatagcaat ctgtgggtgt tcggaggagg aaccaagctg
1560acagtgctgg acaagaccca tacatgccca ccatgccctg cccctgaagc
cgccggagga 1620ccttccgtgt tcctgttccc tcccaagcca aaagatcagc
tgatgatctc tagaaccccc 1680gaagtcacct gcgtggtcgt cgacgtgtcc
catgaggacc ctgaagtcaa gttcaactgg 1740tacgtggacg gtgtcgaagt
ccacaacgcc aagaccaagc ctagggagga gcagtatgcc 1800agcacatacc
gggtggtgtc tgtgctgacc gtgctgcatc aggattggct gaatggcaag
1860gaatataaat gtaaggtgag caataaggct ctgccggcta gcattgaaaa
aaccatttcc 1920aaggctaagg gccagcccag ggagcctcag gtctacaccc
tgcctccatc tagagatgaa 1980ctgaccaaaa accaggtgag cctgacttgc
ctggtcaaag gcttctaccc cagcgacatt 2040gccgtggagt gggagtctaa
tggccagcct gaaaataact acaaaactac ccctcctgtg 2100ctggactctg
atggctcctt ctttctgtac tctaaactga ccgtggacaa gtctcgctgg
2160cagcagggta acgtgttttc ttgctccgtg ctgcacgagg ctctgcataa
ccattacacc 2220cagaagagcc tgtctctgtc cccagga
22472762232DNAArtificial sequencebispecific antibody AB7K7
nucleotide sequence 276gaggtgcagc tcgtagaatc aggaggtggc ctggtccagc
ccgggggatc actgaggctg 60tcctgtgctg cctcaggctt caacattaag gatacctaca
tccattgggt ccgccaggct 120ccaggaaaag ggcttgagtg ggtggctagg
atctatccaa caaatggata tacaaggtat 180gccgactctg tcaaaggccg
ctttactatt tcagccgata caagcaagaa cactgcttac 240ttgcagatga
actctctgcg tgctgaagac acagcagtat actattgctc aaggtggggt
300ggtgacgggt tttacgcaat ggattactgg ggtcagggca ccttggtgac
cgtatcttct 360ggaggaggag gatctggagg aggaggctcc ggaggaggag
gaagcgacat tcaaatgaca 420caatccccct catccctcag cgcctccgtg
ggggataggg tcacaataac ctgccgtgcc 480tcacaggacg tgaacaccgc
agtggcatgg tatcagcaaa agccagggaa ggctccaaag 540ctcctcatct
acagcgccag cttcctctat agtggagtcc cttcacgatt ctctggtagc
600cgctctggga cagactttac cctgactatt agcagtctgc agcctgagga
ttttgcaact 660tattactgtc agcagcacta caccacacca ccaacctttg
gacaaggcac caaagtggaa 720atcaagggtg gcggcggtgg aggatccggc
ggtggaggta gcggcggagg cggtagctcc 780agctctagta aagctccccc
tccttccgag gtgcagctgc tggagtccgg aggaggactg 840gtgcagccag
gaggctccct gaagctgagc tgtgctgcct ctggctttac cttcaacaca
900tatgccatga attgggtgcg gcaggctcca ggcaagggac tggagtgggt
ggctaggatc 960aggtctaagt acaacaatta tgccacctac tatgctgatt
ccgtgaagga caggttcacc 1020atctcccgcg acgatagcaa gaacacagcc
tacctgcaga tgaacaatct gaagaccgag 1080gataccgccg tgtactactg
cgtgagacat ggcaactttg gcaatagcta cgtgtcctgg 1140ttcgcttact
ggggacaggg caccctggtc acagtgagct ctggaggagg aggatctgga
1200ggaggaggct ccggaggagg aggaagcgag ctggtggtga cccaggagcc
atctctgaca 1260gtgtcccccg gcggcacagt gaccctgaca tgtagatcca
gcaccggcgc cgtgaccaca 1320tccaactacg ctaattgggt gcagcagaag
ccaggacagg ctccaagggg actgatcgga 1380ggaaccaaca agagggctcc
tggaacacca gctcggttta gcggatctct gctgggaggc 1440aaggctgccc
tgaccctgtc cggagtgcag ccagaggatg aggccgagta ttattgcgct
1500ctgtggtata gcaatctgtg ggtgttcgga ggaggaacca agctgacagt
gctggacaag 1560acccatacat gcccaccatg ccctgcccct gaagccgccg
gaggaccttc cgtgttcctg 1620ttccctccca agccaaaaga tcagctgatg
atctctagaa cccccgaagt cacctgcgtg 1680gtcgtcgacg tgtcccatga
ggaccctgaa gtcaagttca actggtacgt ggacggtgtc 1740gaagtccaca
acgccaagac caagcctagg gaggagcagt atgccagcac ataccgggtg
1800gtgtctgtgc tgaccgtgct gcatcaggat tggctgaatg gcaaggaata
taaatgtaag 1860gtgagcaata aggctctgcc ggctagcatt gaaaaaacca
tttccaaggc taagggccag 1920cccagggagc ctcaggtcta caccctgcct
ccatctagag atgaactgac caaaaaccag 1980gtgagcctga cttgcctggt
caaaggcttc taccccagcg acattgccgt ggagtgggag 2040tctaatggcc
agcctgaaaa taactacaaa actacccctc ctgtgctgga ctctgatggc
2100tccttctttc tgtactctaa actgaccgtg gacaagtctc gctggcagca
gggtaacgtg 2160ttttcttgct ccgtgctgca cgaggctctg cataaccatt
acacccagaa gagcctgtct 2220ctgtccccag ga 2232277743PRTArtificial
sequencebispecific antibody AB8K amino acid sequence 277Gln Val Gln
Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln1 5 10 15Ser Leu
Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30Gly
Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40
45Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr
50 55 60Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe
Phe65 70 75 80Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr
Tyr Cys Ala 85 90 95Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr
Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ala Gly Gly Gly
Gly Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly Gly Ser Asp Ile
Leu Leu Thr Gln Ser Pro Val Ile 130 135 140Leu Ser Val Ser Pro Gly
Glu Arg Val Ser Phe Ser Cys Arg Ala Ser145 150 155 160Gln Ser Ile
Gly Thr Asn Ile His Trp Tyr Gln Gln Arg Thr Asn Gly 165 170 175Ser
Pro Arg Leu Leu Ile Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile 180 185
190Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser
195 200 205Ile Asn Ser Val Glu Ser Glu Asp Ile Ala Asp Tyr Tyr Cys
Gln Gln 210 215 220Asn Asn Asn Trp Pro Thr Thr Phe Gly Ala Gly Thr
Lys Leu Glu Leu225 230 235 240Lys Gly Gly Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly 245 250 255Gly Ser Ser Ser Ser Ser Lys
Ala Pro Pro Pro Ser Glu Val Gln Leu 260 265 270Leu Glu Ser Gly Gly
Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu 275 280 285Ser Cys Ala
Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn Trp 290 295 300Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg305 310
315 320Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys
Asp 325 330 335Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala
Tyr Leu Gln 340 345 350Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val
Tyr Tyr Cys Val Arg 355 360 365His Gly Asn Phe Gly Asn Ser Tyr Val
Ser Trp Phe Ala Tyr Trp Gly 370 375 380Gln Gly Thr Leu Val Thr Val
Ser Ser Gly Gly Gly Gly Ser Gly Gly385 390 395 400Gly Gly Ser Gly
Gly Gly Gly Ser Glu Leu Val Val Thr Gln Glu Pro 405 410 415Ser Leu
Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Arg Ser 420 425
430Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn Trp Val Gln Gln
435 440 445Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Asn
Lys Arg 450 455 460Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu
Leu Gly Gly Lys465 470 475 480Ala Ala Leu Thr Leu Ser Gly Val Gln
Pro Glu Asp Glu Ala Glu Tyr 485 490 495Tyr Cys Ala Leu Trp Tyr
Ser
Asn Leu Trp Val Phe Gly Gly Gly Thr 500 505 510Lys Leu Thr Val Leu
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 515 520 525Pro Glu Ala
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 530 535 540Lys
Asp Gln Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val545 550
555 560Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val 565 570 575Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln 580 585 590Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln 595 600 605Asp Trp Leu Asn Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala 610 615 620Leu Pro Ala Ser Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro625 630 635 640Arg Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 645 650 655Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 660 665
670Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
675 680 685Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr 690 695 700Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe705 710 715 720Ser Cys Ser Val Leu His Glu Ala Leu
His Asn His Tyr Thr Gln Lys 725 730 735Ser Leu Ser Leu Ser Pro Gly
7402782229DNAArtificial sequencebispecific antibody AB8K nucleotide
sequence 278caggtgcagc tgaagcagtc tggaccagga ctggtgcagc caagccagtc
tctgtccatc 60acctgcacag tgagcggctt ctctctgacc aactacggcg tgcactgggt
gagacagtcc 120ccaggcaagg gactggagtg gctgggcgtg atctggagcg
gaggcaatac agattataac 180acccccttta catcccgcct gagcatcaat
aaggacaaca gcaagtctca ggtgttcttt 240aagatgaact ctctgcagtc
caacgatacc gccatctact attgcgctag agccctgaca 300tactatgact
acgagttcgc ttattgggga cagggcaccc tggtgacagt gagcgccgga
360ggaggaggat ctggaggagg aggctccgga ggaggaggaa gcgacatcct
gctgacacag 420tcccctgtga tcctgagcgt gtctccaggc gagagagtgt
cctttagctg tcgcgcctct 480cagtccatcg gcaccaatat ccattggtac
cagcagagga caaacggctc tccccggctg 540ctgatcaagt atgctagcga
gtctatctcc ggcatccctt cccgcttcag cggatctggc 600tccggaaccg
acttcaccct gagcatcaat tctgtggagt ccgaggatat cgccgactac
660tattgccagc agaacaataa ctggcctacc acattcggcg ctggcaccaa
gctggagctg 720aagggtggcg gcggtggagg atccggcggt ggaggtagcg
gcggaggcgg tagctccagc 780tctagtaaag ctccccctcc ttccgaggtg
cagctgctgg agtccggagg aggactggtg 840cagccaggag gctccctgaa
gctgagctgt gctgcctctg gctttacctt caacacatat 900gccatgaatt
gggtgcggca ggctccaggc aagggactgg agtgggtggc taggatcagg
960tctaagtaca acaattatgc cacctactat gctgattccg tgaaggacag
gttcaccatc 1020tcccgcgacg atagcaagaa cacagcctac ctgcagatga
acaatctgaa gaccgaggat 1080accgccgtgt actactgcgt gagacatggc
aactttggca atagctacgt gtcctggttc 1140gcttactggg gacagggcac
cctggtcaca gtgagctctg gaggaggagg atctggagga 1200ggaggctccg
gaggaggagg aagcgagctg gtggtgaccc aggagccatc tctgacagtg
1260tcccccggcg gcacagtgac cctgacatgt agatccagca ccggcgccgt
gaccacatcc 1320aactacgcta attgggtgca gcagaagcca ggacaggctc
caaggggact gatcggagga 1380accaacaaga gggctcctgg aacaccagct
cggtttagcg gatctctgct gggaggcaag 1440gctgccctga ccctgtccgg
agtgcagcca gaggatgagg ccgagtatta ttgcgctctg 1500tggtatagca
atctgtgggt gttcggagga ggaaccaagc tgacagtgct ggacaagacc
1560catacatgcc caccatgccc tgcccctgaa gccgccggag gaccttccgt
gttcctgttc 1620cctcccaagc caaaagatca gctgatgatc tctagaaccc
ccgaagtcac ctgcgtggtc 1680gtcgacgtgt cccatgagga ccctgaagtc
aagttcaact ggtacgtgga cggtgtcgaa 1740gtccacaacg ccaagaccaa
gcctagggag gagcagtatg ccagcacata ccgggtggtg 1800tctgtgctga
ccgtgctgca tcaggattgg ctgaatggca aggaatataa atgtaaggtg
1860agcaataagg ctctgccggc tagcattgaa aaaaccattt ccaaggctaa
gggccagccc 1920agggagcctc aggtctacac cctgcctcca tctagagatg
aactgaccaa aaaccaggtg 1980agcctgactt gcctggtcaa aggcttctac
cccagcgaca ttgccgtgga gtgggagtct 2040aatggccagc ctgaaaataa
ctacaaaact acccctcctg tgctggactc tgatggctcc 2100ttctttctgt
actctaaact gaccgtggac aagtctcgct ggcagcaggg taacgtgttt
2160tcttgctccg tgctgcacga ggctctgcat aaccattaca cccagaagag
cctgtctctg 2220tccccagga 2229279744PRTArtificial sequencebispecific
antibody AB9K amino acid sequence 279Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30Glu Met His Trp Val
Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Ala Ile Asp
Pro Gln Thr Gly Asn Thr Ala Phe Asn Gln Lys Phe 50 55 60Lys Gly Arg
Val Thr Leu Thr Arg Asp Lys Ser Ser Ser Thr Val Tyr65 70 75 80Met
Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95Thr Arg Phe Tyr Ser Leu Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
100 105 110Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly 115 120 125Gly Ser Asp Val Leu Met Thr Gln Ser Pro Leu Ser
Leu Pro Val Thr 130 135 140Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg
Ser Ser Gln Ser Ile Val145 150 155 160His Ser Asn Gly Asn Thr Tyr
Leu Gln Trp Tyr Leu Gln Arg Pro Gly 165 170 175Gln Ser Pro Lys Leu
Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly 180 185 190Val Pro Asp
Arg Phe Ser Gly Ser Gly Ser Gly Thr Tyr Phe Thr Leu 195 200 205Lys
Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe 210 215
220Gln Gly Ser His Phe Pro Tyr Ala Phe Gly Gly Gly Thr Lys Val
Glu225 230 235 240Ile Lys Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly 245 250 255Gly Gly Ser Ser Ser Ser Ser Lys Ala Pro
Pro Pro Ser Glu Val Gln 260 265 270Leu Leu Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly Ser Leu Lys 275 280 285Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 290 295 300Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile305 310 315 320Arg
Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 325 330
335Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu
340 345 350Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr
Cys Val 355 360 365Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp
Phe Ala Tyr Trp 370 375 380Gly Gln Gly Thr Leu Val Thr Val Ser Ser
Gly Gly Gly Gly Ser Gly385 390 395 400Gly Gly Gly Ser Gly Gly Gly
Gly Ser Glu Leu Val Val Thr Gln Glu 405 410 415Pro Ser Leu Thr Val
Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Arg 420 425 430Ser Ser Thr
Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn Trp Val Gln 435 440 445Gln
Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr Asn Lys 450 455
460Arg Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly
Gly465 470 475 480Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu
Asp Glu Ala Glu 485 490 495Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Leu
Trp Val Phe Gly Gly Gly 500 505 510Thr Lys Leu Thr Val Leu Asp Lys
Thr His Thr Cys Pro Pro Cys Pro 515 520 525Ala Pro Glu Ala Ala Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 530 535 540Pro Lys Asp Gln
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val545 550 555 560Val
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 565 570
575Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
580 585 590Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
Leu His 595 600 605Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
Val Ser Asn Lys 610 615 620Ala Leu Pro Ala Ser Ile Glu Lys Thr Ile
Ser Lys Ala Lys Gly Gln625 630 635 640Pro Arg Glu Pro Gln Val Tyr
Thr Leu Pro Pro Ser Arg Asp Glu Leu 645 650 655Thr Lys Asn Gln Val
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 660 665 670Ser Asp Ile
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 675 680 685Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 690 695
700Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
Val705 710 715 720Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn
His Tyr Thr Gln 725 730 735Lys Ser Leu Ser Leu Ser Pro Gly
7402802232DNAArtificial sequencebispecific antibody AB9K nucleotide
sequence 280caggtccagc tggtccagtc tggcgccgaa gtgaagaagc caggcgcctc
cgtgaaggtg 60agctgtaagg cctctggcta caccttcaca gactatgaga tgcattgggt
gaagcaggct 120ccaggacagg gactggagtg gatcggcgct atcgatcccc
agaccggcaa cacagccttc 180aatcagaagt ttaagggcag agtgaccctg
acacgcgaca agagctcttc caccgtgtac 240atggagctga gctctctgag
gtccgaggat accgccgtgt actattgcac acggttttac 300agcctgacct
actggggtca gggcaccctg gtcacagtgt ccagcggagg aggaggatct
360ggaggaggag gctccggagg aggaggaagc gatgtgctga tgacacagtc
tccactgtcc 420ctgccagtga ccctgggaca gccagcttcc atcagctgta
gatcttccca gtccatcgtg 480cacagcaacg gcaataccta cctgcagtgg
tatctgcagc gccctggcca gagcccaaag 540ctgctgatct acaaggtgtc
taataggttc tccggcgtgc cagaccggtt ttctggctcc 600ggcagcggca
cctatttcac actgaagatc tctagagtgg aggccgagga tgtgggcgtg
660tactattgtt ttcagggctc ccatttcccc tacgcttttg gcggtggtac
taaagtggag 720atcaagggtg gcggcggtgg aggatccggc ggtggaggta
gcggcggagg cggtagctcc 780agctctagta aagctccccc tccttccgag
gtgcagctgc tggagtccgg aggaggactg 840gtgcagccag gaggctccct
gaagctgagc tgtgctgcct ctggctttac cttcaacaca 900tatgccatga
attgggtgcg gcaggctcca ggcaagggac tggagtgggt ggctaggatc
960aggtctaagt acaacaatta tgccacctac tatgctgatt ccgtgaagga
caggttcacc 1020atctcccgcg acgatagcaa gaacacagcc tacctgcaga
tgaacaatct gaagaccgag 1080gataccgccg tgtactactg cgtgagacat
ggcaactttg gcaatagcta cgtgtcctgg 1140ttcgcttact ggggacaggg
caccctggtc acagtgagct ctggaggagg aggatctgga 1200ggaggaggct
ccggaggagg aggaagcgag ctggtggtga cccaggagcc atctctgaca
1260gtgtcccccg gcggcacagt gaccctgaca tgtagatcca gcaccggcgc
cgtgaccaca 1320tccaactacg ctaattgggt gcagcagaag ccaggacagg
ctccaagggg actgatcgga 1380ggaaccaaca agagggctcc tggaacacca
gctcggttta gcggatctct gctgggaggc 1440aaggctgccc tgaccctgtc
cggagtgcag ccagaggatg aggccgagta ttattgcgct 1500ctgtggtata
gcaatctgtg ggtgttcgga ggaggaacca agctgacagt gctggacaag
1560acccatacat gcccaccatg ccctgcccct gaagccgccg gaggaccttc
cgtgttcctg 1620ttccctccca agccaaaaga tcagctgatg atctctagaa
cccccgaagt cacctgcgtg 1680gtcgtcgacg tgtcccatga ggaccctgaa
gtcaagttca actggtacgt ggacggtgtc 1740gaagtccaca acgccaagac
caagcctagg gaggagcagt atgccagcac ataccgggtg 1800gtgtctgtgc
tgaccgtgct gcatcaggat tggctgaatg gcaaggaata taaatgtaag
1860gtgagcaata aggctctgcc ggctagcatt gaaaaaacca tttccaaggc
taagggccag 1920cccagggagc ctcaggtcta caccctgcct ccatctagag
atgaactgac caaaaaccag 1980gtgagcctga cttgcctggt caaaggcttc
taccccagcg acattgccgt ggagtgggag 2040tctaatggcc agcctgaaaa
taactacaaa actacccctc ctgtgctgga ctctgatggc 2100tccttctttc
tgtactctaa actgaccgtg gacaagtctc gctggcagca gggtaacgtg
2160ttttcttgct ccgtgctgca cgaggctctg cataaccatt acacccagaa
gagcctgtct 2220ctgtccccag ga 2232281746PRTArtificial
sequencebispecific antibody AB10K amino acid sequence 281Gln Val
Tyr Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Ile Tyr 20 25
30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ala Val Ile Trp Tyr Asp Gly Ser His Glu Tyr Tyr Ala Asp Ser
Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
Leu Tyr65 70 75 80Leu Leu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95Ala Arg Asp Gly Asp Tyr Tyr Asp Ser Gly Ser
Pro Leu Asp Tyr Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser
Ser Gly Gly Gly Gly Ser Gly 115 120 125Gly Gly Gly Ser Gly Gly Gly
Gly Ser Glu Ile Val Leu Thr Gln Ser 130 135 140Pro Ala Thr Leu Ser
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys145 150 155 160Arg Ala
Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys 165 170
175Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala
180 185 190Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp Phe 195 200 205Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe
Ala Val Tyr Tyr 210 215 220Cys Gln Gln Arg Ser Asn Trp Pro Leu Thr
Phe Gly Gly Gly Thr Lys225 230 235 240Val Glu Ile Lys Gly Gly Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser 245 250 255Gly Gly Gly Gly Ser
Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Glu 260 265 270Val Gln Leu
Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 275 280 285Leu
Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala 290 295
300Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
Ala305 310 315 320Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr
Tyr Ala Asp Ser 325 330 335Val Lys Asp Arg Phe Thr Ile Ser Arg Asp
Asp Ser Lys Asn Thr Ala 340 345 350Tyr Leu Gln Met Asn Asn Leu Lys
Thr Glu Asp Thr Ala Val Tyr Tyr 355 360 365Cys Val Arg His Gly Asn
Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala 370 375 380Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly385 390 395 400Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Val Thr 405 410
415Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr
420 425 430Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala
Asn Trp 435 440 445Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly Leu
Ile Gly Gly Thr 450 455 460Asn Lys Arg Ala Pro Gly Thr Pro Ala Arg
Phe Ser Gly Ser Leu Leu465 470 475 480Gly Gly Lys Ala Ala Leu Thr
Leu Ser Gly Val Gln Pro Glu Asp Glu 485 490 495Ala Glu Tyr Tyr Cys
Ala Leu Trp Tyr Ser Asn Leu Trp Val Phe Gly 500 505 510Gly Gly Thr
Lys Leu Thr Val Leu Asp Lys Thr His Thr Cys Pro Pro 515 520 525Cys
Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro 530 535
540Pro Lys Pro Lys Asp Gln Leu Met Ile Ser Arg Thr Pro Glu Val
Thr545 550 555 560Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
Val Lys Phe Asn 565 570 575Trp Tyr Val Asp Gly Val Glu Val His Asn
Ala Lys Thr Lys Pro Arg 580 585 590Glu Glu Gln Tyr Ala Ser Thr Tyr
Arg Val Val Ser Val Leu Thr Val 595 600 605Leu His Gln Asp Trp Leu
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 610 615 620Asn Lys Ala Leu
Pro Ala Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys625 630 635 640Gly
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 645 650
655Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
660 665 670Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu 675 680 685Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
Asp Gly Ser Phe 690
695 700Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly705 710 715 720Asn Val Phe Ser Cys Ser Val Leu His Glu Ala Leu
His Asn His Tyr 725 730 735Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
740 7452822238DNAArtificial sequencebispecific antibody AB10K
nucleotide sequence 282caggtgtacc tggtggagag cggaggagga gtggtgcagc
caggccgctc tctgaggctg 60tcctgtgctg ccagcggcat caccttctcc atctatggaa
tgcactgggt gaggcaggct 120cctggcaagg gactggagtg ggtggctgtg
atctggtacg atggctctca tgagtattat 180gccgactccg tgaagggccg
gtttacaatc tctagagata actccaagaa taccctgtat 240ctgctgatga
atagcctgcg cgccgaggac acagccgtgt actattgcgc tagggacggc
300gattactatg attccggaag cccactggac tactggggac agggcacact
ggtgaccgtg 360agctctggag gaggaggatc tggaggagga ggctccggag
gaggaggaag cgagatcgtg 420ctgacacaga gcccagccac cctgtctctg
tcccctggag agagggccac cctgtcttgt 480agggctagcc agtccgtgtc
cagctacctg gcttggtacc agcagaagcc aggacaggct 540ccaaggctgc
tgatctatga cgcttccaac agggctacag gaatcccagc taggttttcc
600ggaagcggat ctggcaccga tttcacactg accatctctt ccctggagcc
tgaggacttt 660gccgtgtact actgtcagca gagaagcaat tggccactga
cattcggcgg cggcaccaag 720gtggagatca agggtggcgg cggtggagga
tccggcggtg gaggtagcgg cggaggcggt 780agctccagct ctagtaaagc
tccccctcct tccgaggtgc agctgctgga gtccggagga 840ggactggtgc
agccaggagg ctccctgaag ctgagctgtg ctgcctctgg ctttaccttc
900aacacatatg ccatgaattg ggtgcggcag gctccaggca agggactgga
gtgggtggct 960aggatcaggt ctaagtacaa caattatgcc acctactatg
ctgattccgt gaaggacagg 1020ttcaccatct cccgcgacga tagcaagaac
acagcctacc tgcagatgaa caatctgaag 1080accgaggata ccgccgtgta
ctactgcgtg agacatggca actttggcaa tagctacgtg 1140tcctggttcg
cttactgggg acagggcacc ctggtcacag tgagctctgg aggaggagga
1200tctggaggag gaggctccgg aggaggagga agcgagctgg tggtgaccca
ggagccatct 1260ctgacagtgt cccccggcgg cacagtgacc ctgacatgta
gatccagcac cggcgccgtg 1320accacatcca actacgctaa ttgggtgcag
cagaagccag gacaggctcc aaggggactg 1380atcggaggaa ccaacaagag
ggctcctgga acaccagctc ggtttagcgg atctctgctg 1440ggaggcaagg
ctgccctgac cctgtccgga gtgcagccag aggatgaggc cgagtattat
1500tgcgctctgt ggtatagcaa tctgtgggtg ttcggaggag gaaccaagct
gacagtgctg 1560gacaagaccc atacatgccc accatgccct gcccctgaag
ccgccggagg accttccgtg 1620ttcctgttcc ctcccaagcc aaaagatcag
ctgatgatct ctagaacccc cgaagtcacc 1680tgcgtggtcg tcgacgtgtc
ccatgaggac cctgaagtca agttcaactg gtacgtggac 1740ggtgtcgaag
tccacaacgc caagaccaag cctagggagg agcagtatgc cagcacatac
1800cgggtggtgt ctgtgctgac cgtgctgcat caggattggc tgaatggcaa
ggaatataaa 1860tgtaaggtga gcaataaggc tctgccggct agcattgaaa
aaaccatttc caaggctaag 1920ggccagccca gggagcctca ggtctacacc
ctgcctccat ctagagatga actgaccaaa 1980aaccaggtga gcctgacttg
cctggtcaaa ggcttctacc ccagcgacat tgccgtggag 2040tgggagtcta
atggccagcc tgaaaataac tacaaaacta cccctcctgt gctggactct
2100gatggctcct tctttctgta ctctaaactg accgtggaca agtctcgctg
gcagcagggt 2160aacgtgtttt cttgctccgt gctgcacgag gctctgcata
accattacac ccagaagagc 2220ctgtctctgt ccccagga
2238283743PRTArtificial sequencebispecific antibody AB1K2 amino
acid sequence 283Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val
Lys Pro Ser Gln1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
Ser Ile Ser Thr Ser 20 25 30Gly Met Gly Val Gly Trp Ile Arg Gln His
Pro Gly Lys Gly Leu Glu 35 40 45Trp Ile Gly His Ile Trp Trp Asp Asp
Asp Lys Arg Tyr Asn Pro Ala 50 55 60Leu Lys Ser Arg Val Thr Ile Ser
Val Asp Thr Ser Lys Asn Gln Phe65 70 75 80Ser Leu Lys Leu Ser Ser
Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95Cys Ala Arg Met Glu
Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln 100 105 110Gly Thr Leu
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125Gly
Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Ala 130 135
140Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Ser
Ala145 150 155 160Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln
Lys Pro Gly Gln 165 170 175Ala Pro Arg Leu Leu Ile Tyr Asp Thr Ser
Lys Leu Ala Ser Gly Ile 180 185 190Pro Ala Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr 195 200 205Ile Ser Ser Leu Glu Pro
Glu Asp Val Ala Val Tyr Tyr Cys Phe Gln 210 215 220Gly Ser Val Tyr
Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile225 230 235 240Lys
Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 245 250
255Gly Ser Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Glu Val Gln Leu
260 265 270Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
Lys Leu 275 280 285Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr
Ala Met Asn Trp 290 295 300Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val Ala Arg Ile Arg305 310 315 320Ser Lys Tyr Asn Asn Tyr Ala
Thr Tyr Tyr Ala Asp Ser Val Lys Asp 325 330 335Arg Phe Thr Ile Ser
Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln 340 345 350Met Asn Asn
Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg 355 360 365His
Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly 370 375
380Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
Gly385 390 395 400Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Val
Thr Gln Glu Pro 405 410 415Ser Leu Thr Val Ser Pro Gly Gly Thr Val
Thr Leu Thr Cys Arg Ser 420 425 430Ser Thr Gly Ala Val Thr Thr Ser
Asn Tyr Ala Asn Trp Val Gln Gln 435 440 445Lys Pro Gly Gln Ala Pro
Arg Gly Leu Ile Gly Gly Thr Asn Lys Arg 450 455 460Ala Pro Gly Thr
Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys465 470 475 480Ala
Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr 485 490
495Tyr Cys Ala Leu Trp Tyr Ser Asn Leu Trp Val Phe Gly Gly Gly Thr
500 505 510Lys Leu Thr Val Leu Asp Lys Thr His Thr Cys Pro Pro Cys
Pro Ala 515 520 525Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys Pro 530 535 540Lys Asp Gln Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val545 550 555 560Val Asp Val Ser His Glu Asp
Pro Glu Val Lys Phe Asn Trp Tyr Val 565 570 575Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 580 585 590Tyr Ala Ser
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 595 600 605Asp
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 610 615
620Leu Pro Ala Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
Pro625 630 635 640Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
Asp Glu Leu Thr 645 650 655Lys Asn Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser 660 665 670Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn Tyr 675 680 685Lys Thr Thr Pro Pro Val
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 690 695 700Ser Lys Leu Thr
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe705 710 715 720Ser
Cys Ser Val Leu His Glu Ala Leu His Asn His Tyr Thr Gln Lys 725 730
735Ser Leu Ser Leu Ser Pro Gly 7402842229DNAArtificial
sequencebispecific antibody AB1K2 nucleotide sequence 284caggtgcagc
tgcaggagag cggaccagga ctggtgaagc catcccagac cctgagcctg 60acctgtacag
tgtctggcgg cagcatctct acatccggaa tgggagtggg atggatcagg
120cagcacccag gcaagggcct ggaatggatc ggccatatct ggtgggacga
tgacaagaga 180tacaatcctg ccctgaagtc ccgcgtgaca atctctgtgg
acacctccaa gaaccagttt 240agcctgaagc tgtcttccgt gacagccgct
gataccgccg tgtattactg cgctagaatg 300gagctgtgga gctattactt
cgactactgg ggccagggca cactggtgac cgtgagctcc 360ggtggtggtg
gttccggcgg cggcggttct ggcggcggcg gcagcgagat cgtgctgaca
420cagtcccctg ccaccctgag cctgtctcca ggagagaggg ccaccctgtc
ctgttccgcc 480tccagctctg tgagctacat gcattggtat cagcagaagc
caggccaggc tcccaggctg 540ctgatctacg atacttctaa actggcctct
ggcatccctg ctcggttttc tggctccggc 600agcggcacag acttcaccct
gacaatctcc agcctggagc cagaggatgt ggccgtgtat 660tactgcttcc
agggcagcgt gtatcccttc acatttggcc agggcactaa actggagatc
720aagggtggcg gcggtggagg atccggcggt ggaggtagcg gcggaggcgg
tagctccagc 780tctagtaaag ctccccctcc ttccgaggtg cagctgctgg
agtccggagg aggactggtg 840cagccaggag gctccctgaa gctgagctgt
gctgcctctg gctttacctt caacacatat 900gccatgaatt gggtgcggca
ggctccaggc aagggactgg agtgggtggc taggatcagg 960tctaagtaca
acaattatgc cacctactat gctgattccg tgaaggacag gttcaccatc
1020tcccgcgacg atagcaagaa cacagcctac ctgcagatga acaatctgaa
gaccgaggat 1080accgccgtgt actactgcgt gagacatggc aactttggca
atagctacgt gtcctggttc 1140gcttactggg gacagggcac cctggtcaca
gtgagctctg gaggaggagg atctggagga 1200ggaggctccg gaggaggagg
aagcgagctg gtggtgaccc aggagccatc tctgacagtg 1260tcccccggcg
gcacagtgac cctgacatgt agatccagca ccggcgccgt gaccacatcc
1320aactacgcta attgggtgca gcagaagcca ggacaggctc caaggggact
gatcggagga 1380accaacaaga gggctcctgg aacaccagct cggtttagcg
gatctctgct gggaggcaag 1440gctgccctga ccctgtccgg agtgcagcca
gaggatgagg ccgagtatta ttgcgctctg 1500tggtatagca atctgtgggt
gttcggagga ggaaccaagc tgacagtgct ggacaagacc 1560catacatgcc
caccatgccc tgcccctgaa gccgccggag gaccttccgt gttcctgttc
1620cctcccaagc caaaagatca gctgatgatc tctagaaccc ccgaagtcac
ctgcgtggtc 1680gtcgacgtgt cccatgagga ccctgaagtc aagttcaact
ggtacgtgga cggtgtcgaa 1740gtccacaacg ccaagaccaa gcctagggag
gagcagtatg ccagcacata ccgggtggtg 1800tctgtgctga ccgtgctgca
tcaggattgg ctgaatggca aggaatataa atgtaaggtg 1860agcaataagg
ctctgccggc tagcattgaa aaaaccattt ccaaggctaa gggccagccc
1920agggagcctc aggtctacac cctgcctcca tctagagatg aactgaccaa
aaaccaggtg 1980agcctgactt gcctggtcaa aggcttctac cccagcgaca
ttgccgtgga gtgggagtct 2040aatggccagc ctgaaaataa ctacaaaact
acccctcctg tgctggactc tgatggctcc 2100ttctttctgt actctaaact
gaccgtggac aagtctcgct ggcagcaggg taacgtgttt 2160tcttgctccg
tgctgcacga ggctctgcat aaccattaca cccagaagag cctgtctctg
2220tccccagga 2229285746PRTArtificial sequencebispecific antibody
AB11K amino acid sequence 285Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Met Arg Leu Ser Cys Val Ala
Ser Gly Phe Pro Phe Ser Asn Tyr 20 25 30Trp Met Asn Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Gly Glu Ile Arg Leu Lys
Ser Asn Asn Tyr Thr Thr His Tyr Ala Glu 50 55 60Ser Val Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser65 70 75 80Leu Tyr Leu
Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys
Thr Arg His Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105
110Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Leu Ser
Asn Pro 130 135 140Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg
Ser Ser Lys Ser145 150 155 160Leu Leu His Ser Asn Gly Ile Thr Tyr
Phe Phe Trp Tyr Leu Gln Lys 165 170 175Pro Gly Gln Ser Pro Gln Leu
Leu Ile Tyr Gln Met Ser Asn Leu Ala 180 185 190Ser Gly Val Pro Asp
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 195 200 205Thr Leu Arg
Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr 210 215 220Cys
Ala Gln Asn Leu Glu Leu Pro Pro Thr Phe Gly Gln Gly Thr Lys225 230
235 240Val Glu Ile Lys Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser 245 250 255Gly Gly Gly Gly Ser Ser Ser Ser Ser Lys Ala Pro Pro
Pro Ser Glu 260 265 270Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly Ser 275 280 285Leu Lys Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Asn Thr Tyr Ala 290 295 300Met Asn Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val Ala305 310 315 320Arg Ile Arg Ser
Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 325 330 335Val Lys
Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala 340 345
350Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr
355 360 365Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp
Phe Ala 370 375 380Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
Gly Gly Gly Gly385 390 395 400Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Glu Leu Val Val Thr 405 410 415Gln Glu Pro Ser Leu Thr Val
Ser Pro Gly Gly Thr Val Thr Leu Thr 420 425 430Cys Arg Ser Ser Thr
Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn Trp 435 440 445Val Gln Gln
Lys Pro Gly Gln Ala Pro Arg Gly Leu Ile Gly Gly Thr 450 455 460Asn
Lys Arg Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu465 470
475 480Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp
Glu 485 490 495Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Leu Trp
Val Phe Gly 500 505 510Gly Gly Thr Lys Leu Thr Val Leu Asp Lys Thr
His Thr Cys Pro Pro 515 520 525Cys Pro Ala Pro Glu Ala Ala Gly Gly
Pro Ser Val Phe Leu Phe Pro 530 535 540Pro Lys Pro Lys Asp Gln Leu
Met Ile Ser Arg Thr Pro Glu Val Thr545 550 555 560Cys Val Val Val
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 565 570 575Trp Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 580 585
590Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
595 600 605Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
Val Ser 610 615 620Asn Lys Ala Leu Pro Ala Ser Ile Glu Lys Thr Ile
Ser Lys Ala Lys625 630 635 640Gly Gln Pro Arg Glu Pro Gln Val Tyr
Thr Leu Pro Pro Ser Arg Asp 645 650 655Glu Leu Thr Lys Asn Gln Val
Ser Leu Thr Cys Leu Val Lys Gly Phe 660 665 670Tyr Pro Ser Asp Ile
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 675 680 685Asn Asn Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 690 695 700Phe
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly705 710
715 720Asn Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His Asn His
Tyr 725 730 735Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 740
7452862238DNAArtificial sequencebispecific antibody AB11K
nucleotide sequence 286gaggtgcagc tggtggagtc cggaggaggc ctggtgcagc
caggaggaag catgaggctg 60tcttgcgtgg cttccggctt cccttttagc aactactgga
tgaattgggt gcggcaggct 120ccaggcaagg gcctggagtg ggtgggcgag
atcagactga agtctaacaa ttacacaacc 180cattatgctg agtccgtgaa
gggccgcttc acaatcagca gggacgatag caagaactct 240ctgtatctgc
agatgaattc cctgaagaca gaagatactg ccgtgtatta ttgcaccaga
300cactattact ttgattactg gggtcaaggc acactggtta ccgtgagctc
tggaggagga 360ggatctggag gaggaggctc cggaggagga ggaagcgaca
tcgtgatgac acagtcccct 420ctgagcaacc cagtgacccc tggagagcca
gcttccatca gctgtcggtc cagcaagagc 480ctgctgcact ctaatggcat
cacctacttc ttttggtatc tgcagaagcc tggccagagc 540ccacagctgc
tgatctacca gatgtccaac ctggccagcg gcgtgccaga tagattctct
600ggctccggca gcggcacaga ctttaccctg cggatctcta gagtggaggc
tgaggatgtg 660ggcgtgtatt actgcgccca gaatctggag ctgcctccaa
ccttcggcca gggcacaaag 720gtggagatca agggtggcgg cggtggagga
tccggcggtg gaggtagcgg
cggaggcggt 780agctccagct ctagtaaagc tccccctcct tccgaggtgc
agctgctgga gtccggagga 840ggactggtgc agccaggagg ctccctgaag
ctgagctgtg ctgcctctgg ctttaccttc 900aacacatatg ccatgaattg
ggtgcggcag gctccaggca agggactgga gtgggtggct 960aggatcaggt
ctaagtacaa caattatgcc acctactatg ctgattccgt gaaggacagg
1020ttcaccatct cccgcgacga tagcaagaac acagcctacc tgcagatgaa
caatctgaag 1080accgaggata ccgccgtgta ctactgcgtg agacatggca
actttggcaa tagctacgtg 1140tcctggttcg cttactgggg acagggcacc
ctggtcacag tgagctctgg aggaggagga 1200tctggaggag gaggctccgg
aggaggagga agcgagctgg tggtgaccca ggagccatct 1260ctgacagtgt
cccccggcgg cacagtgacc ctgacatgta gatccagcac cggcgccgtg
1320accacatcca actacgctaa ttgggtgcag cagaagccag gacaggctcc
aaggggactg 1380atcggaggaa ccaacaagag ggctcctgga acaccagctc
ggtttagcgg atctctgctg 1440ggaggcaagg ctgccctgac cctgtccgga
gtgcagccag aggatgaggc cgagtattat 1500tgcgctctgt ggtatagcaa
tctgtgggtg ttcggaggag gaaccaagct gacagtgctg 1560gacaagaccc
atacatgccc accatgccct gcccctgaag ccgccggagg accttccgtg
1620ttcctgttcc ctcccaagcc aaaagatcag ctgatgatct ctagaacccc
cgaagtcacc 1680tgcgtggtcg tcgacgtgtc ccatgaggac cctgaagtca
agttcaactg gtacgtggac 1740ggtgtcgaag tccacaacgc caagaccaag
cctagggagg agcagtatgc cagcacatac 1800cgggtggtgt ctgtgctgac
cgtgctgcat caggattggc tgaatggcaa ggaatataaa 1860tgtaaggtga
gcaataaggc tctgccggct agcattgaaa aaaccatttc caaggctaag
1920ggccagccca gggagcctca ggtctacacc ctgcctccat ctagagatga
actgaccaaa 1980aaccaggtga gcctgacttg cctggtcaaa ggcttctacc
ccagcgacat tgccgtggag 2040tgggagtcta atggccagcc tgaaaataac
tacaaaacta cccctcctgt gctggactct 2100gatggctcct tctttctgta
ctctaaactg accgtggaca agtctcgctg gcagcagggt 2160aacgtgtttt
cttgctccgt gctgcacgag gctctgcata accattacac ccagaagagc
2220ctgtctctgt ccccagga 2238
* * * * *
References